

0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.
0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.
0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.
0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.
0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.

0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.
0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.
0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.
0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.
0000012390-24-09588110-Q Dominari Holdings Inc. 2024110820241108160332160520160520 0 0001213900-24-095881 10-Q 79 20240930 20241108 20241108 Dominari Holdings Inc.

A. Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of September 30, 2024, condensed consolidated statements of operations for the three months and nine months ended September 30, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023. The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation. A Joint Ventures On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (the “DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of September 30, 2024, there has been no material activity in DFHS. Use of Estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions. Deposits with clearing broker A Deposits with Dominari Securities clearing broker consisted of approximately \$14.2 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of September 30, 2024. Leases The Company accounts for its leases under ASC 842. Leases (ASC 842). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset result in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases). Revenue The Company recognizes revenue under ASC 606. Revenue from Contracts with Customers (ASC 606). Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. The following provides detailed information on the recognition of the Company’s revenue from contracts with customers: A Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income. A Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date. A Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within our Condensed Consolidated Balance Sheet. A Other revenue includes revenues such as miscellaneous fees and reimbursed expenses. A Long-term equity investments The Company accounts for long-term equity investments under Accounting Standards Codification (ASC) 321. Equity Investments (“Equity Securities”) (ASC 321). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. A Recently adopted accounting standards A In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (ASC 805-08A). This update amends Topic 805A to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08A on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08. A In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted ASU 2022-03A on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2022-03A. A In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2023-01A on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2023-01A. A Effect of new accounting pronouncements to be adopted in future periods The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements. A Note 4. Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months and nine months ended September 30, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows (\$ in thousands): A Three Months Ended September 30, A Nine Months Ended September 30, A 2024 A 2023 A Realized gain (loss) A \$432A \$(762) A \$3,762A \$(1,249) Unrealized gain (loss) A (421) A 382A A (3,361) A 897A Dividend income A 78A A 230A A 366A A 537A Total A \$89A \$(150) A \$767A \$185A A Note 5. Long-Term Equity Investments The Company holds interests in several privately held and publicly traded companies as long-term investments. The following table presents the Company’s long-term investments as of September 30, 2024, and December 31, 2023 (\$ in thousands): A December 31, 2023 A September 30, 2024 A Cost Basis A Carrying Value A Cost Basis A Carrying Value Investment in Kerna Health Inc A \$2,140A \$4,940A \$2,140A \$4,940 Investment in Kaya Now A 1,500A A 1,500A A 1,500A A 1,972A A 2,794A A 1,972A A 1,972A Investment in Unusual Machines A 1,075A A 1,033A A 1,033A A 1,033A Investment in Express A 1,000A A 1,000A A 1,000A A 1,000A Investment in Masterclass A 170A A 170A A 170A A 170A Investment in Kraken A 597A A 597A A 597A A 597A Investment in Epic Games A 3,500A A 3,500A A 3,500A A 3,500A Investment in Tesseract A 1,240A A 1,240A A 1,240A A 1,240A Investment in SpaceX A 3,500A A 4,867A A 3,500A A 3,500A Investment in Databricks A 1,200A A 842A A 1,200A A 842A Investment in Discord A 476A A 476A A 476A A 476A Investment in Thrasio A 300A A 300A A 300A A 300A Investment in Automation Anywhere A 476A A 476A A 476A A 476A Investment in XAI A 100A A 100A A 100A A 100A Investment in Cerebras A 25A A 25A A 25A A 25A Investment in Groq A 25A A 25A A 25A A 25A Investment in AdvEn A 874A A 874A A 874A A 874A Investment in Anduril A 476A A 476A A 476A A 476A Total A \$19,622A \$24,150A A \$15,197A \$13,771A * Investments made in these companies are through a Special Purpose Vehicle (SPV). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. ** Investments made in these companies are through both an SPV and direct investments. A 9 A The Company recorded an increase in the carrying values of approximately \$0.9 million for the three month period ended September 30, 2024 and a decrease in the carrying values of approximately \$4.6 million for the nine month period ended September 30, 2024. The Company also recorded a (\$0.5) million change in carrying value of investment upon transferring Unusual Machine, Inc shares to marketable securities in addition to the (\$6.0) million year to date change from the above table. See Investment in Unusual Machine, Inc below. A Investment in SpaceX The Company redeemed its holdings in SpaceX in April of 2024 totaling 36,842 shares of participating membership units of SpaceX for \$3.5 million. This resulted in the Company recording a decrease in the carrying value of the investment for the nine month period ended September 30, 2024. A Investment in xAI On May 2, 2024, the Company entered into an agreement (the “xAI Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 100,000 Series XI xAI Units for \$0.1 million. A Investment in Cerebras On June 17, 2024, the Company entered into an agreement (the “Cerebras Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 25,000 Series XI Cerebras Units for \$25,000. A Investment in Groq On July 25, 2024, the Company entered into an agreement (the “Groq Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 25,000 Series XII Groq Units for \$25,000. A Investment in Unusual Machines Unusual Machines, Inc, an emerging leader in first-person view (FPV) drone technology, closed its initial public offering of common stock on February 14, 2024 at a public offering price of \$4 per share and the shares began trading on the NYSE American under the ticker symbol “UMAC”. As of September 30, 2024, the value of the Company’s holdings in UMAC are presented within the Marketable Securities line item of the financial statements, as the investment has a readily determinable fair value. A Investment in Tevva Motors On September 22, 2021, the Company entered into a securities purchase agreement (the “Tevva Motors Subscription Agreement”) with Big Sky Opportunities Fund, LLC, who handled the offering for Tevva Motors. As of December 31, 2023 the investment was valued at \$2.8 million. During the second quarter of 2024, the Company identified indicators of impairment for the Tevva investment as a result of liquidity concerns. As a result, the Company recorded an impairment charge of approximately \$2.8 million and the investment in Tevva was valued at \$0A as of September 30, 2024. A Investment in Tesspay On March 23, 2022, the Company entered into a securities purchase agreement (the “Tesspay Securities Purchase Agreement”) with Tesspay. Under the Tesspay Securities Purchase Agreement, the Company agreed to purchase 1,000,000 shares of common stock of Tesspay for approximately \$0.2A million. The Company also invested an additional \$1.0A million for pre-IPO shares with Revere Master SPV LLC-Series VI, who handled the offering for Tesspay. As of December 31, 2023 the investment was valued at \$2.7 million. Management noted that Tesspay filed an amendment to its SEC Form S-1 Registration Statement on April 30, 2024 wherein Tesspay disclosed its intent to IPO at between \$5.0 and \$6.0 price per share. However, given the uncertainty around the probability of the timing of an IPO, the Company has written its investment down to its cost basis. Through the first nine months of 2024 the Company has recorded a decrease in the carrying value of the investment of \$1.4 million, with a carrying value of \$1.2 million as of September 30, 2024. A Investment in Anduril In April 20

[illegible]

Months Ended September 30, 2024) A A Dominiari Financiacal A Legacy Alkido Pharma A Consolidated A Revenue A \$10,553A A \$1,031A A \$11,584A Operating Costs A A A A A A General and administrative A A \$13,183A A A \$7,138A A A \$20,321A Research and development A A A A A A Loss from operations A A (2,630)A A (6,107)A A (8,737) A A A A A A A A A A Other (expenses) income A A A A A A A A Other income A A A A A A Interest income A A 545A A A 184A A A 729A Gain on marketable securities A A A A 767A A 767A Unrealized loss on note receivable A A A A (2,086)A A (2,086) Change in fair value of investments A A A A (6,445)A A (6,445) Total other (expenses) income A A 545A A (7,580)A A (7,035) Net loss A \$(2,085)A \$(13,687)A \$(15,772)A A A Three Months Ended September 30, 2024) A A Dominiari Financiacal A Legacy Alkido Pharma A Consolidated A Revenue A \$3,684A A \$359A A \$4,043A Operating Costs A A A A A A A A General and administrative A A 4,438A A A 2,801A A A 7,239A Research and development A A A A A A A A Loss from operations A A (754)A A (2,442)A A (3,196)A A A A A A A A A A Other (expenses) income A A A A A A A A A A Other income A A A A A A A A Interest income A A 204A A A 76A A A 280A Gain on marketable securities A A A A A A 89A A A 89A Unrealized loss on note receivable A A A A (429)A A (429) Change in fair value of investments A A A A (955)A A (955) Total other (expenses) income A A 204A A (1,219)A A (1,015) Net loss A \$(550)A \$(3,661)A \$(4,211) A Note 16. Income Taxes A The Company recorded no income tax expense for the three months ended September 30, 2024 and 2023 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company's annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. A As of September 30, 2024, and December 31, 2023, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized. A 19 A A Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations A You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-Q. All references to "we," "us," "our," "Dominiari" and the "Company" refer to Dominiari Holdings Inc., a Delaware corporation and its consolidated subsidiaries unless the context requires otherwise. A Cautionary Note Regarding Forward-Looking Statements A This Quarterly Report on Form 10-Q ("Quarterly Report") contains statements that the Company believes are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance, business strategies or expectations for the Company's business. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Quarterly Report, words such as "anticipate," "believe," "expect," "forecast," "continue," "estimate," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "strive," "target," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company's actual results or performance may be materially different from those expressed or implied by these forward-looking statements. A Overview A Dominiari Holdings Inc. ("Dominiari") is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management and insurance. In addition to capital investment, Dominiari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. Dominiari and its subsidiaries are collectively referred to herein as "Company," "we," "us," "our" or "DH." A Dominiari Financial Inc. ("Dominiari Financial"), a wholly-owned subsidiary of Dominiari Holdings Inc., executes the Company's growth strategy in the financial services industry. In addition to organic growth, Dominiari Financial seeks partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and insurance brokers. Our first transaction in furtherance of our growth in the financial services industry, the acquisition of 100% of a dually-registered broker dealer and investment advisor from Fieldpoint Private Bank & Trust ("Fieldpoint"), was consummated on March 27, 2023. The newly acquired dually registered broker-dealer and investment adviser was renamed Dominiari Securities LLC ("Dominiari Securities") and is a wholly-owned subsidiary of Dominiari Financial. A On May 21, 2024, Dominiari Financial and Heritage Strategies LLC ("HSHS") entered into a Limited Liability Company Operating Agreement (the "JV Agreement") of Dominiari Financial Heritage Strategies LLC ("DFHS"). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominiari Financial and HS are the co-managing members (the "Co-Managing Members"), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement. A Critical Accounting Estimates A We prepare our condensed consolidated financial statements in accordance with GAAP. The preparation of these condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Our actual results could differ significantly from these estimates under different assumptions and conditions. A 20 A A There have been no material changes to our critical accounting estimates as compared to the critical accounting estimates discussed in the Form 10-K. A Refer to Note 3 of the Annual Report for a discussion of our significant accounting policies. A Recently Issued Accounting Pronouncements A See Note 3 to the unaudited condensed consolidated financial statements for a discussion of recent accounting standards. A Results of Operations A Three months ended September 30, 2024, compared to the three months ended September 30, 2023 A During the three months ended September 30, 2024 and 2023, we recognized approximately \$4.0 million and \$1.0 million in revenue from operations, respectively, primarily driven by the commissions and underwriting revenue earned by Dominiari Securities and Dominiari Manager LLC ("Manager"). During the three months ended September 30, 2024 and 2023, we incurred a loss from operations of approximately \$3.2 million and \$3.1 million, respectively. A During the three months ended September 30, 2024 and 2023, other expenses was approximately \$1.0 million and \$0.4 million, respectively. A The activity described above for the three months ended September 30, 2024 and 2023, is primarily a result of the Company's entrance into the financial services industry, overall volatility in investment valuations due to macroeconomic uncertainty impacting marketable securities and the change in carrying value of long-term equity investments. Specifically: A i. Marketable securities - we recognized a realized gain of approximately \$0.4 million for the three months ended September 30, 2024. We also recognized an unrealized loss of approximately \$0.4 million and dividend income of \$78,000 for the three months ended September 30, 2024. The increase of approximately \$1.2 million in realized gains over the three months ended September 30, 2023, was driven by both market improvement and an increase in sale activity resulting in more realized gains. A ii. Notes receivable - we recognized \$0.4 million realized and unrealized loss over the three months ended September 30, 2024, versus no gain or loss during the three months ended September 30, 2023 on notes receivable. A iii. Long-term equity investments - changes over the three months ended September 30, 2024 and 2023 are a function of observable market transactions which resulted in a decrease of approximately \$1.0 million on the adjusted carrying value of the investments for the three months ended September 30, 2024, which is an increase of approximately \$0.5 million from the three months ended September 30, 2023. A Nine months ended September 30, 2024, compared to the nine months ended September 30, 2023 A During the nine months ended September 30, 2024, we recognized approximately \$11.6 million and \$1.0 million in revenue from operations, respectively, primarily driven by the commissions and underwriting revenue earned by Dominiari Securities and Manager. During the nine months ended September 30, 2024 and 2023, we incurred a loss from operations of approximately \$8.7 million and \$16.0 million, respectively. A During the nine months ended September 30, 2024 and 2023, other expenses was approximately \$7.0 million and \$17,000, respectively. A The activity described above for the nine months ended September 30, 2024 and 2023, is primarily a result of the Company's entrance into the financial services industry, overall volatility in investment valuations due to macroeconomic uncertainty impacting marketable securities and the change in carrying value of long-term equity investments. Specifically: A i. Marketable securities - we recognized a realized gain of approximately \$3.8 million for the nine months ended September 30, 2024. We recognized an unrealized loss of \$3.4 million and dividend income of \$0.4 million for the nine months ended September 30, 2024. The increase of approximately \$5.0 million in realized gains over the nine months ended September 2023 was driven by both market improvement and an increase in sale activity resulting in more realized gains. A ii. Notes receivable - the changes over the nine months ended September 30, 2024 and 2023 which resulted in an increase in net realized and unrealized loss of approximately \$1.9 million on the adjusted fair value of our notes receivable during the nine months ended September 30, 2024. This was largely driven by the adjustment to the fair value from the direct write off of the note receivable from Raefan Industries LLC. A iii. Long-term equity investments - the changes over the nine months ended September 30, 2024 and 2023 are a function of observable market transactions which resulted in a decrease of approximately \$6.4 million on the adjusted carrying value of the investments for the nine months ended September 30, 2024 and approximately \$6.0 million greater than that of the nine months ended September 30, 2023. A 21 A A Liquidity and Capital Resources A We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through: A A — managing current cash and cash equivalents on hand from our past debt and equity offerings; A A — seeking additional funds raised through the sale of additional securities in the future; and A A — seeking additional liquidity through credit facilities or other debt arrangements. A Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our longer-term business plan to support our transition into the financial services industry. Our working capital amounted to approximately \$22.3 million as of September 30, 2024. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly traded company or from continuing operations. A Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders. A Cash Flows from Operating Activities A For the nine months ended September 30, 2024 and 2023, net cash used in operations was approximately \$11.9 million and \$17.5 million, respectively. The cash used in operating activities for the nine months ended September 30, 2024, is primarily attributable to a net loss of approximately \$15.8 million, \$3.8 million realized gain on marketable securities and changes in operating assets and liabilities of \$5.7 million, of which \$6.5 million is clearing broker deposits, partially offset by approximately \$6.4 million of change in carrying value of long-term equity investment, \$3.4 million unrealized loss on marketable securities and \$2 million unrealized and realized loss on note receivable. The cash used in operating activities for the nine months ended September 30, 2023, is primarily attributable to a net loss of approximately \$16 million, approximately \$1.2 million of realized loss on marketable securities and changes in operating assets and liabilities of \$4.4 million, partially offset by \$1.4 million stock-based compensation expense and approximately \$0.9 million in unrealized gain on marketable securities. A Cash Flows from Investing Activities A For the nine months ended September 30, 2024 and 2023, net cash provided by (used in) investing activities was approximately \$12.5 million and \$(10.4) million, respectively. The cash provided by investing activities for the nine months ended September 30, 2024, primarily resulted from our sales of marketable securities of approximately \$14.8 million and the sale of a short-term investments of \$3.5 million, partially offset by purchase of marketable securities of \$4.0 million and funds to employee loans of \$2.4 million. The cash used in investing activities for the nine months ended September 30, 2023, primarily resulted from our purchase of marketable securities of approximately \$34.1 million and the acquisition of FPS of approximately \$1.1 million, partially offset by our sale of marketable securities approximately of \$24.6 million. The Company also collected approximately \$0.8 million in principal related to its short-term notes. A Cash Flows from Financing Activities A For the nine months ended September 30, 2024, there are no cash flows from financing activities. For the nine months ended September 30, 2023, cash used in financing activities was approximately \$0.9 million, which reflects the cost for purchase of treasury stock of approximately \$0.9 million. A 22 A A Item 3. Quantitative and Qualitative Disclosures About Market Risk. A Not Applicable. A Item 4. Controls and Procedures A Evaluation of Disclosure Controls and Procedures A We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. A We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, as of September 30, 2024, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective due to the material weakness in our internal controls. A A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonably possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. A Material Weaknesses in Internal Controls A The Company's management has concluded that our controls around the accounting for certain notes receivable accounted for at fair value and certain long-term investments accounted for at fair value or with the equity security measurement alternative was not effectively designed or maintained, and therefore initially were not accounted for correctly. As a result, our management performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with accounting principles generally accepted in the United States of America. Management understands that the accounting standards applicable to our financial statements are complex and will seek to enhance internal controls over financial reporting and engage experienced third-party professionals with whom management can consult with respect to accounting matters and remediate this material weakness. A Changes in Internal Control Over Financial Reporting A In response to the material weakness identified above, the Company has implemented changes to our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) as of the quarter ended September 30, 2024. The Company is actively increasing the quantity and quality of our internal accounting personnel and has engaged external valuation specialists and accounting advisors with financial reporting expertise, so as to provide the Company with resources sufficient to properly design and implement internal controls which will prevent and detect material misstatements to the financial statements in a timely manner. In addition, the Company has implemented a multi-layered process to establish and review the valuation of long-term investments with such outside specialists discussed above. A As a result of these changes, the Company believes the material weakness described above will be remediated. However, due to the nature of the material

weakness, it will not be considered remediated until the controls have been applied for a sufficient amount of time and management has performed testing of the controls to conclude that the controls are operating effectively. A Limitations on Effectiveness of Controls A Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. A 23 A A Part II - Other Information A Item 1. Legal Proceedings A Many aspects of the Company's business involve substantial risks of liability. In the ordinary course of business, the Company may be named as defendant or co-defendant in various legal actions, including arbitrations, class actions and other litigation, which could create substantial exposure and periodic expenses. The Company may also be involved, from time to time, in other reviews, investigations and proceedings (both formal and informal) by governmental and self-regulatory agencies regarding the Company's business, which may result in expenses, adverse judgments, settlements, fines, penalties, injunctions or other relief. In the past in the ordinary course of business, the Company has actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of its technology. A In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives' former employer. This notice was filed against the Company's subsidiary Dominiari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously on this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim. A Item 1A. Risk Factors A As a smaller reporting company as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. Our current risk factors are set forth in our Annual Report on Form 10-K, which was filed with the SEC on April 1, 2024. Any of our previously disclosed risk factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC. A Item 2. Unregistered Sales of Equity Securities and Use of Proceeds A None. A Item 3. Defaults Upon Senior Securities. A None. A Item 4. Mine Safety Disclosures. A Not Applicable. A Item 5. Other Information. A None. A 24 A A Item 6. Exhibits A 31.1* A Certification of Principal Executive Officer of Dominiari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* A Certification of Principal Financial Officer of Dominiari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.1** A Certification of Principal Executive Officer of Dominiari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** A Certification of Principal Financial Officer of Dominiari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS A Inline XBRL Instance Document 101.SCH A Inline XBRL Taxonomy Extension Schema Document. 101.CAL A Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF A Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB A Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE A Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 A Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). A * Filed herewith. A ** Furnished herewith. A 25 A A Signatures A Pursuant to the requirements of the Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. A A DOMINARI HOLDINGS INC. A A Date: November 8, 2024 By: /s/ Anthony Hayes A Anthony Hayes A A Chief Executive Officer A A (Principal Executive Officer, Principal Financial Officer) A A 26 A A 0.0001 0.0001 false -12.31 Q3 0000012239 0000012239 2024-01-01 2024-09-30 0000012239 2024-11-07 0000012239 2024-09-30 0000012239 2023-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2024-09-30 0000012239 us-gaap:SeriesDPreferredStockMember 2023-12-31 0000012239 domh:SeriesD1PreferredStockMember 2024-09-30 0000012239 domh:SeriesD1PreferredStockMember 2023-12-31 0000012239 2024-07-01 2024-09-30 0000012239 2023-07-01 2023-09-30 0000012239 2023-01-01 2023-09-30 0000012239 us-gaap:PreferredStockMember 2024-06-30 0000012239 us-gaap:CommonStockMember 2024-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-06-30 0000012239 us-gaap:RetainedEarningsMember 2024-06-30 0000012239 2024-06-30 0000012239 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000012239 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000012239 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000012239 us-gaap:PreferredStockMember 2024-09-30 0000012239 us-gaap:CommonStockMember 2024-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-09-30 0000012239 us-gaap:RetainedEarningsMember 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000012239 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000012239 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000012239 us-gaap:PreferredStockMember 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-12-31 0000012239 us-gaap:RetainedEarningsMember 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012239 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000012239 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0000012239 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000012239 us-gaap:PreferredStockMember 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-12-31 0000012239 us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0000012239 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0000012239 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000012239 domh:FSPurchaseAgreementMember 2022-09-30 0000012239 2022-10-04 2022-10-04 0000012239 domh:FSPurchaseAgreementMember 2022-10-04 0000012239 domh:FSPurchaseAgreementMember 2024-09-30 0000012239 domh:DominiariFinancialHeritageStrategiesLLCMember 2024-09-30 0000012239 domh:InvestmentInSpaceXMember 2024-04-01 2024-04-30 0000012239 domh:InvestmentInXAiMember 2024-05-02 2024-05-02 0000012239 domh:InvestmentInCerebrasMember 2024-06-17 2024-06-17 0000012239 domh:InvestmentInGroqMember 2024-07-25 2024-07-25 0000012239 domh:InvestmentInUnusualMachinesMember 2024-02-14 0000012239 domh:InvestmentInTevaMotorsMember 2023-01-01 2023-12-31 0000012239 domh:InvestmentInTevaMotorsMember 2024-01-01 2024-09-30 0000012239 domh:InvestmentInTesspayMember 2022-03-23 2022-03-23 0000012239 domh:InvestmentInTesspayMember 2022-03-23 0000012239 domh:InvestmentInTesspayMember 2023-01-01 2023-12-31 0000012239 srt:MinimumMember 2024-04-30 0000012239 srt:MaximumMember 2024-04-30 0000012239 domh:InvestmentInTesspayMember 2024-01-01 2024-09-30 0000012239 domh:InvestmentInAndurilMember 2023-01-01 2023-12-31 0000012239 domh:InvestmentInAndurilMember 2024-04-01 2024-06-30 0000012239 domh:InvestmentInThrasioMember 2023-01-01 2023-12-31 0000012239 domh:InvestmentInThrasioMember 2024-01-01 2024-09-30 0000012239 domh:InvestmentInEpicGamesMember 2022-03-22 2022-03-22 0000012239 domh:InvestmentInEpicGamesMember 2022-04-30 0000012239 domh:InvestmentInEpicGamesMember 2023-01-01 2023-12-31 0000012239 domh:InvestmentInEpicGamesMember 2024-01-01 2024-03-31 0000012239 domh:InvestmentInEpicGamesMember 2024-01-01 2024-09-30 0000012239 domh:InvestmentInAdvEnMember 2021-12-26 2021-12-26 0000012239 domh:InvestmentIn

or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Â Date: November 8, 2024 Â Â Â Â /s/ Anthony Hayes Â Anthony Hayes Â Chief Executive Officer Â (Principal Executive Officer) Â EX-31.2 3 ea021984401ex31-2 dominari.htm CERTIFICATION Exhibit 31.2 Â Â CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER PURSUANT TO RULE 13A-14(a)/(15D)-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â 1, Anthony Hayes, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report; Â 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and Â 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): Â Â a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and Â Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Â Date: November 8, 2024 Â Â Â Â /s/ Anthony Hayes Â Anthony Hayes Â Chief Executive Officer Â (Principal Financial and Accounting Officer) Â EX-32.1 4 ea021984401ex32-1 dominari.htm CERTIFICATION Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Hayes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: Â 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report. Â Date: November 8, 2024 Â Â Â /s/ Anthony Hayes Â Anthony Hayes Â Chief Executive Officer Â (Principal Executive Officer) Â EX-32.2 5 ea021984401ex32-2 dominari.htm CERTIFICATION Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Hayes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: Â 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report. Â Date: November 8, 2024 Â Â Â /s/ Anthony Hayes Â Anthony Hayes Â Chief Executive Officer Â (Principal Financial and Accounting Officer) Â Â EX-101.SCH 6 domh-20240930.xsd XBRL SCHEMA FILE 995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - Organization and Description of Business and Recent Developments link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Liquidity and Capital Resources link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Marketable Securities link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Long-Term Equity Investments link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Notes Receivable link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995318 - Disclosure - Regulatory link:presentationLink link:definitionLink link:calculationLink 995319 - Disclosure - Related Party Transaction link:presentationLink link:definitionLink link:calculationLink 995320 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 995321 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Long-Term Equity Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Notes Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Revenue (Tables) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Organization and Description of Business and Recent Developments (Details) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Marketable Securities (Details) - Schedule of Gains and (Losses) on Marketable Securities link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Long-Term Equity Investments (Details) link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Long-Term Equity Investments (Details) - Schedule of Long-Term Investments link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Notes Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Leases (Details) - Schedule of Quantitative Information about the Company’s Operating Leases link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Leases (Details) - Schedule of lease Expense to Current Period Operations link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Leases (Details) - Schedule of Supplemental Cash Flow Information Related to Leases link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity link:presentationLink link:definitionLink link:calculationLink 996030 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Plan link:presentationLink link:definitionLink link:calculationLink 996031 - Disclosure - Revenue (Details) - Schedule of Total Revenue Disaggregated by Revenue Type link:presentationLink link:definitionLink link:calculationLink 996032 - Disclosure - Regulatory (Details) link:presentationLink link:definitionLink link:calculationLink 996033 - Disclosure - Related Party Transaction (Details) link:presentationLink link:definitionLink link:calculationLink 996034 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 996035 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss link:presentationLink link:definitionLink link:calculationLink 996036 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 domh-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 domh-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 domh-20240930_lab.xml XBRL LABEL FILE Total current assets Total assets Total current liabilities Total liabilities Class of Stock [Axis] Total stockholders’ equity Balance Balance Total liabilities and stockholders’ equity Total operating expenses Loss from operations Total other expenses Total other (expenses) income Net loss Net loss balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash provided by (used in) investing activities Net cash used in financing activities Net increase (decrease) in cash and cash equivalents and restricted cash Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Organization and Description of Business and Recent Developments [Abstract] Liquidity and Capital Resources [Abstract] Summary of Significant Accounting Policies [Abstract] Marketable Securities [Abstract] Marketable securities: Schedule of Gains and (Losses) on Marketable Securities [Abstract] Total Gain (loss) on marketable securities, net Long-Term Equity Investments [Abstract] Investment Type [Axis] Notes Receivable [Abstract] Debt Instrument [Axis] Fair Value of Financial Assets and Liabilities [Abstract] Fair Value Hierarchy and NAV [Axis] Notes receivable at fair value, current portion, Balance beginning Notes receivable at fair value, current portion at Balance ending Notes receivable, at fair value - current portion Notes receivable at fair value, current portion Notes receivable at fair value, non-current portion Balance beginning Notes receivable at fair value, non-current portion Balance ending Notes receivable, at fair value - non-current portion Notes receivable at fair value, non-current portion Short-term investment at December 31, 2022 Short-term investment at September 30, 2023 Consolidated Entities [Axis] Leases [Abstract] Schedule of Lease Assets and Liabilities [Abstract] Total Operating lease liabilities Schedule of Quantitative Information about the Company’s Operating Leases [Abstract] Schedule Of Lease Expense [Abstract] Net rent expense Lease expenses Schedule of Supplemental Cash Flow Information Related to Leases [Abstract] Schedule of Future Minimum Payments [Abstract] Total Net Loss per Share [Abstract] Antidilutive Securities [Axis] Stockholders’ Equity and Convertible Preferred Stock [Abstract] Number of shares, ending balance Number of shares, beginning balance Weighted Average per share, ending balance Weighted Average per share, beginning balance Class of Warrant or Right [Axis] Schedule of Restricted Stock Awards Activity [Abstract] Schedule of Stock Option Activity [Abstract] Outstanding ending balance, Number of Shares Outstanding ending balance, Weighted Average Exercise Price Outstanding ending balance, Intrinsic Value Revenue [Abstract] Statement of Income Location, Balance [Axis] Commitments and Contingencies [Abstract] Regulatory [Abstract] Related Party Transaction [Abstract] Segment Reporting [Abstract] Subsegments [Axis] Income Taxes [Abstract] ASSETS Assets: Current assets Cash and cash equivalents Marketable securities Total marketable securities Deposits with clearing broker Prepaid expenses and other assets Property and equipment, net Long Term Equity Investments Long-term investments, Carrying Value Right-of-use assets Operating lease right-of-use-assets Security deposit LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable and accrued expenses Accrued salaries and benefits Accrued commissions Lease liability - current Operating Current Other current liability Lease liability, less current portion Operating Long-term Stockholders’ equity Preferred stock value Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Liquidation preference (in Dollars per share) Liquidation preference per share (in Dollars per share) Common stock, \$0.0001 par value, 100,000,000 shares authorized; 6,336,286 and 5,995,065 shares issued as of September 30, 2024 and December 31, 2023, respectively; 6,276,138 and 5,934,917 shares outstanding as of September 30, 2024 and December 31, 2023 Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares issued (in Shares) Common stock, shares outstanding Common stock outstanding (in Shares) Additional paid-in capital Treasury stock, at cost Treasury stock shares (in Shares) Accumulated deficit Revenues Revenue Operating costs and expenses Operating Costs General and administrative Research and development Other income (expenses) Other (expenses) income Interest income Realized and unrealized loss on note receivable, net Realized and unrealized loss on note receivable Net loss per share, basic and diluted Net loss per share, basic (in Dollars per share) Net loss per share, diluted (in Dollars per share) Weighted average number of shares outstanding, basic and diluted Weighted average number of shares outstanding, basic (in Shares) Weighted average number of shares outstanding, diluted (in Shares) Stock-based compensation Stock-based compensation (in Shares) Cancellation of common stock Cancellation of common stock (in Shares) Purchase of treasury stock (in Shares) Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Amortization of right-of-use assets Depreciation Change in fair value short-term investments Change in fair value of investment Change in carrying value of long-term investment Stock-based compensation Changes in operating assets and liabilities: Accounts payable and accrued expenses Accrued salaries and benefits Accrued commissions Lease liabilities Other current liabilities Cash flows from investing activities Sale of marketable securities Collection of principal on note receivable Collection of principal outstanding Redemption of long-term investments Collection of loans to employees Cash flows from financing activities Treasury stock, as of cost, 60,148 shares as of September 30, 2024 and December 31, 2023 Change in carrying value of investments Change in fair value of investments Purchase of treasury stock Retirement of treasury stock Retirement of treasury stock (in Shares) Realized (gain) loss on marketable securities Unrealized (gain) loss on marketable securities Unrealized gain (loss) Gain on marketable securities Prepaid expenses and other assets Prepaid acquisition cost Clearing broker deposits Notes receivable, at fair value € net interest accrued Purchase of marketable securities Purchase of fixed assets Acquisition of FPS, net of cash acquired and receivable owed from FPS Loans to employees Purchase of short-term and long-term investments Purchase of treasury stock Series D Preferred Stock Series D Preferred Stock [Member] Series D-1 Preferred Stock Preferred Stock Common Stock Common Stock [Member] Additional Paid-in Capital Treasury Stock Accumulated Deficit Organization and Description of Business and Recent Developments Liquidity and Capital Resources Summary of Significant Accounting Policies Marketable Securities Schedule of Gains and (Losses) on Marketable Securities Realized gain (loss) Dividend income Long-Term Equity Investments Schedule of Long-Term Investments Long-term investments, Cost Basis Notes Receivable Schedule of Notes Receivable Notes receivable, at fair value Maturity Date Stated Interest Rate Principal Amount Purchase price amount Interest Receivable Fair Value Notes receivable, at fair value Fair Value of Financial Assets and Liabilities Schedule of Assets and Liabilities that are Measured at Fair Value Assets Equities Marketable securities: Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis Realized and unrealized gain (loss) on note receivable, net Change in interest receivable Unrealized loss on note receivable Unrealized loss on note receivable

Accrued interest receivable
Accrued interest receivable Leases Schedule of Lease Assets and Liabilities
Liabilities: Current Long-term Schedule of Quantitative Information about the Company's Operating Leases Weighted-average remaining lease term operating leases (in years) Weighted-average discount rate operating leases Schedule of lease Expense to Current Period Operations Operating lease cost Short-term lease rent expense Schedule of Supplemental Cash Flow Information Related to Leases Operating cash flows - operating leases Schedule of Future Minimum Payments Remaining Period Ended December 31, 2024 Year Ended December 31, 2025 Year Ended December 31, 2026 Year Ended December 31, 2027 Year Ended December 31, 2028 Thereafter Net Loss per Share Schedule of Computation of Diluted Loss Per Share Total diluted loss per share Stockholders' Equity and Convertible Preferred Stock Schedule of Warrant Activity Outstanding ending balance, Total Intrinsic Value Outstanding ending balance, Weighted Average Remaining Contractual Life Granted, Warrants Number of Restricted Stock Awards, Granted Granted, Weighted Average Exercise Price Weighted Average Grant Day Fair Value, Granted Granted, Total Intrinsic Value Granted, Weighted Average Remaining Contractual Life Schedule of Restricted Stock Awards Activity Weighted Average Grant Day Fair Value, Vested Weighted Average Grant Day Fair Value, Forfeited Schedule of Stock Option Plan Outstanding ending balance, Weighted Average Remaining Contractual Life (in years) Employee options expired, Weighted Average Exercise Price Employee options expired, Intrinsic Value Employee options expired, Weighted Average Remaining Contractual Life (in years) Number of Shares, Options vested and exercisable Weighted Average Exercise Price, Options vested and exercisable Total Intrinsic Value, Options vested and exercisable Weighted Average Remaining Contractual Life (in years), Options vested and exercisable Revenue Schedule of Total Revenue Disaggregated by Revenue Type Total revenue disaggregated Commitments and Contingencies Regulatory Related Party Transaction Segment Reporting Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss Other income Income Taxes Unrealized gain (loss) on notes receivable Unrealized loss on investment Note receivable, Convergent Therapeutics, non-current portion Less present value discount Number of Restricted Stock Awards, Vested Number of Restricted Stock Awards, Forfeited Employee options expired, Number of Shares Investment In Kerna Health Inc Investment in Kaya Now Investment in Tevva Motors Investment in Unusual Machines Investment in Qxpress Investment in Masterclass Investment in Kraken Investment in Epic Games Investment in Tesspay Investment in SpaceX Investment in Databricks Investment in Discord Investment in Thrasio Investment in Automation Anywhere Investment in XAI Investment in Cerebras Investment in Groq Investment in AdvEn Investment in Anduril Investment in Convergent convertible note - current Convergent convertible note Investment Raefan Industries LLC American Innovative Robotics Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Convergent Therapeutics Convertible preferred stock Warrants to purchase common stock Warrant Restricted stock awards Restricted Stock Options to purchase common stock Underwriting Commissions Advisory fees Other Dominari Financial Legacy Alkido Pharma Consolidated Ownership [Axis] Investment, Name [Axis] Statistical Measurement [Axis] Membership interests Seller paid (in Dollars) Additional seller paid (in Dollars) Ownership interests Interest rate Money market funds Unrealized losses on long term investments Investment Marketable securities Redeemed shares (in Shares) Redeemed shares, value Agreed to purchase shares (in Shares) Aggregate shares (in Shares) Public offering price (in Dollars per share) Investment value Impairment charge Common stock value Invested an additional amount Market price (in Dollars per share) Fund raising Impairment charge Senior secured convertible Principal amount Common shares percentage Principal repayment Interest income Unrealized loss Unrealized losses Unrealized loss Realized losses Lease term Lease rent expenses Increase rent amount Rent payment Vested and the remaining shares forfeited (in Shares) Granted shares (in Shares) Total fair value Share based compensation expense Unrecognized stock-based compensation expense Estimated future stock-based compensation expense Net capital requirement Excess amount Revere's outstanding equity percentage Incurred fees Reportable segments Income tax expense Basis of Presentation and Principles of Consolidation Joint Ventures Use of Estimates Deposits with clearing broker Leases Revenue Long-term equity investments Recently adopted accounting standards Effect of new accounting pronouncements to be adopted in future periods FPS Purchase Agreement Dominari Financial Heritage Strategies LLC Minimum Maximum Convergent Therapeutics, Inc. Raefan Industries LLC Investment Raefan Industries LLC American Innovative Robotics, LLC Restricted Stock Awards Class of Stock [Domain] Statement [Table] Statement [Line Items] Equity Component [Domain] Investments [Domain] Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Investments [Line Items] Debt Instrument, Name [Domain] Accounts and Financing Receivables [Table] Schedule of Notes Receivable [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value [Table] Schedule of Assets and Liabilities are Measured at Fair Value [Line items] Consolidated Entities [Domain] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Computation of Diluted Loss Per Share [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Award Type [Domain] Stockholders' Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity [Table] Schedule of Restricted Stock Awards Activity [Line Items] Statement of Income Location, Balance [Domain] Disaggregation of Revenue [Table] Schedule of Total Revenue Disaggregated by Revenue Type [Line Items] Subsegments [Domain] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items] Investment, Name [Domain] Ownership [Domain] Organization and Description of Business and Recent Developments (Details) [Table] Organization and Description of Business and Recent Developments [Line Items] Summary of Significant Accounting Policies (Details) [Table] Summary of Significant Accounting Policies [Line Items] Statistical Measurement [Domain] Long-Term Equity Investments (Details) [Table] Long-Term Equity Investments [Line Items] Notes Receivable [Table] Notes Receivable [Line Items] Leases (Details) [Table] Leases [Line Items] Stockholders' Equity and Convertible Preferred Stock (Details) [Table] Stockholders' Equity and Convertible Preferred Stock [Line Items] Regulatory (Details) [Table] Regulatory [Line Items] Represents accrued interest receivable. Represent the amount of accrued interest receivable non-current. Acquisition of FPS, net of cash acquired and receivable owed from FPS. Change in fair value of long-term investment. Change in fair value of short-term investment. The percentage value of common shares. Disclosure of accounting policy for deposits with clearing broker. Share-Based Compensation Arrangement by ShareEmployeeOptionsExpiredWeightedAverageRemainingContractualLife. The amount of fund raising. Increase decrease in accrued commissions. Increase Decrease In Prepaid Acquisition Cost. InvestmentsCompanyFeePaidIndirectly. Disclosure of accounting policy for joint ventures. The amount of net capital. Note receivable non-current portion after collection of principal. Represent the amount of cash inflow of collection of loans to employees. Price per share of public offering. Disclosure of accounting policy for recently adopted accounting standards. Schedule of Operating Lease Cost Weighted Average [Table Text Block]. The percentage value of senior secured convertible. The shares of cancellation of common stock. The amount of cancellation of common stock. Amount of (loss) on sale of unrealized financing receivable. Assets [Abstract] Investment In Kaya Now Member Earnings Per Share, Diluted Retained Earnings [Member] Investment In Adv En Member Weighted Average Number of Shares Outstanding, Basic Schedule Of Notes Receivable Abstract Operating Costs and Expenses [Abstract] Deposit With Clearing Broker Policy Text Block Investment Income, Interest Realized Investment Gains (Losses) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Additional Paid in Capital Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule Of Segment Profitability That Are Most Relied Upon By The Codm Are Gross Revenue And Net Loss Abstract Net Cash Provided by (Used in) Operating Activities [Abstract] Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Equity, Attributable to Parent [Abstract] Preferred Stock, Shares Issued Earnings Per Share, Basic [Abstract] Investment, Policy [Policy Text Block] Schedule Of Financial Assets That Are Measured At Fair Value On A Recurring Basis Abstract Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Payments for Repurchase of Other Equity Minimum [Member] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock, Shares, Outstanding Retained Earnings (Accumulated Deficit) Investment In Discord Member Depreciation Lessee, Operating Lease, Liability, to be Paid, Year Three Net Cash Provided by (Used in) Investing Activities Investment In Databricks Member Payments to Acquire Property, Plant, and Equipment Schedule Of Total Revenue Disaggregated By Revenue Type Abstract Marketable Securities American Innovative Robotics LLC Member Preferred Stock, Shares Authorized Investment In Space X Member Treasury Stock, Common [Member] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Preferred Stock, Shares Outstanding Fair Value, Inputs, Level 2 [Member] Prepaid Expense and Other Assets, Current Property, Plant and Equipment, Net Operating Leases, Rent Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Maximum [Member] Long-Term Investments Common Stock, Shares Authorized Notes Receivable At Fair Value Abstract Investment Owned, Cost Operating Lease, Liability, Noncurrent Revenue from Contract with Customer, Including Assessed Tax Operating Lease, Weighted Average Discount Rate, Percent Debt Instrument, Periodic Payment, Principal Schedule Of Long Term Investments Abstract Preferred Stock [Member] Lease, Cost Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Investment In Kerna Health Inc Member Raefan Industries LLC Investment Member Accrued Rent Stock Redeemed or Called During Period, Value Net Cash Provided by (Used in) Investing Activities [Abstract] Investment In Kraken Member Investment Company, Shareholder Service Fee Expense Investments Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect FPS Purchase Agreement Member Significant Accounting Policies [Text Block] Restricted Stock Awards Member Unrealized Gain (Loss) on Derivatives Increase Decrease In Accrued Commissions Gain (Loss) on Investments Lessee, Operating Lease, Liability, to be Paid, Year Two American Innovative Robotics Member Common Shares Percentage Fair Value, Inputs, Level 3 [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Convergent Therapeutics Member Related Party Transactions Disclosure [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Investment In Thrasio Member Net Cash Provided by (Used in) Operating Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Recently Adopted Accounting Standard Policy Text Block Operating Lease, Lease Income [Table Text Block] Treasury Stock, Retired, Par Value Method, Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Notes Receivable, Fair Value Disclosure Money Market Funds, at Carrying Value Marketable Securities Abstract Other Asset Impairment Charges Operating Lease, Right-of-Use Asset, Periodic Reduction Fair Value, Inputs, Level 1 [Member] Legacy Alkido Pharma Member Equity, Attributable to Parent Revenue from Contract with Customer [Text Block] Advisory Fees Member Dominari Financial Heritage Strategies LLC Member Underwriting Member Fair Value Adjustment of Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unlabeled Abstract Segment Reporting Disclosure [Text Block] Marketable Security, Unrealized Gain (Loss) Net Capital Amount Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Lease, Cost [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Equity Securities, FV-NI, Current Notes Receivable At Fair Value Abstract Preferred Stock, Liquidation Preference Per Share Payments to Acquire Marketable Securities Investment In Masterclass Member Schedule Of Operating Lease Cost Weighted Average Table Text Block Lessee, Operating Lease, Liability, to be Paid Share-Based Payment Arrangement, Option, Activity [Table Text Block] Marketable Securities, Current Security Deposit Schedule of Long-Term Debt Instruments [Table Text Block] Payments to Acquire Long-Term Investments Stockholders' Equity, Other Shares Operating Expenses Convergent Convertible Note Member Employee Options Expired Weighted Average Remaining Contractual Life Related Party Transaction, Rate Statement of Financial Position [Abstract] Investment In Qxpress Member Cash and Cash Equivalents, at Carrying Value Lessee, Operating Lease, Liability, to be Paid, Year One Marketable Security, Gain (Loss) Dominari Financial Member Stock Issued During Period Value Cancellation Of Common Stock Increase (Decrease) in Deposit Assets Other Nonoperating Income Liabilities [Abstract] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Share-Based Payment Arrangement, Noncash Expense Number of Reportable Segments Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Fund Raising Use of Estimates, Policy [Policy Text Block] Common Stock, Value, Issued Accrued Interest Receivable Current Interest Receivable Lessee, Leases [Policy Text Block] Operating Lease, Payments Increase (Decrease) in Prepaid Expense and Other Assets Shareholders' Equity and Share-Based Payments [Text Block] Investment Company, Fee Paid Indirectly Gain (Loss) on Sale of Financing Receivable Accrued Interest Receivable Noncurrent Investment In Tevva Motors Member Investment In Anduril Member Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Basis of Accounting, Policy [Policy Text Block] Increase (Decrease) in Operating Lease Liability Common Stock, Value, Outstanding Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Debt Securities, Unrealized Gain (Loss) Series D Preferred Stock [Member] Increase (Decrease) in Interest and Dividends Receivable Income Tax Expense (Benefit) Convergent Therapeutics Inc Member Income Statement [Abstract] Payments to Acquire Loans Receivable Lessee, Operating Leases [Text Block] Convertible Preferred Stock [Member] New Accounting Pronouncements, Policy [Policy Text Block] Increase Decrease In Prepaid Acquisition Cost Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Earnings Per Share, Basic Banking Regulation, Total Risk-Based Capital, Excess, Actual Treasury Stock, Value Investment In Groq Member Joint Ventures Policy Text Block Assets Liabilities Payments to Acquire Other Investments Regulatory Capital Requirements under Banking Regulations [Text Block] Research and Development Expense Proceeds from Sale of Other Investments Change In Fair Value Of Shortterm Investment Schedule Of Computation Of Diluted Loss Per Share Abstract Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Stock Issued During Period Shares Cancellation Of Common Stockin Shares Financing Receivable, after Allowance for Credit Loss, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Investments Company Fee Paid Indirectly Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Debt Securities, Realized Gain (Loss) Investment In Tesspay Member Note Receivable Noncurrent Portion After Collection Of Principal Share-Based Payment Arrangement, Expense, after Tax Net Cash Provided by (Used in) Financing Activities Accrued Employee Benefits, Current Debt Instrument, Issued, Principal Investment Company, Market Value, Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Subsidiary, Ownership Percentage, Parent Other Additional Capital Change In Fair Value Of Longterm Investment Other Member Unrealized Loss On Note Receivable Short-Term Lease, Cost Warrant [Member] Increase (Decrease) in Employee Related Liabilities Assets, Fair Value Disclosure [Abstract] Unrealized Gain (Loss) on Investments Series D1 Preferred Stock Member Lessee, Operating Lease, Liability, to be Paid, Year Four Investment In Automation Anywhere Member Restricted Stock [Member] Operating Income (Loss) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Lessee, Operating Lease, Liability, to be Paid, after Year Five Operating Lease, Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants Weighted Average Remaining Contractual Terms Current Abstract Investment Owned, Balance, Principal Amount Schedule Of Assets And Liabilities That Are Measured At Fair Value Abstract Debt Instrument, Interest Rate, Stated Percentage Other Income and Expenses [Abstract] Investment In Cerebras Member Revenue from Contract with Customer [Policy Text Block] Common Stock [Member] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Statement of Cash Flows [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Proceeds from Collection of Loans To Employees Investment In Epic Games Member Operating Lease, Liability, Current Income Tax Disclosure [Text Block] Increase (Decrease) in Prepaid Rent Acquisition Of FPS Net Of Cash Acquired And Receivable Owed From FPS Equity Method Investment, Ownership Percentage Investment Company, Committed Capital Schedule of Antidilutive

Securities Excluded from Computation of Earnings Per Share [Table Text Block] Liabilities, Current [Abstract] Treasury Stock, Value, Acquired, Cost Method Employee Stock [Member] Commissions Member Stock Repurchased During Period, Shares Increase (Decrease) in Other Current Liabilities Financing Receivable, after Allowance for Credit Loss, Noncurrent Operating Lease, Weighted Average Remaining Lease Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Lessee, Operating Lease, Term of Contract Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Senior Secured Convertible Percentage Proceeds from Collection of Notes Receivable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Increase (Decrease) in Accounts Payable and Accrued Liabilities Earnings Per Share [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Revenues Increase (Decrease) in Notes Receivables Investment In Unusual Machines Member Accounts Payable and Accrued Liabilities, Current Treasury Stock, Common, Shares Operating Lease, Cost Stock Repurchased and Retired During Period, Shares General and Administrative Expense Marketable Securities [Table Text Block] Common Stock, Par or Stated Value Per Share Related Party Transaction, Amounts of Transaction Common Stock, Shares, Issued Proceeds from Sale and Maturity of Marketable Securities Other Liabilities, Current Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Weighted Average Number of Shares Outstanding, Diluted Stock Redeemed or Called During Period, Shares Marketable Security, Realized Gain (Loss) Fair Value Disclosures [Text Block] Short-Term Investments Disaggregation of Revenue [Table Text Block] Investment In XAIMember Long-Term Debt [Text Block] Raefan Industries LLCMember Public Offering Price Consolidated Member Interest Income, Other Assets, Current [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Liabilities, Current Liabilities and Equity [Abstract] Shares, Outstanding Commitments and Contingencies Disclosure [Text Block] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accrued Sales Commission, Current Liquidation Basis of Accounting [Text Block] Preferred Stock, Value, Issued Liabilities and Equity Debt Instrument, Maturity Date Nonoperating Income (Expense) Investment Income, Dividend Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Grants Deposits Assets, Current Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Preferred Stock, Par or Stated Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Operating Lease, Right-of-Use Asset Long-Term Debt, Unclassified [Abstract] Assets, Current Schedule Of Warrant Activity Abstract EX-101.PRE 10 domh-20240930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 07, 2024 Document Information [Line Items]

Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

 Amendment Flag false

Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3

 Entity Information [Line Items]

Entity Registrant Name	DOMINARI HOLDINGS INC.
Entity Central Index Key	0000012239
Entity File Number	001-41845
Entity Tax Identification Number	52-0849320

 Entity Incorporation, State or Country Code DE

Current Fiscal Year End Date	-12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false

 Entity Filer Category Non-accelerated Filer

Entity Small Business	true																																																																																																																																																					
Entity Emerging Growth Company	false																																																																																																																																																					
Entity Contact Personnel [Line Items]	<table border="1"><tr><td>Entity Address, Address Line One</td><td>725 5th Avenue</td></tr><tr><td>Entity Address, Address Line Two</td><td>22nd Floor</td></tr><tr><td>Entity Address, City or Town</td><td>New York</td></tr><tr><td>Entity Address, State or Province</td><td>NY</td></tr><tr><td>Entity Address, Postal Zip Code</td><td>10022</td></tr><tr><td>Entity Phone Fax Numbers [Line Items]</td><td><table border="1"><tr><td>City Area Code (212)</td><td>Local Phone Number</td></tr><tr><td>393-4540</td><td></td></tr></table></td></tr><tr><td>Entity Listings [Line Items]</td><td><table border="1"><tr><td>Title of 12(b) Security Common Stock</td><td>(\$0.0001 par value per share)</td></tr><tr><td>Trading Symbol</td><td>DOMH</td></tr></table></td></tr><tr><td>Security Exchange Name</td><td>NASDAQ</td></tr></table> Entity Common Stock, Shares Outstanding <table border="1"><tr><td>6,276,138</td></tr></table> X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItem Type Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets <table border="1"><tr><td>À</td><td>Cash and cash equivalents</td><td>\$ 3,403</td><td>\$ 2,833</td></tr><tr><td>À</td><td>Marketable securities</td><td>3,771</td><td>13,547</td></tr><tr><td>À</td><td>Deposits with clearing broker</td><td>14,181</td><td>7,687</td></tr><tr><td>À</td><td>Prepaid expenses and other assets</td><td>3,121</td><td>898</td></tr><tr><td>À</td><td>Notes receivable, at fair value - current portion</td><td>285</td><td>3,177</td></tr><tr><td>À</td><td>Total current assets</td><td>24,761</td><td>28,142</td></tr><tr><td>À</td><td>Property and equipment, net</td><td>265</td><td>344</td></tr><tr><td>À</td><td>Notes receivable, at fair value - non-current portion</td><td>1,128</td><td>1,129</td></tr><tr><td>À</td><td>Long Term Equity Investments</td><td>13,771</td><td>24,150</td></tr><tr><td>À</td><td>Right-of-use assets</td><td>3,048</td><td>3,335</td></tr><tr><td>À</td><td>Security deposit</td><td>458</td><td>458</td></tr><tr><td>À</td><td>Total assets</td><td>43,431</td><td>57,558</td></tr><tr><td>À</td><td>Current liabilities</td><td>À</td><td>Accounts payable and accrued expenses</td><td>1,293</td><td>1,036</td></tr><tr><td>À</td><td>Accrued salaries and benefits</td><td>13</td><td>51</td></tr><tr><td>À</td><td>Accrued commissions</td><td>372</td><td>77</td></tr><tr><td>À</td><td>Lease liability - current</td><td>402</td><td>421</td></tr><tr><td>À</td><td>Other current liability</td><td>336</td><td>22</td></tr><tr><td>À</td><td>Total current liabilities</td><td>2,416</td><td>1,607</td></tr><tr><td>À</td><td>Lease liability, less current portion</td><td>2,748</td><td>3,028</td></tr><tr><td>À</td><td>Total liabilities</td><td>5,164</td><td>4,635</td></tr><tr><td>À</td><td>Stockholders' equity</td><td>À</td><td>Preferred stock value</td><td>Common stock, \$0.0001 par value, 100,000,000 shares authorized;</td><td>6,336,286</td><td>and 5,995,065 shares issued as of September 30, 2024 and December 31, 2023, respectively;</td><td>6,276,138</td><td>and 5,934,917</td></tr><tr><td>À</td><td>Shares outstanding as of September 30, 2024 and December 31, 2023</td><td>Additional paid-in capital</td><td>263,303</td><td>262,187</td></tr><tr><td>À</td><td>Treasury stock, as of cost, 60,148 shares as of September 30, 2024 and December 31, 2023</td><td>(501)</td><td>(501)</td></tr><tr><td>À</td><td>Accumulated deficit</td><td>(224,535)</td><td>(208,763)</td></tr><tr><td>À</td><td>Total stockholders' equity</td><td>38,267</td><td>52,923</td></tr><tr><td>À</td><td>Total liabilities and stockholders' equity</td><td>43,431</td><td>57,558</td></tr><tr><td>À</td><td>Series D Preferred Stock</td><td>À</td><td>Stockholders' equity</td><td>À</td><td>Preferred stock value</td><td>Series D-1 Preferred Stock</td><td>À</td><td>Stockholders' equity</td><td>À</td><td>Preferred stock value</td><td>X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). +</td></tr></table>	Entity Address, Address Line One	725 5th Avenue	Entity Address, Address Line Two	22nd Floor	Entity Address, City or Town	New York	Entity Address, State or Province	NY	Entity Address, Postal Zip Code	10022	Entity Phone Fax Numbers [Line Items]	<table border="1"><tr><td>City Area Code (212)</td><td>Local Phone Number</td></tr><tr><td>393-4540</td><td></td></tr></table>	City Area Code (212)	Local Phone Number	393-4540		Entity Listings [Line Items]	<table border="1"><tr><td>Title of 12(b) Security Common Stock</td><td>(\$0.0001 par value per share)</td></tr><tr><td>Trading Symbol</td><td>DOMH</td></tr></table>	Title of 12(b) Security Common Stock	(\$0.0001 par value per share)	Trading Symbol	DOMH	Security Exchange Name	NASDAQ	6,276,138	À	Cash and cash equivalents	\$ 3,403	\$ 2,833	À	Marketable securities	3,771	13,547	À	Deposits with clearing broker	14,181	7,687	À	Prepaid expenses and other assets	3,121	898	À	Notes receivable, at fair value - current portion	285	3,177	À	Total current assets	24,761	28,142	À	Property and equipment, net	265	344	À	Notes receivable, at fair value - non-current portion	1,128	1,129	À	Long Term Equity Investments	13,771	24,150	À	Right-of-use assets	3,048	3,335	À	Security deposit	458	458	À	Total assets	43,431	57,558	À	Current liabilities	À	Accounts payable and accrued expenses	1,293	1,036	À	Accrued salaries and benefits	13	51	À	Accrued commissions	372	77	À	Lease liability - current	402	421	À	Other current liability	336	22	À	Total current liabilities	2,416	1,607	À	Lease liability, less current portion	2,748	3,028	À	Total liabilities	5,164	4,635	À	Stockholders' equity	À	Preferred stock value	Common stock, \$0.0001 par value, 100,000,000 shares authorized;	6,336,286	and 5,995,065 shares issued as of September 30, 2024 and December 31, 2023, respectively;	6,276,138	and 5,934,917	À	Shares outstanding as of September 30, 2024 and December 31, 2023	Additional paid-in capital	263,303	262,187	À	Treasury stock, as of cost, 60,148 shares as of September 30, 2024 and December 31, 2023	(501)	(501)	À	Accumulated deficit	(224,535)	(208,763)	À	Total stockholders' equity	38,267	52,923	À	Total liabilities and stockholders' equity	43,431	57,558	À	Series D Preferred Stock	À	Stockholders' equity	À	Preferred stock value	Series D-1 Preferred Stock	À	Stockholders' equity	À	Preferred stock value	X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2 : http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). +
Entity Address, Address Line One	725 5th Avenue																																																																																																																																																					
Entity Address, Address Line Two	22nd Floor																																																																																																																																																					
Entity Address, City or Town	New York																																																																																																																																																					
Entity Address, State or Province	NY																																																																																																																																																					
Entity Address, Postal Zip Code	10022																																																																																																																																																					
Entity Phone Fax Numbers [Line Items]	<table border="1"><tr><td>City Area Code (212)</td><td>Local Phone Number</td></tr><tr><td>393-4540</td><td></td></tr></table>	City Area Code (212)	Local Phone Number	393-4540																																																																																																																																																		
City Area Code (212)	Local Phone Number																																																																																																																																																					
393-4540																																																																																																																																																						
Entity Listings [Line Items]	<table border="1"><tr><td>Title of 12(b) Security Common Stock</td><td>(\$0.0001 par value per share)</td></tr><tr><td>Trading Symbol</td><td>DOMH</td></tr></table>	Title of 12(b) Security Common Stock	(\$0.0001 par value per share)	Trading Symbol	DOMH																																																																																																																																																	
Title of 12(b) Security Common Stock	(\$0.0001 par value per share)																																																																																																																																																					
Trading Symbol	DOMH																																																																																																																																																					
Security Exchange Name	NASDAQ																																																																																																																																																					
6,276,138																																																																																																																																																						
À	Cash and cash equivalents	\$ 3,403	\$ 2,833																																																																																																																																																			
À	Marketable securities	3,771	13,547																																																																																																																																																			
À	Deposits with clearing broker	14,181	7,687																																																																																																																																																			
À	Prepaid expenses and other assets	3,121	898																																																																																																																																																			
À	Notes receivable, at fair value - current portion	285	3,177																																																																																																																																																			
À	Total current assets	24,761	28,142																																																																																																																																																			
À	Property and equipment, net	265	344																																																																																																																																																			
À	Notes receivable, at fair value - non-current portion	1,128	1,129																																																																																																																																																			
À	Long Term Equity Investments	13,771	24,150																																																																																																																																																			
À	Right-of-use assets	3,048	3,335																																																																																																																																																			
À	Security deposit	458	458																																																																																																																																																			
À	Total assets	43,431	57,558																																																																																																																																																			
À	Current liabilities	À	Accounts payable and accrued expenses	1,293	1,036																																																																																																																																																	
À	Accrued salaries and benefits	13	51																																																																																																																																																			
À	Accrued commissions	372	77																																																																																																																																																			
À	Lease liability - current	402	421																																																																																																																																																			
À	Other current liability	336	22																																																																																																																																																			
À	Total current liabilities	2,416	1,607																																																																																																																																																			
À	Lease liability, less current portion	2,748	3,028																																																																																																																																																			
À	Total liabilities	5,164	4,635																																																																																																																																																			
À	Stockholders' equity	À	Preferred stock value	Common stock, \$0.0001 par value, 100,000,000 shares authorized;	6,336,286	and 5,995,065 shares issued as of September 30, 2024 and December 31, 2023, respectively;	6,276,138	and 5,934,917																																																																																																																																														
À	Shares outstanding as of September 30, 2024 and December 31, 2023	Additional paid-in capital	263,303	262,187																																																																																																																																																		
À	Treasury stock, as of cost, 60,148 shares as of September 30, 2024 and December 31, 2023	(501)	(501)																																																																																																																																																			
À	Accumulated deficit	(224,535)	(208,763)																																																																																																																																																			
À	Total stockholders' equity	38,267	52,923																																																																																																																																																			
À	Total liabilities and stockholders' equity	43,431	57,558																																																																																																																																																			
À	Series D Preferred Stock	À	Stockholders' equity	À	Preferred stock value	Series D-1 Preferred Stock	À	Stockholders' equity	À	Preferred stock value	X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2 : http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). +																																																																																																																																											

ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-8> + Details Name: us-gaap AccruedSalesCommissionCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-599-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapital Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap AssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap DepositsAssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 5:

1Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference) 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 15: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference> 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1Reference) 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 18: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 27: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference) 28: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference) 29: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30) + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any, + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference) 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference) 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference) 5: [http://www.xbrl.org/2003/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2003/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1Reference) 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(32\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1) + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer, + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference) 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference) 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference) 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference) 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference) 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference) 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 8: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference) 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference) 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference) 21: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference) 22: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30) + Details Name: us-gaap LiabilitiesCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available, + Details Name: us-gaap LiabilitiesCurrentAbstractNamespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle), + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1) + Details Name: us-gaap LongTermInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current, + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1) + Details Name: us-gaap MarketableSecuritiesCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease, + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference> 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1) + Details Name: us-gaap NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of financing receivable, classified as noncurrent, + ReferencesNo definition available, + Details Name: us-gaap NotesAndLoansReceivableNetNoncurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current, + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseLiabilityCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent, + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseLiabilityNoncurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease, + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 84](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1)

<http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap SecurityDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2) + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1> + Details Name: us-gaap TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - \$ / shares Sep. 30, 2024 Dec. 31, 2023 Preferred stock, par value (in Dollars per share) \$ 0.0001 \$ 0.0001 Preferred stock, shares authorized 50,000,000 50,000,000 Common stock, par value (in Dollars per share) \$ 0.0001 \$ 0.0001 Common stock, shares authorized 100,000,000 100,000,000 Common stock, shares issued 6,336,286 5,995,065 Common stock, shares outstanding 6,276,138 5,934,917 Treasury stock, at cost 60,148 60,148 Series D Preferred Stock A A Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 3,825 3,825 Preferred stock, shares outstanding 3,825 3,825 Liquidation preference (in Dollars per share) \$ 0.0001 \$ 0.0001 Series D-1 Preferred Stock A A Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 834 834 Preferred stock, shares outstanding 834 834 Liquidation preference (in Dollars per share) \$ 0.0001 \$ 0.0001 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-3>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13) + Details Name: us-gaap PreferredStockLiquidationPreference Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13) + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13) + Details Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fas](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1)

205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writteoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPS), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharestItemBalance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_Data Type: xbrli:sharestItemBalance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: domh_StockIssuedDuringPeriodSharesCancellationOfCommonStockInShares Namespace Prefix: domh_Data Type: xbrli:sharestItemBalance Type: na Period Type: duration X - DefinitionThe amount of cancellation of common stock. + ReferencesNo definition available. + Details Name: domh_StockIssuedDuringPeriodValueCancellationOfCommonStock Namespace Prefix: domh_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI

asc.fasb.org/1943274/2147483443/250-10-50-4-Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10-Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7-Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1-Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1-Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3-Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A-Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A-Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A-Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A-Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A-Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B-Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B-Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B-Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B-Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B-Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B-Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7-Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28-Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A-Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B-Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-599-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap SharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: per Period Type: instant X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1-Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1-Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: per Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1-Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1-Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased and retired during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1-Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1-Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1 + Details Name: us-gaap StockRepurchasedAndRetiredDuringPeriodShares Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: per Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/19432

available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale of financing receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 860 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481326/860-20-50-5> + Details Name: us-gaap_GainLossOnSaleOfNotesReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInDepositOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInNotesReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in current liabilities classified as other. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment in marketable security. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in marketable security. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_MarketableSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482097/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210-9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to reacquire equity classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfOtherEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for the purchase of loan receivable arising from the financing of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireLoansReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investments classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromCollectionOfNotesReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from the sale of investments classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfOtherInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Description of Business and Recent Developments 9 Months Ended Sep. 30, 2024 Organization and Description of Business and Recent Developments [Abstract] Á Organization and Description of Business and Recent Developments Note 1. Organization and Description of Business and Recent Developments Á Organization and Description of Business Á Dominari Holdings Inc. (the “Company”), formerly Akido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Akido Labs, LLC. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (the “Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (the “Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (the “FINRA”) and an investment adviser registered with the Securities and Exchange Commission (the “SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. Á Á On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (the “Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (the “FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (the “FINRA”) and an investment adviser registered with the SEC. Á Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. Á The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings. Á the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller \$2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Á Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). Á The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional \$1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. Á As a result of the ownership change, FPS was renamed Dominari Securities LLC. Á On October 13, 2023, the Company entered into two separate Limited Liability Agreements with Dominari Manager LLC (the “Manager”) and Dominari IM LLC (the “Investment Manager”) which are both wholly owned subsidiaries and whose operations are included within the consolidated condensed financial statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Dominari IM LLC (the “Investment Manager”) was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors. Á On May 21, 2024, Dominari Financial and Heritage Strategies LLC (the “HS”) entered into a Limited Liability Company Operating Agreement (the “JV Agreement”) of Dominari Financial Heritage Strategies LLC (the “DFHS”). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominari Financial and HS are the co-managing members (the “Co-Managing Members”), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Liquidity and Capital Resources 9 Months Ended Sep. 30, 2024 Liquidity and Capital Resources [Abstract] Á Liquidity and Capital Resources Note 2. Liquidity and Capital Resources Á The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings. Á Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the liquidation basis of accounting. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-30/tableOfContent + Details Name: us-gaap_LiquidationBasisOfAccountingTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies [Abstract] Á Summary of Significant Accounting Policies Note 3. Summary of Significant Accounting Policies Á There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2023 Annual Report. Á Basis of Presentation and Principles of Consolidation Á The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (the “GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of September 30, 2024, condensed consolidated statements of operations for the three months and nine months ended September 30, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023. Á The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Akido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation. Á Joint Ventures Á On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (the “DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Á The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. Á The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. Á As of September 30, 2024, there has been no material activity in DFHS. Á Á Use of Estimates Á The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions. Á Deposits with clearing broker Á Deposits with Dominari Securities’ clearing broker consisted of approximately \$14.2 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of September 30, 2024. Á Leases Á The Company accounts for its leases under ASC 842. Á Leases (the “ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset result in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases). Á Revenue Á The Company recognizes revenue under ASC 606. Á Revenue from Contracts with Customers (the “ASC 606”). Á Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. Á The following provides detailed information on the recognition of the Company’s revenue from contracts with customers: Á Á — Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income. Á Á — Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission

are associated with trade execution and are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date. **ASC 321** — Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet. **ASC 323** — Other revenue includes revenues such as miscellaneous fees and reimbursed expenses. **ASC 323** — Long-term equity investments **ASC 323** — The Company accounts for long-term equity investments under Accounting Standards Codification (ASC) 323, Equity Securities. Equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. **ASC 323** — Recently adopted accounting standards **ASC 323** — In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (ASC 606). This update amends ASC 606 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company's unaudited condensed consolidated financial statements from the implementation of ASU 2021-08. **ASC 323** — In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted ASU 2022-03 on January 1, 2024. There was no material impact to the Company's unaudited condensed consolidated financial statements from the implementation of ASU 2022-03. **ASC 323** — In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2023-01 on January 1, 2024. There was no material impact to the Company's unaudited condensed consolidated financial statements from the implementation of ASU 2023-01. **ASC 323** — Effect of new accounting pronouncements to be adopted in future periods **ASC 323** — The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements. **ASC 323** — X - ReferencesNo definition available. + Details Name: us-gaap Accounting Policies Abstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: [ASC 323 — Long-Term Equity Investments Note 5. Long-Term Equity Investments **ASC 323** — The Company holds interests in several privately held and publicly traded companies as long-term investments. The following table presents the Company's long-term investments as of September 30, 2024, and December 31, 2023 \(\\$ in thousands\): **ASC 323** — December 31, 2023 **ASC 323** — September 30, 2024 **ASC 323** — Cost Basis **ASC 323** — Carrying Value **ASC 323** — Cost Basis **ASC 323** — Carrying Value **ASC 323** — Investment in Kerna Health Inc. **ASC 323** — \\$2,140.4 **ASC 323** — \\$4,940.4 **ASC 323** — \\$2,140.4 **ASC 323** — \\$4,940.4 **ASC 323** — Investment in Kaya Now **ASC 323** — \\$1,500.4 **ASC 323** — \\$1,500.4 **ASC 323** — Investment in Tevva Motors **ASC 323** — \\$1,972.4 **ASC 323** — \\$2,794.4 **ASC 323** — \\$1,972.4 **ASC 323** — Investment in Unusual Machines **ASC 323** — \\$1,075.4 **ASC 323** — \\$1,033.4 **ASC 323** — Investment in Qxpress **ASC 323** — \\$1,000.4 **ASC 323** — \\$1,000.4 **ASC 323** — Investment in Masterclass **ASC 323** — \\$170.4 **ASC 323** — \\$170.4 **ASC 323** — Investment in Kraken **ASC 323** — \\$597.4 **ASC 323** — \\$597.4 **ASC 323** — Investment in Epic Games **ASC 323** — \\$3,500.4 **ASC 323** — \\$3,500.4 **ASC 323** — Investment in Tesseract **ASC 323** — \\$1,240.4 **ASC 323** — \\$2,679.4 **ASC 323** — \\$1,240.4 **ASC 323** — Investment in SpaceX **ASC 323** — \\$3,500.4 **ASC 323** — \\$4,867.4 **ASC 323** — Investment in Databricks **ASC 323** — \\$1,200.4 **ASC 323** — \\$842.4 **ASC 323** — Investment in Discord **ASC 323** — \\$476.4 **ASC 323** — \\$476.4 **ASC 323** — Investment in Thrasio **ASC 323** — \\$300.4 **ASC 323** — \\$300.4 **ASC 323** — Investment in Automation Anywhere **ASC 323** — \\$476.4 **ASC 323** — \\$476.4 **ASC 323** — Investment in XAI **ASC 323** — \\$100.4 **ASC 323** — \\$100.4 **ASC 323** — Investment in Cerebras **ASC 323** — \\$25.4 **ASC 323** — \\$25.4 **ASC 323** — Investment in Groq **ASC 323** — \\$25.4 **ASC 323** — \\$25.4 **ASC 323** — Investment in AdvEn **ASC 323** — \\$874.4 **ASC 323** — Investment in Anduril **ASC 323** — \\$476.4 **ASC 323** — \\$476.4 **ASC 323** — \\$379.4 **ASC 323** — Total **ASC 323** — \\$19,622.4 **ASC 323** — \\$24,150.4 **ASC 323** — \\$15,197.4 **ASC 323** — \\$13,771.4 **ASC 323** — * Investments made in these companies are through a Special Purpose Vehicle \(SPV\). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. **ASC 323** — ** Investments made in these companies are through both an SPV and direct investments. **ASC 323** — The Company recorded an increase in the carrying values of approximately \\$0.9 million for the three month period ended September 30, 2024 and a decrease in the carrying values of approximately \\$4.6 million for the nine month period ended September 30, 2024. The Company also recorded a \\$\(0.5\) million change in carrying value of investment upon transferring Unusual Machine, Inc shares to marketable securities in addition to the \\$\(6.0\) million year to date change from the above table. See Investment in Unusual Machine,](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483246/235-10-50-1-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/235/tableOfContent+Details Name: us-gaap Significant Accounting Policies TextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities 9 Months Ended Sep. 30, 2024 Marketable Securities [Abstract] ASC 323 — Marketable Securities Note 4. Marketable Securities ASC 323 — The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months and nine months ended September 30, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands): ASC 323 — Three Months Ended September 30, ASC 323 — Nine Months Ended September 30, ASC 323 — 2024 ASC 323 — 2023 ASC 323 — 2023 ASC 323 — Realized gain (loss) ASC 323 — $432.4 ASC 323 — $(762.1) ASC 323 — $3,762.4 ASC 323 — $(1,249) ASC 323 — Unrealized gain (loss) ASC 323 — $(421.1) ASC 323 — $382.4 ASC 323 — $(3,361.1) ASC 323 — $897.4 ASC 323 — Dividend income ASC 323 — $78.4 ASC 323 — $230.4 ASC 323 — $366.4 ASC 323 — $537.4 ASC 323 — Total ASC 323 — $89.4 ASC 323 — $(150.4) ASC 323 — $185.4 ASC 323 — X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: <a href=)

[illegible]

administrative expenses. Á Estimated future stock-based compensation expense relating to unvested stock options is approximately \$0.2 million. X - DefinitionThe entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/505/tableOfContentReference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/718/tableOfContent> + Details Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNotaAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue 9 Months Ended Sep. 30, 2024 Revenue [Abstract] Á Revenue Note 11. Revenue Á The following table presents our total revenue disaggregated by revenue type for the three and nine months ended September 30, 2024 and 2023 (in thousands): Á Á Á Three Months Ended September 30,Á Á Nine Months Ended September 30,Á Á Á 2024Á 2023Á 2024Á 2023Á UnderwritingÁ \$1,971Á Á \$318Á Á \$6,360Á Á \$423Á CommissionsÁ Á 1,161Á Á Á 525Á Á Á 3,246Á Á Á 539Á Advisory feesÁ Á 638Á Á Á 72Á Á Á 1,409Á Á Á 72Á OtherÁ Á 273Á Á Á 48Á Á Á 569Á Á Á 0Á TotalÁ \$4,043Á Á \$963Á Á \$11,584Á Á \$1,034Á X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-9>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-15>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-12>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-12>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-12>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-12>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-13>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI <https://asc.fasb.org/606/tableOfContent> + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies [Abstract] Á Commitments and Contingencies Note 12. Commitments and Contingencies Á Legal Proceedings Á The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Companyâ€™s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Companyâ€™s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be. Notwithstanding this uncertainty, the Company does not believe that the results of these potential claims are likely to have a material effect on its financial position or results of operations. Á In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representativesâ€™ former employer. This notice was filed against the Companyâ€™s subsidiary, Dominari Securities. The Company does not agree with the plaintiffâ€™s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim. Á In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Companyâ€™s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/405-30/tableOfContentReference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482648/440-10-50-4>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/450/tableOfContentReference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478522/954-440-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482648/440-10-50-4>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/440/tableOfContent> + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Regulatory 9 Months Ended Sep. 30, 2024 Regulatory [Abstract] Á Regulatory Note 13. Regulatory Á Dominari Securities, the Companyâ€™s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Companyâ€™s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of September 30, 2024, Dominari Securities had net capital of approximately \$12.46 million, which was approximately \$12.31 million in excess of net capital requirement of \$0.15 million. X - ReferencesNo definition available. + Details Name: srt_RegulatoryCapitalRequirementsAbstract Namespace Prefix: srt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for regulatory capital requirement for depository and lending institutions. Institutions include, but not are not limited to, finance company, insured depository institution, bank holding company, savings and loan association holding company, bank and savings institution not federally insured, mortgage company, foreign financial institution and credit union. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477270/942-505-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477270/942-505-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477270/942-505-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477270/942-505-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477270/942-505-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477270/942-505-50-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477270/942-505-50-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477270/942-505-50-1> + Details Name: us-gaap_RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transaction 9 Months Ended Sep. 30, 2024 Related Party Transaction [Abstract] Á Related Party Transaction Note 14. Related Party Transaction Á In 2021, the Company engaged the services of Revere Securities, LLC (â€œRevereâ€) to assist in the management and building of the Companyâ€™s investment processes. Kyle Wool, one of the Companyâ€™s board members, was previously a member of the board of directors of Revere until June 2023, and currently holds approximately 30% of Revereâ€™s outstanding equity. From time to time, Company participates in offerings of securities as an underwriter in transactions in which Revere is also participating as an underwriter. On such transactions, the Company earned \$313,960 and \$39,000 in the nine months ending September 30, 2024 and 2023, respectively. The Company incurred referral fees of approximately \$45,000 and \$80,000 during the three months ending September 30, 2024 and 2023, respectively. These fees were included in general and administrative expenses in the unaudited condensed consolidated statements of operations. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-5>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-6>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477968/946-235-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477968/946-235-50-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483326/850-10-50-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/850/tableOfContentReference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483326/850-10-50-6>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483326/850-10-50-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483326/850-10-50-1> + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Á Segment Reporting Note 15. Segment Reporting Á The Company operates in twoÁ reportable business segments: (1) Dominari Financial and (2) Legacy Alkido. The Dominari Financial reportable business segment represents the Companyâ€™s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy Alkido reportable business segment includes Alkido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy Alkido. Á The chief operating decision-maker (â€œCODMâ€) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the â€œSummary of Significant Accounting Policies.â€ While assets are primarily held within the Legacy Alkido reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.Á The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Á Á Nine Months Ended September 30, 2024Á Á Dominari FinancialÁ Á Legacy Alkido PharmaÁ Á ConsolidatedÁ RevenueÁ \$0,553Á Á \$1,031Á Á \$11,584Á Operating CostsÁ Á Á Á Á Á General and administrativeÁ Á 13,183Á Á Á 7,138Á Á Á 20,321Á Research and developmentÁ Á Á Á Á Á Loss from operationsÁ Á (2,630)Á Á (6,107)Á Á (8,737)Á Á Á Á Á Á Á Á Other (expenses) incomeÁ Á Á Á Á Á Á Á Other incomeÁ Á Á Á Á Á Interest incomeÁ Á 545Á Á Á 184Á Á Á 729Á Gain on marketable securitiesÁ Á Á Á Á Á 767Á Á Á 767Á Unrealized loss on note receivableÁ Á Á Á Á (2,086)Á Á (2,086) Change in fair value of investmentsÁ Á Á Á Á (6,445)Á Á (6,445) Total other (expenses) incomeÁ Á 545Á Á Á (7,580)Á Á (7,035) Net lossÁ \$(2,085)Á \$(13,687)Á \$(15,772) Á Á Three Months Ended September 30, 2024Á Á Dominari FinancialÁ Á Legacy Alkido PharmaÁ Á ConsolidatedÁ RevenueÁ \$3,684Á Á \$359Á Á \$4,043Á Operating CostsÁ Á Á Á Á Á General and administrativeÁ Á 4,438Á Á Á 2,801Á Á Á 7,239Á Research and developmentÁ Á Á Á Á Á Loss from operationsÁ Á (754)Á Á (2,442)Á Á (3,196) Á Á Á Á Á Á Other (expenses) incomeÁ Á Á Á Á Á Á Á Other incomeÁ Á Á Á Á Á Interest incomeÁ Á 204Á Á Á 76Á Á Á 280Á Gain on marketable securitiesÁ Á Á Á Á 89Á Á Á 89Á Unrealized loss on note receivableÁ Á Á Á Á (429)Á Á (429) Change in fair value of investmentsÁ Á Á Á Á (955)Á Á (955) Total other (expenses) incomeÁ Á 204Á Á Á (1,219)Á Á (1,015) Net lossÁ \$(550)Á \$(3,661)Á \$(4,211) X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54)Reference 7: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47)Reference 8: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47)Reference 9: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47)Reference 10: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54)Reference 11: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41>Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Taxes [Abstract] A Income Taxes Note 16. Income Taxes A The Company recorded no income tax expense for the three months ended September 30, 2024 and 2023 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company's annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. A As of September 30, 2024, and December 31, 2023, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized. X - References No definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for income tax. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 11.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-2) + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure A A Net Income (Loss) \$ (4,211) \$ (3,541) \$ (15,772) \$ (15,966) X - References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6](http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.4-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.4-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-50-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)

a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K-Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmtdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K-Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Accounting Policies, by Policy (Policies) 9 Months Ended Sep. 30, 2024

Summary of Significant Accounting Policies [Abstract] Â Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (âU.S. GAAPâ), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of September 30, 2024, condensed consolidated statements of operations for the three months and nine months ended September 30, 2024 and 2023, condensed consolidated statements of stockholders'â equity for the three months and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company'sâ annual report on Form 10-K for the year ended December 31, 2023.The Company'sâ policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation. Joint Ventures Joint VenturesOn May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (âDFHSAâ). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services.Â Â The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements.Â The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323.Â As of September 30, 2024, there has been no material activity in DFHS. Use of Estimates Use of EstimatesThe accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company'sâ significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company'sâ deferred tax assets. Certain of the Company'sâ estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company'sâ estimates and could cause actual results to differ from those estimates and assumptions. Deposits with clearing broker Deposits with clearing brokerDeposits with Dominari Securitiesâ clearing broker consisted of approximately \$14.2 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of September 30, 2024. Leases LeasesThe Company accounts for its leases under ASC 842.Â LeasesÂ (âASC 842â). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company'sâ incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases).Â Revenue RevenueThe Company recognizes revenue underÂ ASC 606Â - Â Revenue from Contracts with Customers (âASC 606â).Â Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company'sâ customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.The following provides detailed information on the recognition of the Company'sâ revenue from contracts with customers: Â â Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company'sâ clients are recognized as other income. Â â Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date. Â â Account advisory fees are earned in connection with investment advisory services. Â Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet. Â â Other revenue includes revenues such as miscellaneous fees and reimbursed expenses. Long-term equity investments Long-term equity investments The Company accounts for long-term equity investments under Accounting Standards Codification (âASCâ) 321 - Investmentsâ "Equity Securitiesâ (âASC 321â). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.Â Recently adopted accounting standards Recently adopted accounting standardsIn October 2021, the FASB issuedÂ ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (âASU 2021-08â). This update amendsÂ Topic 805Â to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance withÂ ASC 606. The Company adoptedÂ ASU 2021-08Â on January 1, 2023. There was no material impact to the Company'sâ unaudited condensed consolidated financial statements from the implementation ofÂ ASU 2021-08.In June 2022, the FASB issuedÂ ASUÂ 2022-03,Â Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security.Â ASUÂ 2022-03Â also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments inÂ ASUÂ 2022-03Â may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adoptedÂ ASU 2022-03Â on January 1, 2024. There was no material impact to the Company'sâ unaudited condensed consolidated financial statements from the implementation ofÂ ASU 2022-03.Â In March 2023, the FASB issuedÂ ASU 2023-01, Leases,Â to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company adoptedÂ ASU 2023-01Â on January 1, 2024. There was no material impact to the Company'sâ unaudited condensed consolidated financial statements from the implementation ofÂ ASU 2023-01. Effect of new accounting pronouncements to be adopted in future periods Effect of new accounting pronouncements to be adopted in future periodsThe Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.Â X - DefinitionDisclosure of accounting policy for deposits with clearing broker. + ReferencesNo definition available. + Details Name: domh_DepositWithClearingBrokerPolicyTextBlock Namespace Prefix: domh_ Data Type: dtr:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for joint ventures. + ReferencesNo definition available. + Details Name: domh_JointVenturesPolicyTextBlock Namespace Prefix: domh_ Data Type: dtr:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recently adopted accounting standards. + ReferencesNo definition available. + Details Name: domh_RecentlyAdoptedAccountingStandardPolicyTextBlock Namespace Prefix: domh_ Data Type: dtr:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/214747721/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/214747721/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478326/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UserOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities (Tables) 9 Months Ended Sep. 30, 2024 Marketable Securities [Abstract] Â Schedule of Gains and (Losses) on Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months and nine months ended September 30, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows (\$ in thousands): Â Three Months Ended September 30,Â Â A Nine Months Ended September 30,Â Â A 2024Â A 2023Â A 2024Â A 2023Â A Realized gain (loss)Â A \$432Â A \$(762)Â A \$3,762Â A \$(1,249) Unrealized gain (loss)Â A (421)Â A \$382Â A (3,361)Â A \$897Â A Dividend incomeÂ A 78Â A Â A 230Â A Â A 366Â A Â A 537Â A TotalÂ A \$89Â A

[illegible]

[illegible]

[illegible]

srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInSpaceXMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInCerebrasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInGrogMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInUnusualMachinesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInTevvaMotorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInTesspayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInAndurilMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInThrasioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInEpicGamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=domh.InvestmentInAdvEnMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.RangeAxis=srt.MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.RangeAxis=srt.MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.StatementClassOfStockAxis=us-gaap.SeriesDPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Equity Investments (Details) - Schedule of Long-Term Investments - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis \$ 15,197 \$ 19,622 Long-term investments, Carrying Value 13,771 24,150 Investment In Kerna Health Inc [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis 2,140 2,140 Long-term investments, Carrying Value 4,940 4,940 Investment In Kaya Now [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis 1,500 1,500 Long-term investments, Carrying Value Investment In Tevva Motors [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 1,972 1,972 Long-term investments, Carrying Value [1] 2,794 Investment In Unusual Machines [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis 1,075 Long-term investments, Carrying Value 1,033 Investment In Qxpress [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 1,000 1,000 Long-term investments, Carrying Value [1] 1,000 1,000 Investment In Masterclass [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 170 170 Long-term investments, Carrying Value [1] 170 170 Investment In Kraken [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [2] 597 597 Long-term investments, Carrying Value [2] 597 597 Investment In Epic Games [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 3,500 3,500 Long-term investments, Carrying Value [1] 2,627 3,500 Investment In Tesspay [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [2] 1,240 1,240 Long-term investments, Carrying Value [2] 1,240 2,679 Investment In SpaceX [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 3,500 Long-term investments, Carrying Value 4,867 [1] Investment In Databricks [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 1,200 1,200 Long-term investments, Carrying Value 842 842 [1] Investment In Discord [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis 476 476 Long-term investments, Carrying Value 476 476 Investment In Thrasio [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis 300 300 Long-term investments, Carrying Value 300 Investment In Automation Anywhere [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis 476 476 Long-term investments, Carrying Value 476 476 Investment In XAI [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 100 Long-term investments, Carrying Value 100 [1] Investment In Cerebras [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 25 Long-term investments, Carrying Value 25 [1] Investment In Grog [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 25 Long-term investments, Carrying Value 25 [1] Investment In AdvEn [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis Long-term investments, Carrying Value 874 Investment In Anduril [Member] A Schedule of Long-Term Investments [Line Items] A Long-term investments, Cost Basis [1] 476 476 Long-term investments, Carrying Value \$ 379 \$ 476 [1] Investments made in these companies are through a Special Purpose Vehicle (   SPV   ). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. [2] Investments made in these companies are through both an SPV and direct investments. X - DefinitionCost of the investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap.InvestmentOwnedAtCost Namespace Prefix: us-gaap Data Type: xbrli.monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap.LongTermInvestments Namespace Prefix: us-gaap Data Type: xbrli.monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap.ScheduleOfCapitalizationLongtermDebtLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInKernaHealthIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInTevvaMotorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInUnusualMachinesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInQxpressMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInMasterclassMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInKrakenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInEpicGamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInTesspayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInSpaceXMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInDatabricksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInDiscordMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInThrasioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInAutomationAnywhereMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInXAIMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInCerebrasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInGrogMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInAdvEnMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.InvestmentTypeAxis=domh.InvestmentInAndurilMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap.Receivable (Details) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Convergent Therapeutics, Inc. [Member] A Notes Receivable [Line Items] A Principal repayment \$ 300,000 \$ 700,000 Interest income 53,000 200,000 Unrealized loss 21,000 A Raefan Industries LLC [Member] A Notes Receivable [Line Items] A Unrealized loss 400,000 2,100,000 American Innovative Robotics, LLC [Member] A Notes Receivable [Line Items] A Interest income 22,000 67,000 Unrealized loss \$ 500 \$ 1,700 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section

<http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B> + Details Name: us-gaap DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of principal of debt issued. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3> + Details Name: us-gaap_DebtInstrumentIssuedPrincipal Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B> + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of financing receivable, classified as noncurrent. + ReferencesNo definition available. + Details Name: us-gaap_NotesAndLoansReceivableNetNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-10> + Details Name: us-gaap_NotesReceivableFairValueDisclosure Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=domh_ConvergentConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=domh_RaeafanIndustriesLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=domh_AmericanInnovativeRoboticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Assets and Liabilities (Details) - USD (\$) \$ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Fair Value of Financial Assets and Liabilities [Abstract] Å Å Unrealized losses \$ 0.4 \$ 2.1 Realized losses \$ 0.4 Å X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1> + Details Name: us-gaap_DebtSecuritiesRealizedGainLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1> + Details Name: us-gaap_DebtSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Schedule of Assets and Liabilities are Measured at Fair Value [Line items] Å Å Å Equities \$ 3,771 \$ 13,547 Å Å Total marketable securities 3,771 13,547 Å Å Notes receivable at fair value, current portion 285 3,177 Å Å Notes receivable at fair value, non-current portion 1,128 1,129 Å Å Quoted prices in active markets (Level 1) [Member] Å Å Å Schedule of Assets and Liabilities are Measured at Fair Value [Line items] Å Å Å Equities 3,771 13,547 Å Å Total marketable securities 3,771 13,547 Å Å Notes receivable at fair value, current portion Å Å Notes receivable at fair value, non-current portion Å Å Significant other observable inputs (Level 2) [Member] Å Å Å Schedule of Assets and Liabilities are Measured at Fair Value [Line items] Å Å Å Equities Å Å Total marketable securities Å Å Notes receivable at fair value, current portion Å Å Notes receivable at fair value, non-current portion Å Å Significant unobservable inputs (Level 3) [Member] Å Å Å Schedule of Assets and Liabilities are Measured at Fair Value [Line items] Å Å Å Equities Å Å Total marketable securities Å Å Notes receivable at fair value, current portion 285 3,177 Å 6,336 \$ 7,474 Notes receivable at fair value, non-current portion \$ 1,128 \$ 1,129 \$ 1,372 \$ 1,100 X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482736/825-10-45-1A> + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-3> + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis - Level 3 [Member] - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Å Å Notes receivable at fair value, current portion, Balance beginning \$ 3,177 \$ 7,474 Notes receivable at fair value, non-current portion Balance beginning 1,129 1,100 Short-term investment at December 31, 2022 Å 13 Collection of principal outstanding (750) (750) Unrealized loss on note receivable Å (212) Accrued interest receivable Å 74 Realized and unrealized gain (loss) on note receivable, net (2,086) Å Change in interest receivable (56) Å Notes receivable at fair value, current portion at Balance ending 285 6,336 Unrealized gain (loss) on notes receivable (1) Å Notes receivable at fair value, non-current portion Balance ending \$ 1,128 1,372 Accrued interest receivable Å 22 Change in fair value of investment Å (12) Short-term investment at September 30, 2023 Å 1 Convergent Therapeutics [Member] Å Å Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Å Å Note receivable, Convergent Therapeutics, non-current portion Å (250) Notes receivable at fair value, non-current portion Balance ending Å 250 X - DefinitionRepresents accrued interest receivable. + ReferencesNo definition available. + Details Name: domh_AccruedInterestReceivableCurrent Namespace Prefix: domh_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresent the amount of accrued interest receivable non current. + ReferencesNo definition available. + Details Name: domh_AccruedInterestReceivableNoncurrent Namespace Prefix: domh_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in fair value of short-term investment. + ReferencesNo definition available. + Details Name: domh_ChangeInFairValueOfShorttermInvestment Namespace Prefix: domh_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNote receivable non-current portion after collection of principal. + ReferencesNo definition available. + Details Name: domh_NoteReceivableNoncurrentPortionAfterCollectionOfPrincipal Namespace Prefix: domh_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of (loss) on sale of unrealized financing receivable. + ReferencesNo definition available. + Details Name: domh_UnrealizedLossOnNoteReceivable Namespace Prefix: domh_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of realized and unrealized gain (loss) on investment. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 3: <http://www.xbrl.org/2003/role/recommendedDisclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_GainLossOnInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType

Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of financing receivable, classified as noncurrent. + ReferencesNo definition available. + Details Name: us-gaap NotesAndLoansReceivableNetNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name> Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI [https://asc.fasb.org/1943274/214748546/942-210-599-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747856/942-210-599-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain \(loss\) on investment. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name> Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Section 230 -Publisher FASB -URI \[https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_UnrealizedGainLossOnInvestments\]\(https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_UnrealizedGainLossOnInvestments\) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=domh ConvergentTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Leases \(Details\) - USD \(\\$\) 3 Months Ended Jan. 11, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jul. 11, 2022 Leases \[Line Items\] Á Á Á Á Á Á Á Lease term Á 7 years Á Á Á 7 years Lease rent expenses Á 12,874 Á Á Á Á Á Increase rent amount Á \\$ 51,868 Á Á \\$ 13,502 Á Á Rent payment Á 49,368 Á Á Á Á Lease expenses Á Á \\$ 201,000 \\$ 212,000 \\$ 630,000 \\$ 586,000 Á X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. + ReferencesReference 1: \[http://fasb.org/us-gaap/role/ref/legacyRef-Name\]\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(15\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1 + Details Name: us-gaap_AccruedRentCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase \(decrease\) of consideration paid in advance for rent that provides economic benefits in future periods. + ReferencesReference 1: <a href=\) Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI \[https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidRent\]\(https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidRent\) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesNo definition available. + Details Name: us-gaap_LeaseAndRentalExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1:](https://asc.fasb.org/1943274/214748546/942-210-599-1Reference 2:)

DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1:

Balance Type: na Period Type: instant X - Definition: Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1:

Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(02) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification -Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Plan - USD (\$) 9 Months Ended Dec. 31, 2023 Sep. 30, 2024 Schedule of Stock Option Activity [Abstract] Å Å Outstanding ending balance, Number of Shares 420,168 419,988 Outstanding ending balance, Weighted Average Exercise Price \$ 5.8 \$ 4.16 Outstanding ending balance, Intrinsic Value Outstanding ending balance, Weighted Average Remaining Contractual Life (in years) 9 years 3 months 18 days 8 years 6 months Number of Shares, Options vested and exercisable Å 156,176 Weighted Average Exercise Price, Options vested and exercisable Å \$ 5.43 Total Intrinsic Value, Options vested and exercisable Å Weighted Average Remaining Contractual Life (in years), Options vested and exercisable Å 8 years 3 months 18 days Employee options expired, Number of Shares Å (180) Employee options expired, Weighted Average Exercise Price Å \$ 3,832.72 Employee options expired, Intrinsic Value Å Employee options expired , Weighted Average Remaining Contractual Life (in years) Å X - DefinitionShare-Based Compensation Arrangement by ShareEmployeeOptionsExpiredWeightedAverageRemainingContractualLife. + ReferencesNo definition available. + Details Name: domh_EmployeeOptionsExpiredWeightedAverageRemainingContractualLife Namespace Prefix: domh_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1)(iv)(04) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionXML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue (Details) - Schedule of Total Revenue Disaggregated by Revenue Type - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Schedule of Total Revenue Disaggregated by Revenue Type [Line Items] Å Å Å Total revenue disaggregated \$ 4,043 \$ 963 \$ 11,584 \$ 1,034 Underwriting [Member] Å Å Å Schedule of Total Revenue Disaggregated by Revenue Type [Line Items] Å Å Å Total revenue disaggregated 1,971 318 6,360 423 Commissions [Member] Å Å Å Å Schedule of Total Revenue Disaggregated by Revenue Type [Line Items] Å Å Å Å Total revenue disaggregated 1,161 525 3,246 539 Advisory fees [Member] Å Å Å Å Schedule of Total Revenue Disaggregated by Revenue Type [Line Items] Å Å Å Å Total revenue disaggregated 638 72 1,409 72 Other [Member] Å Å Å Å Schedule of Total Revenue Disaggregated by Revenue Type [Line Items] Å Å Å Å Total revenue disaggregated \$ 273 \$ 48 \$ 569 \$ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=domh_UnderwritingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=domh_AdvisoryFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=domh_OtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Regulatory (Details) \$ in Thousands Sep. 30, 2024 USD (\$) Regulatory [Line Items] Å Net capital requirement \$ 12,460 Excess amount 12,310 Minimum [Member] Å Regulatory [Line Items] Å Net capital requirement \$ 150 X - DefinitionThe amount of net capital. + ReferencesNo definition available. + Details Name: domh_NetCapitalAmount Namespace Prefix: domh_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481586/948-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481586/948-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481586/948-10-50-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481586/948-10-50-5)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481586/948-10-50-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481586/948-10-50-5)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481586/948-10-50-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481586/948-10-50-5) + Details Name: us-gaap ComplianceWithRegulatoryCapitalRequirementsForMortgageCompaniesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of total risk-based capital exceeding minimum required for capital adequacy as defined by regulatory framework. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477270/942-505-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477270/942-505-50-1) + Details Name: us-gaap ExcessCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemTYpe Balance Type: credit Period Type: instant X - Details Name: srt RangeAxis=srt MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transaction (Details) - USD (\$) 3 Months Ended 9 Months Ended Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Related Party Transaction [Abstract] Å Å Å Revera  s outstanding equity percentage 30.00% Å Å Å Incurred fees \$ 313,960 \$ 45,000 \$ 80,000 \$ 39,000 X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3> + Details Name: us-gaap RelatedPartyTransactionAmountsOffTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemTYpe Balance Type: debit Period Type: duration X - DefinitionIdentify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties. + ReferencesNo definition available. + Details Name: us-gaap RelatedPartyTransactionRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemTYpe Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemTYpe Balance Type: na Period Type: duration XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Details) 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Å Reportable segments 2 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18> + Details Name: us-gaap NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemTYpe Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemTYpe Balance Type: na Period Type: duration XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Dominari Financial [Member] Å Å Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items] Å Å Revenue \$ 3,684 \$ 10,553 Operating Costs Å Å General and administrative 4,438 13,183 Research and development Loss from operations (754) (2,630) Other (expenses) income Å Å Other income Interest income 204 545 Gain on marketable securities Unrealized loss on note receivable Change in fair value of investments Total other (expenses) income 204 545 Net loss (550) (2,085) Legacy Alkido Pharma [Member] Å Å Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items] Å Å Revenue 359 1,031 Operating Costs Å Å General and administrative 2,801 7,138 Research and development Å Loss from operations (2,442) (6,107) Other (expenses) income Å Å Other income Interest income 76 184 Gain on marketable securities 89 767 Unrealized loss on note receivable (429) (2,086) Change in fair value of investments (955) (6,445) Total other (expenses) income (1,219) (7,580) Net loss (3,661) (13,687) Consolidated [Member] Å Å Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items] Å Å Revenue 4,043 11,584 Operating Costs Å Å General and administrative 7,239 20,321 Research and development Loss from operations (3,196) (8,737) Other (expenses) income Å Å Other income Interest income 280 729 Gain on marketable securities 89 767 Unrealized loss on note receivable (429) (2,086) Change in fair value of investments (955) (6,445) Total other (expenses) income (1,015) (7,035) Net loss \$ (4,211) \$ (15,772) X - DefinitionAmount of (loss) on sale of unrealized financing receivable. + ReferencesNo definition available. + Details Name: domh UnrealizedLossOnNoteReceivable Namespace Prefix: domh_ Data Type: xbrli:monetaryItemTYpe Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemTYpe Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1) + Details Name: us-gaap GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemTYpe Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) + Details Name: us-gaap InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemTYpe Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in marketable security. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2) + Details Name: us-gaap MarketableSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemTYpe Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 31:

FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap. OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap. OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of income related to nonoperating activities, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap. OtherNonOperatingIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap. ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap. Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap. SegmentReportingRevenueReconcilingItemLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - Details Name: us-gaap. SubsegmentsAxis=domh. DominiarFinancialMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap. SubsegmentsAxis=domh. LegacyAlkidoPharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap. SubsegmentsAxis=domh. ConsolidatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Details) - USD (\$) 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Income Taxes [Abstract] A Income tax expense X - ReferencesNo definition available. + Details Name: us-gaap. IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap. IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration EXCEL 73 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx M4\$L!#10 (&R;D04UB@0 + 0 9&J[C4]O< .087IP+GAM M;\$V.0L",1!\$!QOQ=IP4)B0-12L+(>+QLOD&1#LD)~OCG!CVX>;QA&WPIG M*~*!BV&5& C(CI(/!47BK9.7=>N)=Hi6V *OGDK7A.JNYQ<&4GPZ4A!0W J=0U/RUEA 6#M7E!+ P04 M " M;\$&A9N %<6.1 K @ \$0 &108U!R;WIS+V+O&ULS9J1 M2,P\$> BN2J0:15D=#E9<G1<&IXEM(E;MT8X;DI-VW-ZU;A' @\%#W SN M=W"-#TS\$B1\$2PWR0&K9+TH05.0 %9#9. /U.94YTJ;GKH]>4GW\$09NC MWB-4G->1#)16D8X6(2%R%1CC301-77QC+>FP87/V;XPJ1!A ES*8&J; M&#YCV4.5,\$(HT ?);0+<[- B9TPI],DI-DE-O0<+>S+!N(&XWY75>MW1= M(MT95+>2DW0N&*R7E U>+KJ9*KBUEtA1;?M!600);B!F-R =>%W?>;J=30W MCXTO@J;J!7W>A0@I02P,\$% @ (H69E&ULI5!)<|HX%[OKJ]J9 9M*8V@<:T\$W=1MNTF83M M3A~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~">X50 MAWBM1GBX6.Q.B#D2W/77&HGXZ5,>KT4+L0 AR51-1D049DWM W!39Y1!M2QZ55DFV;5+FH(Y5ZV7\$S);T/4ERO>ZO RDWOH &K&S?Y\$B][QW" =+3+UT M BVX#G+>+CKM+ ;+*#1=UJQ!699ZJ2QJ75N8S-R ?*EMJG I+9>V2AFB M470.RSL=>9L,MLOF M &(&C)<2@&F;?2YQ?>KL#=>@>I>?>QX\$>4J< -6#>J6O(K8S&8)CZJ].#1L M3U.GA.F3>IYVSV4H C-AF);\$#BNX4C&5%>X1-R;/>EVGQ%=>DZOON6SB#M QJ MLD57+3/K[A8E44L,%>6JG(C) >6N3CEOGM6CVCO0AYI29&BWH /&842N[VXN M1N-O&S(<#P<LCIN?>?>1<EMSO\$?>0E*?&E?R6 !=>H9EW+ /Y=2J3J MLDPSA1SGXV75(2X*)MI-I(J;LQIL H+=>Q'FV BMXOBMR85^4J!<#560Y">AOF5 M*#F&8Q&D9#8DM QO Q=40+>VJ6FT DMVDQ\$X<><C/3;&4(R0) =>=VO9=W.D=SDJ,C5\$ M0L,OZ,20W18Y7?>R4Q41OQML9?TDG1G#&#YCQ?>KBMK,FZ0Z=>E8V1[6NAO=":XXN8RYGIC< P4J M1_6%Z5(VR.8B)9+1MU*?&H\$QWU6Q/2Z20BWC/R,T@>QLEKH0EBHB4QTSK M-&4%?>=>0-010M(8K6&BB[V\>UL&K M5Y6&?> HJ\$!(<8C414.2\$*#H+&H<J OW,&J@>H0K5&#>RXYWRF)2+U6D3[1+ M-J[QI/SHM #?>=RE68+>TCQ7?>#9C3;3K1DJ UJ+G0JCI]@ 6 PD4E*?>J0 M=-IV4J)OC3N)*^G<^<H,T_>S 9WS*M8Jv4J[?Y84%8E^M. *RO1R/IR. MTBX(D)Q5-NL@.4 419^MQIJ@*:>D^0<GHIN1OF5+6[>Z";M#QO QOQVMU>UJ MQ4/W];?UF0W_Si:G[TVHS ?*F1M9[?>V]A#M+^Q+>P]5/88Z<N%W2ESZ2?DS MF1?>.>SVK+YQ)<@>I6?>0PGO@O A75ZV3DP+Z';(L+Q&8M.5G VB/UJ@O&A288 MRR1.9R,1Z&R%&W70L?>P70L?>W M[J<[VNVNJK?R7H[R<C M?>Y?77G+QJ MRO=>H.X3&G&P%I?>0% L=GW96VQ8[6ULF\$!(NW4FBB&]>E&6J[XJQ6Z50;I' MHU, >GFUUN65F!A(Q?>OZAPG MNOA-BF78@>J) S0J2P,>@;>(>IH62K,DUC#<@> V1 !< @>IX;W M,J;WKWB\$PVN;? M1(4?>9J>D>E8B?>2J)74 (<4C)=FR3QJQ&WJH(UJXW/TST/JKZ?>83J +D)75#M QO;SEFZ\$U [J]E3V+O&N&A0YF1H?>?EJU(X?K1 !.1LY)<@>#JZZWW?>K@53!W1-KEOV,+N7Z M4&1J?>KJ?>S19JH&B&#> *#E8(K1H I*?>2+V MID! 8 UJZICI<IV XJZ?>9#>58=0D7?>G#T!KJY!>W1Y2B<K8)C[IV, &G5 MTU2-D -K5BS5HM E4%=>?>F22?7SD6D2>AB.<.>O>E4&9J[B=>OP01V7JR M.Z>@>E+>M=>L\$>S&9Q;>B4E%Q3@LBJ 19EL3&6Z?>EZ< .>[S21Z M5] OIE*#>D8[FKW<?>H??>?>M9RG5?>QJ.M0LUU!>X?>7. 28J?E?> 6A.(Q3CS2B-T)A)THOQ?>Q?>6YRRQ0.O*EXE?>J M1=BX*7811A\$&0&O=1SX5D1J1BL(8,")>T5?>Y+TA3ZE<@>R2CA*?%>CCI(R9M&J3 1.#~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

[illegible]

[illegible]

I9XNAZ830TX3;YOR/FC%MXC% JHPN*Y-N@WVZFV#5F.E3;W MS CZBGJ9G#:#C418&?X-Z/6TT>OIH%[O2IV*?95"W>4 0890.6 &;\I5:~
ML\F9.19Q&2Y3>34T,HW1=\/3<+0MPN/PPA"/^:&N=>.98JXD= MIOGTIA3B?M;:INGINEI/U9N,3/>+>T0TCX#>5A\U90IWIU(HI_+
MR860LU+,3>A5RWJ.WF1G76\07\$75\58EN#9>6X(ZWYS&JFE(I^UI@B)>63VO 4QU7U(2:IQK'KYI3 &FZ%K5QD9&%5) MT343<
\$D58S25;JF.KJB#*9AVFYGGFG< Q2D:JE &HR4E^:\$7) M"=10ZSB1^..QRV\;#I3&F(0*8@0U+K%N:KD"(<) VLY94SFZ>F.Y(KJ_1Z M7ENW\!^!-
GKNWKP"/+B<\$="CIMO?U=JIO"1" B%P\$16K?>3R@/H?X9LH/M^T+C;+X^#-49MZL;<=>PYMP_E>I'#D1AG(@\I6IN,=Q:HYTHK**7FX IQ
MJW(24GY.%AA%X%MUF6-S&Z:5Q%PW43%5MJ*EHY? I+>?^'^<+>6:T2POLs
ML&==H9FP4KM>.3W)X7Jc.:=JMLN:UOBPSMVL^1.66^L(LI:>>O%)819: MSIT(IK372D3PV6
IJOP+DX4RM*REG;TS&Z78G39RE@3G%49HXG4U%N/RFW9+A=^:ORI^U2IRO MK+L3I= .YMYXA2WI?P.B'K2\$'!&.&-"3*N?4#X MMACZ?:X-
/>+&14W&=>=IYKZNI13%:0W=7 %00T6.-&HVNVPV=RSMTDE=->Q MJ&9:AUx9-0=>76C@L0:QCXY4 "\$MJ60B06"+HW FI PD M:
MX4.ZHGKJ00I)1#1-353.GF&2MV5C-^2BYCH=I/2 FI+4IWSR M^&XW9\FVL7<15^U8JIGVMC/P&NYT(7/-<@:;)D=%%V/#D=B=>(G.1WCN)?
M.E%)^2IN2INJ_E'FGZ@JL>C::AQO%\$ IO6I^Q F:^^@>@6\$^I?8IPOX/9Y, M1TE?#IP;&K,V-&+GP5AC,+4C-
I@X3('H9LKV'CGO'KX9UJ)@<^&SR& M) <# =>+DPR)LA4;&HH*8 I MORO+I&8,"92:5Y7PWO.I:I\I\,@7#5<IY:NW'AY.CI00VTO^*1Y/Y8K*
M_UZMN=KW*_1BM2=S_5A AN:2,+U<+>)V.GSP^\$M;_Y_J4S)/WE#_XU\$ MXH&5 AEZ0^7QB4E_%"#FA^'GY'UI+ P04 " !L@&A9?C8# I M!P &O
'AL+W=OR+~"1G MSIQ#L+>N>F4IJ0+>I/FJH2IM!5&:WBG<18>1>D>:Q%_ %R M7HLMK! J>+Lc>(^I9 5:B->
IHN:170S0+>E=L7IP<#OBSAW9P\$6KQCSRJ+B MS25."17FGA\$5; 9IP/2K%0S3CVLOXSR)RX+%I0AM4.6M7#XWJB 9>'+132+ MH,".:)2_-I0?
<*IG\$'BY42Y8=2ZCB<1Y(WSIMH'\$X-*ZO8OGO?I+>.26I,"R-Z&Q\$;2&:"(G-1_*REM:E13GEY^%?400U@IA MA7ECI9?HH/_ ^YB'GO*P9YQOL>
I?2^!>P6<?>G@HRZP^X^')FX=P21 M#8I"IC"~A*89 IHDH.X&6=X\$S@93E\^>^M2.6KLC74YQ%Q%11^Z:U>+ M^!>I0U85^X31NTOPTGRI@S?
4<W= YIN:(R+IIB:S;*P69 Z\$+2/IAG*# M KK8)Q6=DGSVT6D9#R52ZODE^_ "MI0>C 5%N0?0Z<+O7:1^17R219(AM2Y
MJ1A#*4^>WM#E|>BZEP.@|@*>DOG2(D+5WB%&TD3S,.\$^4R2RJEbMT7:7(CB2 MD0U@5\I\I G+*7-CV5\0\$!"+VFC4GO=Q^I*/ZF423Q.C!>:5:-
\$4DB7DAEAF MUUK_*(%D\$9<13CJ15YRIF85W^<0 1K%1\I1Z3>D:0IBF<<3 75SWH+F MXI\IY?%|WH(CI5Y0S8JALWKKWQU'48I;V^4I?
3M3RU>^6RTQFD60+99 +C-&I\%XH@I= MA1SC")2=3J:T<I<=&HBXJ/V5:5 ABW:M'L:I MAUV\I-V YU>W-MA4IA MRV<K<@.AR>5T'(%M&W,
I*8.S7!M/+768)TEJ#E!UK2&.. I T1008I+ P%0 M2P,\$% @:(H66.MOB-"! & H !D !X;"I\W:W)K&ULG59M;^X\$|/7>S*5JL644A":*
)%.)KV=JNIGGH+VUOI\$=I, MBHC5Q\$YM\I_OI\$3*\$TIISLI+WYYYO\$S'GOLP5KQY50JN\$E2ID;.HG6^56I
MK:*\$9D2U1\$XYIBRS=C\JERV52XIB:U1EK9IUIU1X1Q9S2P:0IR-"1%3AFG
M#Q)4D65\$;FYH*M9#QW.V#=- 9.M&FPH3T:Y&1)IU3 R1DUMHIEIAEF'L\$BZ M&#IC\^HF_'@+>&1TK?;*8#R9" %D*G?Q?&-0K22!L&@K5G= T-
40HXIGB M="9#&L/IU;I%~L^C(GBDY^&B>+>3)T>@I\$=s&\$5^7VZ^TJ=K^~*1^ON% M=8D-7>B0FF15<:H(&^_) 7:AI\#?H?&B5@6IUEP-
9E5^0!J!..MNO!HUL MIF!>M=8HCQS3F*F6V.003HI^&WQY..R@I0G@ND-W\$551JG71ZXFY%Y2M7Y MH5M*UQ^&0CBK:FY+6 X^V" >"ZT3+8II_-
^C1)W.OVM\$A0_*&4YBWHN\$WP M73XJPM?9^=VQ?W X_?XIG2\$A2,WX<I+XF#P1F\$UVIG\$1TZ. M42NI#JZ M_ F|=*^R VYVLH-
C!&LJX2"F(C;RZL?*JID."CEI(<%SQ(*"Y'BEF5"=HL M I"19GHT=DY\$EA.^?2RIYWOAM8+4B-%&#-N;2*)4"C&3M-L3N4N@ST@/(80 M-*J:/=O<@:-3-
\$=^42@S/J_KD>8IJPQ\$Z\$TW'X%\$R(EINC^9&DA9Y0<) MZYR9(7^EDA/X1DFJ\$YS."I!_WJIB_ ^@V?;- 6Z.=D0^!U#Z36IK@L7VW)- M-J.K%
<=&=H854#<3T0IJPWYO>E>X@I00!4GAGD0)1DTAS VYMOIX"U^!N0 M2D6V<71WWUK^NB,&112JQ)Z.Z.=?D>:*T8I\N/IQ_!f#;G\$7PE604"3MV
M!O:_?O/2KUO,4&|.-@VCV0\L)NO79?NMX:~FH2I?="[\$\$v088ICEAB_BT\56*YXIIQ_!JEMO>"^B%0;V7QX5D M>:-
QDI8/YD(C:ON%+P^ALPW:SIH>EVS^+UNTV08Z3\$%&I_F R9D9B6FY@ MS100V13!<-D2G =>2%\$L\$R
800HQY^H9^X0IT@3L%F%&3/Q>OIR^MNI= MGJ?)"JL_!FG42D>Y3J"JEAAG;:\)M\$G\$JEJ8@%L.N%M@:5'@N#B\$K-
M%BPB&A\$QDW@I2#8_!E"S1U6V^7 5G>0J%<KDI^U\$K+DU; M3/#J14I8/I""+VMF %VE^1/U!+ P04 " !L@&A9<55K:38# !R" M&O
'AL+W=OC*%10U<3VW/XN:LX ME^%6IJIJC6C@>Ys+I2+6QIIG0J 3-19.GV@2I5F6447.T^2M2M^TJ9D#%D? M!4I+Q@7WGCUF4>"@KDW.I-
PIT51L.W5Y@+KKN5+9:I=;%W3J05HIXL&3 H+~NH\I^ID80 3>IUMO;W:X2ES.E4D5^I M&KK5&%X< 12\$+~M-
%OKE&5P54REN;H\$>782YH6I&E@R3 PLXLWBHN4ERR' M22\$K87;IT+>.*I@(\LK;))U+I[#S.#2VC2./I5B@V!%04+JAH9:IAL;A)%/ M/QO)I!\$43=@*
DP X^7)=#AUVO@R(I.I>*TS=75U(+B.HB0 M&V9?/S"3"VEXJB@_#A^@TNI(I!SVX5UY-H\,=@CND-H92-I93^O>1JI7_ & M^2F.2^6N _IG50DI@LEC*Q-
VXIY-K;VD1UPC#YVOI?3;9_ ZI& M<2?I_ I^2J>PIR7C! 2!PN;3=CM-*42U2VA76T:ZJ3N^?N=3>~9FK%AA8< MEP0-
3OI=#U3>XJ>D:7K*10JZE%NN^; E36@>Q>2>S\$UJMI^YDQ @.602P \$ M% @:(H60MGVM6! 10\ ID !X;"I\W:W)K&ULK5?::MLX\$'WW5Q)J4-B
\$IU25+;0)(VZ.I-D8W3IL-B^VAY;I&1 M2)6DI'; ?H>4K"BOI"8;I@BJ;F<S_00I1-18H/A8P14DB3&\$;'Z4-IW* MI5&LCS?
6KRUCWY#*C"JY\$A\>Z;ZFCLG#ID#@N_!L.K#1#R<=<C&J2B^I9E!> M0Z>:9&6RH@&Q:QXTIE"(ZB\$)0*^<5=+(H/U)-JR,IUD0::1FI!JU49P
MKN)D3+7\$MPSUL2.;DW^TR0"(A:DFG^"(T83 Z5N03GABJ;Z+H"ODP0;Y9;7X12R M5Q)Z71X06^/O:"*1&CMA8+I0-U7.Z4E\$M4 3\$H7/6:79F-
=JXR&L'8P9VD M0^I E_Q_YP^#\WN(I"HBO7W6)U/6_WK\I#?SAI\6BCVB3)K1I M#>W"H%W9=%EJ&(I:\$AG(*NBZ%I+R\$JEWV\)+V\$6\$N^XTI
M^MAAM740-8)60@O/S%QH(I\$V)8)\$E&LBD;LK12."FE @14DQ.IL1D\$U^CNM M(DFM&RH2H(B2@BB7EOQY7L/O C#\$0FIP2%?
>QZ:7XDG:=+>J2.5D2MLJA&P ME=5Y\$M\$N=AXI,4TD\$J(VSR,2D6/GWV17LMS;XX.2:=ORN^YS6+GYG@1LI\I_ U M0\0^7/I9P_K@1G8I?7Z'(1=?
SBLQ<I.WY""LV=Y."-IVD^_.C_!%I?> MK2I2F9#S'>:W)GH2=,S+JEBJJD;I87P\FYD,>)1L?HMC7&-Q81:THIGR) M@:6M
NKIIA;XWKU(64ID49&FSTCQZ%6M*Q(P\$SIAB;UVGK!UINI;U.T>(K9 M(R03H;(Y8A9#RW*8T_#9#VL_!3NL;+^~:BQF^N<@<J9+/*1=B*4ZA@*
M'.5T&=X9R&72ITP\$;N;+1-08UXI)T74FI;Z1^1\$MIOS&YK3CH9G='Z.MMPI^X\$U_M_P5D=@I)H(34TR&F.8L<80!L1CN,(IID-W 71@>TMY\$IKMZ;
<I@.\$ MNM/P%0A@;CD,4HH\$X\I/;&O=<4XM?G%78E\$Y<&E^XNR7(-EF=I\I;+&#&^Y(I TOE\I%Q@/CYCSY#U!+ P04 M " !L@&A9)\$1YTMX\$ #R#0
&0 'AL+W=OZ=J17NG=ZG2ZIT;&B#;) ML193ROWZ&SLAA;2/MT+)(GYAM_Y MX9I+~W*%I_ ECA(Y;Jr42@?MMIRO M,&:RQ5-
Z,N#BY@I>A7+MDP%LL 8Q5';M6VO';P:8R^9NQIC(<4U&8X\ MF<4Q\$Y\KCAZU_!VX"~+>E2>J IJ9LB5+4Z?O@MI:I9<@C#&1(4I X&+4
M#B#B#U_ /Q/?#'\$M\$^@I;YEQ_D_? UL#P@CG2GM@I/;_UQA%VA^I^%GX M;0AM6!>O!UNI.N?0#M1HU_8\$N&I9I\Y^E22+ MZWQNOJN
>285CPMCOA""2?I7HIUJ;CXIA\$#MSI#P>XID\$%YPQ0;#P5?@I(M MR9M_#D:P(7)I4J1+T-20I_-Y#2DG^Z1_12C\AFU%3O6G1KOP<)4I<(\X MN(I
IGJB5A")I)@.&^?90 E(C<+>(KM)A_-6=.PFN+;;K2?73/L^&^=@S_MGLRDS\$E0\$QS_7?1>Q^0^9 IFR.HP950D3QC(WOYT^_9U_6_R6+MUWL=3
M:K0@BQ#X @Q8F\$B)2@&I+K@+V2R.OA6B/(2IU@-A\$S\K!&78AIGN26HMS\$1 MH.S3C-8I3EFP^?)=IWI^K<@&8CM\$T0X1^600Q(C">
(BI&U@I8U9>4I(#Z1<4 M15-ALH3W^ID/K.M"\$8<="U7>N.N)MSA2^N MC+O-/AEK)TI\AAIZ>B4I00_3WO&\$A4JI4SOB;Y)AIOF9'@5H_V^"+_ \$0
MB_4_-&\$^A95BMD172ZBX;/(ZN8PATFZS@FOD^#;)&S2O_7I;PU*1\$Z4ZF MU^IWW<#SKAK;JAPG.V7IYH3U/Y\A&A#*QX0!R8.LF3PIR M!OG<#?
>9.*PJI MR1)1-5D12(L2YK*6UI1!UK;\$S\$1ZZ2K%1.5-MSJRJW_IY?;1.0;59AS14U^&G+Y/OIU.UYJNN"FT>:ZH;MX;H=N" L M;W2 V16H=5OZ-?
KV\GY@OZ\5I8IV#N_7LN#HIWZN3KGY9V?T/5_8T2I,(MZ3BE6 373*[@5HM_5<0>..)J"33_OI6J-N+A&M/+>=A%SIT1:MH%:AK;*I MURCTME,H^VT!
IQ!68:0.(^>K6I0ZG;JNM7UR1U/IRZMYQ%..IJJ6">6915IIM3IWEW;#AITI\$5 M(T =R)=.8?*)FMB^I>.^Y.5H>:&9Y.2XW?3I-G3/Q#).)%8D^C=ZM,9
M0>0WC/Q^0\$&2&P0=VIR:W-H965TQN^PIIH-A,+&26/(EN MMG_2G9I9#E@^ 2)3K^TH4O3P8^~J1(+OM=)N%55\$S562N^*+6K@+TZ#F MG9VQM2
V\3YQC451!E"MDDE:SD:2!VMEV^MSJZ7IB4E=-Y9<U=" OC!I4Y
MK*Q=0\$RxE N_*\$*R7C9BCQND0YLRU8RL)2R1NVNDT6!QMxJNQU!1:5D0LXUO@0TA?#J!_C^5B= M<JD^A!&=?
9S5\$;MH'D&).I\$JNC>'MIGC_5A5\$N_.AYV\$12M/(W8H90 M2IV-XGM_#D\I\IUCU@\$G1W@8+*UX+>S>F_!SW9C8_":D&-(N3VE_*ABSO
M2L1^1B/2^WOC-RAA4TE+.,+SV*KT/VY3I(@#>+>DZ.EN.K+);@6%&HJAR MT266\$) "QO438IJ:B9G"3?87\$"6QC!)_D90FS(-
@MV2!EVP\$9_GNI=62Y M+Z>RK>CRT_3^0=SY11X"KB%~^0/F*?2O">);^B.V^3FYIC7&WZ 9:L0 MS YN3=VT)\$ (AL_E:Ji:P_7F3B5P-L3I!#98M%:21
=4"8+~M*J\$QA!JDD^I M^U"(&*)_ ^G^24K_-@BIEEJY 02 /-&~?I0+>==\$I\$QIN=3IOG\PL@I)U!J ME@U5XUKH2PNX,
CK+7I>JR,&H4L RV!#A6.TXLCKD:75L=XIAEY?>W>I K) MBJ8DUSSP@S06@I #ZXI@SGW^B+L9%HUHN.PT+2YJ+@+I*G4K^CWR_!OES,
MCN/H'KEF9\$#D3@ (6SK(TSA-4UC.XBQ=C#XU/OJ\$M_%)O(C/89SE<3I-1Y- M^06+(- C_XSG,+I?>
Q=)!J5+&G2\$&NT^!#WGKU)3UOR&U@U7G<=Y3_WKB M^806?74/3B\MI!+;K=9U!@G196N(NU685OOY0.L=>I'GN^1ZPP<8/CKK MGU!+ P04
" !L@&A9K;H^!@L\$ #1@ &0 'AL+W=O50LP MV<4Q\$X_0_OV>+ILG52A^M.L5 N9RKO1<~9.MD+>JPVBAL2MPRW&KGHW!9+>
(4XMY_/F53QS:Y.41A M?&IM.IU+H_AIO+?^P>9.N2R9PDN1W_%;Z;.R(\$5ZS.I8W8_HYM/@-C+Q6Y
MLK^P:623V(&T5EH4K3%)4"R^6>I\3D4QCXY\$ (6X7Q0MTXLE^&9YK^E)JL M0IILF8&-E6K3<QTH"RT)Y>GIV4*+I^XC@|RE>OMF%
#:=W#UO>9ZLZS, MXH%4#R@U7^8(UW1>+*5F8)7^YINC974ZG6L^QCKIZ3B9I^!G8 @L2KU1 M<%5FF/HWZ<\$NBS"?
187X5&#"ZP\B^P70C^,CIB+NE.K+WHOS^50^9+I261 MI>I#YI^XC0^I-1?P7%4LO:E#-TRA?\$IGIO9-D/COCB05=TG%QZS/%G2ALYI"
M%BNX8U^R4L/<7 MYZU^1L1ZT=CG6^OISQ&I;UP5H20^4\$1_!^Q&AL3HH;\$ M\$:(BR7^6D47N) KC M=0DL33EXWP?MX(I>IUH8TY(4/6
JT>4*5<&\$)XB1?;1??"IUI)3 4GEAN4UOM2Z05.X>+DVF%K8:E+I@ZOOM9;4+;;#I\$EGLJ1)MN K8&..(CYC=SA.X#<(OUXX#Y.(O="CR9&G)&YV?
V\I+8RXP/6 N\> !H!IT MT I>#?T-SCIYJCO&S@FH3!VEPE'KKZ"?/*IK\$ 6^-Q3HI>G!D&Q9P^&C-Z M7VHK="3!%~!F. IV\$^QF5#D=X7<I>5\$6/Z
JIE+B1/S88>6^2VR-2VX0 MC.OR_K=&A9.HCAPPS' TT>I|I+LDNINIY+8#2VDW8KB^QT?8H?Q^KYOI?WA M.5(D^2F25Y.B:BOE7TIKW-
6F+I47.O8&HGAYB4PIJ KB!_5(4R22MW;:E5 M088DK7O\$X<")@@&62Q8;3Y/Y20\$U!^#IE4IZ^K)J'O!HDAT< ;^9VC+T(MKHHJ\$SNJF.UY4-
Z/3%3&1B/3687_HYJF8")XP3^Q <91I)Q4=Ye+ 64M2H\$S:QDM^N12-IU)MJKU
M=O.FI7D2:QK#STRN^0'(<46JOC>D:B2:9JN9:%9I&ULA55;:JHP#IG5QOETI1^J+>D2H_D7C9M M\IJEFX/TQX_.216\$SNS2C_?
L<.9&RBI^4^I/T/WX>#Y.5_>Z03P4I5" M3IV=F/K21_6RP(KI^UECH.A^JHH9VJKXVEW\$RIT-LI^GA>+&.OP9Y.Y?B(YJF5[3S.Y2,5R@T
MEP(4KJ>57AYG=AE_~"X8?V&^5+*1MIO/V=0++>^\$L<6DL_I-EC3=8EA(M;S:87K=D;PT-ZC?W3>2>6+IJC3S>6:6.TCS(S2?
=K_#0<\$H>*4@VA5\$CG=ID&-YRPR:393< M@++9A&8-)155\$SDNI^4I&D513G5FIH\K% W^V9PM2M3G\$|0JHWYROW"=8L0
M08(PACLI3^A^@M^P^IO>)S8=I6A^Z3HZ?"B(I07\$01^B(\$I,X,6=Q-CAQ?^1 M^-JH8VB-
OAY3&2+D1S'L\$ C4M=LBS_/_>VW7+J5Y@P M^C@S@ODLMEU@OJWOF(R3/QV)2I05K^DYEF% M#L.V :BH,!IDH\ X2JHIN9?I2VD7_\$.4"(CR"=
4^A&8R\$ 0IZC:%D"(D 7 M;+!;H.INV262\$<.9%U0K&TT>?7I9FSN.85JMP-*PU+VOC3ONC.VW#JW8, \$EOA^D=4SDG026NJ#2X M&X\4.V
:C=&=UFXH+*2AS>I_@F8Z^IM_9649K^Q^I^W3_ \$K/24\$IL!10 (M &R_#G"/^%Y300 "P*_9>6P=VIR-W-
H965TBEPXH6S.SP<4IOLE^R8X4I&S4W4ES=OKKGU.I_3EUI\$S.PAG.H&G^I^M300^7 M^7 NVUOT M+RYWS&7_#9RKZDI1V+JC3Q6P(*O*GNG-
K!#ETI*>+FJC/O-/IUOX+%9:RJ MNV\!D4_O9CORYJ- J(N(*VX49H,K"(3UZ#O_.Z:[B=[#&I\$D)6QKV MFRR@>IT_0%XIFF.6!SZ+@B@Y@!?
ODHT=70SA9\ZG1NK4I1 MOY5NB;Y4C4;Y<OT(I>IA_O!@GZ%- OEIW 8_7J!+CFEAQ)GIWCIBM6%3B
M8#0>MUHMA.5S40GIPES)>..I.J&#&:WW6>%.XUJP+S@&^ 85UCR (6=7C12) MOK^DN.)@ 661E6BP+6*WK:(VLP_-T)L\X!&T\$1^2>~FY8&R>J&:/
M?GH7(^&Z+WHQ+ 8/6IT10BE07J(XBUB_M\$!(I/D+AV1N^Y^ON#!;<*9FEE,7ZJG_#0GI^ M1EF:M/U(DH@.E=X^+Z/(B?*#I#%DT"GZHGMS8?
S^HG20:\$S1W?%0WXI2I MQ@T T RQIH=^%+I5<@N^VWLF38-6)=BW8=B:"0:@^=:8;#W!;I+ITIQI< MK:1M/^:IV=U5Z+2I ?
SGWMZCCKA%~NO6!0L.#8ZSU.ZO9NT#U8UICXP5Q9O M%XIL3H^FASP.4)A/L^6F!W09S"UI+ P04 " !L@&A9:08W!# "U M#P &O
'AL+W=O1QI>"FQVD^J8S_.\$~Y%SHN9<94USYODXRR^D>R (S^CFDRDJI^IMKZNE! M4P?#N3\@HF?4R&A&,\$P\$K120NSGZ9PE<N9>Z#UW/+M)M9FR'

```

@=5= MK,%*^E<*67L.D+>AF11$P6:N78=7<>@ SN)!!/@=!!$U!$!2?K.MS^G<"^R,.$+B+
%UOYN@/!+A/X71%GZM4+!/Y^9KIUP6.P3U3C>1 L=1D M<^ 2(RELZ(Z:1WGX!%5 8N72!)=DQPIV\ CR4X;F5=@G$.1/FF/RHAC@!A MI I@6
&+&+P'C5P"C"C'ZJX>H D1.F3(4IT- ,5W.E#P09:V1$7FX,1T:PV?)" MKOO:!!QEB#&+!|I6E@U+RT40*8E!)XH5KBTWV9+G3B-#C:3U" L*@R1W2X&K
&M;S0YB;60QO4Y-9U!64^8(/,PD?C& 31:V08#)=(M^F&K$8D%<X%$%+ M/X#)BV>6J;J7.3X1U 7DGVIPW RV4N VX)9UFZCJ>VX/H24%=-
G<.).V3!X)I#&I%$M>13%CL0(.2A2A);2.IS2L>2<*GW> MIF#<-%.IN3+=+W#A!>R= /HZ59:>RJJRC&M9QIVR7**@".B.3K/>1/H%IS ML)/P5WZ)
M@M(FL<5>+>?KCIZ+/F7ODRSNB:PA^V4M^V7G BWWJ?^UE&FV^R-86HI V<:0PK6.8=L802IP14<7(+;Y MPO^!@<2*%&S<K2CIK8-
^FIN<G.RTXGV120/LGBGL@:XH:ISYMD&LSL +? MD ^!JL15136U/IK^AYU; ^&$@WT*=W2PG^QBVY+Z11I1WY:4QC^J8=34H.X#C&RG-
<.).ZJ^OUQ7I02P.$% @ :.(H6&UL057:..MM $/V500TE M@6+!B5M*^N2F!|.#*#8F14/HPUH>R4M6N^KNV$|/^K.2(ISB^*E?2?>YIR9
M.Z)UMCGIPD>?Y5-J-@A51=1&+&EMA^S5$CY3>V>1.6'X2NLBB6-A4 M81Q0P| 44@=I4M -)J8-2FI<6;|KO)*%4 ^<^F.@L@ MA
HSI@R"EPU>HU>B/B.XN>.,6I<>N+1 8!IM.6A7IX;=1WN:35%<K>|E80!0Q^!XAT@ MKN-N.51C6@-)+*F"19;.YO?UJ)*K- @30Q%.18FA*7|<4A
M^V)OE M7B0Q' 7>"0IO!/(WXH3N.OAZ1T6MEI(ZOIU.C85K^)^X) .U7AY, M<;PG;=)N U.G(2; Y|K>?^4<ICPU^8L)N>-&9%
NT4KBI@2V$X22 M3|I=W3413K%K<1$S(K@4 ZH>; M>?>?JW 4&?Q6 G1O+O@1.06VUD-IPIQ14>?><)=IF;#4.E4!A&.>#4VQ5/ M>K3>@-
SNT8CMX'=^/1^10@02P.$% @ :.(H6;>^W$H P O H D M !X;IYW.W)K&ULK59=;|HP/TK5E9-5%J;3Q+H M6(I|$:I.JTV.IY-USSKWGVCAWM./B
M0:X!%E.DTR.C:52FPO3E-$:4BK/^08R7%ERD5%*0!$RY48 C0M2FIB.9?EF M2EEFA*-BID:$(VZKA&5P(CX.TY2*7Q-
^&YLV.9^X!MUDI/F6H0U 4/A72TLJ 2KGCRC<5|/38&|HEA2?S MW2?+=ZC|+5>Q1-9))=A.4.S52;0B8BP8IR/H0?S|<G6Z?4Q&<^|L|
MANI6!/>E$;R*X+T!0KB&.-TGM1N^E5-IPOB^H-0Q35+I48+Y:IMT0!>5Y(3BYSLC<E^XC3D+ _9HV@Y+X="LH?EVO&&?>F^U7UOM
M^I5ZGXD7FBUU^H?A/<=NN&V$W$'3:(>OZ_H-I5D:-1@&W5|I|VM_U.N4:5D. M^!=D6<13Z#+IMZ(&@X%-L10K8%-L;U_8!-J:O/F.PJ T&1PW>
<463+EM! MZ^@.A@U;Z ^NFQ &G MOOFNK&K=E.F!PMC)!&.- 0T^79W&V55UOUI9&3D80!L#.SM0 ^D(R-VTM)M M.2/V_#&1%?6KD; ^H9O^POL2
P62IOLISQOAM=K4^TNZF^:FW>EIO:S.UUGI MIKS)^W??NK=->T/U97I_5-E6>?NT;KU;DUF2Q.UUFQ;EXOWM.5A?ORIME
M560R61GUI7J=5; G* ^*Q!S.)^WXIKJZ;|L.G%^!0IOL@<IYN9%5^/I MHW)9K/~-790:HJ ?3CY;+Z39I;VP>X5 U/D^HGCXWM6 E.EM^W/P27^TXF
M^MVRW^5 FRV1)9^|= BE?K:92NOV =NC)8Y ;AD?/^CNILVW; ^9K5N>?RM7 M%6I>18>3Q/C.O^6WZ:Z;7H?MZIH?G66Y;K-O= X?I:Q?S$V-Y6S?
ENFO< M;L&ZV-S F2W611/&BS PVLKH/U;(^UUVI;(^-9UVV^VO.T0-YUV!^; ^+ MKL BV 9G78.S8QN<=PW.GS=@W> M^GO $SLN|MI-X-
G.XN:2^X>./OR.C/KKIX5Z)>2@L1LSG-(S^4QC1$|@M(+^2QB.1B$A.DEI18 M2F(2PI2XFSW+W4RG7WS9M6/552^O-
8E76=UT81%%RU&6@TVPPL^O;RCNM M/3;O2.PF.8?57!+S2.PGL8#$PGMILL<VARAW%VGV _>G|XJ33^RSYC$Q/X;
MFE^T^WDP%=I|J2F(0P)3FCRSUUX94?P@V%$>ZF-#B.1L$G-(S^4QC1$|@M(C M++S^YD^<^M_A$"+
C$E^/I<S&K+&E.0DA^D9M^C.H(4V|H|HQIO>R;ZM23FDUA 8N^B|IIM^T3Q/ (3F.2$T>?>^<^P@X3L-"4Q"6%"0T|I^M+9D0=%|2C-
^+SMYQ_&T6^_I|J7@Y-36FYL.)&836(. MB;DDYI&83V|(B84D%|683&^*Q!(22TE.0I@2<>>)$7?^>G/QYV3|OFH%|L:B&H1JL6H)E
M0:44U22EJ8%G18%G<X< M6V=3^4-J-JHYJ!-BFH=J|JH%I!-B6H1J!-H)5$M0+44U26EJY_07+ 4WM^MHQ MU=T=3^Jv:CF=K3
0@Y.YRT5X15/-1+4U$-4B5M13!:@FHJDE^4V.L M7; K1K5Q-C^RIJO0PIC90:GF=U719Q^TINA4(S4;U9Q.FU=I=3^20J^JKY
MJI:@6HAJS:K%I^"90+4&U%-4DI:EIUJ_I-XI=^+^<C^N45_G7^JOU4W)H.0^J
M^V:CFHJ|+AZJ^@:6M|J|(&A;G|@:F4^UIM135)*6I|=7&B+5YR20^4U.U M-0?57%3S4.U^M0#50E2+4^U&-8%|":JEI^8I33-9;|3IH)VZJ:AFHJ|
J%|!|A6HQJ M425$M135^FF|I|8^I72O) M^V;DT^H%5+!;J?2YJ^%5":CFH9I|&@JA:@6H5J|:@+5$E1+44U2FAI|J286" MJ2114?"DO*K53|9A|8HH)J-
@ZJN:CFH9I|:@&JA:@6H5J|:@+5$E1+44U2 MFGHYU|ZPP9J|WF2 M%9LXKZ8JEOEN.&N7JU56U<9-7MV/T U&|4<5^-1S4.U^I4^5
M1+4^U&-4$J|B6HEJ^I#0U^?2J|@O1%>T^"D$ MJMEHYJ!-BVH>JOHFH%|L:B&H1JL6H)E M0:44U22EJ8%G18%G<X<M6V=3^4-J-JHYJ!-BFH=J|JH%I!-B6H1J!-H)5$M0+44U26EJY_07+ 4WM^MHQ MU=T=3^Jv:CF=K3
+JIJYJ.C6HJ|I%I!|:CFK#Y2VN>WXBK>XFRNMX|I(Z;IE MDM+46.IK^J7P|A6-UE1I6|I>9U5%15.YA^8G7H5J|:@ZJN:CFH9I|:@&JA:@6
MH5J|.L+:OY%G8.@D+L.IH|$/OZH!J M^JYT_WJ^G/HAN8>VJV|:@&JA:@6H5J|:@+5$E1+44U2FAIK?>7#1.BJAX-G M^?3$Z
M^RQM0S4$U|A5/-1+4^U$-4B5M1372!F^<-30-;|^"ZVSH7 K M29+2U^#JBQ+&AIIP^E2NU^7&JPMR^E5T33UID=>R1FHUJ|J|JYG;
<^<^N="N^8$SL&K)HBG^K38KL M7=YNEL$T0PL4_U&-0?5W.G^4ANP^PT6T1@#5 E0+42U^M1C5!HEJ|:BFJ0T M^<IZO1=%PZ? M4T
+&$%-1C4^U5O4^U#-1I4 U4)4BSI-N2S%P.@P1GL5|D9.|PL5YH.G/^* M DI3HFG65Q;.I4%|NWF|JBRHBXV5T.OI&^<-I90S48U|I5<5/-0S4>U -5"
M5(LZ39FQNOI|T<3V^K- M0354E23E&8&6%&E.^Z^W^"HZDZL3K^T&H 5^-0 MS44U^I55 M0+42U+9 ^PUS.^0=2ZHEJ|:BFJ2TM0$L_H$TZ_S2U;
M^M=5%13PGHP=%QABIP1S4^U5O4U#-1I4 U4)4BU M1C6!@FJ|:E^F*4T-O:X^* M8#9I05."I0_-5L5-0S44U^I55I
M0+42U^_5B5I.HEJ|:BFJ2TM3ZPL_MVH= _I|2 GA O=>CFHUJ |B&J1|@6HYKH-VUT@9>.ATZ&X!N MF^0T^97ZVH^9"4#1TVFH?4"J&:CFH-
+JIJYJ.C6HJ|I%I!|:CFNBTES(G M07M-44U2FI@?;G _;S=IYR:8FEVY?M^N^GIS=&@AI8.HJ|:BZJ>:CFHUJ M:B&J1|@6HYI
M0354E23E^&F|U^_5B5I.HEJ|:BFJ2I046_2+ Q?Z MQ?IQ>3B M<M^9EMU RWO99_RZM^TZ99>U1V?X^V^Z>TR14JJ^K^V<*RL7^<DEYS
M^0002@I8 _+U1O4U -5^"M0+48U@6HJ|J6H-BE- MC3FCQSGK1|>+>+^* E2S4#H1J>134
```

>=&PO=VJR:W-H965TNH0+2M&KC ^#FUP;:XX=+<= 'K.3AHZ\$&,VBO=,%#J|8YJYFNG6A;X%2)SSRWQ3AX&T".2J86 MJD9M/VJ3CQ>8*6"|+VR;W"WB
:&VL3*ALP2*BYKJ. LH>G#H'IXN@Q XB?D@. MO.(&K97YLBZ99>EJ(RUHETUL:N%|X|4#9=NBG.KZ9035JSQC7<,%&4S#8 M<0=>^AA_=@?<4C?<EL2|EES\$|PGG M6/4@B5Y|,6#+CW_#7D|VDGE'B^Y'DFI&6R,%:3V_&U:Q3U58/NJYQCG)N* M93@.R|(<Z@T&Z?)@/S\$\$\$HZD3G'Z^F M.,/4SLXV:=2CD6SVB @|)^|UYVQ'VH:MMN%|:3= 5S9|<K\$#FUE QK>|,JBRRA1 MKIQS&LCA46MK;+=K=UIGPW|/7^F'FULU|QQ>+2@, E0:/>@Q*J|>I ZLJ;S@+ M9&ULQ5I=^(<X%TK5G;T MFDK3|)D|'I|N -.H=J5V1UF9A|&Y^V"" MS->S/|I=4*.\$# NR1KU1*X M|I@<^>)
|+OL3<840..5Q@+I#..\$CZT5D*LIVR:ARL<(WY#USB1 RPHBY&0MVQI M|S7#):XGQ9'M.D|7CA%K-\$@ ^Y<C08T%1%)|..#/(UCQ/|IA'.Z'5K0>OGA M.UFN1/;#|JLT1|/L2BZ?+&RSBY1YB3&"2#>@ Q 2PAC A&|);O M78-L*#>GL:/>9#R|EZA".T^AO.A>KH=6WP|PO4|J)SW3|RX&U.GP0AKQ _!-LBUC' F*|8V+& M9'F"2|, 2S(<@>?HG\$MPBP3TWP2L2O'.3 _+|/S+&A4R3D0I'=W8|<^>Y| MHP&C6|'R:(F67>3LYIF2+YD)M^|V4/DOD7EB=^(\ J|OE&) %<^>|)"@>8#K1M|ZQX E< |T(Q\$1|*#P2L "TOB?>6NP50^M'TRA_&L(15\$>@Q#|XQXBG# MEC?7J 0YD.W1/D1Z=ZL|K MRFAS^>X@X0 1..; J(38M>VKV|XFMCN^1B\$>6G&FXIAM|.#7Z1|?8=7Y3R6(2 M^1)-C.\$5A@P?7T=.BCR8|TETET% RZSFV=FR|FY|SZ<=&|O|FDI#H|>Q^ 5 (MHPM)YKR90BLOI=?N5K^<?I^A9R5\$YK^>?GF7SP.0Y3+I^"5A'3^<^QD(I" M; _<4F@<(K\$9AIZ2PHZ7P3RKDM_|PB,DFIU". "HMLAADD| (<N18QAA_|UIUE M^IR^ULX18VZ <|<#J<8P>X>D:GO:E%1+8#52NR6IWP|?>D*3ZS.(|1X BM#M M^S^K#+HJ8?>W;;&L^<K#>=LKF>UIF? TKE=3.P9J14#).7BK.8@<Z0ACLY">%8F7&H=^/J M|5R:G"SCO%2*.)-N>VP4+3**C.&%5C^J|8"7.&>.NKP=\$15Y?7<0SY46(YSP<|JTY1|JLK8(Y)+DG 0 MX85.PMK=8/R.H.G.:-\$;%H%<^>S@<|JHCE6D(|/24\$E8<9.JN52^>Z\$Z M#U|+ P04 _|<H&A9B?G|:QTS_#8%0_&0 _'AL+W@>+&NVL'SSRQ=>+8|JW).&\$+> +SG#PHO.N67F8| MJJ&Y%\$3| _N\$2<^<Q_N'86RES3+>_FW>RBXJF(<|+06|<_ U9P M#5&D/6\$<_OL_<6NWI->+8.W.P|6_<N8SL|SHC#ID|J.61N910OP% M|..^J|?2*>_Y*48ZW5(F&HCX|<(8(XBYR/_9UR(1&P:HIJG+PSI78->BT%0 M& 09T*RR#-8-.VPR50*%#L:O=F+#+>9- +APM+X9|2^Y6AG|K>.*_#112D0 M.2>W7# 1|S_-Z#XBMFE- MDG-C'M9\$?>CNN6\$>=>E@X(<|'3C6H%9LBN>JSDAH|1B*_\$6? 9YOOTB'6:64ZUPD+X^"Y9|:7|R1@<0|?2|ISH= MU.%\$>S^>(&|:BASQSVIG6|POJ|X|X->8(U%MNO-E@%6|8U@<Y?2|'3|>=&05 M|ZB=^2,IUF@DHCXOUA7(JFU+2X"5|S&@<FL*U^ES7Q)<=5@<^J9MAG96PSIRP M+L-0I8B)"UOQN,1>P>-TMB^>LQJ>MAI O:KE>TX|CNV2;=|^X|GJ/K(D67N MN(<ZK Y@<MNNUYIS:53867?NH'ZPCM_-G4|=>VGQ)'LAOA&@M_6|Z#Z-5# M274E%<^|@<_9GNSK=3F'UO|1S+D|W| U=X'7|PV"8-"R-"L-UYW=+>+."Q& M_1IE09TRNAOXKY 3M-(3|.<\$A|L#.RBKBP7LOZ- =Z+V&#<C5L*8ZTTA34+2KV M+<|N;_O61UH7%7X:HDI34+>HJ&I%18WMP|7":_1V4#5|ZW+BM*VIT4I04+>+B M;J5+<^#5B'KW4'<SE20_1ZWQMB78/0%h"5 J%N'2?7M\$99:6%02EJ8 JGAH2X M^|M1'52|'K;=@<J|K4+/_C>2?> 2@4NA0W3K8 JB05Y+M5T_VN^&I9:HTUO'D| MIOGV58|F|+!+!>U?R2;+2+9M^3_3|R3JHW=>#KK?>G7DW8TSLMC29H|_-0EE*DO^ MYE,^+8|G+|_-#N9W5_3|.C|DK-SD9YYW3\$.SGLB81S-&E|W:(9^C|&#&_3+)_ M3N^FTA@99Y+&8-0=>^<Q"R@<9|94N-(W_#_7%Y1<6|JZ(OMYC| M|(9> MSH'C-&.OT|OT^<6:7CY_-3&YX.LH8+<EHD^<DX%N&Hf(<6JYV|W*_| MVZ,W1_<:SCF/G3|MW>H\$?<^&/_L|U4|JU>7D2J|KR#R+>?N9CMA(-<KNT_'J*8=272^8MT MPF*=L(5.6^<@<N0DOW&2W^<NDRV?)Y|V17|XKJ|5).79|EBU|_3#8U_ M;=:,+=B>OVVZG.CUQ+<Y3X07Q3=GJC5WVJ-X+6 MV|(>NBUCQ>SPZ83%.F;G+<I\$>S^<S(OFFCH7^ AM6W5_7J3S613V|<V|<G2L6S+ MLHXM&76\$V4XK+<Z^>15'ENTP|S|X4EFC|S:EY|&?> IVH0Q^<EG|J#ZF MEM:F7.F|DIYHWUNCR.IHSVVOXQJ.V@WOCK\$^H3DBT8RF M4EEG@=>@3:74P M5-UP4JICAEO".<ULK59K M_:YLP%|TK%|JNF5EK*PG*%*%>:;&J\$JN;=OOLP'58-9C9|NG^ 6Q\$#6DIZ|J| M_3_N.9QS+<82'1A_SCF L1|+<72|R6L%K8MDAP*+"Y9|:7|R1@<0|?130K% MO0&G|E10VW|R06E|2PAU|HBX\$S|J> V6|I>5+<POW|)=+ MO6#<485WL_Y6-UQ-;_|E|I044 K"2L0A6UI7|F(5ZG@3|<O 0?3&2#09,O:D M\$S?ITG*T(*02,V U6T^Z|4\$RD9?ULJWND|O;^<S?C?E98L%K|C|35*9 M+ZW00BEDN*RGAV^<0^MGJQD21H6YHD;ZU@<HJ85D10M6^<I2-G'W.A|W_# M=PI>)" ^<O;@<@<_LJ.K366. (XX.R'NHQ6:'JC<+<1R0TI=<QBDW:J5 H|U2SRHN:3 M%?<O2E130^Q#9AM="0%2(C%RFZ);@+;.%\$>6.H.2+<I?V M7: S1\$KTD+<_J|@<1V5|IT_QVTJ|X:E1X|ZC80'6)?<+<|APO&(^<OON%K2|3< M-7#_&<ZK?^1)|J|D>C/<?X>O|:L8|M_<@V&@<G/<+>4>\$E|8Z4P+X'JSX|R=W MYGP=>=>R M_L\$<C?J=O|FO-W|S%.8#Y14+AZL0=OK^47T/3&<Z|'A|^S|W|ZKQ2-KJOYFU M>YU^= T2E.I(^=0W5|TSN5&PO=VJR M+W-H965TPT MJ|UKKN+8EC5*9D>Z044K^VTDM M\$USADP;2LG.YA:6%7D^C-J?>.;+<VOF|N;@<ML09NN_-DZ\$H'E@<J+E%9KA48 M7\$RCF_3J=N+S0|(<CFN|<0:O9* |U|P>|JFF4>\$SHL'2>>=>=60A79DSBW=;O#^?U|<H.H(<6%ZP5|E|FO|VOYISSE\$K8|<5U MGYS\$4+<6:=F#28'DJONS|MWX2M@<9V1Y U@<RH+LK%\$3>.>|>^*W.@<U|<:X0 MK 8TB>^*K_&5KEA'^<6Q(YE^<Q_NT3\$N|EX'|>8|_|Q|K|_PA^<WLRM.W2?>NWRUFF9|<B M>^<S*JS\$<41-9-&L_|J.C|+SY|J T_@=<R|O7@<EO^K4|8BS4NDMO-<Z:4+ MKOT<^<G|67H>C F^EO_#6R0&7NRRICATF<=\$BY|<N2|'V|VD&%=08 ZXF@<ZO| MO|F|N|U|JQRO2-QK9Y>'KE'|<A\$K^<P5H5R2C-X|6VQ'BKG?S+<1(69|5>6|>:S M2D87U|JFZ_8N<+<H|3:7COHU^<M5Z<X'|I?2_-W>|>1^TPY;_ %02P.\$% M @<:(H622AZ-P" P O D |D |X;|W:W|K&ULK59=;YLP%|TK%|JNF5EK+9VB3|4A-R+|)1|HUZ_8PI<(\$)-P\$5;&:_|IOW MLP|U@="LV0H" CCG^<YK@<|P2|DJCCP\$>L|2PD=>+&\$0^_<V^C^"=>(<F0.3, MBK(|JEE^Y/G#"D25EJ|E:EFQE.B!\$|=B.14-B#0A.&.(%UF&V_|QI'0I M.FQC-W?"K&A|LQ@<E.USS\$<F;F>V:M\$B49\$)YD@<ABL|L_|U9CZ'|U7Q8 MKTYV4DX6&#ZJ\$J=H9%@<I(\$A490'E|J|-3'|E9_XV>E;=1+<N)>^Z? ^07N7 M7A:8PX2FWY)(Q"/CRD 1K|^1BGNZ_0B5GY|26|*4ZR2:5EC+0,N^"YI59|E| MEI^RC9^J/P|I|X\$WP:D(3IO@<4-P^X+|TA6|BN"|<=<5>1=<#6S=* |3ER|<O2& MC&X14VB|IAHZ^YHMY40|4F@<LG91|<S<_<RRQR=AB|PDO(S=|<F|BQ&|O|J MKE"JIM'T21Y+<18430G@<@T Y;0^-WEP+<#<2Z)<_<0G9Z7|+<S M\$' _<05RK7?(L1RO(Y|D R^ENEYW_6WWSZSLWMDN'6|);5>NYS>KOC=;="XWC M^?UZO603G_ZKCTO5|UN524|V|<+<V%DR|!=|8| (WCIQO:M|UT)?TVQ|<#7 M|J|DUM@<K|X:|YAZ4V-9%|J|MT0*1=6E"J^5E\$7R2:P+Z^<YF8_PUV8?A,3 M^F)ZKM?<3 |O7M^J.OV=O<IF|ZC->4R9.!? LLJG B-!>0|J|_9R0:T8U|20 ML'L<5N0|2#2|UMFCT|<7OW;JW_4ZV=9^OS-GG^<08L>R6_ZXW+<3.GB|5VY MY?_0T|J|6S3WKL_V%K6 5R>QH^ (<|3C|E|EQ6^<85OC8BWLPL3O&OUF'E)7\$ M_ FRKKK%|W|RRB'E5\$<NKB4|<1^*6J'L"KKRW|A|O=<3.6Y14P9\$<TKM_KJ|6J NVX#=<02P.\$% @<:_ (<H6&UL511|L.P\$<XK)S.A38(E2|LQ1A|H9B8Q\$2U M.GA_|+C|E'FV.%VVO^O.3M|^*+<7%UX2W_GNN^<S|YONM^FR%:*YU|H|V65 M<|UE%-FPIK;4|V@<HIU2FYH|L|TLJLH|7H2D6D9')|<1->96G\$P4V6ZM9) MH7|NP+9US20>@<Y^PUS|Q>+<F6-GOAT|?& M#<+<6.EWWR<2@<%|K|I^? ^"82DN#<A^1/2+<OKE|I><=<=SU^C^Y|<^*Y19 : MLHF<4Y/2L|J|OKJ |EWU|<DE3A^ 8=>|>P%MH8T-4JG4K30)2S;I|E(^<^<^<XA&MN M^|BE:XO|J;6#|J<^E- QA 4Y2#<W8\$0L'72K>6J^FD2>?<OEF4|VQ|E?2D|4I0 MX5XK5UGXJ HL LV2-|<I@_MF^G^4' 128G.(H2-<JG(SA<7\$<J|T-?Z- F7|@<VQ5BO(O9:2M^C|J#3VX95^PCW8^?|Z_ 9NPSB:CB\$1_|I^*) M=CJ|V|K_*O1OWW\$R\$LD2H|3X|V\$>@<EFL3< M:D+<+|6C:0K+BIX0-#Z |JDNMW=;P|88'<L'2#4\$|L!<0 (&R_*<DZWCG> MU@<(<(<9>+<PO=VJR:W-H965TR<=>6I3+<M?C:J|)FHI|J= SOU|I2 5.L\$Z0>78NPC|<T;8'=| (<66V-D4IES_F@<F M7X|Q@<B|H) KX^U90570^E1TAR_-Z>YVD'M|9W_<S^NX00|*50Y M|E|I^<#<# 55W?<T9-<G%1B_G5-I2M|<W|<@<Y8U4O- H\$<X*!_|*GS8|8BL@_MBO8\$1)N R^*W119R@<A7.1H^OD3^|M9H9V%|MM(8CS+R5F1+Z+M%Q^<KL|G9)\$ MOQ-0F%|Y@<D|I3+<_YHJ&^ ^<)=ZH1@<X) (U53H2E^<UF|S272\$<^W)6|D9H4< M^4Jc&\$\$_ W|A>M8K^1ML9U&>H^WQ4 41U#T><L-H@Z3OZ574F73|IET|YD=7O| M=%_J_O- B+<I7OG|O^W>KWW?KFS-R+FN10S4&@7M@<^|=WJYQK9;45UF8B- Y<#I M=SC|@<S@ (L|"+\$<H56+MQ'28>I&B#N\$^<T(B0LAWD5(8S="TB\$D;T48N|'2 MUR...H3|6Q%2%)@<IV&O|D6T@<XA/8AP7X(N^<@L%PF68|AB&^<DBX'8>=X _"P M(U>8NLR&V|L_-UC%<@<9_ZV|PT.X&|S3V3\$%.5|<V@<H B<|XPY2QOPO|<:1CT M|F|6LE>?P|C;7&@<16|@<104YD|)7A_%.%\$<W\$W4VW#GV03#^<G|+? Z@<^<FUIYBL2L M.HN%#<@<O_|CHT|T;O=<JX;5O&G^<O=<RPU'T^A-F@<JRX5R13TX6Z|Q?<9^U|+ M.P04 _|L@<A9A\$<J^Y.# P\$0_&0 _'AL+W=OF8YE^69.TI (I|K+<0^<GK|)96L M M)Z+<^<I_7D^<MC/#-AXOW*7K1^H+9C@<MZ1H6|AM;SE.S|8E3G.H1.H^PF\$U M.J |9EW|<5PDZXS^*61%W3E0I2|8>|U_|C#|LQ0@<RB^2^H^CBP|RR3^<SAC^<I- MJ_-J1+W\$Q_1W^<OBL9@<E%3|GW7|T:RV1F3 2P2X|E6:OCVP_0^%12>|!+<A/Y| <MMDVL99^H\$1+E33(RR-B/M(C^C|U|'8AS.L|&IS^L_|<)|+<=<6A-3=UC65 M_|QRM5<12..M;Z|R|B|V4.BXDQ|LYLPG.SKE\$Q_<W (GBX1R'|<@<Z11 M)OXD:|D^|_1-7&1^V|G.6EY6D6GT<7J=9|2\$<^S^Y+A#J^|2F|IGIK\$C|HJ5\$45 MYPD|_EAA4P\$^<N(<|<FFUA66YQ\$6-N5TPNX@|/'N- 8;XEB=-X+/_23W1XZ M.BNUJ _M.S>:7G4R^ 2U2">8&N/\$^<^_<|V4K MV|2^<B7&0&=;_<06&J|V/2R29|1N\$<A4R|4J|OVTJG|^J211E.OJDT86-|S MGDS- S7Y|OV^<+<0W#<L0W:4DAWUDIVS8@<NYJ#036\$<8E|OSHMD MRW22^>|>HY+<0<DI&RXE&^X.D8GF.; B|C7NOSUVK<Z Z_<2M\$<+VS@8 M4Y|P#K2V->N+<_&7#M|V3|S_|&@<7 @YN^CNH3W^AB|E _<=G32+<O8KJ M|L;|5N2^?2|AD+K^N#L|!>V_|A\$>Q|:Q5YY>|V7W-C#G&|H|J|<?2X=^ M@<X+?<*<GK#<SKB&R^<SNB+Z5:O| YBN|_GOA|D+K^<K^KMNS12 MZT\$Y|*+2N M+<M>S_|M9|WM7_L.SLOH>|XDXV_6|T6^O8>|M|7@: |TE^<C5|J|U5|V| MVFI|W^G-|L^U_ 4Y0.JI=S^UMX0:RMX229 MO/RV/DV OL|5_-Y2,28?|V|J^B-^< M02P.\$% @<:_|H66W8Q_*F|O M\$RP |D |X;|W:W|K&ULK59|YLX&_2^2L| M33M|K@<?2;HT4EM^|7335>MMJ|V^Z\$1S0\$C3 F>TTV_WU9P.EH5 7MD=>?7|3M_|M^|EP2|&|YZZ? J#L'J|2(M^W+<WYQ6@<KQ_|<_<AR2|*8G|\$<R>4G:J|R6.A.MMC^XCI^X501E|J6&9IFMD<9^%O.B|<8MYG00TB0G-PSQ29:_%|L52>GA8H|_M#P4? DLU6|J.C.=_%<W>+Q.?=<#9-W1DU9|1G)>4|SQ.C28G2|SR.150%<CA) M.^?3:Z1>Y8I2+<^<KFW>|B9^HG(BE9^H6Y9|J7C_0 M@<^<EY|)\$<7&2|M_1&_3QUD.O?OML|<CY3|IL+<O|IZU+?>D?H^BX^T^?<I&=&N;DO:V^|KVRM_<JOD9PO>ULDQKW-4>+<O^_ MEN(<V66XW=4<^<O|L|AYI|P_O_P+O7@YI3#GU_|J.\$>63J5=<V>M.NOAEWP M_|BOQN<_<JON|SR3C_W|R^4|L^X65M/5.=_2%W(QDO.1)^<R<C|80N^Y7?2-ME M^#B8|PGS(6\$!)^R\$A\$5 L(9)Q|5|OSKZX|IFFE"5P" <6&|UXA08RF\$|L|WTHNO MDAS=%B5= _5%CS4A) PKX0Y|<8PMONX7KFVIM2=&_<G_H(4#7^A|'B4504 MFHB&D-06=6V> (8GW99P:TNX6DO|+7&U>:>VVT^W6H MB%<TCA.&|N-T3|IL5!+<?WY|LCK#_#>=>=A@<D#0/E:~#T@<0|6@<A^BZ|H31L>T|7XE^<6K.6C^<I3F M@=>)|4%<H 2@M!|<1\$4K>G68|X:ZQ/7|'BUR_YO_T9UW13E?88|Q>TW=4F|GM M57U M6GG|J|N9W7MGB.HEVWV|C\$<2C7LEF^O11C^T^I06@<M|'4 M%?D^1FMX|J)KZQ^<O|F1= \$<2C- Z7YH+<0 E!_"TB(H6M.MO^<O|UF^G+S<_<1C9R M_1JKS7S1ZW+<+MO|3|J^<N^F>="^B/B@M *6%<H+<0(BM;TUC\$9C_79^<)%#N=JE M|G36M.4%|(P=9_8H_|473QL@<?F06D|^"T\$|450M-):Q|F|PHRP37&ZE.N^M^CX7Y0F|JNK0^<P7I9G-M|5. |A3G:TK\$PXT2J|!+<_X^4\$|<#1|0 M (&R_*%EY|J|JH_..._9>=&PO=VJR:W-H965T|>G3U:K=;J-1HOBXG@<D9VB1+<*<68RYAD(G^<LH7LY=HV#_ML? @<6XUKN/8..9<_<Y@<Q|<= M^<@<3/ 4S8Q+<+<F/OQ4-K^X%|<@<:1V|PI-9QP<6X>=>^<1@9L^Z8HKY?<7(+<0U MH>D^HXXO|FECB3^_C5 EZ&Y.? |>X^P13T(4L|VYKN=VWL|USSQ6&V|9^>_<MKS^H>=>18@<3A@<#<#<_|JPI|H5BQ|<N^LYA2ND5YF5\$YVW#A^<9@<I^>?<O|UT7DYI MO|5TAN<37V=7L^U^_ZM|H|<|V#(<^<XRI9QCQW|)9C^D|PG848^OK^<^T| M@<:>38.35 EYA<\$_ JPPIQVM4|EWG^<2W|WCW|JPRATRAW|<P&L_A14S@<^8A2 M4Y|TGF5S&3|4&NX0#|<^<F8;V+>:<L(V9JZ9)_J9X\$<X^X6I_ %\$1SZA8OUFI MOJX;EW+<| AQ85|<DBA5: IM7;MMY7R7.P|<?192M6LQ_? R74VZ9R36@<QY M|H|B%<::@<@YVP+<^<|TX OS&E^4-6|E-YO-3J=S=MUI8? W6|(<P|JR3)Z|WX;6>/_<^=U0^Q=DE|74O|2ZZD8@<7#0Z)G M|^|7+<(<3(F8|JGL WUB25_*O7:(Z5: JY?XQ=ZCO4&U# M)50)NJR\$NES^*|4IGYA\$S:(A O+<J|+<RN12\$;^<KM^?<@<T2M^|<J#L3|EN|T M^Y\$ ZQJ.X=FNU0+<1&I5^<^MX3@<^<KRX|>6&COA8\$^<W? +<K1Q1+<|5%&_<O#8P\$|J|XU|K=|R3|S|X|Y|3^ZV\$^6|4> M|E|X;F8E^Y:0L^<S3|4=93E=O!#T|?<O|R+<I0^<6B04E|20X)U?<GHD.WDB@<Z MZF^<^<_ (T|3.NJ4UCQ%|A:#0|O1^<SKG:#?0^Y7>_<OJ02P.\$% @<:_|<H M62B|_<E: P ZPH |D |X;|W:W|K&ULK99M M;|P.\$>_RBD@!<_V^|5|&^<VD;F_Q-"TBO\$|^<|<_<KHVUQ_ZVTS^<#X M9&G& MTHP_|^J^Q= _|Y^<R\$VW7-S^M|^%ISSQC<_W9Q0YD13.W8EHBDO54897@<F099X3<7>=>=>+<Y M^|BFZU29_3>:%F2- |U12BBNA>V|C|<S;_<DDY_X&KE3|W3T|T|C83<4MI+<5 M|^*DO: T_F8S|S|&E&L3(NB^Y|L| RSS^C2^#|J|TX3|QBQV_?>=>+<VSR.IDE MD7C&LZ|T4>G.<3N0X|J4F:KEVP|8)W|L_4|D_8?MO5@<R0|C2>|J\$0F| U@<M?G MJ_C-Y|LXA(7>+<4FD_<57^<4@<LJF3C?<I%(F)I%<_ (X^T Y=HGYS|L7WJ-MT M4@<-C>L53JL\$<C|T3."2.Y5*>.<23|I_NUJ_1I^<7|T3H^?A HLC^+<T^"+<Q@ M _"!9D2@<:_|^|S0(&|U#<R^<^<^<Y8GW|I^WAH|< <=<J|3A1|TAS|G^<D06|..9 MHP^<M1+<%)WKP4|L|W|L2&32)<^<J|1Y|<U|<H^<FC4|_|UCBFC^<V5H?E8RP&.%7 MIVX5>^<7|V^HWU|NOEF@<T(P6HIMO MM1=1C66L<8LO_J&W83^<AG^X|E|KM62X#>^<|(Z_|J|<W|2R>:>U_|UQ+<LRH@<L|L| M3SZ+<N?

D#BX(0?7!#LA+;@/WZC3KTVXPWT8#09P!CO.X)DW(+:+D;Z^ VG=;O8&G?WN@=I70_22 MJIT '^~\$!(508(9LW^H/0=+42.8JUK;
(DO+QDJB1)FM&FDM7I4&7A^M;V@&K;ZTJ7&PO=VJR;W-H965T72G^UD ^P&^W#A<2)Y_53&;&8P8;QA_?^D"BIS3)Q-1929G? MN*2(51
2T6(Y9.K-@O&42*7D2U?D^\$ALC-+\$13VOZZ;\$9LYH8)Y-^6C "IG0 M*#80L(V0P<|SP|>Z^(E|0-W-.C)\$F8@O^=3KD9NC1+3%#)1688X M+(;.&-J
<\$<@;F1D_*&S\$WCW24N;./>KJEWCH9?)H1!)!#4^490T321?^F^C1 MJD="=>DUMN^ C/19B%=BYD3^A^4_2Q70R=T4 P+4B3R@6U^ATJ0(1BQ1A)?
MM*GF>@Z**B%96ADK|BG-RBMYJARQ9^!WCACXEF8# JD0%01&;G.R+HCDHP& MG&TOUJ,5FKXQOC^62@W-I&>2;
|>4F4G1S?)HL<52V+@/XOVIT>J3^C^5T^E M^X\$SL1A.6K8%+D1 396#@>7.(D33^5W<@^4W\$1_01S51XQ86;Q1:5VV^Y^4S3 MA&3J_???:KZ|@:|S_ 7R/?
|X.F/G;S\$>3*W#E;F0N=H/9_8/"8WC"#26|:T_P|C MN912(\$KUCT^7M6H_>OH>|MX^BGGAM^6KC+*+;R^A>+.-+CE5U3M^TA2--*V@C>#VHP*_^/
M'^<>A0E^+>D2SHUS+|5|G_?7J+8N>*|J_JO_|J3:0-FLW_>^J M^B^F50" R)+M-K7.5?L)6BV8H^W#B-17ABOM;9BH^E2\$(\$|_5LX^-(WO5FV-
Z<^1=|06M@QSY;Y 5HUH*PZ_&PO^K+&62Y;_F52G7W_|J|CJT^>K|<3#XJ1 +U M^OZC?P%02P.\$% @ :|(H68X16^87|_SAD_!D
|X;|TW;W)K&ULQ9G;MLX\$(9?A= 6100L1P.ME/0&^TV (;| G MNQ=+VAK; N51")VW;+RG)LG6(\$+<\$%7= N9?+B+^5"WK^UR;
<.2)0G18E16Y9O1B3.C.DX M^W;/IF.Z\$TFFA^W?0D(|/P;OPXBUIPO.Z%#&6@9;|KB@:9DL9Y#&6?%)?I0+>|98@=-T)=IE@-O/<M^Q*
<L)Y|0ANF">^=@2O3A+>XO^X4+B^#3.;_Q%2TIT^+?7S;+E>=>8V MREPP^3:6>+Z_?O^(-H ^!")|(G^)/ZITLOQVB Z H14D52=(P^8D|6:P9K
M(BI^B^?JQ>/S\$F3FTSO_!Y|1LJ0G*^#=UODD5|; HY4S6>N2QG=5O.RGYA M5@ZZHYG8ZROFUT<.^?KVV&\$ZU9YR>*9UNT=5CGG- MMV0)\$T-:
(@>V1VZ C2L6Y^Z(-S)"W^0DVPEF810)P;Y16A44Y9R^A51\$<5>A5/ MT@8<4BSM;HZQVD^V"=N2I^<>^GNTPD=.)^3;.%GZEA?FQN^KE\$XG+.-)
M^S7|:M(-ND&^HVC/^GGO^FC 6X81SQ)P;C.<.<1C2>+W&K1^A)G)MILYAE61 MPJYZ9S1-8ZZ^#0->U^BE7+K+U;.(G^|0\$ZPFQ:B280FKC^2*9U.6*
3%F| MU:3#UJF|L3Z1DFK&0?VF|:1\$>797L.Y.H(A5EJ@E1;JHM4EL4^2V&_B(N6PN@3420NTTD)=M+J MIZ83IS9&%SN)T_^-8=@TDG:OP&
|Z2^H&N1;H2Z1J^K)I4V8-1W=K2L^L|J MZ 5-\$1^H+<9@3(\$>|Y+>2^H|UD-|S\$SAG38.O1<VCI)=UEHCZBJY6|_@W
M^>?UX DM0IACN>1.O@/SY|!^*_|7>\$K6/9|R6PD-95P.D|L^X(L:0;?Y M^?^"5D3^ ('#^*F N3C:7B>*&|X-X;OT4\$!#1!0 (&R.%E(NJEZ M2P(\$H& 9
>@PO=VJR;W-H965TVF56JF^*FWAVH^/ER^51M3VX3TV|V|A^R;2I>PD^M^W^Y +CZ.J;B4>8 "NT9+63LY\$|54|>5:0X.RP\$OH= G&RX85CH46U>6
G|F M08RZON>%>L.D<+|(BU\$S\$O%*45+ 0B|9;L%)PPHKV-GZ|PVEF2;*/A)E&^ MMJ "=5NNA(|(\$S;+&GXW ZFYA|F "=0"/VUL44L;IT02W6>OX
MOA|02)5APJ/Q@VN@U|H|TM|J-@N^Q^O^L^H^V;=N;N;UC="=><B^9RF/G08R.R MV.^*JB6OOT|;SJCIP9Q^*XQJPC<^9164G^6@K4#1HKF6?M^W \$|T3
+1% M^-9W(V1=WF""DTCP&@F3K=G.PI9JT^H<^*_0J DEC=+^Z09<7 M5RIJ7.VS.^*MW9GW+& S=L.=/D.W^ICV6>P(1KU\$YE.GH2IQ |N14EB|TX
MR=LWPI#|<.<9FT-D.SK\$G7_6|E.*2*\$QUWSY51(|N815GLR\$*+9Y?W);T|^% M7N3N>O1^G?|HK/ZG20I2(LQXU;_P.VFFQYDK^KO.L;_81+T^89S=0C.
H^~|DO4\$!#1!0 M (&R.%EV^V^+OP(^!T) 9>@PO=VJR;W-H965T8#6@^1 M;U:4Y5A(DZU-7C^L;0;EF>E8ULC<4H.^Z+>WYLR?T?)D^8\$Y0IS.
<|R<KR&C MVZE&|N-NW2^="45A^|L^KV\$|XKZ8.VF94N7K0CP4E500^"Q_>M^*45\$ 15.0Q MC>&N^P^G^|CCI@;^+<+&N.^X-4 |ITIAC5 EVY6M6OA
BRP M/V%TBYCREQJH=77.*F72M1WLA!ODTE3OAWD&\$1.9IC)I1#X8)QU4+3P(O M.WX^?J^|A;_OEIRP.3QIR+ZXK5ZY95)|N8\$SB^J2&|+@Y|
X9_?2&C.KLPNO1) M^&AR2+>P0V8O6>\$UKO^M^YV9H.-#@^G?LLTN.Y.G/29Q2WM^LM^M|JL %@>1 M|C#O^E%;EN:7@V+C6|Y#>S:4O?
F|I)3D67@/LA22^QOIAI2WY^H9\$S^M+M58 0%."CXTJ2>O1^G?|VE(VM9J2M8^PIK^~"UUIGURBOL^"G1JH^5MS<+>V
MU@.8HXB61%1^9+;/S@K=KVJF^V.*A&J3^:ZN)PBI2Z1OEL)*4UN!9L;J M85P9@A9ZVBRID++>+Q-Y?P&F.3|%;5B9Z@ S8W(PM02P.\$% @ :(|H
M6:~S|8@_@ B 0 |D |X;|TW;W)K&ULC93; MCM.P\$|9?Q3(2 @G5;=I=V)S;G=|<+>2U0|X0%RXR32QUKV6M|>-|2I M5-PT/L\$ S3 |3+>FR2;
^|Y;|6R.6TONP5CMFR@Y7:B.U#N9J|R-J|M3

KN8V 5|N|/9L37PE.ZV?_9S ME=(\$&P)7H^=X|CW(.4^N1L_1R8=\$SIA>?K\$ UCJ-W5LN.6(K7|)BIL4E >+NAW\$SD\$K5\$SRV^\$JG
DML+>D@ZJ@>E/O/G+177IRMTJO M K203<@L42)U|X|L_0O:KIO=Q-ZXT2E|V|MEEF|7A>UX^3EU M V^|(\$6+U|Y.W5|S.1Z_S_0B>N0|"
<1&V_200BY^1_@<Y^KS6>-C|!^/!P?@-02P.\$% @ :|(H6801T9?| M|@ ("D |D |X;|TW;W)K&ULU5I=;|LV%/TK MA%
<.;^4XH_Q?7NN>2.G10|G.Q9\$R1+UF%Q>#15^KE|A.5NRC180Q(K^E^INY MDIE5^|U<^<N59#2IG+|TB(|@&F:4YX|>?79C9R 5?#DE M<>E06?
S^V4.OIQ145.ZY%~R^N4HN|D\$9\$4093|405/|^E+TQD)Q_#03K8 M.6:IN/ Z\$?U-15Z3N:<%FXKT:YZHY<5@- |F|UJCZ(KS1832@L|68B+J
MX*^V#09@MBZ4R&IG^4^&|^U^J5>B^T^C6-W0+4#>JH^KAUP170:647KDBHZ M.9?B YJR|16H)56 2@:N15&BD|PEX&ZE\$W1? M?LG
|WE=67P5HJBT8;EJ|9H^D^ M15^~|J|P|J|NR8XWJ|=|QWSJ M^M^219-|JY\$ O1.^*16RPKJ>Q->Z>@KK&>X6|_064Q0^K6.4.99-9#!!
MT4C7F8 J|X1^1.(0|PZ.046H|?)GDM^OF^35|6RJT0^<^~)K.\$UW&G- MGOEXRW)-|W^CR;ZHN:%^LEOK^G98H5IRTT(K5RTC6^&
(YZ\$=U|^1^M^?0^F4F1^ M1Y-8: M^?6^2P.VQ>(Q0A%+ G P.FVP?N2T3?R21XSKYH&5@PW>-Y/A.9M69J)\$ 7 MBB^T)N|E0.=N=GR=I!UNA|0>OZ
FA21H8B<%^|RQ32D; 5\$ 70SU;^9ZTO|W4K+MAL+;GBS^|ISCI +|HR<#M3D;#0'
M=+;@R5VN|ZN4_Z2>1%K>@S3I7^BFTV19XYMR#;S\$C^CK=N^G S6)W\$ W>I@ MNJ3Y@I52?DZY!N:KB0EQ2.-+M#R|F|N1U\$.:G
S69P4G^G4U |\$H\$W93% M 792Z^F79->H YC^")@*Z4216LNMZC(5%0-G81BTXD8H6#4YGI1#- M&MZQ M|9U|:~N/O-
\$@|LEU?Z&:5VK/ 2+&X:A5Z18C&^!H+W1D9 F^T|XZ L A|T9|&7VA-OD:C(+=& M.6QJ01.Y.@|@S5=|QCN#3?
-4(U@06|!>|0LR@>6Y|X^-80XW8_0#JY M&I2-|H\$N37)\$X88U!4=<=2N^M;PO=QMX>5^X(TN06Y8/MAC#J=I6L3 M1WV7B-
\$0R+T>=>SH@2R|@>1U(K|M302CR|XS-CT.NWOTD5.#|K;FLW\$8MH^V M646D3T1CT|Q&V>A8.%?
X54^@0BV%|EF%H>CG@|T^;#HP=G=@^E^C^W4YZA|H.MW7!M9A^HYZBQ7MG\$^Z6.17M1J0|H4J7K?>8PN^YO(2^XF@>SV: M|
(767%.C\$|10Q.U9V.O|X7>==^PCOA?^300^Q|18^IG+@|0FGQ-^<^ MCRFP|4CW+DU=|U0@%|/.(9>|?>CBK<Z=|+0|3^I&(F
Q078TNXO^+ID^"B#>3BR(UQ+7VA-WD98D-.-+SN|U2@|Z F1-1.RDG^L2Z M!= J8M1O>4(GUC4<4U^|I5?MD|F^H^W00^SC>5?
MVZSZU3XO M+9NES."TFW.%K5OL^I7^|2T;^Y)Y>YJT=^|/8 |5K.X@#WO6O+SE^B|J V MC9KIAVVU;S.#81RC5FS#06?0.B87U:-
Y|9B)=ZVCZ/M|MT|Q>J>NABM.RW MSP>4|G@>0%2-M>NP8M8KXOBIS^|U+! P04 _|L@&A99T^0+ S^_#*0_0^_AL+W=O
M^*FH21+JH@|J|DC4N|1BA-CIVH;Z%H|^VLR^*PXN \$RIPGOJUI<5|G|DPV&1ICP|W-5;+&01Y6LM.K\$! PG4^CCV|5E+>|E5V6&0Y<0."B.
(Q#|>H Y..9 -HW? M^1W1SKA|?A_~|6R|KHF\$NV0|FBK^GS\$J84-VS-S(YA(Z/O|=KY|^R=J MVM@XQJCR;2-Y)|89<^K-|JEW|W
DL)QA0=0)HN>^Y 5|W EB|3-S^M:\$S\$R M5.D&*^1=M:6|@|Z:KK1|JW^|=<6&5YV=69_5H4D@|Z?700Z&P|AE^FS|S^+=+; MH+V.WYVE@|DN-
B@ZXJPE1B|08W0MA-DT^B^* J YM=GV|T2^\$6G02NH|ZA M.^RHC|^1^Q9OUX>69 \$T@G|F|L|KX3-3?V<|K61ME|=201:6@9|CDZG.B.U) MAFT|:E
/@-W|A87X9D)FI+A48.M-A89CC|9.E=MYV@G1M;^~^2VY+VPHV6U NP.YOI#2^B3N@:|Y7U!+ P04 M " |L@&A9C |GIR<# |H\$>#0 ^AL+W-
T>6QE(C)8Z206G|W^*=: LN:A^X5SKZ4.U;Y+4E|2|J#|+51)M M|J|ZD11DM7@5^*HU^DD44F8^=#L2AO2U^J|DO>A3V6U|@:|^S4=A-WH>!
MHYO(C|^|OXNW/Q92W|P/WLW=E9Y_9RM|J^88+^/2|H|@O>J8^V6V\$?:M^\$=B|RCOCZ^*@ S1CS8);KSPV|ASNW;E%3LO\$PEV)3N3AT|L-
+2AH\$3X^M^X2S|6+@E9.2194S1 PDUR|0N6.8&Z8^E^;CK9M|^#4 |A^60VMHO^ DZ: MY7O>@8^>MP^|H\$-:
A1:2F2MR:B5ULC<^@H|D K^JCL%|DU>WUPXV^O9D@ M4ZDRJ|HPW7|M@&|YS4&8L4<|E|6\$8|:R|C|D8^*8C5L/9H|H9V1CF AT?M M>
|H^OHEV:0U0T?C)L^S^>XMXVE?QAM4|G|3PNS6^GT&+T3M< M;+>U|F<^/8NSDZ|BJ|+70^CG|8Z@J|U@|G@D33\$>M^?
|T|^92>|C|!^V2 2 MQVGJ1P#\$XAC#&(G\$4BS61^X|J102P.\$% @ M;|H69>N4S SP^L L^23T|MP>:4#M.^2VBZD8_1|2 M:5K5N % (MB6/:(7>==
M13W;+T|L^X^O.DQO0FE(2S..LW2\$S+W|PPU1>5^Y5;&GC3Y^YVX\$G1H2)8 M%I^R=B:5^_7_17<|S ^* #P ^AL+W=OD/C|9^_A@S^X5I7:S49;
|W=GX|^MU|)Y09@<8S M^Y.KZ?P>0L9N9T6#&@Q|W<|<3R;3<265^GWY>+S7PH|^~.A|IH+&P^|A0| MN9 GFT.Q5TX|J+Y^PV54?
BIA^JES:6>H9B-B|AMN;|V5|L1%>EJOE1^9;#K&|ZZS;=|117M_B8Q|P|JW1|4W MEZKT8.22PY_6U_N9-
|UM|^G^P6.T<3A^=D\$|L |EC&:|5CG.35Y7H^T71PME M ZC=5NW<2&A9P6OT829@F^?|/|@JNF?S^15\$R|X|&&OBA;|S^T47H|T4 K|Y
M4ZH^).OKONRRSD\$D\$#&1^9|0|CX.L^).CDY^*K1P4|R|2 3\$|H^M8D1D|F M1X1 L@1 3GEA?QJ-U^KY_!SD+H0R&OU3Z1^*^C;
MP@NY45COBB4X4|L<? #YD8|R N NYJM^V@&3;S41BN3^C&HOSO/6^5+>W1A|K#)S5;/3F 2W820R18VU?7.WX^QS M58^1|
RS:&XP9W#8|)0>IG^|4N2BT1|LULN|+B318U- WP4FE4BL).ROA#|KN18W21.3LB0M35;H;+X|!|I@< W: M^?J.C-
!\$Q>V@FQJ+C3V\$1)03(F81+M)"S\$6P6TF(KN|52.JG.B|TF1)D^"S^R^ M^6R:7^~PNS.VJ=\$0C+)|S&R#^YV:"L2M_-9K7\$SYR6
VP4(>Q>X=TMK+F^G M7+E|^INC61QY8&8V07VBDUPS-P0;X^9 M>S.& "H">#MW|H3>G1^01.ZMB.^43O|PV>Y=2\$F9(F8V|97:(6R(21DD9C:(
MR_1N.(Z4/6)F^Y|Y7F^F-U^B9F5TN5Y01+^*|\$S\$)YG2^-(E)^29B50F9^ M 44BRC|OLV7^S2P&T>N7C+&Y56J.\$A:25AU@JYXM^08\$HK"?
<.A^K.Z&2 M7Df80?*& >98|L|^15->2A7L\$C|S4.RBX|LUU(\$ZE4W9)E.WRVV(M^I9U2 MHDFY12.FH7@O5G6(2 M^). CKG94)^AC).R&^V-
D2ADGY38.B=GK MVI1O4F1C|B|KIDT^ V2Y^C^F^7\$B3CM^">8WP3(2:EG>RDI^2|T^X^O^M^+P2<#/\$SG0\$M^U^9|V8>R
M^#@>3F75|^91^|526> RL2LW_9|YR:2CQVTDWY|M^O^K=^Z:4ZZ7+9L^ZC M>75X/G|OXGD YG8;S|=2|K |<|VGZ@^#TWH|O99?
SU^Q>NG&|U63|@|7 MW25=-G)SGMPLGEY7S?CT^DVJ:001/6#*#(L|U|^D-@^ |JLD09EP1)ZP)M|D6@B|@1;|.06)%L(S|9\$6PC4 M^F1;"-
P6A|L(Y!|D6PCL^L1:"|16U|L)I%:46PGTUMG#-H>^BGHK@Z^>BN!
MWHIZ^X^>BGHK@Z^>BN|MWHIZ^X^>BGHK@Z^>BN|WH9Z&X^>AGH;@XV>UE"
MH+>AWD:@MZ>1|"WH=Y&H+>AWD:@MZ>1|"WH=Y&H+>CWDZ@MZ>3|"WH|Y.MH+>CWDZ@M|>=A/H|BW\$^<CMJ+
<3Z.VHMQ|H|BW\$^<CMJ+>3Z|VH=Q^H^AW M\$=@J^<L|VH=Q^H^AW\$=@LX^5^H^ZAT>@?J^01Z|^H=|^H^ZAT>K>H
M=TN@=XMXZM^I=^YD^~^H|E<|I6>^N2|HYZGYNOE|LOW;~L^%Y2^S^W^15|+ M P04 _|L@&A9UDS DN!_#C(P \$P
%M#;VYT96YT7U1Y<&5S72YX M;6S-VLM.PS 0!=|?B;) %C>M7>8BR ;:0|3|@D@F-FL26;~#V4X^E4^EHBH2
M=1.HM3UWXT^JITZ_1P.V|S3VW(L^O-QB^KGAOG MVJ8T.VSE|JZEC+Y2^C2R7%6#8NG^0=-N9_!S^|/QIOZ^O&|JRA&QSO3 MI5ULW;
(OUW^Q2X2.WJT=V45-GRN4M^BN |F2HLB6+7%|NB) N38|I|AVGSR
MH_/OL^T|Z^MRZDB7DZ|YS)/|B4N^R=F RMNSU|H|^AFE75/TR.UWO MJ_6K<1Z|C8_C|_CKC+?U#^Q#/@0A0?
I0^CUHD^YF^V<@O1Q!M^M^4@??(K2 M^JH^54CF|1T5HZC^45CE^*YR%#%@YB|P^15:|Q M D56@R^I09|4HL@H4 M606^K)5\$H\$B|T215+<
8JL^E2BR2A198JL\$D56B2^K1)5\$HLB|4&15+^J M^M^5D5BJP^15%JM^D56AR^I09^4HLF4636^K|P15HTB|T:15/|(JE^DU2BR M^A19-
8JL_Q199 |VZZ.UJ\$^_Y|Y9YK^Y^-_~Y>@=02P\$%^_4 _|L M^M^A91^T%-8H\$ "Q \$ @ % 9&|C4^O<^087|P M^M+GAM;+| 04 Q0 (&R.%FX 508|P
"L" 1 " M _|D:V-O&UL4\$! M A0#% @ :|(H64|@ SR_!@ ("|H@<^_AL M+W=O&PO=VJR;W-H965T&UL4\$! A0#% @ :|(H69-" M|H^T|O 1T |@
("|@QD ^AL+W=O&PO=VJR;W-H965T M&UL4\$! A0#% @ :|(H686>1.Q^0 8AH !@ M ("|S^" ^AL+W=O&PO=VJR;W-H965T&UL4\$! M A0#% @ :
(H6^0 Q @ (\$<3@ >@PO=VJR;W-H965T&UL4\$! A0#% @ :|(H6 M62(1XF9U|P^!<|D ("|F ^AL+W=O1>T P^" >#P 0 M @ (N9P
>@PO=VJR;W-H965T^M^X;|TW;W)K M&UL4\$! A0#% @ :|(H6=9>-NR2|@ 9Q(M^|D ("|S^" ^AL+W=O M>@PO=VJR;W-H965T&UL4\$! A0#% @
:(H6?^D?U|P N0< (& D M^C|^DX\$ ^AL+W=O&PO=VJR;W-H965T M&UL4\$! A0#% M @ :|(H67N|Z2:" @ F 4 |D ("|)X^ ^AL+W=O M&PO=VJR;W-
H965TH^KOP(|H 9 " @9F4 M |X;|TW;W)K&UL4\$! A0#% @ :|(H6<4? M^Y2N^#0^S^D |D ("|SY< ^AL+W=OC8# |P &0 M @ ^X|>@PO=VJR;W-
H965T&UL4\$! A0#% @ :|(H67%5:VTV P <@>@ |D M ("|WJP ^AL+W=O&PO M=VJR;W-H965T&UL4\$! A0#% @ :|(H65T&A^W| @ ? 8 |D ("|
M^KH ^AL+W=O&PO=VJR;W-H965T&UL4\$! A0#% M @ :|(H6<@ ^X7E-| + H |D ("|JL0 ^AL+W=O&PO=VJR;W-H965T&UL4\$! A0#% @ :
(H62HL;- P |PX |D M ("|A>| ^AL+W=O&PO=VJR M=VJR;W-H965T W |X;|TW;W)K&UL M4\$! A0#% @ :|(H6;H_ F|0 %R<|D ("|E^H M
^AL+W=O&PO=VJR;W-H965T&UL4\$! A0#% @ M;|(H6<%FF:2O V @ @ |D ("|V@@! ^AL+W=O&PO=VJR;W-H965TC< @ _+P) 9 " @5.. 0|X;|TW

W&O#&PO=VJR:W-H965T&UL4\$L! A0#% @ :(:H6&PO=VJR:W-H965T&UL4\$L! A0#% @ :(:H66W8Q *F'0 \$RP ID M (!!!H! 'AL+W=W&O#&PO=VJR:W-H965T&UL4\$L! M A0#% @ :(:H6546VX4&! A ID ('!2@! 'AL M+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ :(:H M678#8(N @ 'OD ID ('!/C!

'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ :(:H66=&'P @R@4 M ID ('!:S!) 'AL+W=O&PO) && @ \$-2P\$ >&PO

M7WJE':O=VJR:VJO:VLN>&UL+GJE':02P\$ % ,4 " !L@&A9UDS DN ! M #CP P % @&30\$ 6T-O:G1E:G12\$EP97-=+GAM:%!+ 4!08 10!%-H2

/73P\$! end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null;Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName=='TABLE'){var ref=((window)?w.document(document).getElementById(r):if(ref!=ref.cloneNode(0); e.removeAttribute('id');a.parentNode.appendChild(e))} if(e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){else if(!e.style.display){else{var d,p ;if(e.style.display=='none'){d='block';p='-';}else{d='none';p='+' } e.style.display=d;if(a.textContent){a.textContent+=p+a.textContent.substring(1)}}XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 *//* v2.2.0.24 *//* DefRef Styles */.report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute;.report table.authRefData { display: block; font-weight: bold;.report table.authRefData p { margin-top: 0px;.report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right;.report table.authRefData .hide a:hover { background-color: #2F4497;.report table.authRefData .body { height: 150px; overflow: auto; width: 400px;.report table.authRefData table { font-size: 1em; /* Report Styles */.pl a .pl a:visited { color: black; text-decoration: none; /* table */.report { background-color: white; border: 2px solid #ac; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em;.report hr { border: 1px solid #ac;.report th { background-color: #ac; color: black; font-weight: bold; text-align: center;.report td { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left;.report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */.report td.pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden;.report td.pl div a { width: 200px;.report td.pl a hover { background-color: #ffc;.report .Header rows... *.report tr.rh { background-color: #ac; color: black; font-weight: bold;.report .rc { background-color: #f0f0f0;.report .Even rows... *.report .re .report .reu { background-color: #def;.report .reu td { border-bottom: 1px solid black;.report .rou td .report .reu table td { border-bottom: 0px solid black;.report .fn { white-space: nowrap;.report .num .report .nump { text-align: right; white-space: nowrap;.report .nump { padding-left: 2em;.report .nump { padding: 0px 0.4em 0px 2em;.report .text .report .text { text-align: left; white-space: normal;.report .text .big { margin-bottom: 1em; width: 17em;.report .text .more { display: none;.report .text .note { font-style: italic; font-weight: bold;.report .text .small { width: 10em;.report sup { font-style: italic;.report .outerFootnotes { font-size: 1em; XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 215 269 1 true 66 0 false R1.htm 995100 - Document - Cover Sheet http://xbml.sec.gov/dei/role/document/Cover Cover 1 false R2.htm 995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 995304 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders??? Equity (Unaudited) Sheet http://www.aikidopharma.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995306 - Disclosure - Organization and Description of Business and Recent Developments Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments Organization and Description of Business and Recent Developments Notes 7 false false R8.htm 995307 - Disclosure - Liquidity and Capital Resources Sheet http://www.aikidopharma.com/role/LiquidityandCapitalResources Liquidity and Capital Resources Notes 8 false false R9.htm 995308 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 995309 - Disclosure - Marketable Securities Sheet http://www.aikidopharma.com/role/MarketableSecurities Marketable Securities Notes 10 false false R11.htm 995310 - Disclosure - Long-Term Equity Investments Sheet http://www.aikidopharma.com/role/LongTermEquityInvestments Long-Term Equity Investments Notes 11 false false R12.htm 995311 - Disclosure - Notes Receivable Notes http://www.aikidopharma.com/role/NotesReceivable Notes Receivable Notes 12 false false R13.htm 995312 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities Fair Value of Financial Assets and Liabilities Notes 13 false false R14.htm 995313 - Disclosure - Leases Sheet http://www.aikidopharma.com/role/Leases Leases Notes 14 false false R15.htm 995314 - Disclosure - Net Loss Per Share Sheet http://www.aikidopharma.com/role/NetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 995315 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock Stockholders??? Equity and Convertible Preferred Stock Notes 16 false false R17.htm 995316 - Disclosure - Revenue Sheet http://www.aikidopharma.com/role/Revenue Revenue Notes 17 false false R18.htm 995317 - Disclosure - Commitments and Contingencies Sheet http://www.aikidopharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 995318 - Disclosure - Regulatory Sheet http://www.aikidopharma.com/role/Regulatory Regulatory Notes 19 false false R20.htm 995319 - Disclosure - Related Party Transaction Sheet http://www.aikidopharma.com/role/RelatedPartyTransaction Related Party Transaction Notes 20 false false R21.htm 995320 - Disclosure - Segment Reporting Sheet http://www.aikidopharma.com/role/SegmentReporting Segment Reporting Notes 21 false false R22.htm 995321 - Disclosure - Income Taxes Sheet http://www.aikidopharma.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbml.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbml.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.aikidopharma.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 996001 - Disclosure - Marketable Securities (Tables) Sheet http://www.aikidopharma.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables Sheet http://www.aikidopharma.com/role/MarketableSecurities 26 false false R27.htm 996002 - Disclosure - Long-Term Equity Investments (Tables) Sheet http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables Long-Term Equity Investments (Tables) Tables Sheet http://www.aikidopharma.com/role/LongTermEquityInvestments 27 false false R28.htm 996003 - Disclosure - Notes Receivable (Tables) Notes Sheet http://www.aikidopharma.com/role/NotesReceivableTables Notes Receivable (Tables) Tables Sheet http://www.aikidopharma.com/role/NotesReceivable 28 false false R29.htm 996004 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities 29 false false R30.htm 996005 - Disclosure - Leases (Tables) Sheet http://www.aikidopharma.com/role/LeasesTables Leases (Tables) Tables Sheet http://www.aikidopharma.com/role/Leases 30 false false R31.htm 996006 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.aikidopharma.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables Sheet http://www.aikidopharma.com/role/NetLossPerShare 31 false false R32.htm 996007 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Tables) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables Stockholders??? Equity and Convertible Preferred Stock (Tables) Tables Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock 32 false false R33.htm 996008 - Disclosure - Revenue (Tables) Sheet http://www.aikidopharma.com/role/RevenueTables Revenue (Tables) Tables Sheet http://www.aikidopharma.com/role/Revenue 33 false false R34.htm 996009 - Disclosure - Segment Reporting (Tables) Sheet http://www.aikidopharma.com/role/SegmentReportingTables Segment Reporting (Tables) Tables Sheet http://www.aikidopharma.com/role/SegmentReporting 34 false false R35.htm 996010 - Disclosure - Organization and Description of Business and Recent Developments (Details) Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails Organization and Description of Business and Recent Developments (Details) Details Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments 35 false false R36.htm 996011 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies 36 false false R37.htm 996012 - Disclosure - Marketable Securities (Details) - Schedule of Gains and (Losses) on Marketable Securities Sheet http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable Marketable Securities (Details) - Schedule of Gains and (Losses) on Marketable Securities Details Sheet http://www.aikidopharma.com/role/MarketableSecuritiesTables 37 false false R38.htm 996013 - Disclosure - Long-Term Equity Investments (Details) Sheet http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails Long-Term Equity Investments (Details) Details Sheet http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables 38 false false R39.htm 996014 - Disclosure - Long-Term Equity Investments (Details) - Schedule of Long-Term Investments Sheet

<http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable> Long-Term Equity Investments (Details) - Schedule of Long-Term Investments Details <http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables> 39 false false R40.htm 996015 - Disclosure - Notes Receivable (Details) Notes <http://www.aikidopharma.com/role/NotesReceivableDetails> Notes Receivable (Details) Details <http://www.aikidopharma.com/role/NotesReceivableTables> 40 false false R41.htm 996016 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable Notes <http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable> Notes Receivable (Details) - Schedule of Notes Receivable Details <http://www.aikidopharma.com/role/NotesReceivableTables> 41 false false R42.htm 996017 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) Sheet <http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails> Fair Value of Financial Assets and Liabilities (Details) Details <http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables> 42 false false R43.htm 996018 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value Sheet <http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable> Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value Details <http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables> 43 false false R44.htm 996019 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis Sheet <http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisTable> Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis Details <http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables> 44 false false R45.htm 996020 - Disclosure - Leases (Details) Sheet <http://www.aikidopharma.com/role/LeasesDetails> Leases (Details) Details <http://www.aikidopharma.com/role/LeasesTables> 45 false false R46.htm 996021 - Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities Sheet <http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable> Leases (Details) - Schedule of Lease Assets and Liabilities Details <http://www.aikidopharma.com/role/LeasesTables> 46 false false R47.htm 996022 - Disclosure - Leases (Details) - Schedule of Quantitative Information about the Company???s Operating Leases Sheet <http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationabouttheCompanysOperatingLeasesTable> Leases (Details) - Schedule of Quantitative Information about the Company???s Operating Leases Details <http://www.aikidopharma.com/role/LeasesTables> 47 false false R48.htm 996023 - Disclosure - Leases (Details) - Schedule of Lease Expense to Current Period Operations Sheet <http://www.aikidopharma.com/role/ScheduleofLeaseExpenseToCurrentPeriodOperationsTable> Leases (Details) - Schedule of Lease Expense to Current Period Operations Details <http://www.aikidopharma.com/role/LeasesTables> 48 false false R49.htm 996024 - Disclosure - Leases (Details) - Schedule of Supplemental Cash Flow Information Related to Leases Sheet <http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedtoLeasesTable> Leases (Details) - Schedule of Supplemental Cash Flow Information Related to Leases Details <http://www.aikidopharma.com/role/LeasesTables> 49 false false R50.htm 996025 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Sheet <http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable> Leases (Details) - Schedule of Future Minimum Payments Details <http://www.aikidopharma.com/role/LeasesTables> 50 false false R51.htm 996026 - Disclosure - Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share Sheet <http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable> Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share Details <http://www.aikidopharma.com/role/NetLossPerShareTables> 51 false false R52.htm 996027 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) Sheet <http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails> Stockholders??? Equity and Convertible Preferred Stock (Details) Details <http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables> 52 false false R53.htm 996028 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity Sheet <http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable> Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity Details <http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables> 53 false false R54.htm 996029 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity Sheet <http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable> Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity Details <http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables> 54 false false R55.htm 996030 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Plan Sheet <http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable> Stockholders??? Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Plan Details <http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables> 55 false false R56.htm 996031 - Disclosure - Revenue (Details) - Schedule of Total Revenue Disaggregated by Revenue Type Sheet <http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable> Revenue (Details) - Schedule of Total Revenue Disaggregated by Revenue Type Details <http://www.aikidopharma.com/role/RevenueTables> 56 false false R57.htm 996032 - Disclosure - Regulatory (Details) Sheet <http://www.aikidopharma.com/role/RegulatoryDetails> Regulatory (Details) Details <http://www.aikidopharma.com/role/Regulatory> 57 false false R58.htm 996033 - Disclosure - Related Party Transaction (Details) Sheet <http://www.aikidopharma.com/role/RelatedPartyTransactionDetails> Related Party Transaction (Details) Details <http://www.aikidopharma.com/role/RelatedPartyTransaction> 58 false false R59.htm 996034 - Disclosure - Segment Reporting (Details) Sheet <http://www.aikidopharma.com/role/SegmentReportingDetails> Segment Reporting (Details) Details <http://www.aikidopharma.com/role/SegmentReportingTables> 59 false false R60.htm 996035 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss Sheet <http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable> Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss Details <http://www.aikidopharma.com/role/SegmentReportingTables> 60 false false R61.htm 996036 - Disclosure - Income Taxes (Details) Sheet <http://www.aikidopharma.com/role/IncomeTaxesDetails> Income Taxes (Details) Details <http://www.aikidopharma.com/role/IncomeTaxes> 61 false false All Reports Book All Reports domh-20240930.xsd domh-20240930_cal.xml domh-20240930_def.xml domh-20240930_lab.xml domh-20240930_pre.xml ea0219844-10q dominari.htm <http://fasb.org/us-gaap/2024> <http://xbrl.sec.gov/dei/2024> <http://xbrl.sec.gov/ecd/2024> true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0219844-10q dominari.htm": { "nsprefix": "domh", "nsuri": "http://www.aikidopharma.com/20240930", "dts": { "schema": { "local": ["domh-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd", "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["domh-20240930_cal.xml"] }, "definitionLink": { "local": ["domh-20240930_def.xml"] }, "labelLink": { "local": ["domh-20240930_lab.xml"] }, "presentationLink": { "local": ["domh-20240930_pre.xml"] }, "inline": { "local": ["ea0219844-10q dominari.htm"] } }, "keyStandard": 244, "keyCustom": 25, "axisStandard": 14, "axisCustom": 0, "memberStandard": 15, "memberCustom": 37, "hidden": 1, "total": 149, "http://fasb.org/us-gaap/2024": 130, "http://www.aikidopharma.com/20240930": 15, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 215, "entityCount": 1, "segmentCount": 66, "elementCount": 657, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 798, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "" }, "menuCat": "Cover", "order": 1, "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R2": { "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 2, "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R3": { "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": 3, "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["div", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-

10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "1NF", "ancestors": ["div", "div", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R4": { "role": "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R5": { "role": "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "longName": "995304 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders'2019 Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders'2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c56", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c56", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R6": { "role": "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "unique": true }, "R7": { "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionOfBusinessandRecentDevelopments", "longName": "995306 - Disclosure - Organization and Description of Business and Recent Developments", "shortName": "Organization and Description of Business and Recent Developments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R8": { "role": "http://www.aikidopharma.com/role/LiquidityandCapitalResources", "longName": "995307 - Disclosure - Liquidity and Capital Resources", "shortName": "Liquidity and Capital Resources", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R9": { "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies", "longName": "995308 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R10": { "role": "http://www.aikidopharma.com/role/MarketableSecurities", "longName": "995309 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R11": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestments", "longName": "995310 - Disclosure - Long-Term Equity Investments", "shortName": "Long-Term Equity Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R12": { "role": "http://www.aikidopharma.com/role/NotesReceivable", "longName": "995311 - Disclosure - Notes Receivable", "shortName": "Notes Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R13": { "role": "http://www.aikidopharma.com/role/FairValueoffinancialAssetsandLiabilities", "longName": "995312 - Disclosure - Fair Value of Financial Assets and Liabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R14": { "role": "http://www.aikidopharma.com/role/Leases", "longName": "995313 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R15": { "role": "http://www.aikidopharma.com/role/NetLossPerShare", "longName": "995314 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "

```

true, "unique": true } }, "R18": { "role": "http://www.aikidopharma.com/role/CommitmentsandContingencies", "longName": "995317 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.aikidopharma.com/role/Regulatory", "longName": "995318 - Disclosure - Regulatory", "shortName": "Regulatory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.aikidopharma.com/role/RelatedPartyTransaction", "longName": "995319 - Disclosure - Related Party Transaction", "shortName": "Related Party Transaction", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.aikidopharma.com/role/SegmentReporting", "longName": "995320 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.aikidopharma.com/role/IncomeTaxes", "longName": "995321 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true } }, "uniqueAnchor": null } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c8", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c8", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.aikidopharma.com/role/MarketableSecuritiesTables", "longName": "996001 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables", "longName": "996002 - Disclosure - Long-Term Equity Investments (Tables)", "shortName": "Long-Term Equity Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.aikidopharma.com/role/NotesReceivableTables", "longName": "996003 - Disclosure - Notes Receivable (Tables)", "shortName": "Notes Receivable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables", "longName": "996004 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.aikidopharma.com/role/LeasesTables", "longName": "996005 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true,
```

US", "decimals": null, "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R32": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables", "longName": "996007 - Disclosure - Stockholdersu2019 Equity and Convertible Preferred Stock (Tables)", "shortName": "Stockholdersu2019 Equity and Convertible Preferred Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R33": { "role": "http://www.aikidopharma.com/role/RevenueTables", "longName": "996008 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R34": { "role": "http://www.aikidopharma.com/role/SegmentReportingTables", "longName": "996009 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R35": { "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "longName": "996010 - Disclosure - Organization and Description of Business and Recent Developments (Details)", "shortName": "Organization and Description of Business and Recent Developments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c66", "name": "domh:InvestmentsCompanyFeePaidIndirectly", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R36": { "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "996011 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R37": { "role": "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable", "longName": "996012 - Disclosure - Marketable Securities (Details) - Schedule of Gains and (Losses) on Marketable Securities", "shortName": "Marketable Securities (Details) - Schedule of Gains and (Losses) on Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:RealizedInvestmentGainsLosses", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R38": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "longName": "996013 - Disclosure - Long-Term Equity Investments (Details)", "shortName": "Long-Term Equity Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:PaymentsToAcquireLongtermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R39": { "role": "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable", "longName": "996014 - Disclosure - Long-Term Equity Investments (Details) - Schedule of Long-Term Investments", "shortName": "Long-Term Equity Investments (Details) - Schedule of Long-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R40": { "role": "http://www.aikidopharma.com/role/NotesReceivableDetails", "longName": "996015 - Disclosure - Notes Receivable (Details)", "shortName": "Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c134", "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R41": { "role": "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable", "longName": "996016 - Disclosure - Notes Receivable (Details) - Schedule of Notes Receivable", "shortName": "Notes Receivable (Details) - Schedule of Notes Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:NotesAndLoansReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true }, "R42": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "longName": "996017 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)", "shortName": "Fair Value of Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:DebtSecuritiesUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DebtSecuritiesRealizedGainLoss", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-10q dominari.htm", "first": true, "unique": true }, "R43": { "role": "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareaMeasuredatFairValueTable", "longName": "996018 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value", "shortName": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:EquitySecuritiesFvNI", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0219844-

10q_dominari.htm", "first": true, "unique": true } }, "R44": { "role":
"http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisTable", "longName": "996019 -
Disclosure - Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a
Recurring Basis", "shortName": "Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair
Value on a Recurring Basis", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44",
"firstAnchor": { "contextRef": "c157", "name": "us-gaap:NotesAndLoansReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1,
"baseRef": "ea0219844-10q_dominari.htm", "first": true } }, "uniqueAnchor": { "contextRef": "c159", "name": "us-gaap:ShortTermInvestments",
"unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div",
"body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "unique": true } }, "R45": { "role":
"http://www.aikidopharma.com/role/LeasesDetails", "longName": "996020 - Disclosure - Leases (Details)", "shortName": "Leases (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef":
"c166", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-
10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c166", "name": "us-
gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-
gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true,
"unique": true } }, "R46": { "role": "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable", "longName": "996021 -
Disclosure - Leases (Details) - Schedule of Lease Assets and Liabilities", "shortName": "Leases (Details) - Schedule of Lease Assets and
Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": {
"contextRef": "c2", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true } },
"uniqueAnchor": null } }, "R47": { "role":
"http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationabouttheCompanysOperatingLeasesTable", "longName": "996022 -
Disclosure - Leases (Details) - Schedule of Quantitative Information about the Company's 2019s Operating Leases", "shortName": "Leases
(Details) - Schedule of Quantitative Information about the Company's 2019s Operating Leases", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c2", "name": "us-
gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm",
"first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div",
"body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R48": { "role":
"http://www.aikidopharma.com/role/ScheduleofLeaseExpenseToCurrentPeriodOperationsTable", "longName": "996023 - Disclosure - Leases
(Details) - Schedule of Lease Expense to Current Period Operations", "shortName": "Leases (Details) - Schedule of Lease Expense to Current
Period Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48",
"firstAnchor": { "contextRef": "c8", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-
10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:OperatingLeaseCost", "unitRef":
"usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"
] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R49": { "role":
"http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedtoLeasesTable", "longName": "996024 - Disclosure -
Leases (Details) - Schedule of Supplemental Cash Flow Information Related to Leases", "shortName": "Leases (Details) - Schedule of
Supplemental Cash Flow Information Related to Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "49", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1,
"baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-
gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table",
"ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique":
true } }, "R50": { "role": "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "longName": "996025 - Disclosure -
Leases (Details) - Schedule of Future Minimum Payments", "shortName": "Leases (Details) - Schedule of Future Minimum Payments",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef":
"c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOffiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef":
"ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c2", "name": "us-
gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOffiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-
10q_dominari.htm", "first": true, "unique": true } }, "R51": { "role":
"http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "longName": "996026 - Disclosure - Net Loss Per
Share (Details) - Schedule of Computation of Diluted Loss Per Share", "shortName": "Net Loss Per Share (Details) - Schedule of Computation of
Diluted Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51",
"firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef":
"shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body",
gaap:EarningsPerShareTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique":
true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div",
gaap:EarningsPerShareTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique":
true } }, "R52": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "longName": "996027 -
Disclosure - Stockholders' 2019 Equity and Convertible Preferred Stock (Details)", "shortName": "Stockholders' 2019 Equity and Convertible
Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52",
"firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first":
true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares", "unitRef": "shares", "xsiNil": "false",
"lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html"] },
"reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "unique": true } }, "R53": { "role":
"http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "longName": "996028 - Disclosure - Stockholders' 2019 Equity and
Convertible Preferred Stock (Details) - Schedule of Warrant Activity", "shortName": "Stockholders' 2019 Equity and Convertible Preferred
Stock (Details) - Schedule of Warrant Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "53", "firstAnchor": { "contextRef": "c183", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef":
"shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body",
gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-
10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c183", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef":
"shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div",
gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-
10q_dominari.htm", "first": true, "unique": true } }, "R54": { "role":
"http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "longName": "996029 - Disclosure - Stockholders' 2019
Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity", "shortName": "Stockholders' 2019 Equity and
Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c187", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef":
"shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body",
"html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c187",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div",
"body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R55": { "role":
"http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable", "longName": "996030 - Disclosure - Stockholders' 2019 Equity and
Convertible Preferred Stock (Details) - Schedule of Stock Option Plan", "shortName": "Stockholders' 2019 Equity and Convertible Preferred

Table (Details) - Schedule of Stock Option Plan, "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable", "longName": "996031 - Disclosure - Revenue (Details) - Schedule of Total Revenue Disaggregated by Revenue Type", "shortName": "Revenue (Details) - Schedule of Total Revenue Disaggregated by Revenue Type", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "R57": { "role": "http://www.aikidopharma.com/role/RegulatoryDetails", "longName": "996032 - Disclosure - Regulatory (Details)", "shortName": "Regulatory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c2", "name": "domh:NetCapitalAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "domh:NetCapitalAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails", "longName": "996033 - Disclosure - Related Party Transaction (Details)", "shortName": "Related Party Transaction (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c208", "name": "us-gaap:RelatedPartyTransactionRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c208", "name": "us-gaap:RelatedPartyTransactionRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.aikidopharma.com/role/SegmentReportingDetails", "longName": "996034 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable", "longName": "996035 - Disclosure - Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss", "shortName": "Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c212", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c212", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.aikidopharma.com/role/IncomeTaxesDetails", "longName": "996036 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": null, "name": "us-gaap:AccountingPoliciesAbstract", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": null, "name": "us-gaap:AccountsNotesAndLoansReceivableLineItems", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.aikidopharma.com/role/NotesReceivableDetails", "longName": "996037 - Disclosure - Notes Receivable (Details)", "shortName": "Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": null, "name": "us-gaap:NotesReceivableAbstract", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": null, "name": "us-gaap:AccountsNotesAndLoansReceivableLineItems", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.aikidopharma.com/role/AccountsPayableAndAccruedLiabilitiesCurrent", "longName": "996038 - Disclosure - Accounts Payable and Accrued Liabilities Current (Details)", "shortName": "Accounts Payable and Accrued Liabilities Current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": null, "name": "us-gaap:AccountsNotesAndLoansReceivableLineItems", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.aikidopharma.com/role/AccountsPayableAndAccruedLiabilitiesCurrent", "longName": "996039 - Disclosure - Accounts Payable and Accrued Liabilities Current (Details)", "shortName": "Accounts Payable and Accrued Liabilities Current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": null, "name": "us-gaap:AccountsNotesAndLoansReceivableLineItems", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.aikidopharma.com/role/AccountsPayableAndAccruedLiabilitiesCurrent", "longName": "996040 - Disclosure - Accounts Payable and Accrued Liabilities Current (Details)", "shortName": "Accounts Payable and Accrued Liabilities Current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": null, "name": "us-gaap:AccountsNotesAndLoansReceivableLineItems", "unitRef": "stringItemType", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AccountsNotesAndLoansReceivableLineItems", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0219844-10q_dominari.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.aikidopharma.com/role/AccountsPayableAndAccruedLiabilitiesCurrent", "longName": "996041 - Disclosure - Accounts Payable and Accrued Liabilities Current (Details)", "shortName": "Accounts Payable and Accrued Liabilities Current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "unitRef

```

"acquisition of FPS, net of cash acquired and receivable owed from FPS", "documentation": "Acquisition of FPS, net of cash acquired and receivable owed from FPS", "label": "Acquisition Of FPSNet Of Cash Acquired And Receivable Owed From FPS" } } }, "auth_ref": [ ] }, "ecd Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r682" ] }, "us-gaap AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 3.0 } } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ] }, "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r44", "r611", "r832" ] }, "us-gaap AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ] }, "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r451", "r770", "r771", "r772", "r773", "r806", "r834" ] }, "dei AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ] }, "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)", "auth_ref": [ "r738" ] }, "dei AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ] }, "lang": { "en-us": { "role": { "label": "Additional Securities Effective 413b", "auth_ref": [ "r736" ] }, "dei AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ] }, "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [ ] }, "ecd AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r695" ] }, "ecd AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r695" ] }, "ecd AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r695" ] }, "ecd AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation, Footnote" } } }, "auth_ref": [ "r695" ] }, "us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ] }, "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [ ] }, "domh AdvisoryFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "AdvisoryFeesMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedByRevenueTypeTable" ] }, "lang": { "en-us": { "role": { "terseLabel": "Advisory fees [Member]", "label": "Advisory Fees Member" } } }, "auth_ref": [ ] }, "ecd AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r729" ] }, "ecd AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r645", "r656", "r672", "r707" ] }, "ecd AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r648", "r659", "r675", "r710" ] }, "ecd AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r730" ] }, "ecd AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r695" ] }, "ecd AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r702" ] }, "ecd AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ] }, "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r649", "r660", "r676", "r702", "r711", "r715", "r723" ] }, "ecd AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ] }, "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r721" ] }, "us-gaap AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ] }, "lang": { "en-us": { "role": { "label": "Share based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r288", "r290" ] }, "us-gaap AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Estimated future stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [ ] }, "dei AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ] }, "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [ ] }, "dei AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ] }, "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [ ] }, "domh AmericanInnovativeRoboticsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "AmericanInnovativeRoboticsLLCMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "American Innovative Robotics, LLC [Member]", "label": "American Innovative Robotics LLC Member" } } }, "auth_ref": [ ] }, "domh AmericanInnovativeRoboticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "AmericanInnovativeRoboticsMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ] }, "lang": { "en-us": { "role": { "terseLabel": "American Innovative Robotics [Member]", "label": "American Innovative Robotics Member" } } }, "auth_ref": [ ] }, "dei AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ] }, "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r652" ] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ]
```

diluted loss per share "label": "Antidilutive Securities Excluded From Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r147"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r12"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Schedule of Computation of Diluted Loss Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r12"] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r75", "r87", "r103", "r121", "r151", "r160", "r169", "r172", "r186", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r316", "r318", "r354", "r410", "r492", "r579", "r580", "r611", "r624", "r794", "r795", "r818"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "verboseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r99", "r109", "r121", "r186", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r316", "r318", "r354", "r611", "r794", "r795", "r818"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r652"] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r637", "r640", "r652"] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r637", "r640", "r652"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r637", "r640", "r652"] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor [Text Block]" } } }, "auth_ref": ["r734"] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r718"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r719"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r714"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r714"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r714"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r714"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r714"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r714"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r717"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r716"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r715"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r715"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": ["r640", "r652"] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Liquidity and Capital Resources [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r11", "r101", "r570"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r60", "r119"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r60"] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Cash Flow Information Related to Leases [Abstract]" } } }, "auth_ref": [] }, "domh_ChangeInFairValueOfLongtermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ChangeInFairValueOfLongtermInvestment", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Change in carrying value of long-term investment", "documentation": "Change in fair value of long-term investment.", "label": "Change In Fair Value Of Longterm Investment" } } }, "auth_ref": [] }, "domh_ChangeInFairValueOfShorttermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ChangeInFairValueOfShorttermInvestment", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value short-term investments", "negatedLabel": "Change in fair value of investment", "documentation": "Change in fair value of short-term investment.", "label": "Change In Fair Value Of Shortterm Investment" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r693"] }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r690"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdGrntdInPrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r688"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r95", "r106", "r107", "r108", "r121", "r141", "r142", "r144", "r146", "r154", "r155", "r186", "r199", "r201", "r202", "r203", "r206", "r207", "r225", "r226", "r228", "r229", "r231", "r354", "r441", "r442", "r443", "r444", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r480", "r501", "r524", "r555", "r556", "r557", "r558", "r559", "r747", "r766", "r774"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]", "terseLabel": "Stockholders'2019 Equity and Convertible Preferred Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r106", "r107", "r108", "r154", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r441", "r442", "r443", "r444", "r590", "r747", "r766"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r26"] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r26"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r694"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r694"] }, "domh_CommissionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "CommissionsMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable"], "lang": { "en-us": { "role": { "terseLabel": "Commissions [Member]", "label": "Commissions Member" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract":

{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.aikidopharma.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r65", "r193", "r194", "r564", "r787", "r792"] }, "domh_CommonSharesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "CommonSharesPercentage", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares percentage", "documentation": "The percentage value of common shares." }, "label": "Common Shares Percentage" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r615", "r616", "r617", "r619", "r620", "r621", "r622", "r770", "r771", "r773", "r806", "r829", "r834"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r42", "r480"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, shares issued (in Shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock outstanding (in Shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r5", "r42", "r480", "r498", "r834", "r835"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, \$0.0001 par value, 100,000,000 shares authorized; 6,336,286 and 5,995,065 shares issued as of September 30, 2024 and December 31, 2023, respectively; 6,276,138 and 5,934,917 shares outstanding as of September 30, 2024 and December 31, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r42", "r412", "r611"] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValueOutstanding", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock value", "label": "Common Stock, Value, Outstanding", "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares." } } }, "auth_ref": ["r42", "r480"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r699"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r698"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r700"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r697"] }, "us-gaap_ComplianceWithRegulatoryCapitalRequirementsForMortgageCompaniesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComplianceWithRegulatoryCapitalRequirementsForMortgageCompaniesLineItems", "presentation": ["http://www.aikidopharma.com/role/RegulatoryDetails"], "lang": { "en-us": { "role": { "label": "Regulatory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r560", "r561", "r562", "r563"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFinancialAssetsatareMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r123", "r316", "r317", "r318", "r319", "r385", "r565", "r793", "r796", "r797"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFinancialAssetsatareMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r123", "r316", "r317", "r318", "r319", "r385", "r565", "r793", "r796", "r797"] }, "domh_ConsolidatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ConsolidatedMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "terseLabel": "Consolidated [Member]", "label": "Consolidated Member" } } }, "auth_ref": [] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": ["r640"] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": [] }

"presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "domh_ConvergentConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ConvergentConvertibleNoteMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"], "lang": { "en-us": { "role": { "terseLabel": "Convergent convertible note - current [Member]", "verboseLabel": "Convergent convertible note [Member]", "label": "Convergent Convertible Note Member" } } }, "auth_ref": [] }, "domh_ConvergentTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ConvergentTherapeuticsIncMember", "presentation": ["http://www.aikidopharma.com/role/NotesReceivableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Convergent Therapeutics, Inc. [Member]", "label": "Convergent Therapeutics Inc Member" } } }, "auth_ref": [] }, "domh_ConvergentTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ConvergentTherapeuticsMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": { "role": { "terseLabel": "Convergent Therapeutics [Member]", "label": "Convergent Therapeutics Member" } } }, "auth_ref": [] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Convertible preferred stock [Member]", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": ["r225", "r226", "r228", "r619", "r620", "r621", "r622"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r8", "r33", "r34", "r76", "r78", "r123", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r585", "r586", "r587", "r588", "r589", "r609", "r767", "r788", "r789", "r790", "r813", "r814"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"], "lang": { "en-us": { "role": { "terseLabel": "Stated Interest Rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r36", "r209"] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "verboseLabel": "Purchase price amount", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": ["r441"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"], "lang": { "en-us": { "role": { "terseLabel": "Maturity Date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r105", "r585", "r809", "r810"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r8", "r123", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r585", "r586", "r587", "r588", "r589", "r609", "r767", "r788", "r789", "r790", "r813", "r814"] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/NotesReceivableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Principal repayment", "label": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": ["r8"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r8", "r20", "r22", "r30", "r68", "r69", "r123", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r585", "r586", "r587", "r588", "r589", "r609", "r767", "r813", "r814"] }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Realized losses", "label": "Debt Securities, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": ["r422", "r761", "r762"] }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/NotesReceivableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss", "verboseLabel": "Unrealized losses", "label": "Debt Securities, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": ["r423", "r761", "r762"] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": ["r664", "r665", "r679"] }, "domh_DepositWithClearingBrokerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "DepositWithClearingBrokerPolicyTextBlock", "presentation": ["http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Deposits with clearing broker", "documentation": "Disclosure of accounting policy for deposits with clearing broker.", "label": "Deposit With Clearing Broker Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Deposits with clearing broker", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": ["r758"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r3", "r19"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable"], "lang": { "en-us": { "role": { "label": "Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r250", "r591", "r592", "r593", "r594", "r595", "r596", "r597"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r250", "r591", "r592", "r593", "r594", "r595", "r596", "r597"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType",

"nsuri": "http://fashb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.aikidopharma.com/role/RevenueTables"], "lang": { "en-us": { "role": { "label": "Schedule of Total Revenue Disaggregated by Revenue Type", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r801"] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": ["r664", "r665", "r679"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other.' } } }, "auth_ref": ["r640"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r637", "r640", "r652"] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r637", "r640", "r652", "r703"] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to 100a7240.10D-1(b)." } } }, "auth_ref": ["r637", "r640", "r652", "r703"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively. with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt.' } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": ["r638"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r626"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r640"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r640"] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth.'" } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report.'" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r680"] }

dei DocumentType: { "xbrltype": "submissionTypeItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other' } } }, "auth_ref": [] }, "dei DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r629"] }, "domh_DominariFinancialHeritageStrategiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "DominariFinancialHeritageStrategiesLLCMember", "presentation": ["http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Dominari Financial Heritage Strategies LLC [Member]", "documentation": "Dominari Financial Heritage Strategies LLC Member" } } }, "auth_ref": [] }, "domh_DominariFinancialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "DominariFinancialMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "label": "Dominari Financial [Member]", "documentation": "Dominari Financial Member" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/dei/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r692"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Share [Abstract]", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r116", "r129", "r130", "r131", "r132", "r133", "r134", "r139", "r141", "r144", "r145", "r146", "r150", "r312", "r315", "r327", "r328", "r396", "r419", "r573"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r116", "r129", "r130", "r131", "r132", "r133", "r134", "r141", "r144", "r145", "r146", "r150", "r312", "r315", "r327", "r328", "r396", "r419", "r573"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r116", "r129", "r130", "r131", "r132", "r133", "r134", "r141", "r144", "r145", "r146", "r150", "r312", "r315", "r327", "r328", "r396", "r419", "r573"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.aikidopharma.com/role/NetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r138", "r147", "r148", "r149"] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)", "documentation": "Effective upon filing, 486(b)" } } }, "auth_ref": ["r742"] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)", "documentation": "Effective upon filing, 486(b)" } } }, "auth_ref": ["r742"] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)", "documentation": "Effective upon filing, 486(b)" } } }, "auth_ref": ["r743"] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)", "documentation": "Effective upon filing, 486(b)" } } }, "auth_ref": ["r742"] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)", "documentation": "Effective upon filing, 486(b)" } } }, "auth_ref": ["r743"] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 462(e)", "documentation": "Effective upon filing, 486(b)" } } }, "auth_ref": ["r741"] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)", "documentation": "Effective upon filing, 486(b)" } } }, "auth_ref": ["r743"] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)", "documentation": "Effective upon filing, 486(b)" } } }, "auth_ref": ["r745"] }, "domh_EmployeeOptionsExpiredWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "EmployeeOptionsExpiredWeightedAverageRemainingContractualLife", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "label": "Employee options expired, Weighted Average Remaining Contractual Life (in years)", "documentation": "Share-Based Compensation Arrangement by Share Employee Options Expired Weighted Average Remaining Contractual Life." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r289"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Options to purchase common stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/dei/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance." } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "

Address, Address Line Two, "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] },
"dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine3", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of
the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": {
"en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] },
"dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressPostalZipCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation":
"Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"],
"lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship
between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] },
"dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressesLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable",
"presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]",
"documentation": "Container of address information for the entity" } } }, "auth_ref": ["r628"] },
"dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label":
"Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the
preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or
15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No
indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this
element." } } }, "auth_ref": ["r632"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": {
"en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed
disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r628"] }, "dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other
ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by
adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the
Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityContactPersonnelLineItems", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation":
"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation":
"Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject
to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing
the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the
entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures
are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and
geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] },
"dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityEmergingGrowthCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r628"
] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityExTransitionPeriod", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Ex
Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for
complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r744"] }, "dei_EntityFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file
number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional
suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype":
"filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate
whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories
are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the
related disclosure." } } }, "auth_ref": ["r628"] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"],
"lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home
country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity
Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype":
"dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation",
"documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype":
"edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": {
"en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an
entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": {
"label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityInteractiveDataCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data
File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files)." } } }, "auth_ref": ["r733"] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"],
"lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate
Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management
Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT
Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": ["r732"] },

"dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingPrimary", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity." } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity." } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r652"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r628"] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r628"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r628"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r628"] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r735"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "documentation": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r686"] }, "ecd_EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r728"] }, "ecd_EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r728"] }, "ecd_EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r728"] }, "ecd_EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r728"] }, "ecd_EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r728"] }, "ecd_EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember": {

"domainItem": { "auth_ref": ["r183", "r184", "r185", "r308", "r748", "r749", "r750", "r802", "r803", "r804", "r805"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership interests", "verboseLabel": "Interest rate", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r183"] }, "us-gaap_EquitySecuritiesFvNI": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNI", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable": { "parentTag": "us-gaap_MarketableSecuritiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "terseLabel": "Equities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r104", "r353", "r571"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r696"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r645", "r656", "r672", "r707"] }, "ecd_ErrCompRecoveryTable": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r642", "r653", "r669", "r704"] }, "us-gaap_ExcessCapital": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessCapital", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/RegulatoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Excess amount", "label": "Banking Regulation, Total Risk-Based Capital, Excess, Actual", "documentation": "Amount of total risk-based capital exceeding minimum required for capital adequacy as defined by regulatory framework." } } }, "auth_ref": ["r402"] }, "dei_ExchangeDomain": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category" } } }, "auth_ref": ["r702"] }, "dei_ExhibitsOnly462d": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)", "documentation": "Exhibits Only, 462(d)" } } }, "auth_ref": ["r740"] }, "dei_ExhibitsOnly462dFileNumber": { "xbrlType": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": ["r740"] }, "dei_Extension": { "xbrlType": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "domh_FPSPurchaseAgreementMember": { "xbrlType": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "FPSPurchaseAgreementMember", "presentation": ["http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "FPS Purchase Agreement [Member]", "label": "FPS Purchase Agreement Member" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Change in carrying value of investments", "negatedTerseLabel": "Change in fair value of investments", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r3"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "label": "Schedule of Assets and Liabilities are Measured at Fair Value [Line items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r330", "r331", "r344", "r603"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsatareMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r216", "r253", "r254", "r255", "r256", "r257", "r258", "r329", "r331", "r332", "r333", "r334", "r343", "r344", "r346", "r386", "r387", "r388", "r586", "r587", "r598", "r599", "r600", "r603", "r605"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.aikidopharma.com/role/FairValueoffinancialAssetsandLiabilities"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Assets and Liabilities", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r339", "r341", "r342", "r343", "r346", "r347", "r348", "r349", "r350", "r394", "r603", "r606"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets (Level 1) [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r216", "r253", "r258", "r331", "r344", "r386", "r598", "r599", "r600", "r603"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2) [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r216", "r253", "r258", "r331", "r332", "r344", "r387", "r586", "r587", "r598", "r599", "r600", "r603"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [] }

"http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable",
"http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": {
"role": { "terseLabel": "Significant unobservable inputs (Level 3) [Member]", "verboseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs,
Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants
would use in pricing." } } }, "auth_ref": ["r216", "r253", "r254", "r255", "r256", "r257", "r258", "r331", "r332", "r333", "r334", "r388",
"r586", "r587", "r598", "r599", "r600", "r603", "r605"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation":
["http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "label":
"Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair
value." } } }, "auth_ref": ["r216", "r253", "r254", "r255", "r256", "r257", "r258", "r329", "r331", "r332", "r333", "r334", "r343", "r344", "r346",
"r386", "r387", "r388", "r586", "r587", "r598", "r599", "r600", "r603", "r605"] }, "us-
gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [
"http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": {
"role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r335", "r336", "r338", "r339", "r340", "r345"] },
"us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [
"http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": {
"role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
"documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative
liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would
use in pricing." } } }, "auth_ref": ["r335", "r336", "r337", "r338", "r339", "r340", "r345"] }, "us-
gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [
"http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Financial Assets that are Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Net Derivative Asset (Liability) Measured on
Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of financial instrument
classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the
entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r335", "r340", "r345"] },
"domh_FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable": { "xbrltype":
"stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname":
"FairValueofFinancialAssetsandLiabilitiesDetailsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "presentation": [
"http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "label":
"Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value [Table]" } } },
"auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax
Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r649", "r660", "r676",
"r711"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang":
{ "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of
Enforcement, Amount" } } }, "auth_ref": ["r649", "r660", "r676", "r711"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-
us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of
Home Country Law, Amount" } } }, "auth_ref": ["r649", "r660", "r676", "r711"] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"],
"lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery,
Explanation of Impracticability" } } }, "auth_ref": ["r649", "r660", "r676", "r711"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel":
"Name" } } }, "auth_ref": ["r649", "r660", "r676", "r711"] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": {
"en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": ["r639", "r663"] },
"dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"FormerFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former
Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] },
"ecd_FrValAsOfPrrYrEndOfEqtyAwrdGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards
Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair
Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [
"r691"] }, "domh_FundRaising": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname":
"FundRaising", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Fund raising", "documentation": "The amount of fund raising.", "label": "Fund Raising" } } }, "auth_ref": [] }, "us-
gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GainLossOnInvestments", "crdr": "credit", "presentation": [
"http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": {
"role": { "terseLabel": "Realized and unrealized gain (loss) on note receivable, net", "label": "Gain (Loss) on Investments", "documentation":
"Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": ["r54", "r56", "r746"] }, "us-
gaap_GainLossOnSaleOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GainLossOnSaleOfNotesReceivable", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": {
"parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow":
{ "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } } }, "presentation": [
"http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement"], "lang": {
"en-us": { "role": { "terseLabel": "Realized and unrealized loss on note receivable, net", "negatedLabel": "Realized and unrealized loss on note
receivable", "label": "Gain (Loss) on Sale of Financing Receivable", "documentation": "Amount of gain (loss) on sale of financing receivable." } } },
"auth_ref": ["r390"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 },
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": {
"parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } } }, "presentation": [
"http://www.aikidopharma.com/role/ConsolidatedIncomeStatement",
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"],
"lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The
aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not
directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r52", "r503"] },
"dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"IcfrAuditorAttestationFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "ICFR
Auditor Attestation Flag" } } }, "auth_ref": ["r637", "r640", "r652"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [

"http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r190", "r191", "r192", "r336", "r340", "r345", "r426", "r428", "r509", "r568", "r604", "r828"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": { "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r191", "r192", "r336", "r340", "r345", "r426", "r428", "r509", "r568", "r604", "r828"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://www.aikidopharma.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r122", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r305", "r306", "r307", "r447", "r602"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": { "http://www.aikidopharma.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r88", "r93", "r136", "r137", "r151", "r164", "r172", "r294", "r295", "r304", "r424", "r602"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r2"] }, "domh_IncreaseDecreaseInAccruedCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "IncreaseDecreaseInAccruedCommissions", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Accrued commissions", "label": "Increase Decrease In Accrued Commissions", "documentation": "Increase decrease in accrued commissions." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Clearing broker deposits", "label": "Increase (Decrease) in Deposit Assets", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Accrued salaries and benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInterestAndDividendsReceivable", "crdr": "credit", "presentation": { "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatAreMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": { "role": { "label": "Change in interest receivable", "label": "Increase (Decrease) in Interest and Dividends Receivable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInNotesReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInNotesReceivables", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Notes receivable, at fair value", "label": "Increase (Decrease) in Notes Receivables", "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r752", "r764"] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Other current liabilities", "label": "Increase (Decrease) in Other Current Liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": ["r764"] }, "domh_IncreaseDecreaseInPrepaidAcquisitionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "IncreaseDecreaseInPrepaidAcquisitionCost", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Prepaid acquisition cost", "label": "Increase Decrease In Prepaid Acquisition Cost", "documentation": "Increase Decrease In Prepaid Acquisition Cost." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInPrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidRent", "crdr": "credit", "presentation": { "http://www.aikidopharma.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Increase rent amount", "label": "Increase (Decrease) in Prepaid Rent", "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods." } } }, "auth_ref": ["r2"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "label": "Individual", "documentation": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements", "auth_ref": ["r649", "r660", "r676", "r702", "r711", "r715", "r723"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "documentation": "Insider Trading Policies and Procedures", "auth_ref": ["r641", "r727"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "documentation": "Insider Trading Policies and Procedures Adopted", "auth_ref": ["r641", "r727"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": {

[http://xbrl.sec.gov/ecl/role/InsiderTradingPoliciesProc](#)], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r641", "r727"] }, "us-gaap:InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOther", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/NotesReceivableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap:InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"], "lang": { "en-us": { "role": { "terseLabel": "Interest Receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": ["r757", "r836"] }, "dei:InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": ["r665", "r666", "r667", "r668"] }, "dei:InvestmentCompanyRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": ["r681"] }, "us-gaap:InvestmentCompanyCommittedCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyCommittedCapital", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment value", "label": "Investment Company, Committed Capital", "documentation": "Amount of funds committed to investment company from investors." } } }, "auth_ref": ["r453"] }, "us-gaap:InvestmentCompanyFeePaidIndirectly": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyFeePaidIndirectly", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional seller paid (in Dollars)", "label": "Investment Company, Fee Paid Indirectly", "documentation": "Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction." } } }, "auth_ref": ["r445", "r503", "r504", "r505", "r506", "r509"] }, "us-gaap:InvestmentCompanyMarketValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyMarketValuePerShare", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Market price (in Dollars per share)", "label": "Investment Company, Market Value, Per Share", "documentation": "Market value per share of investment portfolio by investment company. Includes, but is not limited to, per unit, membership interest, or other ownership interest." } } }, "auth_ref": ["r830"] }, "dei:InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": ["r681"] }, "dei:InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": ["r681"] }, "us-gaap:InvestmentCompanyShareholderServiceFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyShareholderServiceFeeExpense", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment charge", "label": "Investment Company, Shareholder Service Fee Expense", "documentation": "Amount of expense for shareholder services. Includes, but is not limited to, fee and expense for transfer and dividend disbursing agent." } } }, "auth_ref": ["r833"] }, "domh:InvestmentInAdvEnMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInAdvEnMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in AdvEn [Member]", "label": "Investment In Adv En Member" } } }, "auth_ref": [] }, "domh:InvestmentInAndurilMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInAndurilMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Anduril [Member]", "label": "Investment In Anduril Member" } } }, "auth_ref": [] }, "domh:InvestmentInAutomationAnywhereMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInAutomationAnywhereMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Automation Anywhere [Member]", "label": "Investment In Automation Anywhere Member" } } }, "auth_ref": [] }, "domh:InvestmentInCerebrasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInCerebrasMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Cerebras [Member]", "label": "Investment In Cerebras Member" } } }, "auth_ref": [] }, "domh:InvestmentInDatabricksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInDatabricksMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Databricks [Member]", "label": "Investment In Databricks Member" } } }, "auth_ref": [] }, "domh:InvestmentInDiscordMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInDiscordMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Discord [Member]", "label": "Investment In Discord Member" } } }, "auth_ref": [] }, "domh:InvestmentInEpicGamesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInEpicGamesMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Epic Games [Member]", "label": "Investment In Epic Games Member" } } }, "auth_ref": [] }, "domh:InvestmentInGroqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInGroqMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Groq [Member]", "label": "Investment In Groq Member" } } }, "auth_ref": [] }, "domh:InvestmentInKayaNowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInKayaNowMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Kaya Now [Member]", "label": "Investment In Kaya Now Member" } } }, "auth_ref": [] }, "domh:InvestmentInKernaHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInKernaHealthIncMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Kerna Health Inc [Member]", "label": "Investment In Kerna Health Inc Member" } } }, "auth_ref": [] }, "domh:InvestmentInKrakenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInKrakenMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Kraken [Member]", "label": "Investment In Kraken Member" } } }, "auth_ref": [] }, "domh:InvestmentInMasterclassMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInMasterclassMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Masterclass [Member]", "label": "Investment In Masterclass Member" } } }, "auth_ref": [] }, "domh:InvestmentInOxpressMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInOxpressMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Oxpress [Member]", "label": "Investment In Oxpress Member" } } }, "auth_ref": [] }, "domh:InvestmentInSpaceXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInSpaceXMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in SpaceX [Member]", "label": "Investment In SpaceX Member" } } }, "auth_ref": [] }, "domh:InvestmentInTesspayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInTesspayMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Tesspay [Member]", "label": "Investment In Tesspay Member" } } }, "auth_ref": [] }, "domh:InvestmentInTevvaMotorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInTevvaMotorsMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Tevva Motors [Member]", "label": "Investment In Tevva Motors Member" } } }, "auth_ref": [] }, "domh:InvestmentInThrasioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInThrasioMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Thrasio [Member]", "label": "Investment In Thrasio Member" } } }, "auth_ref": [] }, "domh:InvestmentInThrasioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInThrasioMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Thrasio [Member]", "label": "Investment In Thrasio Member" } } }, "auth_ref": [] }, "domh:InvestmentInThrasioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInThrasioMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvest

[Member]", "label": "Investment In Thrasio Member" } } }, "auth_ref": [] }, "domh_InvestmentInUnusualMachinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInUnusualMachinesMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Unusual Machines [Member]", "label": "Investment In Unusual Machines Member" } } }, "auth_ref": [] }, "domh_InvestmentInXAIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentInXAIMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Investment in XAI [Member]", "label": "Investment In XAIMember" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeDividend", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Dividend income", "label": "Investment Income, Dividend", "documentation": "Amount of dividend income on nonoperating securities." } } }, "auth_ref": ["r53"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r151", "r163", "r172", "r579", "r760"] }, "us-gaap_InvestmentOwnedAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments, Cost Basis", "label": "Investment Owned, Cost", "documentation": "Cost of the investment." } } }, "auth_ref": ["r437", "r468", "r469", "r533", "r536", "r543", "r549", "r617", "r624", "r831"] }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Investment Owned, Balance, Principal Amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": ["r464", "r470", "r531", "r542", "r548", "r617"] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Long-term equity investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r421", "r437", "r438", "r439", "r440", "r534", "r535"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": ["r465", "r466", "r467", "r468", "r470", "r529", "r532", "r538", "r541", "r544", "r546", "r550", "r551", "r552", "r553", "r554", "r617"] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": ["r408", "r409", "r613", "r614"] }, "domh_InvestmentsCompanyFeePaidIndirectly": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "InvestmentsCompanyFeePaidIndirectly", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Seller paid (in Dollars)", "documentation": "InvestmentsCompanyFeePaidIndirectly.", "label": "Investments Company Fee Paid Indirectly" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.aikidopharma.com/role/MarketableSecurities"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r83", "r96", "r181", "r182", "r351", "r352", "r827"] }, "domh_JointVenturesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "JointVenturesPolicyTextBlock", "presentation": ["http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Joint Ventures", "documentation": "Disclosure of accounting policy for joint ventures.", "label": "Joint Ventures Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseAndRentalExpense", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease rent expenses", "label": "Operating Leases, Rent Expense", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseExpenseToCurrentPeriodOperationsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.aikidopharma.com/role/LeasesDetails", "http://www.aikidopharma.com/role/ScheduleofLeaseExpenseToCurrentPeriodOperationsTable"], "lang": { "en-us": { "role": { "totalLabel": "Net rent expense", "terseLabel": "Lease expenses", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r369", "r610"] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Lease Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.aikidopharma.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of lease expense to current period operations", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r816"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "domh_LeasesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "LeasesDetailsTable", "presentation": ["http://www.aikidopharma.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } }, "auth_ref": [] }, "domh_LegacyAlkidoPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "LegacyAlkidoPharmaMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "terseLabel": "Legacy Alkido Pharma [Member]", "label": "Legacy Alkido Pharma Member" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "LegalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": ["r625"] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Quantitative Information about the Company's 2019s Operating Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r368"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.aikidopharma.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum

Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r817"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r375"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r375"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r375"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r375"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r375"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r375"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Period Ended December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r817"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable"], "lang": { "en-us": { "role": { "negatedLabel": "Less present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r375"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.aikidopharma.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r815"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.aikidopharma.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r363"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r8", "r33", "r34", "r35", "r37", "r38", "r39", "r40", "r121", "r186", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r317", "r318", "r319", "r354", "r479", "r574", "r624", "r794", "r818", "r819"] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' 2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r49", "r79", "r415", "r611", "r768", "r785", "r812"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r35", "r100", "r121", "r186", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r317", "r318", "r319", "r354", "r611", "r794", "r818", "r819"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiquidationBasisOfAccountingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiquidationBasisOfAccountingTextBlock", "presentation": ["http://www.aikidopharma.com/role/LiquidityandCapitalResources"], "lang": { "en-us": { "role": { "terseLabel": "Liquidity and Capital Resources", "label": "Liquidation Basis of Accounting [Text Block]", "documentation": "The entire disclosure for the liquidation basis of accounting." } } }, "auth_ref": ["r32"] }, "us-gaap_LoansAndLeasesReceivableDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAndLeasesReceivableDisclosureLineItems", "presentation": ["http://www.aikidopharma.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Leases [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": ["http://www.aikidopharma.com/role/NotesReceivable"], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": ["r361", "r781"] }, "def_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "LongTermDebtAbstract", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Long-term", "label": "Long-Term Debt, Unclassified [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestments"], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Equity Investments", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r66"] }, "domh_LongTermEquityInvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "LongTermEquityInvestmentsDetailsTable", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Equity Investments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Equity Investments", "verboseLabel": "Long-term investments, Carrying Value", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": ["r102"] }, "us-gaap_LongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Equity Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Equity Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": ["r80", "r754"] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]", "terseLabel": "Marketable securities" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "totalLabel": "Total marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r754"] }, "us-gaap_MarketableSecuritiesGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesGainLossAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Gains and (Losses) on Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Gain (loss) on marketable securities, net", "label": "Marketable Security, Gain (Loss)", "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Realized (gain) loss on marketable securities", "label": "Marketable Security, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": ["http://www.aikidopharma.com/role/MarketableSecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gains and (Losses) on Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 2.0 } }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized (gain) loss on marketable securities", "terseLabel": "Unrealized gain (loss)", "verboseLabel": "Gain on marketable securities", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": ["r54"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r195", "r196", "r197", "r198", "r259", "r291", "r334", "r392", "r425", "r427", "r434", "r471", "r472", "r530", "r537", "r539", "r540", "r566", "r567", "r584", "r590", "r601", "r603", "r606", "r607", "r608", "r612", "r798", "r820", "r821", "r822", "r823", "r824", "r825"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure" } } }, "auth_ref": ["r694"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r694"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/RegulatoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": ["r195", "r196", "r197", "r198", "r259", "r291", "r334", "r392", "r425", "r427", "r434", "r471", "r472", "r530", "r537", "r539", "r540", "r566", "r567", "r584", "r590", "r601", "r603", "r606", "r607", "r612", "r798", "r820", "r821", "r822", "r823", "r824", "r825"] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": ["http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Membership interests", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r714"] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-

month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r722"] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r695"] }, "domh_NetCapitalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "NetCapitalAmount", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/RegulatoryDetails"], "lang": { "en-us": { "role": { "label": "Net capital requirement", "documentation": "The amount of net capital." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r118"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r118"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r60", "r61", "r62"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r51", "r62", "r82", "r98", "r110", "r111", "r114", "r121", "r127", "r129", "r130", "r131", "r132", "r133", "r136", "r137", "r143", "r186", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r312", "r315", "r328", "r354", "r417", "r500", "r522", "r523", "r623", "r794"] }, "us-gaap_NewAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": ["http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Effect of new accounting pronouncements to be adopted in future periods", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": ["r665", "r666", "r667", "r668"] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)", "auth_ref": ["r739"] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": ["r739"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r694"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r649", "r660", "r676", "r702", "r711"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r685"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO

NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": "r684" } } }
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember",
"presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel":
"Non-PEO NEO" } } }, "auth_ref": "r702" } }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted
[Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": "r722" } }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated
[Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": "r722" } }, "us-gaap_NonoperatingIncomeExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit",
"calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0,
"order": 2.0 } },
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": {
"parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.aikidopharma.com/role/ConsolidatedIncomeStatement",
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" },
"lang": { "en-us": { "role": { "totalLabel": "Total other expenses", "terseLabel": "Total other (expenses) income", "label": "Nonoperating Income
(Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding
major activities considered part of the normal operations of the business)." } } }, "auth_ref": "r55" } },
"domh_NoteReceivableNoncurrentPortionAfterCollectionOfPrincipal": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.aikidopharma.com/20240930", "localname": "NoteReceivableNoncurrentPortionAfterCollectionOfPrincipal", "crdr": "debit",
"presentation": { "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsatareMeasuredatFairValueonaRecurringBasisTable" }, "lang":
{ "en-us": { "role": { "negatedLabel": "Note receivable, Convergent Therapeutics, non-current portion", "documentation": "Note receivable non-
current portion after collection of principal.", "label": "Note Receivable Noncurrent Portion After Collection Of Principal" } } }, "auth_ref": [] },
"us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": {
"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.aikidopharma.com/role/ConsolidatedBalanceSheet",
"http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable",
"http://www.aikidopharma.com/role/ScheduleofFinancialAssetsatareMeasuredatFairValueonaRecurringBasisTable",
"http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" }, "lang": { "en-us": { "role": { "periodStartLabel": "Notes receivable at
fair value, current portion, Balance beginning", "periodEndLabel": "Notes receivable at fair value, current portion at Balance ending",
"terseLabel": "Notes receivable, at fair value - current portion", "verboseLabel": "Notes receivable at fair value, current portion", "label":
"Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amortized cost, after allowance for credit loss, of financing
receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": "r395", "r782" } }, "us-
gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet",
"http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesatareMeasuredatFairValueTable",
"http://www.aikidopharma.com/role/ScheduleofFinancialAssetsatareMeasuredatFairValueonaRecurringBasisTable",
"http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" }, "lang": { "en-us": { "role": { "periodStartLabel": "Notes receivable at
fair value, non-current portion Balance beginning", "periodEndLabel": "Notes receivable at fair value, non-current portion Balance ending",
"terseLabel": "Notes receivable, at fair value - non-current portion", "verboseLabel": "Notes receivable at fair value, non-current portion",
"label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of
financing receivable, classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_NotesReceivableFairValueDisclosure": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableFairValueDisclosure", "crdr": "debit",
"presentation": { "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" }, "lang": { "en-us": { "role": { "terseLabel": "Fair
Value", "label": "Notes Receivable, Fair Value Disclosure", "documentation": "Fair value portion of an agreement for an unconditional promise
by the maker to pay the holder a definite sum of money at a future date." } } }, "auth_ref": "r811" } }, "us-
gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NumberOfReportableSegments", "presentation": { "http://www.aikidopharma.com/role/SegmentReportingDetails" }, "lang": { "en-us": { "role":
{ "terseLabel": "Reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the
entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information
on that component in the entity's financial statements." } } }, "auth_ref": "r576", "r583", "r776" } }, "us-
gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingCostsAndExpensesAbstract", "presentation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement",
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" },
"lang": { "en-us": { "role": { "terseLabel": "Operating costs and expenses", "verboseLabel": "Operating Costs", "label": "Operating Costs and
Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": {
"http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order":
2.0 } }, "presentation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Total
operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for
the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and
administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 },
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": {
"parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.aikidopharma.com/role/ConsolidatedIncomeStatement",
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" },
"lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the
period of deducting operating expenses from operating revenues." } } }, "auth_ref": "r86", "r575", "r775", "r777", "r778", "r779", "r780" } },
"us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost",
"crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseExpensestoCurrentPeriodOperationsTable": { "parentTag":
"us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.aikidopharma.com/role/ScheduleofLeaseExpensestoCurrentPeriodOperationsTable" }, "lang": { "en-us": { "role": { "terseLabel":
"Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining
cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by
amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": "r370", "r610" } }, "us-
gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLeaseIncomeTableTextBlock", "presentation": { "http://www.aikidopharma.com/role/LeasesTables" }, "lang": { "en-us": { "role":
{ "terseLabel": "Schedule of Lease Assets and Liabilities", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation":
"Tabular disclosure of components of income from operating lease." } } }, "auth_ref": "r152", "r377" } }, "us-
gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Payments [Abstract]" } } },
"auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": {
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 },
"http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true }
}, "presentation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable",
"http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" }, "lang": { "en-us": { "role": { "totalLabel": "Total",
"terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted
obligation for lease payments from operating lease." } } }, "auth_ref": "r366" } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight":
1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap

"http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Lease liability - current", "verboseLabel": "Operating Current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r366"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Lease liability, less current portion", "verboseLabel": "Operating Long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r366"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofSupplementalCashFlowInformationRelatedtoLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows - operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r367", "r372"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "verboseLabel": "Operating lease right-of-use-assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r365"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r765"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationabouttheCompany'sOperatingLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate \u2013 operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r374", "r610"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.aikidopharma.com/role/ScheduleofQuantitativeInformationabouttheCompany'sOperatingLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term \u2013 operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r373", "r610"] }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments"], "lang": { "en-us": { "role": { "terseLabel": "Organization and Description of Business and Recent Developments", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r31", "r74", "r435", "r436"] }, "domh_OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsTable", "presentation": ["http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails"], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherAdditionalCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAdditionalCapital", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Invested an additional amount", "label": "Other Additional Capital", "documentation": "Amount of additional paid-in capital (APIC) classified as other." } } }, "auth_ref": ["r45", "r413"] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment charge", "label": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": ["r765", "r786"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "terseLabel": "Other income (expenses)", "verboseLabel": "Other (expenses) income", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other current liability", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r34", "r611"] }, "domh_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "OtherMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable"], "lang": { "en-us": { "role": { "terseLabel": "Other [Member]", "label": "Other Member" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": ["r117"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r694"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 17 or Item 18 specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r640"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r647", "r658", "r674", "r709"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r650", "r661", "r677", "r712"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r650", "r661", "r677", "r712"] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": []

"http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails"], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": ["http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails"], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r683"] }, "us-gaap_PaymentsForRepurchaseOfOtherEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfOtherEquity", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of treasury stock", "label": "Payments for Repurchase of Other Equity", "documentation": "Amount of cash outflow to reacquire equity classified as other." } } }, "auth_ref": ["r59"] }, "us-gaap_PaymentsToAcquireLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireLoansReceivable", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Loans to employees", "label": "Payments to Acquire Loans Receivable", "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services." } } }, "auth_ref": ["r10"] }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireLongtermInvestments", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses on long term investments", "label": "Payments to Acquire Long-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term." } } }, "auth_ref": ["r763"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r784"] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of short-term and long-term investments", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": ["r57"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of fixed assets", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r58"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r693"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r693"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r685"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r702"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r695"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r684"] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r686"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r731"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r685"] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": ["r626"] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": ["r626"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r633"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r635"] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": ["r626"] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": ["r626"] }, "us-gaap_PreferedStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liquidation preference (in Dollars per share)", "verboseLabel": "Liquidation preference per share (in Dollars per share)", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of" } } }

the share." } } }, "auth_ref": ["r20", "r21", "r41", "r766", "r799"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r615", "r616", "r619", "r620", "r621", "r622", "r829", "r834"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"] }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r41", "r225"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"] }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r41", "r480"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"] }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r41", "r225"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"] }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r41", "r480", "r498", "r834", "r835"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"] }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock value", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r41", "r411", "r611"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"] }, "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r759"] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatAreMeasuredatFairValueonaRecurringBasisTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Collection of principal on note receivable", "negatedLabel": "Collection of principal outstanding", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": ["r9"] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "terseLabel": "Sale of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfOtherInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "terseLabel": "Redemption of long-term investments", "label": "Proceeds from Sale of Other Investments", "documentation": "Amount of cash inflow from the sale of investments classified as other." } } }, "auth_ref": ["r751"] }, "domh_ProceedsfromCollectionofLoansToEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ProceedsfromCollectionofLoansToEmployees", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "terseLabel": "Collection of loans to employees", "documentation": "Represent the amount of cash inflow of collection of loans to employees." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"] }, "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r376", "r398", "r416", "r611"] }, "domh_PublicOfferingPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "PublicOfferingPrice", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Public offering price (in Dollars per share)", "documentation": "Price per share of public offering." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r683"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r683"] }, "domh_RaefanIndustriesLLCInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "RaefanIndustriesLLCInvestmentMember", "presentation": ["http://www.aikidopharma.com/role/NotesReceivableDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Raefan Industries LLC Investment [Member]", "verboseLabel": "Raefan Industries LLC [Member]", "label": "Raefan Industries LLCInvestment Member" } } }, "auth_ref": [] }, "domh_RaefanIndustriesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "RaefanIndustriesLLCMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Raefan Industries LLC [Member]", "label": "Raefan Industries LLCMember" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/RegulatoryDetails"] }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r195", "r196", "r197", "r198", "r252", "r259", "r284", "r285", "r286", "r291", "r334", "r389", "r391", "r392", "r425", "r427", "r434", "r471", "r472", "r530", "r537", "r539", "r540", "r547", "r566", "r567", "r584", "r590", "r601", "r605", "r606", "r607", "r608", "r612", "r617", "r791", "r798", "r809", "r821", "r822", "r823", "r824", "r825"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/RegulatoryDetails"] }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r195", "r196", "r197", "r198", "r252", "r259", "r284", "r285", "r286", "r291", "r334", "r389", "r391", "r392", "r425", "r427", "r434", "r471", "r472", "r530", "r537", "r539", "r540", "r547", "r566", "r567", "r584", "r590", "r601", "r605", "r606", "r607", "r608", "r612", "r617", "r791", "r798", "r809", "r821", "r822", "r823", "r824", "r825"] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Realized investment gains and losses" } } }, "auth_ref": [] }

"Realized gain (loss)", "label": "Realized Investment Gains (Losses)", "documentation": "Amount of realized gain (loss) on investment." } } },
"auth_ref": ["r420"] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Notes Receivable [Abstract]" } } }, "auth_ref": [] },
"domh_RecentlyAdoptedAccountingStandardPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.aikidopharma.com/20240930", "localname": "RecentlyAdoptedAccountingStandardPolicyTextBlock", "presentation": [
"http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"] }, "lang": { "en-us": { "role": { "terseLabel": "Recently adopted accounting
standards", "documentation": "Disclosure of accounting policy for recently adopted accounting standards.", "label": "Recently Adopted
Accounting Standard Policy Text Block" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery
of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } },
"auth_ref": ["r642", "r653", "r669", "r704"] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number",
"documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": ["r626"] },
"srt_RegulatoryCapitalRequirementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RegulatoryCapitalRequirementsAbstract", "lang": { "en-us": { "role": { "label": "Regulatory [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "presentation": [
"http://www.aikidopharma.com/role/Regulatory"] }, "lang": { "en-us": { "role": { "terseLabel": "Regulatory", "label": "Regulatory Capital
Requirements under Banking Regulations [Text Block]", "documentation": "The entire disclosure for regulatory capital requirement for
depository and lending institutions. Institutions include, but not are not limited to, finance company, insured depository institution, bank
holding company, savings and loan association holding company, bank and savings institution not federally insured, mortgage company,
foreign financial institution and credit union." } } }, "auth_ref": ["r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407"] },
"domh_RegulatoryDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname":
"RegulatoryDetailsTable", "presentation": ["http://www.aikidopharma.com/role/RegulatoryDetails"] }, "lang": { "en-us": { "role": { "label":
"Regulatory (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit",
"presentation": ["http://www.aikidopharma.com/role/RelatedPartyTransactionDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Incurred
fees", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the
financial reporting period." } } }, "auth_ref": ["r29", "r382"] }, "us-gaap_RelatedPartyTransactionRate": { "xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionRate", "presentation": [
"http://www.aikidopharma.com/role/RelatedPartyTransactionDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Reverse\u2019s outstanding
equity percentage", "label": "Related Party Transaction, Rate", "documentation": "Identify the stated interest rate per the agreement, for
example, leasing and debt arrangements between related parties." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": {
"role": { "label": "Related Party Transaction [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock",
"presentation": ["http://www.aikidopharma.com/role/RelatedPartyTransaction"] }, "lang": { "en-us": { "role": { "terseLabel": "Related Party
Transaction", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party
transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a
common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r379", "r380", "r381", "r383", "r384", "r448",
"r449", "r450", "r507", "r508", "r509", "r527", "r528"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 },
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": {
"parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } } }, "presentation": [
"http://www.aikidopharma.com/role/ConsolidatedIncomeStatement",
"http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"] },
"lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation":
"Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or
otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture
formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in
research and development activity." } } }, "auth_ref": ["r292", "r568", "r579", "r826"] }, "ecd_RestatementDateAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel":
"Restatement Determination Date" } } }, "auth_ref": ["r643", "r654", "r670", "r705"] }, "ecd_RestatementDeterminationDate": { "xbrltype":
"dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel":
"Restatement Determination Date" } } }, "auth_ref": ["r644", "r655", "r671", "r706"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock",
"presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Restatement Does Not Require
Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r651", "r662", "r678", "r713"] },
"domh_RestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname":
"RestrictedStockAwardsMember", "presentation": [
"http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"] }, "lang": { "en-us": { "role": { "terseLabel":
"Restricted Stock Awards [Member]", "label": "Restricted Stock Awards Member" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [
"http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable",
"http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Restricted
stock awards [Member]", "verboselabel": "Restricted Stock [Member]", "label": "Restricted Stock [Member]", "documentation": "Stock
including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified
performance conditions are met." } } }, "auth_ref": ["r12"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit",
"calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0,
"order": 4.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"] }, "lang": { "en-us": { "role": { "terseLabel":
"Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings
(deficit)." } } }, "auth_ref": ["r46", "r70", "r414", "r432", "r433", "r446", "r481", "r611"] }, "us-gaap_RetainedEarningsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.aikidopharma.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label":
"Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r97", "r124", "r125",
"r126", "r128", "r133", "r135", "r137", "r187", "r188", "r189", "r301", "r302", "r309", "r310", "r311", "r313", "r314", "r315", "r320", "r322",
"r323", "r325", "r326", "r362", "r364", "r429", "r431", "r451", "r834"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable"] }, "lang": { "en-us": { "role": { "terseLabel":
"Total revenue disaggregated", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including
tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax
collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing
transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r84", "r85", "r151", "r161", "r162", "r168",
"r172", "r175", "r177", "r178", "r249", "r250", "r393"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
"presentation": ["http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenue",
"label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from
contract with customer." } } }, "auth_ref": ["r94", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r569"] }, "us-
gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.aikidopharma.com/role/Revenue"] }, "lang": { "en-us": { "role": {
"terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue
from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of
revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset

recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r94", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r251"] }, "us-gaap Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"] , "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r84", "r85", "r115", "r121", "r151", "r161", "r162", "r168", "r172", "r175", "r177", "r178", "r186", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r354", "r397", "r579", "r794"] }, "us-gaap RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "lang": { "en-us": { "role": { "label": "Revenue [Abstract]" } } }, "auth_ref": [] }, "ecd Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r722"] }, "ecd Rule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r722"] }, "us-gaap ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": ["http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable"] , "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "terseLabel": "Notes Receivable [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": ["r43", "r50", "r180", "r783"] }, "us-gaap ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": ["http://www.aikidopharma.com/role/NotesReceivableTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notes Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": ["r43", "r50"] }, "us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable"] , "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r12"] }, "us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.aikidopharma.com/role/NetLossPerShareTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Diluted Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r12"] }, "domh ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Assets And Liabilities That Are Measured At Fair Value Abstract" } } }, "auth_ref": [] }, "us-gaap ScheduleOfCapitalizationLongtermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCapitalizationLongtermDebtLineItems", "presentation": ["http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable"] , "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://www.aikidopharma.com/role/LeasesTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "domh ScheduleOfComputationOfDilutedLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfComputationOfDilutedLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Computation Of Diluted Loss Per Share Abstract" } } }, "auth_ref": [] }, "us-gaap ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Investments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r8", "r20", "r22", "r30", "r68", "r69", "r586", "r588", "r769", "r813"] }, "srt ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"] , "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r183", "r184", "r185", "r308", "r748", "r749", "r750", "r802", "r803", "r804", "r805"] }, "us-gaap ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities that are Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r807", "r808"] }, "domh ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Financial Assets That Are Measured At Fair Value On A Recurring Basis Abstract" } } }, "auth_ref": [] }, "domh ScheduleOfLeaseAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfLeaseAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Lease Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "domh ScheduleOfLongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfLongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Long Term Investments Abstract" } } }, "auth_ref": [] }, "domh ScheduleOfNotesReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfNotesReceivableAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Notes Receivable Abstract" } } }, "auth_ref": [] }, "domh ScheduleOfOperatingLeaseCostWeightedAverageTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfOperatingLeaseCostWeightedAverageTableTextBlock", "presentation": ["http://www.aikidopharma.com/role/LeasesTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Quantitative Information about the Company's 2019s Operating Leases", "documentation": "Schedule of Operating Lease Cost Weighted Average [Table Text Block]", "label": "Schedule Of Operating Lease Cost Weighted Average Table Text Block" } } }, "auth_ref": [] }, "domh ScheduleOfRestrictedStockAwardsActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930",

"localname": "ScheduleOfRestrictedStockAwardsActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Awards Activity [Abstract]" } } }, "auth_ref": [] },

"domh_ScheduleOfSegmentProfitabilityThatAreMostReliedUponByTheCodmAreGrossRevenueAndNetLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname":

"ScheduleOfSegmentProfitabilityThatAreMostReliedUponByTheCodmAreGrossRevenueAndNetLossAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Segment Profitability That Are Most Relied Upon By The Codm Are Gross Revenue And Net Loss Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.aikidopharma.com/role/ScheduleOfSegmentProfitabilitythatAreMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r16", "r17", "r18"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.aikidopharma.com/role/SegmentReportingTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r16", "r17", "r18"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Plan", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r6", "r7", "r72"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Awards Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrant Activity", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r26"] }, "domh_ScheduleOfTotalRevenueDisaggregatedByRevenueTypeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfTotalRevenueDisaggregatedByRevenueTypeAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Total Revenue Disaggregated By Revenue Type Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfWarrantActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ScheduleOfWarrantActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrant Activity Abstract" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r627"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r631"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Security deposit", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r753"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r630"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r636"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.aikidopharma.com/role/SegmentReporting"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r87", "r151", "r156", "r157", "r158", "r159", "r160", "r165", "r166", "r167", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r576", "r577", "r578", "r579", "r581", "r582", "r583"] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": ["http://www.aikidopharma.com/role/ScheduleOfSegmentProfitabilitythatAreMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "domh_SeniorSecuredConvertiblePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "SeniorSecuredConvertiblePercentage", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior secured convertible", "label": "Senior Secured Convertible Percentage" } } }, "auth_ref": [] }, "domh_SeriesD1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "SeriesD1PreferredStockMember", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Series D-1 Preferred Stock", "label": "Series D1 Preferred Stock Member" } } }, "auth_ref": [] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesDPreferredStockMember", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Series D Preferred Stock [Member]", "label": "Series D Preferred Stock [Member]", "documentation": "Series D preferred stock." } } }, "auth_ref": ["r755", "r756", "r800"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel":

"Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Stock Option Activity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r278"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrant": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r278"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Granted, Warrants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r276"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrant": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Granted, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r276"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsWeightedAverageRemainingContractualLife", "presentation": ["http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Granted, Weighted Average Remaining Contractual Life", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants Weighted Average Remaining Contractual Terms" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of shares, ending balance", "periodStartLabel": "Number of shares, beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r273", "r274"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrant": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average per share, ending balance", "periodStartLabel": "Weighted Average per share, beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r273", "r274"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrant": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue", "presentation": ["http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r73"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r277"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r280"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrant": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r277"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation

Arrangement by Share-Based Payment Award [Line Items], "terseLabel": "Schedule of Restricted Stock Awards Activity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "terseLabel": "Employee options expired, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r280"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "negatedLabel": "Employee options expired, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r272"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted shares (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r269"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r27"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r265", "r266"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r265", "r266"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "terseLabel": "Total Intrinsic Value, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "terseLabel": "Employee options expired, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r272"] }, "domh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGrants", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Granted, Total Intrinsic Value", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Grants", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {

"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "terseLabel":
"Outstanding ending balance. Weighted Average Remaining Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average
remaining contractual term for option awards outstanding, in 'PnYnMnDThHnMnS' format, for example, 'PIY5M13D' represents the reported
fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r73"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemain",
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingC",
"presentation": ["http://www.aikidopharma.com/role/ScheduleofStockOptionPlanTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted
Average Remaining Contractual Life (in years), Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation":
"Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDThHnMnS'
format, for example, 'PIY5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to,
unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance
condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r282"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Vested and the remaining shares forfeited (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Options, Vested, Number of Shares", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-
gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock"], "lang": { "en-us": { "role": { "terseLabel":
"Stockholders' 2019 Equity and Convertible Preferred Stock", "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
"documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to,
disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan
(ESPP)." } } }, "auth_ref": ["r67", "r71"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding",
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-
gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShortTermInvestments", "cldr": "debit", "presentation": ["http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatAreMeasuredatFairValueonaRecurringBasisTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Short-term investment at December 31, 2022", "periodEndLabel": "Short-term investment at September 30,
2023", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities,
held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r80", "r81", "r758"] }, "us-
gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost",
"cldr": "debit", "calculation": ["http://www.aikidopharma.com/role/ScheduleofLeaseExpenseToCurrentPeriodOperationsTable": { "parentTag":
"us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofLeaseExpenseToCurrentPeriodOperationsTable"], "lang": { "en-us": { "role": { "terseLabel":
"Short-term lease rent expense", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for
lease with term of one month or less." } } }, "auth_ref": ["r371", "r610"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of
Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all
significant accounting policies of the reporting entity." } } }, "auth_ref": ["r63", "r120"] }, "dei_SolicitingMaterial": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that
is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12
under the Exchange Act." } } }, "auth_ref": ["r634"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet",
"http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
"http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails",
"http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "label": "Class of
Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r95", "r106", "r107", "r108",
"r121", "r141", "r142", "r144", "r146", "r154", "r155", "r186", "r199", "r201", "r202", "r203", "r206", "r207", "r225", "r226", "r228", "r229",
"r231", "r354", "r441", "r442", "r443", "r444", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463",
"r480", "r501", "r524", "r555", "r556", "r557", "r558", "r559", "r747", "r766", "r774"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]",
"documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r42", "r47", "r48", "r97", "r112", "r113", "r114", "r124",
"r125", "r126", "r128", "r133", "r135", "r137", "r153", "r187", "r188", "r189", "r232", "r301", "r302", "r309", "r310", "r311", "r313", "r314",
"r315", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r364", "r378", "r418",
"r429", "r430", "r431", "r451", "r524"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet",
"http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
"http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r124", "r125", "r126", "r153", "r364", "r393",
"r437", "r463", "r473", "r474", "r475", "r476", "r477", "r478", "r480", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491",
"r493", "r494", "r495", "r496", "r497", "r499", "r502", "r503", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r524", "r618"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } },
"auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } },
"auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } },
"auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementTable", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet",
"http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
"http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation":
"Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and
shareholders' equity." } } }, "auth_ref": ["r124", "r125", "r126", "r153", "r179", "r364", "r393", "r437", "r463", "r473", "r474", "r475", "r476",
"r477", "r478", "r480", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r499",
"r502", "r503", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r524", "r618"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label":
"Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r646",
"r657", "r673", "r708"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"],
"lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)",
"documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined
time period." } } }, "auth_ref": [] }, "domh_StockIssuedDuringPeriodSharesCancellationOfCommonStockinShares": { "xbrltype":
"sharesItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname":
"StockIssuedDuringPeriodSharesCancellationOfCommonStockinShares", "presentation": [

"http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Cancellation of common stock (in Shares)", "documentation": "The shares of cancellation of common stock.", "label": "Stock Issued During Period Shares Cancellation Of Common Stockin Shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r5", "r41", "r42", "r70"] }, "domh_StockIssuedDuringPeriodValueCancellationOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "StockIssuedDuringPeriodValueCancellationOfCommonStock", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Cancellation of common stock", "documentation": "The amount of cancellation of common stock.", "label": "Stock Issued During Period Value Cancellation Of Common Stock" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r28", "r41", "r42", "r70"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Redeemed shares (in Shares)", "label": "Stock Redeemed or Called During Period, Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": ["r5"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Redeemed shares, value", "label": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": ["r5"] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "negatedLabel": "Retirement of treasury stock (in Shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": ["r5", "r41", "r42", "r70"] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of treasury stock (in Shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r5", "r41", "r42", "r70", "r444", "r524", "r558"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r42", "r47", "r48", "r64", "r482", "r498", "r525", "r526", "r611", "r624", "r768", "r785", "r812", "r834"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityOtherShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOtherShares", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Agreed to purchase shares (in Shares)", "verboseLabel": "Aggregate shares (in Shares)", "label": "Stockholders' Equity, Other Shares", "documentation": "Number of increase (decrease) in shares of stock classified as other." } } }, "auth_ref": [] }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "StockholdersEquityandConvertiblePreferredStockDetailsScheduleofRestrictedStockAwardsActivityTable", "presentation": ["http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity [Table]" } } }, "auth_ref": [] }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "StockholdersEquityandConvertiblePreferredStockDetailsTable", "presentation": ["http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": ["http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable"], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsidaryOrEquityMethodInvesteeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidaryOrEquityMethodInvesteeLineItems", "presentation": ["http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails"], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "domh_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": ["http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r701"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r693"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r700"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth_ref": ["r721"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r723"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r724"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r725"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date",

"terseLabel": "Expiration Date" } } }, "auth_ref": ["r725"] }, "ecd_TrdrArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r723"] }, "ecd_TrdrArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r723"] }, "ecd_TrdrArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r726"] }, "ecd_TrdrArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r724"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r24"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet, Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, at cost", "verboseLabel": "Treasury stock shares (in Shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r24"] }, "us-gaap_TreasuryStockRetiredParValueMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockRetiredParValueMethodAmount", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "negatedLabel": "Retirement of treasury stock", "label": "Treasury Stock, Retired, Par Value Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method." } } }, "auth_ref": ["r5", "r23", "r42"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.aikidopharma.com/role/ConsolidatedBalanceSheet"] }, "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, as of cost, 60,148 shares as of September 30, 2024 and December 31, 2023", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r24", "r25", "r42", "r47"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.aikidopharma.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "negatedLabel": "Purchase of treasury stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r5", "r24", "r70"] }, "domh_UnderwritingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "UnderwritingMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Underwriting [Member]", "label": "Underwriting Member" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r720"] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/NotesReceivableDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss", "label": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": ["r3", "r518", "r519", "r520", "r521", "r545"] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": ["http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatAreMeasuredatFairValueonaRecurringBasisTable"] }, "lang": { "en-us": { "role": { "negatedLabel": "Unrealized gain (loss) on notes receivable", "terseLabel": "Unrealized loss on investment", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": ["r3"] }, "domh_UnrealizedLossOnNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20240930", "localname": "UnrealizedLossOnNoteReceivable", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.aikidopharma.com/role/ScheduleofFinancialAssetsThatAreMeasuredatFairValueonaRecurringBasisTable", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilityThatAreMostReliedUponbytheCODMareGrossRevenueandNetLossTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on note receivable", "negatedLabel": "Unrealized loss on note receivable", "documentation": "Amount of (loss) on sale of unrealized financing receivable." }, "label": "Unrealized Loss On Note Receivable" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.aikidopharma.com/role/AccountingPoliciesByPolicy"] }, "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r13", "r14", "r15", "r89", "r90", "r91", "r92"] }, "ecd_VstngDtFrValOfEqtyAwrdGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r689"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock [Member]", "verboseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r615", "r616", "r619", "r620", "r621", "r622"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement"] }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding, diluted (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r140", "r146"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement"] }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding, basic and diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.aikidopharma.com/role/ConsolidatedIncomeStatement"] }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding, basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r139", "r146"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r737"] }, "ecd_YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation", "SEC": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b", "Paragraph": "1", "Subparagraph": "1", "Sentence": "A", "Text": "The Global LEI Foundation is a non-profit organization established in 2011 to promote the use of the Legal Entity Identifier (LEI) system. The LEI system is a global standard for identifying legal entities involved in financial transactions. The Global LEI Foundation is committed to providing accurate and reliable LEI information to the public." }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2", "Paragraph": "1", "Subparagraph": "1", "Sentence": "A", "Text": "The SEC is responsible for enforcing the Exchange Act and its rules. The SEC has the authority to issue orders and take enforcement action against persons who violate the Exchange Act or its rules. The SEC also has the authority to conduct investigations and bring civil actions against violators. The SEC's primary goal is to protect investors and maintain fair, orderly, and efficient capital markets." }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2", "Paragraph": "1", "Subparagraph": "1", "Sentence": "A", "Text": "The SEC is responsible for enforcing the Exchange Act and its rules. The SEC has the authority to issue orders and take enforcement action against persons who violate the Exchange Act or its rules. The SEC also has the authority to conduct investigations and bring civil actions against violators. The SEC's primary goal is to protect investors and maintain fair, orderly, and efficient capital markets." }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2", "Paragraph": "1", "Subparagraph": "1", "Sentence": "A", "Text": "The SEC is responsible for enforcing the Exchange Act and its rules. The SEC has the authority to issue orders and take enforcement action against persons who violate the Exchange Act or its rules. The SEC also has the authority to conduct investigations and bring civil actions against violators. The SEC's primary goal is to protect investors and maintain fair, orderly, and efficient capital markets." }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2", "Paragraph": "1", "Subparagraph": "1", "Sentence": "A", "Text": "The SEC is responsible for enforcing the Exchange Act and its rules. The SEC has the authority to issue orders and take enforcement action against persons who violate the Exchange Act or its rules. The SEC also has the authority to conduct investigations and bring civil actions against violators. The SEC's primary goal is to protect investors and maintain fair, orderly, and efficient capital markets." }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2", "Paragraph": "1", "Subparagraph": "1", "Sentence": "A", "Text": "The SEC is responsible for enforcing the Exchange Act and its rules. The SEC has the authority to issue orders and take

[illegible]

[illegible]

[illegible]

[http://www.xbrl.org/2009/role/commonPracticeRef](#), "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification",
"Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479532/912-730-25-1](\"https://asc.fasb.org/1943274/2147479532/912-730-25-1\")" }, {"r827": { "role":
"[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "[https://asc.fasb.org/940-320/tableOfContent](\"https://asc.fasb.org/940-320/tableOfContent\")" } , "r828": { "role":
"[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477363/944-310-50-3](\"https://asc.fasb.org/1943274/2147477363/944-310-50-3\")" }, {"r829": { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147478009/946-205-45-4](\"https://asc.fasb.org/1943274/2147478009/946-205-45-4\")" }, {"r830": { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic":
"946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147478494/946-205-50-7](\"https://asc.fasb.org/1943274/2147478494/946-205-50-7\")" }, {"r831": { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic":
"946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)",
"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478795/946-210-50-6](\"https://asc.fasb.org/1943274/2147478795/946-210-50-6\")" }, {"r832": { "role":
"[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147479109/946-210-S99-1](\"https://asc.fasb.org/1943274/2147479109/946-210-S99-1\")" }, {"r833": { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic":
"946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(c)", "Publisher":
"FASB", "URI": "[https://asc.fasb.org/1943274/2147479105/946-220-45-3](\"https://asc.fasb.org/1943274/2147479105/946-220-45-3\")" }, {"r834": { "role":
"[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147479134/946-220-S99-3](\"https://asc.fasb.org/1943274/2147479134/946-220-S99-3\")" }, {"r835": { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic":
"946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-
09(7))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479134/946-220-S99-3](\"https://asc.fasb.org/1943274/2147479134/946-220-S99-3\")" }, {"r836": { "role":
"[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477802/946-310-45-1](\"https://asc.fasb.org/1943274/2147477802/946-310-45-1\")"
} } ZIP 81 0001213900-24-095881-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-095881-xbrl.zip M4SL#I!0 (&V:%EKGIP|6Q.
&C) 1 9&IM:"TR.#(T.#DS."YX MMSYSB2_SY |VMJ8@<\$!(PID & Mi(&TI? T^("GO/I!"2EIOWEYL\$T"C&||H!%H@K_|j3YSP#.B#+OD=?UMKD#
M\$+<>%Y/>!#<+?MD/O Z\$.Z%.B:F"@ = G 7BXIJVL UKV.ZGW>.LA%E3-L .6B&B_ !NSU' MQO Q X NG.UP Z>(R|O.O.X7(37I?ZNQ _0.IV)>!!#-
GKKTDDEC=00I/> # ?D\$ M^-=>PAI/@+-|L|(2 /& C:KC>=% :%) +!)WBOS?2C84:C\$?244=VTXXVIQJB M>
09BJO/< 5?IF3MUO/Q<4.6OE4#IA(@+HGXCRCBS(K*9Z*(=N69?S M:/O+ ^DF6IQMA85S=F?3I4,\$IFGO@/'/"ANI:M&CO-O=vJU)AK!F&#%A/B06
MVGP?) @) Z(DQ/6ASYZ7~1/0IGD8| #9.R#@BOIQAV)(3V(HFO/Y""??#\$9.M=QB>>8X ISZ;4C0^W>2P!2I9">G
T5.Q.8UP44HNZ#M(CV"H5ZR18PY10@\$D Mto5SKM#"BN.|LUBN6=OKMMB->1.]\\x7TR/E]E6IFIM@3Cd<8 7"]>)R:X MO*MHRM61|YX?+Q/NT
J<0JI14HO(JEP.(P^<GMYS2)=ES#7P:8P^6?0\$=-Y M.\$6(6QILAZ+ _2?]45EHQ\$+ P.&OYWQI/?]>IT67WZ&7.ODXL!_\$?
>R=j9QC8(1%6T3=.ZDVXHIS|# M4:#NO%,CA5-NJTPIP# |D@)HF"(CHV I<.:l:8\$9I9-N7PME)+wXB3IK(I,(QKL/KDI'
MW~~~7@?P'.UGN?7RV+vZX9JLLJ#+AC<.)3Y3PJ?"2OG H@.^?IHZZVL G? M?PVPO \$VBI=2PK,IJJL?'UDT?IT\$S>XAD@EB
.LP0#:B.NK(O:+|LUC'Q|^ M7QPIL:'E.STI2?)?\$9Q_||I/=A_X&OW5HG-IQE7RP!%@YA5 MA?V-.5(W \$07I<I> |OI.H\$\$\$ZY.=VEOCIA\$L2?^<|=G
<,<.,:>?Y#%?!<4< M?/I>20IY#>G(|JF3_ @&'G"?6X+*"('YL/L3<|GI'I"\$^(>95GB8)TA V6JP3 MM5(L E>(:MB'S'B".O*1PUU8L"%"+
|FS6W")5B5Y%"RI/F?7 M |=VE M2CR.WB,Y""|'+G4 FJO)=(=2TG#G-K-G*'DY8'O=A U35'^LO1XI8+>NCYCP#'/\$ MU043-DRSWI:67
Ds':"B4LI? IP7\$~-/T FO.IJ WdST.'0Z%'2.(W7&(ZP MD)=XOHU_ &QG L34@200AJIE|R#L0?HFB3Y|>->7GD&6=1S#1V5!(!=@>9>SNK)
MAO5X-ZT:I]=QQI(RGA.YKIERDPFOZYXZ9)('@_@3@9LC06'4^*>8R).X7(M M=DRK_-4R2B4KIAWT|9J63JGIG|.NCH);+9@ZF%;CKD!=@)X1'"=
(3,'y6'OA'H MY0(24=MZKU02EYS<.@./AS.%'#01R>U>=I?4,T,E+A+TXHSFHEC'GS KGRDI T MZ)|9KH'L YLL5:D(Q*II?6"G'7U'A-3ID/H+F9<%+<
<,%)#IHK.B AH:(58SNS)!1 M YI<2-"K==+Y\$6+B\$,P>2XSQB'M*60+RWRI=BZH\$)\$ 2OKU6I/(SRUOH)? MS-J2?2*OBYZ\$+8&LGD-@!: ?
*CZ%;" j9<1334I/_2-9EZ2%(2Q_UA8PV+=J9I+_ XMCVQU4JARIVLP N v>/2JY-Z-@IR%V!65K<4N%Pl_M3A2MUN%73SAEU+l
M@'(G6CEGH39I<|PI89|B|.LVFI8CF0G|KQ<KW.CT MXDT7UE0%HK@..5"> B&!'&H4-HN55K&PINDN7Z'N'S @>WF P
MIWP)V.#Z:4NKI5L+P Y75(>EN+E-X+%<0)OTM.JG4I'CTK-Y:0%BGG<BU+ M *B'WN'X2B-'>II'6(UW@OL:FR X? M2W'TO&#^A>P?VI.GR=?
%N3A'/BY'*3/AU?MOQN(%PY?+: -9T/?L2H@ ? M#O>>YBWKFV ^<?7'EXUGN=G W2_-9WM(C SBIZLG#|Z'D>U^v_F 7JTWS T8 M.;>3Fi?
9E_Y9,O.-5W28Q_SIW/TUX+N<LSV^+CIB+|L:=|JL@/4# ||E(A)_@#>T|U|@Z5-> M3X'_G IQ^<@>W9%g [cSYIII^'|<#^~.!]?&|6I2SKOI?Z
VIUCPY^8/M_/2KTZHS3O'C)n9%QI>23=P0!/APSA="#ZUI/VIP-CL|^>,oCG2IU5 MZ.VYCOC8^O@ZW%CNM?N3#!>]
OPT TRIPX/J.L:N

^5XJ!G@MI*)RMFN..?CGJ:(J: NN. ^.^P.F+33F RNS+&!\$9U4P%^,HU3TEFLPCT M17:HDQ.=:19HVQT>8W\$3.< ULI&SIOYPYD&BK7T#A #Q
MK3%:UPX*U!C0@0-.QJ:0S0%11G3Z) J1: MDL<5KU!%2N"6S!@RYJ!|BBV>W6^>3.1OJ!K7!B4P/MJ!>100J!R40E< 5T2!GWM M(1LPM
J2H\$VEIN\$)=3IT&- (1Y\$!U-9Z(JXO:/(8Y48SCD, "47M:&-)A9:0 M%5>>1K9-1@P(J)O)VLIFD04ID&6*YE|PG, 9,E9TR1D.CC"C&4:*31,4!QJOI
MDGE.46%+YO "SO"1L/LBA ^XYC)B|R'SQO1F93Q5WC_XC\$6TS!C_ OZ(+W2*5 MUV0!0G7IY=C"O!XUIRI W6OC)W|@_ FIJCX2388/L- X3Q=1JT2
71C JM MS.0!LIS6?|BE^P>_ /)=@XW5=N|+W1N. @UV:3_ K_&6!VB|P\$Z|TZY!_ M_ &6XN=S^/PCS_ 5^P_1-6S>&P^=<^=#R?N=2I_ O,!?
>^>7PROU0*O6I^# M8?WY:V7:A8YOKC|=CF:D"1W8U1 &R!..!@|=ZZUYL^|UO7QO!|IK23|=#DQ M&1W*747YU'V
<131!:%>KVKIKG)KSKYU!A @P/P9WS|IY+&|< J!/=Z_ G_-M MYV14C"N2+|=TO3/FP_!|U7X14|1AY7KAWL:=Y10!4BS!(R5ONS?CAO=<^.)
MNET=95'T'UH-EJ5EM?|RL JZ51E!V,OM: ^&?P.E*U9K=VUT7WZMW0O|E| MIG>AWN0.#W!).VTIRH^!%G2120MR>|/O!LP:|&(3C)4H14@D*
W.PY15H4 M%*J D9+086IS "N|E1E!IN L1WM U^R|> "K2!J|<^U> M9:Z@>B 0T3-4MVXE=-ANRYIBN3!|YV08@YAOM, WR9IU^K^ 7(4IW=!
(G+>0^ M18=BZG/>5!_&19=ZT27U|R)JML/ P#12|V9!A1X!|!|VG3F3\$+>2GK+C|Y(=L MBA Q\$/*J'D '62Y.YJ|>+U.+?
%&B' L|TT"0L=>5!_!|GBH!|GL2T4N!G,=L MDR\$J=SC.)H/4! %!(3JO=B^WR.OPH?7!O-(BG3^"OH,258 %!%2^!I P09ES
M,"1<@5"U!0DEGS0S|<)/<KJ86EE<* L:T^K222,<8>V!S+1HBSS+!EEI M'>LZ5-C7RDIZ03 M5CP&: ^YOK;287Q5)MBJ16-
B6)N(Q!4\$C!1.5K9EYE_S@MV4G!#7Z!83Z=S. MHFFDK2T9K+P3 80PR3V_6C:=2,5OBL.(@(/%>F)=0#TD"K34Z/PH;3)2A1W.T*F8#D6-M
|C">5*8PJKA!Y @/F:3A MV""6%&A ^OB_E; \$_*"K=RZ1!|=YAS1N94G, G8!M@QJY=V!E+8\$>Q=C=LIYQ91 MRP^6W!QP<D^?F2BR.DY_<*NONI" &GS6-
CC0\$>1P&Y W|T"12KM8V=R0>==| M+9M; "V!HW7=)H.LB+&XG4.NXO-MIGN!|E:74/IOOA.N'N+/(M15Q.YIP(L|H72?F).)
<807HI4AT)5 U^EJOI!78COE8!KI!J5WCO,*\$=8!+FJL_700W:-LH0KLE V:K!|=YGI|=#KS MYV!A<#&I(4\$VOVJ|N14 +:EGT_*:H@8E1"8R'-
E24U*!GX#<C_0T35WTA *\$0Q&JS M=Z&1*OJFBBSW> RHVZ16AK!B,JMMK2B:7ABUH*NF<8N4NCFRPTK2E\$=ROFO! MQ6V_?|U3-1?Q!
>S.O.P1JR/8A.O!T:JKM0U1#MCI\$YH(AO7U1!+PDF#> MHZPI^!%K395(!_!|I09O!7#IRMBY!1!)^8X"!_ JSMB7J&5+DE)F2S M_JJWG8!>A
4++HKX&C)/>RE.OZ=BY781/!|AA-Q-YR(6H=|7W&6>5MDQ\$)R MR.%J?P=YI>Z\$TC\$0"(L>=89&PW||>_9&@BR:X9
M\$>QZ!>ZQ.#|JF4\$R\$G)29^"S(VL_5!+ P04 _!M@&A9H&BV> @| M(#L0_ %0!&10;6M C.R-# Y.S!29&5F+GAM;U!7/CM!+N!_T5WKE?
M|IJU_ \$M1.8SR#G:2LSD)29^#@0I(YM;^!@5 4B+&%X @ MFA J|MHIF&28Z;3#:#1Z/M. OGIOA(D3N1Z9_ CB MN;EZ;TXN+Q?
W HZ/_& 7!X!^H@I|BC"IM^!N@T6*Y'N'. HEB(2S@*Z M//J T2+ _!T6D31Z00CX!?'QWZ!|= "OZ,X#&+JX#_ X.CE2S9@-N0IQ7S
MIX_J7=2!R3PKJG_C!#CJ^!^K5V^!L%U!DQ_G!\$ J!X?U80PGB@#)YY13 M1#&)%CCR;2')MC>'1)H%A=L)2!Q3<3^O&3D=#G?'2;AU@R!-
XPN7!>2^R!0 M#W_7K2^98.1>C;-MPVC"*8-JL!0H7YWPJ OIYGO&GA'FOG2.B/=#!|Z(MN&L@PB%?2!X#|Z(<[N?FF+!^GT-
^3')B>=VPY.QIR1V&(I|Z&+SUT M!J FMI:TIC'Q8V:CM!)U6H8^8^!Y:1=&X\$P;=0!^N2^H^E9LH<#<X7CD_@
MQ05.KYGD.1V.L!Q!=@50!A|JVDWLCF4!^PT(7\$K=+>3XIL.RD)*|9DX MWW+9A:2E.FD.OB2!4SR/210%=-
T.N.U7IC1RBGUNIC"SEYEF_+!&XVM..J M>@AS)S6>:COPA"NW..OGH6 M H^F7-LI6!PGM^2Z*&%7HN;VN>VZX(=K!?
&ON=::QS200; &B!GD\$8J!WQ! M^%MC-M L M!D WYPO^?TP8:@ITQS MV J!^!|O<%) F!M EPBW&ASG!N(5^XSOVIC/WAIRR?*WZRCH+&H=0B
;5!RQ M3>*(|XJR7D!0NNL!V#>1/M!"<012IY7SCP_9J!5;&6!F:@-#..&GO"EXL6" MK7S^4*< BVJIS&4-W:4!L^!4AM^|(BH&OI@7V%D!O=MAS8:
MZR%;1T-?7QH:M-NY>|369M:!(S:_ OTI!%|^6.SCL!|S!M/AM'E, J!/@ M M:=2A9@AC|LZ!\$FJP5_ %UQAFBCBIS-
8&L61PJCV#J!N'98V#P0.7+IZAV(I> M^5D1NONOQ!(>P_4Y Y|C|>2I!88Z!?)*(JO)UUNS H+9!1N".OS!>KDA MW(I?@%R:Q!\$8
'RR5>WF:.\$MW"TYNK.P27R/2!<8 V#\$!-0C'M^+AGM ME /<:UTBI@N3PT!1)BYVTV!O1M,/G.)O^#PD!:#99SZZO_Z/+^+PY1RAU9^; MH&#&
(+Y)?P\$+0(792&33K!^YCO2.2.C/NY)*< \$T\$MHJESVY23X!A MM7!1+!A(Q!0<JEG3^0*H^8AZ3T_ D#<K^N^Q^&V/WQ!43C_ "0U!7!JHS
<^YZ\$7J.CXCE.IL=U.B M^G?231H5M^+26&68RG+;E8N68!\$M\$3RZA\$#@4%K19692/X49!U&EC7B95 M""D(PY T_GS5CSR A9!9;P#2X
BE|GAM>"/^E\$ISBU>PJJ0_!MM-5#*+6W# MXBE:5%6B|!=|"KM6\$TZ&IRUQCTD)OI9+IN8BU#@ Y:4%7*%Z407@LY22P
MZZ2FZJ_*M#&UX\$U30V#M^&SDV:NU2CMJ!^9UQ6Z(BA!&PH^HH@#G4# JF\$IE4 M#M!:=C7@IJGWGPI C6=W:<^
I87DTTQ!9"1H13+ZSK",TJO6.K7VC3LXBZ,/ MPYHM89)B JZT9!P!&* #<2!IG^?U#H MO%JL-!+!D+!+H\$FC.1W12U!3Z)/
MPPE:\$3N^Z03YCD!>G^E3+&B7:FA9_.JT1^4F8!_ P#M+OUG^&A!&4A-B UI4_-B@OJ/^H8!&IC=52&=&5:(7C1 27R=Z!0Z**\$38@
MG>S9F6^"=+D J:U:N3HP7A!"S4BH1;.D"Y+4!M5.2<(Z!L0&C?Q="\$\$8SZ M^Z.M("M|BA8M(WE.KCSIER&!RIHF=G>
0&30VEXFXNAC0\$N^A<O5NCZXK M<\$#^!GN!4D+!IN^-!90L7M>MO-^+5(P#L)!^FHCK<%61P6!|(8FC"AW8)^>4 MIT@2I'Y
E#&1S1PY3K21KJ&!"GARZ!N^0!5N=|UJ!57A M W|C&\$77^Y2TBC4/^ZB%EU9Z:=!\$9W3/(:6L!DDQ"W!0.)Q!UQ:5
MVIX)T(5:2!3V=4_ %E/%#RH^!4A?\$ M'<:0J|<%NZ!R^O&S@:@(ZXR7P)O MHRD9781AW(M4D+| E+5A!&X!&XCB.>/MA5_2Y A=-GMH0Y5-
"^(1MT@V MZ4TJRM F_X"33M\$P@J|F_+B-K@8XJ3^RXI-C3^\$:"L4!B\$P)*ECLJ/(@^V(M)DKIIS=NQ DH^ZQ\$!1RJ*!R!!^!B&#&#
S(H\$S&QD#\$X54!&4RQO!V MRH^M^#OG*7Z_S@/E:3LMMJ<+>P_!644MYI J!2U=|L8^"LH!+A_2MM M+P&F%G\$Z#VMU!&:
(I1D!D0(#'89!&8<3?B!R.2&0MLC!#48X"M!|^<4^8L)H M^SS#SUTR@#@IWE0MY<"PS&34!-WNE;4W+S#"ID5,<8C8U7GPNUT0&1F+
-MM"P&@D!3!(<6'S&KJOP.2!B!<#_ \$4NBEF@J!|(+&@:SQV:YR'DH<0,H6EXK, M293!JPVGI@H2RCU8!T\$F-Z6DC(0EFTD<I?
L_*N34+X&\$687!/(7@IHR M^19L1W-2Z@>+!|ASH^*>190_!R13_D8\$UY6F+S:S=RT>2^A-B2I2!3.15U1+9!F#=#R M_XJ3?62<:-LUO5*:-0UJUY7
!O.V?AV0H&@OP=S"ZNE8-5O:2ZD!_#*|FVL< M@=GYO:\$XVI!@40!>"WDLV2KJ!V!|(6> V3<-J:OMU+@I<1^I6!JHP=VE,WQ=095!_NF^U2S-
N4LR^*5<^!B177G+M!>+9QK53V(^XDV#4\$H!+8 Y!PWY+L!NOHV:1/U62L1M,HV|QG&#""(ODT# M5UDC!/#=#,NM+OD&(HIF6A:|J!2D:
%&#%-42..(I|ZL/8N!MP@J|@OE0I M^40N-40&L+2 5 21!\$S!4PX.L0 OG6T&|L_+8:6!ZW3R?11(22=I-Z=Q911
MFF#J!4G^>0:@5V^!;IDE+U*1(59C.P8&D*6E RM(K&0-(XF^V1!P(P?|7E=| M^U6SM1.2TD_-G:2U#ZOB ^GN6N!T7YUI5DTAIYG|^V+H
9+;G00\$BB0:6<M>|4)L>U\$|S!B?T!)(P""M>4M^%\$>. MKT!E)SB54R!=|^XROH^%<2@V\$|1:SES\$)2 IE+,H2!J8W=&KB<3E,3<|KHR
M6O^FD9 KK8GL &4=0BE!1L,K+D1<5,F>E|JC:0!MPZ:@907B3C\$-7>52^5(MVMZ|J!8Y3!L_!>"Q(5BDTYL_!92"E")DFXDL.APH3&9!O D-
'CP&Q\$U(\$U!SS Z0&2+!@!FKY:>#-!B3!:=BL<+&E%#8=ZWBNR%AFSG6D;K. MR-R.. "M\$>L!+L V@&+0_03PC-
KP%U/!RO"0%2!6N*\$B\$RQ^<^U.D&\$%\$SE"\$?H#HLJ2%#!T>=J_+>5 -ACZ:\$B4+!^5ZTC9+H>/!L M?VW"9SCY:XIQ-
"0:KHJS^N&!"A0=>TPI.H"GR3M4@&J\$QE:DM@ZZ!G!^2/F!8C.IL8> X1F8T @SP@LPM4ZOI.M4WZJWB4."OU<-ILWUJZ_A>
(:MB"15HQIAV.W?"^ MGQ03MW@8QOY>|A47(XEW.6) J!#4.13&N.L!M!>99X@Z>|V"/9>3&S"OY C*CA%2E)F\$HX2L<
!M5>E^|SV!49XS5:2J-U+@-.\$_4J(S?J7V(3XE3/RX* MNWPP\$W0#;9!":FJZR@9M4Q8< 64D<K.2\$^BRL^&:>P9G9!F6YWJ&L!J M@HACT?
78Q!S<#TV @Q2_30!T<#NBVAD9X\$(!5!0CNWFIH!A59E(3F#"M M=#3YM|9@I&W&BG?BB#I7AS#OC JOD1G02AQI!88@2Y\$!)SO #IH-
5P4U MO21.KJ!&C!-MH2FN"12=4!PRHFD5SE0!R_8BE#&LQF>=#V03M3!O)K44450
M+1.LB5!JUVL7G"KVK)XM1M604*K\$N!25%#Z8!>+28SN7R!ONMB>DH3!JL9PN8 M88[K=P3=TVU\$=C+=H&4N(8?6:)
<3+NWR&XUD:Z<_!&AE|4:3YM5!3;Y M-2(DHVH^!5!#57BY1!0=SZL!%FGL?P\$#>L3MBZ=SS#|Z0!%31LG!NJ4^
MED""6AN"1"VGL\$N%6BCHI8BCQ4.C3+>4-G0*)A 2Z&15_3HX"TI)MHJ3M>|D&Y8(L^J:=CSE2B(K&"R54.D4O45
M1K5KOLL,*70N3P5(D:LHZ'H6Q%NW (3O1YL:#SD2!>!)@IV3XD&*1=U7PM> MN!>73;V_8.N(2(XI=M>O2% TM'
V9+>00?@1E(=++>|<=633.MB^<^!G*G_ MKQ\$):7@D@:G1Q^VZ8E0H.ZMQN@ MLJCY6Y;!_!DB8!<2&GG.K)K0M'99H3NEJ>V(3)V>:&#-
1J)=6R27!B8F?; MNI":N'0H3WQ!K!-G(GO!1BN16!J!J\$4_R1Q=QT/LA>AL6X<#?AG>\$UGR#2
M<9(D*2^&^N1B!X!XC(EIE!+0)FLU= B3H9Y75<T^J34!1O2CQ6R7G!S35. M&E C=%4 1VNT0VM|T8%ZQFY%6_!(4:(#M7I:\$K?
G+172A\$)864N8K:ZO*9! M/M>9<=2;J-L(8W^W ZZB341N7*MWPO88#G=8G;Z!4Z=UK1^H=PP<>H+!
M|9R;J!|=YG3FXLZ<+> TOIM9:4#R>.@%O!:*3EH6<(|JM;RDB?7+RC5) Q(O!4 MT(SVB3DM! CZD:|&XO:4+!<*\$F!+R:8&KPN\$YO;
<|ZDIWC^!ZIN?&+ M_|X42^?..C+>OAW!H12\$H!4!6872D19N.FKP&?QD\$>=>MRB)_O%9NAP>|L M3922%=-10N*"JE-T!T7T&
(.P4X&T"SN: ^7XQI/U|/37>-KRV>MAO7G2"4 M _^4JBL25(K2J.9K.166*GP.VN! 8D!&(4'9&P< *K25Q MBUT16TFQ+>9@M?>VL=:P7X_8C27"
|I:9FP@1 M%U0*7YP!K>A>S+KV<#ET\$-4L!P.8XYL&W!25X%<K@TM28_!!K8NRNOLM=K M8N)MH7&+^UVR'P:C.K.WXVSP&L
M|IORE+8+PL+&84.EY00MKH26Z8 JZD-D-8-E)*X19 L!\$S\$MS+&M^D 2V6TC MXFZJ9.50 U!^3FQNS84TP4!46PO>E@U8!U!F3V#Q&MW#
<4\$OQ&!2RN..(D MW3&92"K.*(_7/EJ_OB1@X4+WJCV^KGBOM.%AX<4H?T("S:N7 MP:-KMUI@RTTDRB+>"7G"15FY<);*M.G0JIE
|/^_V0!>R<I\$T2?LS1?< MF_G_F7>#<:AZ_ ^Z8H/U7J!=85.9702VOPX<="5D2%KQ!6)9!&I!AWC/?!^ M-E:6X^SF7!UX2=&?
KXB1V!:CLN!KPN@3:X.W^JLHD:&V;M|DLH+JLSX" M.E.MA2D>DB.H!_256C@+&(3#4!A0YIP^!>2S8YIP!+!+DMX"242.TV#)!NT M7!1?Y2P
&+IINKO!@P\$A&ZM>|G85-("N:L^DD.9&-ZI)?*\$4(A%8SKE!F/ MST1M^"Y"C4: ^CC#=:2L<37^7WO.(WP#; MO6MGZ
LR"QB2HK7*.OW">Z.5EP.JV5<#&V:1153GH/91P:K\$B(T!PA"" D- MC^TC.I8SPQGL4JVI6(D!02YWA?>2# +C1/OK_>Q!L:U9I&R=3(NY-XW@ M
8535!6!1V^*2!9W#S!8I073_&LHR%\$54?EUJ5OB5?>2:QJL_>2S!6C#^TC M7^CUD_\$UL&UB=-05S1.N%T@W+J4=KOALT"7T1X:5!%V!^6=VX7@_0+
M0JZ\$U=0@-HUD>_7V/8ZHBSH!|BU81.483G M 4TUZZPA8/(I9@F\$&2B>9E_!L%5(T:D/TO)_WG*SM" Q<GJ'8
MCV#EQL\$S&M@GH@SS%NLOF!+T\$|M=1 MFOE:MLIKX-LD@-EVSZCO)O12#HKY M'
D'3:1&U!&CK@0*7UOU^W^7GOHB#Z;)5!7JW^_!\$70L7-T_!LJC6+S=D2_M @VVE5YDG4!0^7!S7!| M7-B+&"A4?^J\$^(>5YWO\$>2^T! ?I
5N<2BD-9PZ&CUAN\$)K:8_60- D=M_0EE3IJ_T_*2AW3=@+PIWCREBD\$+^FJ/L4.IN|>>|UEWDRD_&B:L@Q'
M=L\$RY1DJD_1"AO!A":PI9#WEAT<MS-Q:N6=|<#1:\$7Z|RA: ^C/P.#AGR MYM(S2Q1<10D04LCLGY&8(HUA5 ID+T^TXI"J0->8>|04!>@M^+
R3Y<46!S@782VZ>AL74IY1+36@0:5>J0C;BRA^H6/0=M_!M52F/RJX<00^HRJ!B^FIW!X.F7RB2R8OR!J396Y(EX.RV!)3-9*2KEP(M"
I?>3+>N/H-G20K2ITK+J!+K\$S0!F0^Q2!8!&B_KN^\$XS458P_":L: M+>2^9(4.1&OY.G8# NI5M5X>8R POS!^H/FLB4!60OFZ2@0GD2PK0\$!FE
M7"D:OL9:W)-D8!@SOV4!P>:"(Z!>|T307^*F+Z0"WBCXT4NV+YZ>=H"JJO M4U7_X3!?
OCSZ|J!TGO!WIG ^W5G%3W^>0_ KZ!7!Y!F^!Q!G=G!>|>G!WY M|J?>3KTOWUPOKSR?XZ.HQO!Y=OWWY^>NU<I_!_?7J^YN:7XX>GDI_7CVX
M- 32!J!GN9WJY OW>#++U6_KN!F-W!JU_KWY1^3D @25W!Y_!Y/!YT! MOIZN/3Z217Y.%< K=NW!\$!>33Y?>+UDC|Z
MF^/W WRO^!L.WTWG|!"S">/_!<G9U/CU9GKS|M/MX?+5XNQ_E_NKZZOWU MKZ_?_?W^>G/U_!^HMW^7Y!|MS!|M?R!>_GE^?_!N_?
OYQ_!Y.KV9OGQ!MT=6EK-@&@82%SE:8NHY!"ODDKT^> ^B^RCG3=7+H+&Z.R!|(H!&@!<=M M5!P#6P:40%MO!#6I=2YJ0+W+ %&E>L-
L.O6\$T931O(O8_IH392>P?T!O6 M>HVSJZ J^Y%Y-F+5F!WAXDPC!EAKZ%;TPKY!#+=H671ZV90BKL PE3.W2C+ MAD?CCN2L@:WH-
:@EHB!JTO#KN!K@X*UHI&!&3 L&+BL5*.7QTM!+^!-!C:/3 MF+>\$>V=%U0!R>Q9@C.4S#4PU-Q9ZIT.1.57W&H@6* M\$ _#2MKDH&BSG8
4K6K;8K1@.2%&EKW0+U5F>5+>@JOM3W<&820YU=&9-MX MH>^5!<#<=0/8U!\$80C-YZ\$?N79_9&MTYH^66_!^!_!^8-!L!\$#1@>53!&KS M)
<I!@JILD28!1LOIWH9DRK!(NBCS 2+ (UXYV+T!_#6!_!J91!835%_!L!K M:N-AZV%?2\$Q2=1^!TZ=A.U.)P8!^9@!|3H!)!JTI>J!M:152K!^0K#."U54
M0F_NFN?57!OVKS+&1/KN"2)@G:(I'G#|>>88E5DK : MY@YV!6!&6SU557!A!&X-E:BI4!>=%&B)5BM_!J'V7L;K'NZDFL!G/7!A
M55C&&Y!H:WB.VZ9>A!+0%"QAWRSA!R3G6> ^HSVXUQR290-N"7!O:2!@+&_ MM.7(W>JL:2EN0!FV!J.CJ!^*(1S!>@>^Y_!J XG\$5JWJ66??
Y|2/ 6VK M>HU# ZF+&LMN+M5!+&Q"D^I+LWDU+S5 MW:1AP1!M!A&DUL.SXK!MS5J0B8VN6(.SXF^Y33<+&7_!RXDIYWNV#T5CAN MF7'4.(
=CYJ:95>1PS@%0: ^@8-Q2N8%W!<|X>+0=V2:=8P/GBS!U# M^S!S6\$!@|&G:C.IGX: ^#YVD@R M.YD. AH6M2M5BV10MZ2L+1-

XII+6%\$S&GDII:-QC+A/=(9(K,(TSO/-2FJ->:S M NAJ8:GUI =!6\$V4!PLVT+S9O.CDF1.R792X;XJO9Y)4P5>J+H%-YP-/Y M6T!%K33GZPIOR
;YZI:K"9Y6I!X9WU@1X3,+NLFL:79X#78&VZEAM&IH(X M,!(1(E, GM,NUBEX"LIJ3N<@=:,-Y+V\O)6D?&AUEV1XF?>P,(F!P!WJX@
MQ5^E^8W)XJS.,J/V1"~Z7+Z>I:V.KKRJ30MWB@4B<I;J9M+CF7)1 67@-J+ MA=I07I?
FW0IDW<8/2.70+CI2I1UY0%:X",MIQCF8Q:G=T'T84.6HZV&I M#D15Z:B5G'60+5X6"7\$ MK-IYBJ*1X06SL65-/7BM0:CE4T7"BD2,K*!P!3>*
VNG:IW:CDINU9UD!8I6*%:XI9LZB&:CI2&K9LIU(IHP&IDOL:(IY)RIH\$E04TZ::)IH,XBA:X-%BN
M\$F'Q'03G(KBM:~S)F^U*N)"74WEQ'QLRI_PESS'Q"(IH?VTSF>8JY^V3IR97D- MNC04R%M>:Q(IUZI:%63!(N@:61&MFF.BJDVG==:
I%'(5^6=5\$:"D2AW=09*1YMT"P3;I)W2\$-&70 ;2\$K"-C6 M AKAU*MIJH&CZ6Y,ET T* E4\$B !*!@ K9* M:~22HG!QI@>I/?
MWBGV+P!\$%20:NGEID9#=#PI9Z+4W:A;Z>I!,:2 SY+~ M4I^ MCPQ'WBUB 0@P8_W8&0%WGX.E1@!W=Y:A:P'E@20=T0DKZ\$K9*B95RX
M=1:S:P^~8I;Z60* 12GI6AZ>12*QQUVEVJHA/JD66F%: P&F=8MT:VJE9 MG22KZ@S *E="3@G(=*2I)I6*IR MC#5:-@C:L.B, 3#I)I)W4S
MEVQ# E.)P. !^Y8>I6F.W=ID187~5*8>HA-C@/#SS\$J+ E52>X^~IDQ2V5 MU*LY>D34A7*R&6!(< L)I5\$8CC/0QU2DND,XRAH(I=V*RI\$X"~T9F
Y+=W5;& M9 0@~CJG ?6J.PRDBNX5(A ?9!::8)X:IHH67::2'55*B6@CE *- (W16:1R MLNIB,24JL(917\1M%6V'CD-
^QS>:E:1ZN22"Q!"NGK%XIAY!"TQO%XB,5R+G MICH0E!>P>QT#"8 QJT&X,#8/CT*72&6LHJZNY,% 9&QOC,4X4V5N^&IM'Q* M-
B!)ZOL"IH"XHP3?- +IW;?>FJC^9SB.90"18FHQZP,IJZGK&\$=AA(CKD3F\$ M\MN:BD5'\$Z#,6U,,H.XJ< LYQWU=?9/3@((N1CY%MI:SQ*
'C,SJ PQM"- M2W/H9X\$T:O ,/A<+>I)I0 M54A)ZB\$8B<2@1PT5(R,/I:~(5)A&K(T5X\$E/L,-\$L=C&KC1TJPQ'R_ %!M_U;#ro?78!9=3Q\$8?
0G+70(IY^:6 2)SNE!A:, '36G\$1K1KKA 5107)I: MJ0)AG2)0IC(=QFCQV6AW":05!I@W2^!^K8,^K MPPE9,3RO'C:POIY7ZP-EJFM-
~9.I\MXCML'W9O:8\$+DBF.(GLXNWG==A M%P24&:-!O,S.P_H#M#W,C+G! TNi/ZFY,<6I(1,#WLI:3>I@NP I MBT*MWSZZQ7\$/?
<(<~S'W6&0\$U/Q,OQ%7Y/ZR, YP04YIP@BCH?FEXB)I & MZHUHF#P:FO:EO(GI>I^HY6 07L(ZJ)217:9>FO+W,MJMI/127C"U/%"/*&>
MLS>8TNN(98W&2)-DM JU1IRA,HAGCOKI+N+E ,IM^ZN>N>5ZG06:QJZ= M /D&0EEIGL\$~IBF85N2^*QO'DO507)9DXNQB\$Y96F
<)W0:1^EYP>I?>VF^ M^K-IV(^-"" ,KJ5IS @.ICC9 XW.#@ID:|I:~VUZ1,#DIQZ^9QT'D0I8#I M5MC5I&JIB.NLL==I9J(G:A7X2/9#ZB5\$LYM'
ML:AX5W^Q=R&4#AU^~YIJ6 MJDI/RGY3N^JYW2+V+W3I>QB(T*?M&K&S* ?TINDV68>"9>:6=PS&?>VWVK96
M8OEKU?IBSU153'TBCKRS!.. EU5\$H0J3)1+KV96CV:A2>X W+I"/9+CO^ ML241B(T=8H?,(GQ&3-PLON?>I.I2HS29LC371VVPACW?
Y28F5@H\$.I9)2 M\$+0Z16?B7V2YAOH)S#R4P,U&Y M_XR^N?%V8@:5"79&J(@54::=DM%Z*@M JR4I]"8EQ6QJMYR*5EM2R'28&I
MI>IMN<*S;7/SG7ZR-ORD7E5K8T:2I'B,IL^&Z5M8F/15M#B-PXCQ2AG+2LS#AD9A MB-G_N;2HR? J<~1/1GJW#"T,%:9D<#3.Y*
IS80&,RI^YIO1>MH@2)S1540 M1E/L>I)B16P7DGO2T8GX/KMB_?1*I~931L2IQDS1PQ D-21A;X17 >6'9\$IT MBMD=S6',DCD7"=0-OBUU?
I1P#H,QI?I2D19D3'1E'9/M 010>5QV@#3@/(M0BODI#@%< KNCIT\$2V>ZKH"~C7=S VM+F*%4&RV:-IDM;M;8U*UJ
/7>ISEY+Y.IW5^%N)ISNN(P'B13&JLK\$1@IBW><)H8:W726LYX*N M/6LIMHY&IJC!+E+9H0ZZI\$%M^\$EPH9K@7'MQS8#T*4(UT_90
8S4ST?,_E M:T^M".ES_9=;ZMF:I?E-IEIBV6S:"6P>YLA6X!4G'FZDA@S"PN%('E'X)"= M\$TED(6%73Z D>3FIPGC<7*1JX!3!@R+4D:-
M8G1)=R%~H01B)OB\$+Y+AC9,I:S'ZSX&#SUTS+YNE08MMLO\$&E(S39IHX M=[FK'VKIS\$8MI@I5,J5H 13 M2)"JO.%G%XIDG1"IL:
MIG9>0VTIK7G26"36^8ZLBH?2SI7JGHZOS?V&A TWKAX0Q~8/>HXB#B=SGM M0&6S'NB8SA'QOH@76.2OWZ%#9&&\$LO.XI#-
@S9S_D>3+DR3HJM?%H\$;FZ)8;,"G6Z,B9 5XS5^~6:H01U0M7?I05^S:0 MS@RTW0-IVBA%2*~<2\$1YPL+Y50\$#
IIVG&C#":.04G UMJ 2=M+M+~#&+ G+@F=M=9>T.G'HTBD01) 0LA:86AF95&4P&@Y@D9-4BV0Q(#LKH25)BLJX M
LG.7XDF(8+;V5HHRV.9S\$6#V[KW(,=+W? @EC^J NB18WO\$J5^X&KO&5U MO-;(#E6)KK4MJ0W JHEPW8/I?L+4B1 =HETJYIO M.)W4S
MICX(KQ\$CF,B1I)G~*~. H5X~*=8V/MI+P>2!I%@U;YP:SIOG")I%>>22@ MHII*GZRX7#"3CI&GX=SV*GFJU_19\$\$(T7=Y25I-L-PI7+
(UK::TY\$X2D2C1PG MB E_E9@\$ON

TGJIM?2'E:L:IRT\$/(RR5?23T/& MT)W=FN,2S<:57K6V14 MU>8I\TH&HY^S)@I>I^D^M^?Q'TY"(^,@/O*#CWS??>0'7I8P??F>X+I\GB U MC?
30L:~J&V<,@'IZR2,13PE,CB*3A&E:W9V0Q2'EE\$;@-D"@FFR<)

M;+>TAM D/S&IJ= <&V,RLJJO24#V M%N+;IMBKH6*B+IY6=#j6/2V AB\$IX-32I?W^WDIM"Y4 ZI\$#*!L2)P12 Z>"
M0#16>5,9)F&YF52A1I4D>(R+>,U<6KD8;B3C=J#WEMJVI3GD;IT^L U8 M0/84T*ZT@XA6A>T:LND/HXIU#01>IW*2E/ !IQK^PB:LF1HH(G
M2)C@P1'=[VYCQ/?<>.,I>)/WN>#IWG/O< :~#S*ZLF3\$*84NP*JT =7&AS MEVR@9+J2OWUK'IM;+)-+B6NZ(#XK:-(H^'OP0.I.Z K1)
I<1QKIK8ET MJE:~NW-/G/3-QPW6%)U1^~P(1OX5=~=& Q MPP.Z"MAOZ@JA/+P#LP*%2IRG6%/@Q7:~T> YK^XN&4\$QS%I: IX3V"/B
MQM1K4TN LIA@KTS?VD=EFZ:06#M1?H:G:AZR&"O3:~8653F1' 6'G.I:7 MJ0I?T T+9<2I(9IJI=7D OP*>C)HG:EOI:VF%":OT EFN^,Z2GR?
>R>.:ID/L'4"JR!:+&9:5*U6+JKJ;P ME/&\$*6X)0I1SJU(U&I- RAY%L.IZIU)VM)E%CVY)UM(C:Z\$*L MOTI>D*~U!7(2W_N>YI-L-
ZCEJ>15WPT'I JIJI0"E(C(N\$PPNX16GD1 M)@VO#~F10>YL'C :~6S5TA5+EFFI-Y@^~TYQT UN=01I?+QV1)=PXZT32P(M8S8@8@L6Y^,XCL((S=
I*W+ISFRC9C#1%1%)C?2G(ZLQ+X@/ILHKD@+T<34!FOIIF;869+D=S.C.M:1DU 8G/BEF>3.3I781ABW/I9TB+RP=7#6V?/IWI:P-
R>:89FH:ISIG>&88X MNF!KT~B;~*5-S=^FVVB-~A#IP:X3\$AF? I"&6XP0I(JW(LA"PA48CIIJ' M=04=:E:#PC #N^BJ
)PWRSPV)U"/<S^8@XFVWVB>.MD#I:IG1+8.9 \$IT! MKBE%#-I&@RE28U(XEJN:)/AT0 (T9&I+FA6U7CAG^#ZZ("S:1(0XA&&
MWBVD>2^89EKV>I4LJI\$S=W18I#=# DI M(9D),HB4F#*U?I&C>+V4R-4D9JT(F\$HR(V<QD@DB;~NM&08BF3I5#9)-U M5R
F*~#~9DPWDNHNUI1PZ;I&Y(F%Q8*E195A<+3DBI8)DKC&#C (KB5! M2!2I1H(6A)UQR!\$U=@J2NVROK5\$ML_~I
(3KVJUDL#~*5:1M:IXH9Q&L5@M MF-~C"UOI,K^Q1NEU@BE8XCCPGO"L.B^IMV1CV 'BRG2!WGY+).C/\$5, M7I@%
<6&8UR)=~NK:B\$E7&L6M!@E!~*0*U&B)*2^I24%(I,~P<I#>X MK#M:MBN6JC#~,62@A A7P6N0R'17SG#0
NA 70RUIN^S1J72Q0551RH)D8#~2 MYMK"6 S~/14VKKI4@BPRIKV73&=EUOT 8ZLIY:~I>IWI4I-
GI'41GO1#Q5H#;I2^<^11\$6P1S#8UZI6#N)N(>^FA M>I7:@2E^MOO/-"N^8:4ZC>W:2C'TBUDCJ8Y.G.,~IRY.K:T-PF^P)3SM M4V0E8E-
IFX2?P.G8N(IU=;*)I05T!L_9\$(IAOZR@0SJB:~95UOQ00W M#M67TRY!7F :~8:N.WELVGC#I M::A T.J.N)94VZ)UK-%4&.13WGTA ^3,%-
PV9D8T=Y54(&8!S"RFB+I\$1)73F?>UFP.UPQD&8#QIH MI#8:12:2%\$28+6GI!H3VFSJDLW&NJI)PVJ7P@#H,EQ)T2F\$U!;"EB#;I8'U
M&=:IIT6 8?WA:9CCBHV.V#6V4#7R C VIM8=5=S 14?>6 2+ EE8N^8-X MC@VF159W72N*!~\$)U<)
Z3U3GGI~6^4X\$S1)N=*>:IBTZ4GDU^&VJ3S=I M;Q-DR-MGP:P:)Y46AU72I)F>3HP:V7 A6IP83* =IK08I4KD>JF 5"0
M5.E4U3TR ~QSRQI(48KH65);R8;E4T :CR&LF5:~%YI?CGA0806D#IERZ:P M/VU# IJA\$W/TOO=LW2(XK18 L9:KC7,0> S1)SM!
L#D(C0&2C\%P\$25C+6>X+ X=N173@GH4B0Z\$(50A5I: MR%A+@!^6*SJ88YS6U:WFX3I(NB\E/H10I%~WWDHOG40 8&C*7:~>%1SH9E M#L2
GS(PAO'D)I54I6T^IK'(UGM^CIR@:Q(6XO-WP)K&^4ZG.,DQ.U3/8YIK MQAHJ#XK/W=XL:M/7K38TDQK&\$~QG,LDLSCS@X%-
)JC.4YJO)I@P*5-L MZ7I=WI7CYN!13.SUT?658LCF=CAX009(3KJ48.2)K;:<<"VL^4H@2: M%2 K.N'WGH I&>UV!~I9>I>I6V%-
\$>C~J5 MY:HEHA:F%7Q-/X: M?&@6IEB! 61Q^R=J&2H*AM<<I)5/K)H D\$=V5@%*~XM*Z/3PX.OYA^&I6Q M+= F 215@Z%"-I1
VIWGXEP/HM'ZEBJVNW#XO")#7D=W:HAIE320DM->I#4C M3ID/YF#H&0S*D55E'FU;T0-IBIE#5K);Y*5ZQ'=HCF^&W69I NMU\$2?
N4W@R:DM/&8@I^07N MIJX@NIV,I6JH.FGW#I><(< 7X/O4 P02P,\$% @:8IH656M=Y:OA M<X& I4
ID:VUH+3(P.C0P.3.P7VQ48BYX;6SLO6MSW#;6.(SYV5!>6 MEE.CQ^IDIM[=I=V)!'N.XY.)< :~G380><9J%2?SG+UYI=?
0%PK&?I&%) ^@_ O1_#P 16QSCU.MQ@.IVZ'39;& (\$-VF7IRMD22#GN6; M+I\$A>LCS?I?/GW \^\$KGRW3^6&*LV27^CB#7Z#~#0S).>5)BF"
I]@;~s07 MR2,Z^A^I^/IHZ^? 4U>GII@EX>O?PO-N0 A2#I8<[+I.(P!UG? ZBL=+3 M71IIE3WSU>I>UZ7G(XI?OR^"?
X1>OJC HUR^~^~ZIY 20U:=9R/N03/OB M^= ?G= X#WCC'89QEGNO#PMDX?<9 >5YXGLYI>0>7\$CXI?Q76'YV+I?Z/'R M1-6+KYZRX M&-
X3^E"810L9K1"" /MJOI9^ R.+-@*Z.I>4KSF Q*EZ7.8 M_SS&ITZ6.0I6.3%UI#(IXI?WQ*OP.~>8Z^0#Y^~LS(6+?M29LC'QN\$VIC
M8+MPI0#S.S&G@ J^E"3436(3P.S.)3C.. UQV#FQ&I]X&X&DYD^IYRIV MPV&IYVW NR.@E.;? IY3F.I]SIS2^AM* M/S?#0002HB&I6>
I=+S0(DB>Y%Q07L&;NGI%#1.XG9#MOI..H"28Z338#I.D3 M&5K/ S** I,P'H MV&TIFY?7C%?X8:IP7D).(0221I)"(=
+NAG~%DC^B'Z%3I1IR4;#B1C MD&~.9%C"YOWDODRRT,2I43!OWO79CO)Q>6W@N(I^I^&+~(VM,I^ ^~E MBV ^B# =UCA+G)PF8H:UA86+
I0_3\$SW+4I#~BF>Z#~ BD/8&KJG MB9X;(8SD!Y=1SHD B#M'HD /4%~8W.OQI#V<~ P>4FWY,ZA707)6U"GEQ ML."34I7I
F5.3I:XI420.LM.#K9#I^/IUTO:V> 1*~I^Z+5@T\$J2TGY<+5% MYRZU.Z% F@+I'W1)S1)S?%QI+IYTDVFTP5GC^U=40,AS OX\$P*NE**1Q\$WC
MS:E4I'G\$E8L.CFU=5TLZ+I(X:<I:R-S\$B)>9WI59E!6A.#(Y+I~?I0I2I MR PRKBDX/IWM+FV2HWO M;CYXA:.7NQO>R2&
<8&I'56I^9J22+B2~548INAG&~. VYDNW2A,1AUH&I>I>Y MB1I1U@PF\$@D/BDNG3LA^A:XTVM\$2DJI/ @ MS6Q*IBFJO^V^,SARMBGPC_O:
(1)IC&6#I/O>IAD/(67HQX*; MB1I^CDX.X^K&C.HO'E%#7BB0698B #IYCIJ 63^IT'ZH'W'PC^I#715@ZO MUIB?OC.O
(.O*UV.93LM:"8I3T+BGG@OFI;\$%X9Z3IPO3:I95I!IO NU/9U M(^C#>V EZ:6Y"A0E[3Y]Y%:##J(1L\$'HX3;4#=(?OPSB&NRIP(P:B6I5L
M\$OF9;. THS:M^I&I \$S=TE\$ 9/2IH7@T6@X=LYBP1(IITX (V^>))D<99\$ M84I (*M>~\$>DAB1 ?+I>~%N9%EB&+I;XA^N(ABEEK14#;1GY
M1^RD8JMV-N,6VI@;OAI^I!\$W(PDT (UR.V)MPWA.^?Z3?E2JVCXWZ8 MJJWS?C^INKKRO>370P^G^L'LBXCJ\$'LXC7I*)E8I97(EAD(@4S>
IS<9+IS33 M(KR/PW7H>@TK:=IY43+12>=I*WL3Q/R1^Y3V7?L'Y=Q^A&^S04A:(HIP M29>~(9)S)F0R6 1^5@I1I1B^+D0^I5-D5JD
33>U&'8L&&0.+9#@VV9-6@ MIUU:"E,S8DP,"V_NMUX80WR.O6W>6I+B;("C^A>I1PL".212X6&.)IT16

MPI>?(LWVR0E- S99NN%Z68& MKIP\$-G.2QX/LB\$>6DG)ETJ(JU!KUF>#4QN1?U(>?=GC +>@:AG?0XV_N MTP,4XIRM W7) C*~#7>>Q>W-V-
VP1 HY6GNE2;7I&3WL00089).?I(OU 1 MZJ88RKM7:3^#2.QE24W0 /#Q^JZNEORIOR1DIP%+IMN20@\$0E-B.#+?E"D MDX-,S*&F> B0-\$X(
>JP^ @W5RG"V1\$FXYXSOJBQ ID)OIZ ?U"#A)BYJ2 M(<)SOI5TBN_RLYC.M0.IF^OX"Q@^=#H0R 0#O@0U5INY- 0

I2V4X\$5*6944&BTJ8 BB8I14#TU(59QC?H.&FG^ M"W(9JK"X*6*MI.D0:~IZII_#3%IM_V' 3F:LYP."DNZDH I5-BV(UA@K@
MQ>IG1>2%Z#&~*WS#=#/G 7E8I4YXD79_5="Z&KLU0I"YOIN%3C:D:\$S)VJ M8*6U@N7E:
UB^@~@<.ZAD)I)C&MIF#U"9I592D:~D^16IEHDW.K4^NF3(IIX*V ME&~CYOWJ1+~7(3TRI Q_D4LS\$RCJI:"I42%"#C%>#JLO&@S4=TV&7DYJIV
M\$S.P327/7@6VE^/WW^?~*M!*" 27580Q_ \$ M5_NBY+O.'6HBYI&9HYI5!A +G@94ILW_?&(TNL:CNMIO@V=V57/8>ER%>YI
MV&AB#C:NO2^I)E< ?I?V(ARC0IYH50J?F-O&I/SUBUBM(H:A/OI1G!~ M>IC#~VM8/YMYD\$ @XIT+3M&K?P0Q.BEXZ(B\$AZV:IS(4) Z24JOI I?
&MYI M+~3\$2%~P8HCRH7I7G8K#K:96G^SSK+Q.RYRQD64MS\$3,8W^C^YI=I!TJDM M0"K^UA>E3S8^1^7W3P50*OPITIASUCI-
XAQ2B&>+GVE/Q-QON[VIT\$B&?K20 MUVP^JUH1_V<#~I'W(-D) +.TKU MSI+D^Y<^O.=Z-)TJ+4F3^59 Q(TJ9CA5&2BZ3#GIU 7I1:NX*+XJ@\$4I
MD^AM^&D^B1@5M3FXV<^D4#&4#QORKSU\$S:O&=4G2_XQ&3#GF.S^IL#~.J! M8!FIB@C?)"(7KX,~I=VH88< C1F:33_\$I
I8B(Q-9E.ANHE)DN5S\$ZLM>+&U<~7>7Y^QRU+E&Sj<I27E6:~* M8U1I7>VA:QBF74TVZTEC8I!A+2TIN4S=E47I2N~NRAX+N.SFG %V@O16I+SK
MGFTE70^I)1S:\$Q90S=1I%3>)4=X#6VU!UV)&JS)0^O^?S6ZIC6A!%"I" MM X3S-S2 *YQ1)U,>2^YZI/V5Z~2B6ZU#G4:FJN??
*V6K^EI:DSI'0WE^QJ M+6VU:I(&8 HB_&7\$IT-000C<+;H^?2!<59FPICL&DD(=HO16D7V"-.-=: MQ7Y26-9IT5I5V12I(Y-(G6VIDTD12Q-?

```

F00010"A*P*TE,=A*S%SY@>$H M D*B/-&=80*K! (8HRG:XXUQ4B*J8@:3:Q7G81!&.W!>U(G<+($:IV(O."Y MV)6EX+I@. Y$IR0<#
(GI#;K<|VAF'> >T"ZVXJIAN02A:=6;."8|I <9ZPO:J" &?7'04(IW|2>=TK+ZZ*4|@ZL MG.VJBA<7M-9J=>I'0T!4<7.P@ &=J4;8&MZL^!;80%&E/I
(I@*B:T1=6B. MJCIMZ9A45D6VEF!-FN.F2?T3JVUH2TDN1V?&KJ|MW?)_17!>|ACG|5N
MIV<=X|>DZOSBAR&5Z. SIW30**>E)AUT'ZH+&JAR'BH'4Y<* MA _#>EQ#>4-82E 46.MF 2^I:#/NPAEHBVY$QI7O|Y%M:TT*N$P|IMP>Y$
M<:98CEBR4M 4I(I.QI+904NSW'VDS+IE5G 7.M.60/4.TBHTNY#F>=<3? FT>2E=I Q?#<=|/T+XO4330TPPU2D(EZ.$TL3ZMFJ M|
G:G3+!#;/9LSYHO)T1TOD R4<5(E.2>U8A16!+>A8313K.0G1|NI!_IV5 M|@9@/18'=6TW.L5^>KN5+XTS4|_#T.8D-2X$<>|&
IY(2>=>4)4LMF818<98KPGM(I M UOMI@!+=|T|72Q0|I%Z:ZIM&| MODIJZIC(I%&1GAGEF=7Y0:"Q+0.D38$3 (YK|>.6E^?26Z?H9F1'4N=FT
MK8'EK-ZP0I (98ME?)=QI#%P.;DGJEOM*VP*Q#":F P!^|N.C.U#E'W=DMYT.T5Q>|) M1_W5(IK4"#C2$@8.8J8Q.4SUQ 6>9M?>(92LY/NX@
C|I.5)+CP09E&ZMP+N^ ME2?&V #?2K*NMZ0*BD.#R9>N IYVA+5*5K(O8Q|H)5CT|9-<2M M2:'0*8P#>|$154Q5 )G !Z>ZD#+WJ#- "L^
V.8)T0-Y2$>|E M AJV50TN|.(FW.Q|:#. Y 282^EPMI|@&GKD5'RK)V X1Q|N:QU6*MUX8 M%|54R65$1LWCFE|Z5%1UTPE0 2R|;PJ9*#1.#
MZBI-MCC-JU>SECF9A2<+3B +O#T$B=9RD4M5AE 0B%COZAPX?+| Q3CW/7Y MI<+>MF0-8& |*^>>Q?
SIN/BK6#>=>4|0M3|A7R|JL-R$%|CB%.32.'15IE M :9N %L":+C%E.FGW9Y.V0$|#:=.C*2?3N.L!;L'11YK">Y.E^7|14F7B|
MRM>ROG&EX(=>S>&KPVI|N.O|Q(O0?)Z)2|WRL:SG0?A4FF'DC:8!AESV?| M'>.-7EBY^U|)LF3QEH3V|Y.X
X(P4(%JA0+VF=/(>#Y+VB$)?2.N^L:M+HX13>WER<_ /7R /3U14U5 M| "IV>WO|A5|S09W|W=">@T@63.^RPG6?
+A$3LEOTAT^BM _LM.Y.W.D=6.S;2N^2'R M5-8R+ +2L^GWA5#78>M*|S(VI#|#"1(NE|IR(2^OD)">+1: |JIS0|_M 8|YM7?>=5G.LL;H2'
UOQF^>|XORU>U>$ (WUG(C1$1)U|O|A=X5D8833* MXH4>4GT6*YQ3'8I.F%#H2G6T|9?2)M4KXN?+FCY|9|TYE.4N9+M0#KH>8UY7
M(SP'NLV2U/O)*WB|CHC-8M?>P&*C@* M81-QJ|L.RQ|5RA%:GO+*2R|36D|EH+.7/!=F%1GAHFXBUU1 4Y.M |3U4B9@ MZ%D8H|DBKPT|XOX?
^GTA^|CO5@.I40RUH2?| B|ZM= I'DX6|XF4@>XNY MB=50*Q|ZQ|S|O*|@8Z|NVL%8L:EP|F:K|J|<S^&=#NHJ%&M78E T12|D M@UP:
L/L&Y^C/N)3^5ALZD|0PNBU|QM"?+4@>S=3|)ZY.(DBV2|C?|TF$J M&3L/B8$0T$|W|XGK0(M,J$F%)>+E@B|U|+=I6^P^J94NX|J7|@>NAF#H.
MGAD40>-&FO.Y5W%KF(>?0=>Q$S JY82$>4$ZSUO^T+J B IOTGD|E+ K^C MKXZ.CE|4YMH|>G%T=#$ K^O1?1?
7WPZM77U?>_ 9K&30SAX+OO G|P|4|2 MYMH1|FA7|ALB*YAV:WAU=(:' 9'30*?+>W|Z@OWU@.CO+88&^CC:POHO0_GZ
MX.6K;|L7UOW^7P7L|@O1*B|&YV|Y:6 M- P9|K:FW8^IY%TJ47LZV'G$5>N>)ZC|OC4@.MHD 2+V.L=H(8V2.LX>|V|MSX
S8$1*|A^..R|Z.H.W@|LX|L.^|XZK>(>D<88|BRB6O|H:09660R|)'AO M.D.P|SKA6+D$8V.'SFV^O6R7|JER8A)A?>BT1&OX|P%0(CD|JR^*6|+D
M)UGNUG88YQ3=N08.#@2@'BUK|K|:"|J'EW22-BQ&^V&N<>Y&.@|=>&L K M)5OY_FZSH|T630$Z|'Y.|73NE.FRL7EC2$RET=E^R|'GC.|/L
S^&N_B|ZPYE1L$Q>G5PWU|' M1.HQ#44 YRK.<#P>D|J3+D10B?>XJDA^4*18G$O@|UE.A05IGA%(B.VT MD$>VD*^<|S|/EHS9_FIQ3%:(H#Y|L
GC$&|J|=BG8DW J|JMA +| ^1.B|B M#"M|T|KGU+NCR.JF>+G&:RY:USC#|'XH<|'|JLHH35 Y$S^H5.EH.D.$= MCBVAL'Y(%546^E(L2 F*(I+G&
(6N%|:S4 M3AS'AZDQ|L=T+.?>1?F O:BX.@EE2!+>$X5.78Q6GY8T1F0DE.8C(+2JM9 MNL7H27BY:EQN*.*D)DGP+O^
<2$J|^*#" .DSOFM*BYVDN+Y5YN^4TY|@HWWD7$|@+ M|S TRVFO^Q^9I.9T(I4Z49|JR:12%G)K^*25. C>@XN3?<0?KK>W 4Z@%X(3R
M.'$D>T+EFCA|Y|O|D*.*Q04P^U|'N|KFDVZ@T(QO&GHSM369'KL1R|T|2 M|9&6$M^T.1 $|(|D$=-&E.DV8L^C^4EO&P4R|;Q$?&>6*P-
'#18D@: M2ED9P,|^I^H^D*>2.SZ$S<6@5QY0GT|JFY|@.:8 7JO% (GE2KU8-24W<5D MSHP0"
4Q?Y28OCLA2#8TEUSXA&DB:D:URN&YD^>4&@>:AT^GWWZHA^Z(B9 M.=IYV?^TNX:WY^X#>RO=SH|>-Y#+
|JDE"ZIZOL/8A.NAW$0?|OE57<=> MCLL|M 82*1 7HCX'D|DISK^&|Y|L=HVW1#8>X|SO@S^"EBI?T|HKT$| MHD)XQ0@0U:R=.[4H-4"]P;U:2
Y@B(P30 N=1M_N^T8QZK*W%)>1"OC=|)3 MO"7G3CB^EZXM?UGD>:R GEJ?N+X|.7QH2D5/6PT^QZH 7CR0+>#9 $>+TRI MJP+>ZXA
08^E.O)8R8.@.J5UY8:7"+>E0Z&2W9-AA=#>.83MMOD3^4$S@Z M9PRX6G&_I293.D:Q25|I:(68K-7(IU-QR8A:X95!%HEH|6BW-LU)P)G)
MLLMO":C|4|WWTG0/EG8E4U^9DEZT|B5FHDX|+09X^VS|@X$>BVZ|J|"W: MA>L 95.^A|GELWF@T.3GV+VWX:U5M1$F|EAH:&P?
9%2!TYZC4=EP$UDFA< M952WJ/W>|>C|L|^*=*ILE$= 7|R8|H@5?>^C|O|H$> ZP|?Z/P|N|@J>=$@
M6=.$3G$=+SH4:=E85E?>C5Y$.9EQHBS7966ZC:BH^ZN^WFCRC9Q O-9UQEP*MM&3|I8BQ&#JQ|Y$S(2T|SMT'|.UZ-I39<|VN: .4=
1^FVRMT50%5X MH@ZSC"?>C:2S24)3AFA LOSZ2W=FB Z+*BM$&D151*J&D|>|M* S MKNV81&7(1&W2X*.FKXB|T.VR P8J*
(X<6YBF+G^6@-@>ZPP%O|W(5K|L >1# M)BW9X|N|N=*X#%F4LWE%B44.9=%0N2ENY0=@+>U@'WWX
M.<&|O|YUTT4.1|&GDHP*%K >F&H*R:HSK*|J&M|N|E^|Q^&=G|/DR2^H)TC MA-O.6XY)=56G<0>:9|:%O|I%
(3$.34^U.OVX)=K^C|3PXNTU+Z":3TYY.HM6@/9@2E=3 M|.(@EA=6|7PUPF%>DRL+>8=:$|@3V|)OPM@C=X,|^I^U4&P|(L5 F4BA;JNIOA
MV1|J@CPH6*A$Y#*U4$L=H5|MS.T2H06<^Y 10%1^:F6L9$+>#1 7Q|@=O/B O MZ:M>S|I0MWHQH4X.
PCH=2TW$|JXK;JK.A+M<> >YGJ3: QR=>R&^>J|J|O|) MVW.A34I:0K6."WE.Q5NAZZH0>#.0GG=|/O|RCXZ|J|S|?^_"|Y0L_P=
MSA^>2|>MB*BTYU602F$NH$Y9V5K5CTT^N^*|1D+>|T>DUA+>3?)KSPFY6R| MUO:BEN84/MFR3|J5T|IG$7
"#@>Y|>H7|05^"T4QR&RC^T|U@>L|(#8BGK M2:D2S00EG3.(Q-123K-9$ 60V^03*> +B/2N5300*OZOG OH|IYOZKF|
M4K1+=YLDI1+|V>+:>5$YIG#N3@B8 TF?#QJA:B#|/LET7U8->1OHPXVP O' MUMPI$|YXHWTOFKX4<|B89-P%G7CC5$#3B#?|8=Z$KX4$1>S?
DAI|22R2 *C M#AS@=EXP$B/G@> G%|>M+>MAT-
```

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j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|> (X2)+SNBF0B4JO5FJA7.[R+/?B@)RL\$[NA M:'7I=,DT\$CR_#J&U.PB^VYXO.BO1F) M?>3^R*OC8KQ-LG/KV9? SK"DT\$GRC"JIBJFJDE>%.C.W%BB\$%;#R37WMAUOQ:!!9>[WNK::R-A042 %^@F'WBU&#C MT+0RU+IH&*O/I!/#' IS7>MX)5?F=LG)5G)UV7"AT=>#G:@H"ISKWS9B\$W\ M.SOI&09(&_..IF: M%-&@T6W"5)JS.I M.ET4I9_**PIA>|&Q1ZCHXZLTZC/UPZT4KJL7-IJG(UK1_5BG)I7(^EEIU5_5_ MMKD"5_G:RI)S-KS4..^K(U3R:14 ? E\$%ISBN_PLSO)T!_+/%HQ#OPBPJTLXK-<5\$7KF@UT_:FO10V1"GWD\I MYC:' TRC'I-LWCILIA-I@J8)/?T5'.0S]8 0.FV!I(20?NKL-4/(GO:E MQ\$=OY)E4Q_5PPK4/>|<5I.SII\$5C8/74T:;21TS M+%X.1".I_-DB^YCA7+V GR72FY:EBJ:FW^=I|JMKPV_!H;G\$'J7(OJ8I MJ>:IL:C:W!2 7:YTW16I\$S:|8<(F\$TK_.\$!3"35E9CA59=3BY4H1 M|Q%J+IUR^0?78.E'IX3@|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|HNJ6ZG!&J=2"?=E)E9%KJ/Z=3GCKNSB M*.* 3_R\$#4JS 6WYNT!1DS%90?2\$E# ^Y.KWE&N13=*B^NOI!^6:10095J7% MH.CM)#!E15?NE:A_G6%AS/UG!7<5-OBPN+ M^#PB7Z<<^I95&ZB:6330+I5/ MC_M- 8&9=2DUG:N!>E89S_1(BX@PI1F3^S'CUI::+I|N@M@4'3'8^8ZIH?0^SS<^I5GK4@/D=;3)IM R< MT52N3HFE6(7YSV^22_KZ M:2IB) (W118XWN\$W!+0R28:"Z"[+B8HN/Y\$F.RIB. MXW+9Z1-BRG*+ TK?^UG-8I5CS#DOC^D+:-*IS@B^D>+I@^?@VE*3IL>M>= M8W@.B:/K(E"CS\$EV=W PX&7B19ZEO:DU@TS70B\$Q:!!GELN15\$Z&LE.E- MP8115\$TT.2.RF5IZ% ACPI&O)C^YIT_?MS:|JBGMY5TXJG2!%#TCKI28SI&J MC"ILIN6U-"8YH17 EW&1?1*EL:D>JZZZNIP+0<I8\$2-MO:FZN2Z_-"" M/I#(30 4JJE2XW>JZ0CA\$Q7:O:E Y E5\$T*ITL#IUBX076+I&Q!9FO_ S71B^FJV&Y#^+Y0..MRE MY*Z'NW9J\$PZ"TN^OW.ON\$>C8E1\$AID ^_@8>5#1JIS0MBUOSV69Q&U%Y_#P2I+4W:5U*%#9E1 MFD2+V:E+J@.6K2HI+O-DIU|&^&E\$F"J^3NP2.\$CW30F4>VYM= 291YIUB)*T^HG+L M@5"<;\$N3N|N|:5*EB4F9_6L\$NI\$#@_D^I&^&T+O\$+>4G<3^F.PZRTW17V-B TD>_5_2@4U+!EL&DIU MH UO2Y)LN MYI YI-585_7F.5.ST\$C >&? B/KT.S7:6RN11>ABJ0I)SW>?RIJ58%6P&YO M.D5#6A=>S<F.MRTO-. OIT(I&N)957=I|AIUQV7I9=4Q_OKBE&#I|L E#M=:VZYP M.L\$FBD*%RL7T>U0-H_2LQ>HGSK700#R-N-^447TR&3TH5S.FZRH|<95E..|C M.<I# IRZ:|NS4YQI89251T.RYGV4/WBYEY80!UY>S<I|D21T38!LN1BMH18 M|+8A1WI=|M6H|NHL09Z5H#R)3I\$S3M!|#G A^Z<@D5(CIWEENOI'Q'B#L0 MICKF#W_: 1UI<.:%5: %RQNI^YZK=+ +O1L68X5F_Us#<5A#P.LI9WE=6I@<"NR63 M6IKSY%")@WZK :@:(I943M_ 'MR5V&4VK8G,7_2TL3BZ?*"1NRCG\$-8% % K4I E)X2RV))QI" BZQ?*B6SH-I'(HKHD|\$8:0#L.K^K.I PXN9I5Z&H)&I/K2 M& (J:>9'0B>^:\$.7.MGS8@OQU<#^+SC<55X_ ^=SNP \$KKB0AID|P_+IYDNA M+6MVA5\$&&3F1I0I@+.=93HII|I2OSI Y=SHI=4-.0\$B?Q2Q-4#7+Y 3"IW@ M87J(VILW1I'P6PEF:IM8#+01I|J:18R+X|1163JQJ.DRI.9C37&%^M1B M|A9S01N^@PSI:GA7%3DN/W00HS_3* ^#X=YXM!E^UD5=PD@0QE.Q1B4I(B. M6D1XN@(+.5E- 002G%0Y%I)Q0A8=6V(HJ&6H^TJ)"D2Z@(#Z)QI:8P1".IU M14_ d\$6Q'^MK+O(IV&FE.COMSH;H^WO7SL\$S@)5WJTPG9).VO^ Z-F?9. M)H* @|DEZSBX(KP23:OR^P#6LUUG0\$D1E^MPV.X'E.EKAM11B7UDBR#I M32F: 2201_%.Y.CYI!^TF4A^3.NR*. T_-Y8JWHU X=896/E\$[29=W^? XOO"RU>HF@PU9CN@SMKBBV5E4&L+3I(O8^4(IRNG76*|0*82.KDZ-T MMN<I\$=7MGI%ZP&G(I%6:K:."MLIXE&3I)@0S|X MFT*?D07E^TYI17G+/P_Y=|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|BBVC\$JK(D1L6T M7SGUR^O@K<I+|VUFUA45N\$C.@QD.3%OKFXN< I|".^>@BZZU8>!_#I_ (C M^19\$A3QMCA1:1UR=7_8DS9ZY-I^8_90%2I/ W(5.C.#. ^_ BJKSMY:IL35F 38C85@:3G8064(WXL6P=\$1\$1TOI_ E3. MX9? I2DCV.*E|F@5P|>:I.W.1IV%YHL"V*^61I6P3G.(BJL\$Y(GI65W6'N)9M- M\$M/T?BAV"/%Z1_3:):XT^8I3&B.TO|5^3\$Q 3^C.(%+ /POI18POVM+Q)IJD^&K M9.@C607YQ3+HCJIC4 I5Q.W^0#VB65=I7A.C)IEC?FC8K/73UNX:W_4+>+|MW+FL^7B=HTAIH=? I+>>KX^\$Y0).#&I M..>+>S9\$;7.(XI:?)|B&NS9:7\$59:<J|N0I702P8I2I@B.7:5XZX5! MPI8Y23A65I0QW G<6HF (X34680.%=I(JG O=D|+)^%S:"RIA:|&XRI" MWEDBPF M=FN_R7#LL6J8(9MM0N<%XIS%:WZU90#I'WY:)C+JZD+?(B2.P<7#D0H<9S MD%Y!^G12KI:\$ MZ#>1>I'EYCM|CR"R5&>(%Q.IW+3I^@QVH|VEF_IJYV=^I\$OURO.2@)BSY M0KN: A&<7LR|I2LQ(2IG67.HS_DNPE#R"DH9E@ MFG3I,30P9I#IS4I)U2(SDEM.53.BHIIBT@AI#C.OA_)H/Q08H2I3:DIY+W^Q^6:YJ\$=8%V4\$XCOB:*BK&7QN (%PN*^1<90I3\$U)ZFN:|SLSDD|&C M..|S>0)"6M^Q?2C16Z809#7:5(WG2VZ&Z-57J00S?I|_#Y.LI>%O^>^ "O1= MOFU:3?1ZOZHX^8RH8MF7T- Y|IBEQ^MF1LR28I: V:;NW4>VQ4H8S-HO&T MS7.VNLOH6Y60_0KJ&OYG=MDGC:31+L+10WZ/CECV+?_#YVD7RL:YZ(=, MPVL^%\$D#&#*EN2|N A<4I\$:.8ISMU.FT6:4A'IR\ KJH'96=3EWGJ BOX MDBYV&I@&O(I0A04(DE_KR:U3QX%LE.SJVL4.X(I8- /L+W/5I5XII!<@&:|FIE^&B- MAI#>+9U8KP:IV+=7F0I1=O&Q:.""#D/I_V. OG:OZ\$JSX&O!&6RW#>+I:K1XU^VTI6^1 M0-EE_D3F3I20+@(:5Z5C: (P\$C@AB+>DULI^2SG=IL J OQ\$>A M^A|T^XE1>\$|FI\$9"(OGG0U)J7T&+3\$8MX NQ>9"SNCU40T(I5+V)1D45 MF#55L_H4=#0B|L %SN^F M-#3(YX# C3\$ R8C@!^0RY8EIS5G(9O:15LR-5S^CS^PH MIOQOOQ0R@X:X.VL^:3>=BVXIFIRD0>8^I4S@4' M1S.8CMRMS\$BK.HI^@QT<^I@X@VI:7=7G^2R)>W>I|IA M^=I8US52U: MXP|PHM72).D.AYAX::GS8UN^S(AWM.IX+2-18_X: X7*_ Q/TI@D^OYYI_M_GF:P^I>|^4#S|JCN4:13:CY5YRC"KW*D_@3"PZ^I)B5F#*#SD7:OISO@C MMIS="80E"KC|&E#EQWIBDA33H" V^74I" "=^7I5)REW&MBQ(3^F)O.EKG2 MKDS^AMVR(KS+5HU/@I0ZXIR>M&(D>^Q8@AURYSHAIWQYK|+<*)MJ\$%>_MC M 6\$W+14@FX5+>#HJII=THHY+|TVM7KU:|I5RS75X3A^K.30B)."B9.CZ(I MAI>Q^>Q^+2LE.MF057A=EBE?7Z^T2%\$ICZ."1:T?8X)= *WHMJ\$53\$IM: MBV(A4LKO85 ?=S^X#5.UW *K:.._P_4SBI^U^KOH8J!/\$MXI:4Q9 MV^H>LR*@F.UWA:-ER|7I.6):- "M:I82=VZ1\$TNX1>+>ACJ^V82RXFJ B M52P<_#6I|0T8AYO=IAYU6GS4\$&_UW)ZP16R3N).:|FUTIDGMS%606X >V/I MYIEE@TIEG>>UFS^X^W3.*#0.28#R1%L\$S|_..|62=OJT:8FI(WH;W|AWM#>AX8EV^Q^U)2JZZ4V+>K^OV_OO7U(L2I^Y M1= <.,@D1G=&MSUJ: -I&CYB%*C5 P6.QV|>MOV+#! =IIL:#N^_K1AUGC>=U M(<6<).6=>KEWEX: ^AX&\$R.IU4XU:5")P%OGY+ <3%W^H3J=S8MTGI(+@'CD" MR(XGM_A-9+|=BOKI^&YSLC6.R|RDD.S)WF@+TRES.Y2S5.98YU3I|=MV MM>_70S.UHWR8:<D1T%I| 29:N2 CM+9G.T^FN:E1I|D>@ I.<3IA9M^> M|IH_P*R+IGV.B0^SVU 4^O^T3LO_8I: "MS"2IS.MO4?VO4N|>ISWO\$1%CM M:15YJ#R(KY.D)_J I/S1^X1ET-1/1:5@USUVIE%|C9 M:XJ1K:U^EVIYU>2JK9.4X6I|V7H^_KN.MXDIH^ W2DHX55N::5A5UCZ^EM^I:E/Z^+NGDL |JL^R#RT? 0%T3L7B14<^I POPSJGLT PYI(Q=) @N&H(G) M22PIU09CI^0%RD|761643I V&(TR@4.C\$*NBYC2.B|J|<1F9E?& 457,< M%8A2/@>^B.1? 4BR^C^+S)Z^>Z_SJ^T^HPX0'8=>+J7:F00KF&B6#9@(#61559F54< MT!@8%N(VT^6I|E4C4_/189Q(3^Y5- X'KG#^SHV@U=+>KBA5Y\$B^PASTM M1VO.SWH ">G:T2G|B^&^IWA@&^@I&VS:1".I|S:\$C.ZS(=DC\$<S<OHX# M(SEX)!|A0C:SC:F4_5N |M|>URA)*LN8^P.OY(5YFEN6I3+05PNDI^81P MLH_JC2MOIP9ZC/PCT\$+YMU_*7-KL-BYVZ<(18MD M|H4#CN->?&O_H_Q\$N(AY=IB0? RMA3ETBV_6>22I2\$Z54A:R3K."X@.8I9S M(ZI2P|^>4_4RXIOY/K^I|M6KGSZ-7.S+B8#L(\$I:V-(4+5)=&\$86=VD<+@> M:|TKQI|M5- <>Q(W^D6^V(I|CIBS|:VA70=:LG=8I1W65YDZ'I6>Q^>P^P(F M_Q?<D_BP&X66@&DON5DZ'L.M\$UM.XIR.2\$J9TID2I>WO@%>=>PU)J33:=DI M14YCIG=Q2NWE99A7 I&(VZ1J|I|W5>+<9P@O^&B.U5DSLX.DIIW\$<:ITIHXX<9 M.:Z64_>+CJ%)IP>I- E0&A2NW18S1(8I)=08.HNA\$S4\$Q^V^CTF-IAWG(+U+)_@Z5P1V:75:TM0.WT@6KQ= M-?ZPKAJ_&U|BA?WA|TFA)-NFCB-O:IB+IH? R+FAU5031B(VZ^PPB|IXZ'5 M4Z_5Z&"+*|<>7D.YO: CFY5LVO/SDIK &B">ZL>+&HGHL:@UVG6^O@%F^I^K4 ML-K8U_? 3':1#D7.#I06: E:N<<9&T9#.UOKB^N>7^M(N2LE>XP 3I3NX M3\$^I*. (4A19I|I0_+8=#?1XV 6(S%+ZI@V6\$7BAARHVCT*"1795>|<5I|(+ M2IY? NA(HH8^R&CA(2S>I3S^DW>@LU4V7>AWTW6K7330DF&L5/7R=O52>_>_M^+2^E>8JLCO>8#S@_6APID)BEB(=@ZIB(D1F6D3DHA:2ID=O9:I9- :H2DA)R MGE5NCFIX\$<>^K8UB+>:B|JUO.B>N+>BCHFE516T6^*07 MSQI=(DMC3M28=&G&4 VIP54_QA#6ZEX^#_#_ (7#1T8M %*Q6I^W040^0&.: MF|IH2:E4J+I|253I3I_ O\$ 7F)XO^VI7E.Q*@\$C'9:4P|>#ERHAI O'Z MG5^VIS^0\$.?M"7I|ERBA(R^IB&FIN3PBX? >#>+KOA+L^6)OKFZNBMM^VJ L4 MXI8ES@.HASX|8CYXN-H2RY>:-X7T3I|V0Q_1B5I.1>+AH4LMCCO-|SU^AF"> RK=:XH9FI@0WB&#>+V MW7B&|INN"" +3|AOH_3HE4T^BD?>GZ7DY=>%GQ%:SF7^CC:):9G^PO41^C MOF#7IX|U'A:18D:-GMOI|>^|AO@:60:Y.2C=I6KE(//I) =IHWQ:AT MP.AQG &I1+I%I=4RHV|+=K;-8DQ+>A^M1Q2+!UK^YI54QJ6.R)=79CXGCBTX3 M>WX\$D0\$K27OB&N^C2B^M@580BWKFGI@A:3ZM%I=A=

["T"]+U[]%3HGv6T MU=>J O'SX&3/(+D4HJ);&JVCQ2OZs+2[K]6K)93U>Z97U>.7JY7IL407KIVV8 MTC'966IAE=.L.=.3:P7.QRZ+1?+UP=J] MGM
IFMMW@W M? 68U!SD!>L' %ADJG&X"&L KWNUK3-N%7'EIOKEI-Y/IY6+V@, Z'DJIT C#M2B:7W1N@K!%L
M):38)Z'ALP9]=>)J1BO:W3YX<>O@*/7(3G:R6VCI=TJNR[KI5(9#)Q<<@HV-(3!C1(0KG,%*L"/2:~?
>>3+FDLJL \$>:12)6!>@R/C!CL5G1NC7R#BHE:ICE5C*7*=IQOZ\$>ZIS70Q:636I.IYD MJD:CQNL%N_5= 7KU=M?B7X678VM?O27.
I3:KCID^=(MSA-2@=5N5RWU7TQQ_9N43B+3=.K_N_HDE!UE%=(6)9W8?TIK@.OE/NC'Y: MSL5RC3=>="SU5R^HZ.R""@LOEF7VIC27"F14
IQ6O' MF[!MNL&1>:]S51'^LIV6!%Z:LD-.17NQSZKID0#5@U QRK%<+D: MJY/86_3 IOVS*[A*KQ_I92J=GA=&#I/UX7N(OH?9&M7C MKG&P
IOMSIU:5L/8#YM8AJ2TJT2P@AI=F#9L>:DR(X7>I\$=>+VQI!>F)?(IO M/7^_OLO!LD5V2D:3X+ICUB Q_1L8#<6A\$;O1M(CX^+!@0L*31C3DX XR6'
M!RO!VB5YVEXMV.J+WB.WMOB1\$PVN^21=E'5A14B&09+>"BIKCD\$-77XO M@PZI+#AI#+&GW:S>"HHMO2IX>3"-#I#U--F'L16%1
LR+M DK(T)@ O2!\$ _\$IJZ.CIWHYI2HF0>4LJ2&ZT!9Q<6A@W"/7_ K4LFEIOH) M4?LLIC*SX7LZQYI="!;00IJC00@YIRIGNI=\$!*=I>-
@_:"D"QOYEF0XU M&#&3IEP!=6I!2G*2ZK)@(-JNTQGD8A-\$.\$@9J'P+H<8!N!LV1.>F9M#E^K67 M@H.50MVIIU;^U-.J)T W8.&6K YNIPZRWLK
W/OA.(C93E2OJ!15(0>9?3%ISSO MXFP5!U6EY/H)4*O 4SDIM)'H7>?C:04>2V07AN!88I(G%TX3! M5^L4:OXO0I'<%&4)3?WR WOOT>_%&3I=N(T(G
L/LA<=;<IV JW[14%&1F* MS5)=I:F.V= M<1T\$J8 K:SDT=2U;J5I5:L.IHR7T1M
M"E54^5:J!IGLIJ54LL8W7NAU71@A12:07K%2^%1+03;K09DIO1JP/+AUQEE2 M1^Y^D=SR^@Q-Q_1-Z9GJL.10SIA7C93I1=@@:QMYH+7S0?
G.)MDH7!U#R M1UIY_@AJ@4S_I&@Y:CYX!#=%J@G7#?P!-C JIC^9.6_#J1.OX2L P.14 MLJB)!&P5X\$>:BBM8I(C5+&Q_-5@5%)Z_."%IG<74D!>?
NER>\$/;ZEL:A9 MIV#47/8O_ (0'E.E.9:7#VU4#ER.HP^S2^&N_ J!7)QZ%JX22P&#>S>:_D
M#R9:75T2=RNUI/*=S!.UT+5;3EH^E*%B6M64=YC:7?S#*)+T&#X!@6TG8G!+ M)S)S&^TJD>T!9'S5 LA0KQ3JD=Q:>8C1#AY7!IQU>>E;IYA-
I]90%OI-!TE;. MH00I(02NME;.I3.C3F H1R^FJZ<E)MJD?)+%X.39 [CTI.K26+--DFI=%^7>1#; MP.FI4I(ORGI[IS]>3^4B\$AIS^(\$Z?
E_00#<45I.D.Q4-5^+9&SQMI>=F0VRZ MLN4JBQUS@/@164_F:O5S!Z^L!#?IOI^:4M-PANIMMWK?@TJ6OF2IGIQKG
M00!N.0\$K0>:/@:J""^T5*>+BTI.%TFJZ#A ?#>ZC M58:Q76I.J2LUZGD)EDJ\$XU?AI3:9I?99YS^YGT0:M M#1/I=2
L^>=Z.%@5IEJGQ&UX'66AQLO!<#S01E;*Q4?G=O=GWYM?I?Q75F M^11LAWL;@H6S1GFHXF>1070T7W\$5%5C):ZL1R3N(LIJOV+BZ5-
A_7!J!>=%CG ME.R:UPFF'P'NQ3A4#EPFW+2G>U7=1S JW?J!"X@/IHORV;_9XX/9N9I.MIUCR\$3L(;;NI?R#A-JV3N&39?KH!I#P.1)
I6B0\$<=%KOGS@5:XH7PY8 M4C.N\$B:NIUB^KDVRJQ/KE*!]<+@M\$A>+^S^51R8/L44Y8^!J3:01LR\$SG MO)D10>TM1IV<-
L/QP+IA=X3@'IU6A0R@IKSM#(3*(L.Y)ERVH"JFC00V1#; M=+1IS=6Q:6#G>C^4LH;@H3-BNJ:8SZJOE!2.20 ZG:3D^4#W?^:J#S'W^C
MJE'%XJ8L(UPNXOL/G=&=NB12?3V(3_0)80AZO6IWKH%EL+6>V1K7^+!+I+MUN/K9S_3J9:5D69TUIOY%XTMAU03RV0\$G_1
ML.@^Z40&=D>X2D0=OQNLN!<3V_JNA4I#OTTM>!)\$ UBXUML"\$S&X!JK1 MPVY1LI1 T8QW@M+@C!MD?
D^~KY15DQO.T)*!#P18ORA+0M0UC&X?B\$%I[Q.LI!#."G=RCUZCCU!P MV5U+JN\$Q:GGWU.B@FCAI&ZLNIG#% M4E(%Y7\$6*J2PNGD:-?
Q\$VJ_X)F1E# ?U?T'NOM("EB?)*> BTLWRP7^&#E9HF M.2FG3P_<3.Ow3.9INU!>Z:E>J%UD>>4\$!-I(U#MR MEES&U^#T@>7
Q?KES^MZDJ1!V.MGH/27*_.IQOG GO2M3H@9TYT56I(VH.51# HQ I;MX!^/G2#/:Q8ERE:5R^L!WL MJNA!
+>9+Y+K!N.Z2^4IU19IIS+%18"8@FNEBTU5L6G:"IO#@&*/!IOIOL= M^T9W@&X3.@!>AIF\GAA^&#SJ"O"TE%1I;=I\F^=&CX?FFAZ#4.~
M3C*%\$YW"++0H=.C_.\$N\$N5KVEYJ317@20H^T-\$G-I ML'YFPIA6#-WHV?*=?)UX^=1L4S^WNL_U4P-&Z4QZX(7)&T:UU=S)0>N_CD ML-
U ABIW2.HOE*%K3&C&+V YVP6:F"MM_OX A163EOHA:DZ+&C OZNN7"TI4 M'DA7?OZPJ4L66"GSR M'D7:L[CRJ4"%TR3-VYTP
::70.=J.AJLCIIC:K7OJRD:)JE*BAV8 DTJ!. M4UU6BN?J=+4^1JHN+KHXG;1+LNZ_CXE0=4EO=U*2I?
G3G5:700M#J_C5)4HJ/G(E>60=H.4J7G!^/5 M.6SUC:I=7.^4UJ Y:U6VKA6IEHP7VEA2YB/ ZKD_**>?2=AN9AE6V^O5!R1 M#EE2
<\$66M#+8&Q2+UJY;T^YI33RODIU!>+J3I(H(A<=M9NNR!UPRV+8>= MPC AO^!N9\$=%4SPIV.360(^_&+TV#N2K!-4+ 7?0JZW"%L_+ID=A:
ME^M;I\EXP5Q3VFEDJD4HRZ^H7)>D^G%/3HWQ9U6F*P(7&:5>[3K M!:"H)9ZN1QT<9SA.GY\$WWF6<6T^PM4^M:
X%>%10KZV^R)GJIN:IP8AC5@K M8834_A UX9-/GW5U/I^T.OCDUS^"RF\$IS+>^5=&"R FZ7V.<9@_A
MENO@GZ!/@#S>7WDR!>#F=Y>Y0>BEY(BKAJ-Z/3=ZJH)@L1-L->:&@3RNYK
M\$FL3%02T7H.7#23*%5VUJL_+H>=>GL:Y!M^BID"MS?JIB0L3+!>?E@M/N JN M(&BRG(\$2JF B.D^BBH!DR+^V(IPI0(C=P>R+>'8 => LT?
6'@X6@S7K(KJL MR5+;R6*#&[4\$Z81F)OQS^9-Q)!(=NU27^R9: MM=4LZ-/=> @7!\$5OR;JE78/ZDY&I^!INV-A9@<(YD.PH-*Y\$2QG?9?IMQ1Z)
I2 MZ^P>KG8OJT B O12MHXV)=BB(T%Z< MR4+LCI#>Z^J.B >RS3_IJ4?\$.9Z)!)RR739(I7JFH6:TC@X^A8^NDH.
M")BJ@Z9UJG.&!%BC_&#H:CEOR)QKTG>:2IFJFMET^32G.GTGF5U\$X2+ M6-#8NKMGTGB_(D)B\$TV(T?^
^D)>*?M/8C.G7#6B9VXQALOAJT)TE.W6DI M+X+W GF%#"0@||>%S"..S(M%_K8AIF4V8R RI@<(8-2I%&275N)2V;W!RT\$
M_/O!U@8ZI@OOB.6I]&^J1^&^13)/MM/TNW!@3N!>=>I"GN56SI@:_J M:12Q=U&A_M62A\$%:IOE:5:5!#)=@B_B#:^IG+6##J
0VEZ:2LOH.Q^#>6>7+K5L7C1P64=>P*19P7&LZ9H<0!>I(L(MK M2?)1OPDVJ D1EIO4RW1>>HQM!7Q9A(WM5X2-M^S7G\$!2I?
WK7TMHTDX: 2 MP%X20%ED9N>R1T> P')R#(F)DC+5(V%PIID)03J_?KGZQ258 J\$C5C/=H MBIWLJB99U?7XOE,I"*=C:W?ZS!I!>'=N/(R-
I_VBF5BQ.IYV<#<\$=>S>4D7 MTR2IYDB.9X?FZXXXMFR18_D3=3:~H HX3!+=IX!<=>E!%:_K_%YTIIXNF
M2+GXR2)P62"FRIVO=NJOFN+I2EOKJ0'8!> YIKA8!0A.XXIT>9+A#I?2A^2 M_V0S0I!>^Y@35I Q>#A/K8<_%<@54SPC9+K'GCWBC9I-
'FO"G9J!>+GNB/ MA_KKQ\$LX\$U.IIU:4I8>>M;B..H:LOM!+=GDO:BD.7IQ&#F+<(0V0G*~XGPR MYOH@WH#9:5B0_&V24!7S@1:IK
R!JEP#3ZIE"++6N7K=O8T17+&3C6V EYX M1QH?I=X+Z=MK6NF68NIGAF3\$#&#Q:FPKS-EFW2JR4DU//ADP.Q:5Q!>
MRJIOOV9=BUIS.I\$C\$Q\$A4+ET<4YD.%9NP_B1!^<@>:5!BP"+>80U(PR@8\$; M2^V7C)JLLVJ T#0.5Q(SYHT\$V1L.1)>F<&<N.YB9
4K4> DAK):A8 L.5R/\$Q(450M?@AK*VE&AH'Z_>+A9X'TJZC* 9>@I-C=? MBOP**Q'UZ?-FA R*)@&_KF>5:18+>0ZF)C!S# @G8-PLC8F-
NH!I4) MS"52_I^+I!_AOG-\$4Z#;:=5>8>=1"7.9IU:HKO"!4%DU5/#@0.N2@IY6!+;XI/N<#U/Y.J9JT7\$D!Q"!P7
M3Q#JBQ\$W.FAU83GYENK)X:28S1G)L^_UEJJI62X76T0XD=H@/I@W&M
M@Q^>EA=QA6AV64A#>3XLXQ/KX2I!C>A9MGIKQOML@+AVR6I26T_I9:~\$ M/E\$K?K%I(I3I6".IO:G FEGYS^JN/G(I8
C%.6"!I8'C#_5#S^Z12OD1("> M'796*%#;5=2/BK**JBB^P M^IDK&#Y)R9%_#6766#P3E0#A+23:!)QIPUBKUB71GTUVT/C=G.W*PFE1?
2&_K)1X1&:I1BOQ6-I>D.E(CI!>798:&#J0Y!&+L(1QUA37)U6* MW^>I?N^V.I3\$?_YV#V4UKWE%#65Z:~HJ@*!@DT-I!I(16F.JQ4FOXWR5\$N
MW!0\$2828^7:(712A8)56I @ID.# C.XQZDY.F51ZIJL48^E9.Y2^~I M82I"ISPU2?>*>*>2V9WIL.)WE3<4^<."M%HT4\$X0?
<4/6B7T5.\$RA^6D#E MDT_DFJHL.H(>+?BHH_5@?XJN9?RJ\$PEVHQU9P2*XM5.DYID.U!0*7NLV302 MURV^A=V&%Q(TQ
R2:1+I3B>HBSL4&7\$)B.O6M&T(GK3^2I5USILFJL MI(DCFCBIV50_SJPA4T&H+B37K_YD=(QD2X!&F0JIC42LITS: MSG7;A-E-
!#B7I6I63Q)&NJOR!XL8BTVK?SG0^D8ECV>>L@I RV:Z!>= MJI0P10U3!?"=3P80%&K24OH7LX4/9:UQ: 2?0_BM_A!E3#0?TF&#QD4;
MO#(3\$Z(TJUE5_E<\$WJ_555L?RESOGN77_&90EJ(ZX&4I>W8P&%?M#&_ ^SYP M(+N)%Y% ^UJP.IJL?YVVR3T.+<@T0?
F(KNTI)"PRAI4V@=\$Z+Q194M!4W! M_TJ2BDKNPP_Y_5Y)~RXF!\$X)ULCQ%<2%1.RPV3A.2U!BB=1.H07&W(C'
M\$3FPI(G\$S7)UEVQY:YNLN9Y>4Q*QO#&AP7+GA>L1N5CGESIY&A!>A! M.N'S@?IXAR-\$*UYZS+;9%L;FP/8Q0!&GA9IUT4-
8=06(NKGT.C.DPUO(D MQ2?3]>.(BXY2?T7ON?9_7U3W"M'2U5)Q.%#P>#LZ(I'W!>@IAPE);9+J23 M!%OSKZOUG.(\$X6^Z!&@RRJD
MZ#&Q_>>I^E TV-UFQSIZUE1^!+MH/WUZYW_Y0#6CVIET2!#I!=DI@^ M1"Q=M?PIE:K?2)!%I=NT57.KTM4Q0A
M+IG^RED960HXF?Q)QIV^4S_LBMHYHR32K#AYN\$VDX M^2UZYD@7-2?P59?2I_Q=M@DZ^!+%K9(Y#9YI) VU A.(UII*4FI3@?9_TH#/?
A6I/LRK8PWI9+0T3X MVJ3U^JRD7J!\$> MY\$73RO:3&1Z)P^QB<SO^5^+Z.H=OQ9F\$ MF81!>=GH@L:(2FGC1794U0/G)LQ3DK;8UL")<-
53F12Y MKI^WW^!5T; JUU7/DES\$3KUI/>^9I+<37 L*FH72B\$GP4:A.XKN^OX;L MK%#Y:UM ^48WTNH#V#76SK*^(-L@+BM?^H
WW+PF^M3\$-8/6TZSFELF M=?#2J! \$N2NYGR?KCP2SYF:OVN=*(F'0O_I8.FI^N@-S/CE@'E\$28G!QI'J MH73=KIMB7_)NJOV=WELNK2\$43I)N
YS=N#"(M@U->IC?%?U2:=WQ.K?B0 M-^<#<#NG? TC8I!>@INAH:(BXQ?I!68UZG?>I]>\$/+3I6B<3+D<I
#YTK5XA3KJFO*IBUWP@!*:IQQJN+GZGX M564JJI:)"<#STM:0&F:E.R^U7AZLMAI9\$ _\$G%A>6.FIJSV_75.A#BI_3FO M7OWVZQ)I2-
WE:1_4YC:Z3VJZ:WNZ<^N< K=YV@I>+&19%)#6#10+UEUV M#&#I@7-EZOKH107_P?PPKX=6.LMQAF@>#>)VDS^YYP;J1C:IV[80GUK7@7:2
M%I/CWM3L-WRD->IOUA=>N:MCY_903.M.N%#FTJMJ7I+;;^Y+2I>GMSI?I>_ WOI\$6W.(W(64M^T18YCIU37 MESU3(W7^JIGL>D:UID
V8I!>E/ MWISIZYMO3C!U?)20Y4_2W-V^&MV+R^~_2W+R'W_SU>O3CYBBAD*L7MR MOST9^<O-K4.Y@S18.&S!_OQW H.^<O/EN^?O?FS?
O7N1U!OG-0_#M#W* ^5I_-MO!WSX!K^K^U VOJ3L% FP.U=GUUZSSP&KTB_@1=02!@P8 MQ#^IAT4QDLY.ND!C?&SWU!M?NV5^-
&KM^>O7_IU?2:1VIG)WGOXLE> MG.2< QAN- BG;P^RWGB^H?AG^X87WWVC^N05^R'Q_>OQ%#1_QDS_8V.2 MIKY77"IA^2")=RN.
Z_1%#W1TN<+E!YGLM7 MAO_(O)NYWRO=SYIK)MS2@QL^~2!-@=>Y7W1%NO^>LP?W(OM\$25?XT4! M4?<IPXC&_ \$W?W\$;:83B(.
GV&('WB&I#G:P282NJL3P129:X(1ICE&^2 M8I0A?2)FNT5293:UXPB&810I6J1V J+6I^D9.'MG88CQ&C&O=M!H5PB!J M?
\$N_#:#;10^XQ#=> @6.QCH2?_I=I#ZPV53Y=SS-:U5_2IQRSRG!>@4 MF\$=>B_A_8F!>N^\$*N>#G4^O(,)^15Z\$<4%>X;L\$2-
@@"PH20"+HGGC+4 MTF."P8^YZZ*&=?%W+9P@I_K/PBFF.6I!^TA4^AI^C^LIGW^8HECB?ZS4+ M^=>A*?<X;=>^!>5UAZUD>&D/..
I"8V4I@OI!^OX8'(FB1K0S)QI>3R.S! I M3NI&@61WAI>1AT"?=4\$M_!2B-GV!N#W=[N6LF@CCD?+>=I:OR@+IY:KP4
MB.SPOF<^#R6I^*X+I)FISU^CVHJEOT.CIEC/^~T_!D2<#I1H%CMTE@6^WT/13Y;1H*~+>R7JK8/;>+R.K.BSKGBR("CLO&EJ1_OYR
M@REX.I!4#H.G.34!9U_K7&AIWB8R!G?2AI9V40YIEH FG5R5MB-/&Z_ M^Q&AL=H>>3I/ZU<IY5FH\$S!H.KOJ>I@^^(VH#>7RM\$
LY<:F6I@QI?I2!_MA5ILF4:0+A"(\$_5_KOGR&_ \$U_7IG:~%2?0(F="NPM97S8)T4QH.^&?<(H" MTD8)V0%6^<=B\$VUKM7I/6ZL>\$UIY?(L0=IA"%Y
%24G^\$EF1Y_TH#=#8 M'.AN@TF&W\$HOT6!2CT9MB&H)\$QQ_ \$SAIWF^*I^V.N.7R%WXW)!>V4^9^V
ME#&#&:VNMMHP\$3ZS:R=NK#CIX@Y@8 [S.N:Y2ABZE-XF_IJ8=H&T.O&PD>+>D?2I^W%\$X?2IAP:~^"I\$>P>I?Q MZ?
U6I(R3.OY^X(^_YVO*7<1TCBZ#9C07%@_YCICD191*IAH30028J7>34F MJ3:P9:C1DTC@6:XIK^COKL5HP R:IL2E*#>I6A06LI8A=11T-R'
I(MYDKI M/AW:U")~K_#T9I&I(R0:08J9I?)MRF354T7X:8NOA0 MXIOI>KZ3^QU'Q!CI!>AA^QZII.W42I!P=>FCWMTMZ.2P)AKH@ BN1<IK.\$6
M52L10KNXS+D+>Q\$IM@+@IU/#!S(I8KQOYT40?9#_X^I2X\$)+_3#% MYX_82DN:~(Y5E\$-EQP_IY^SYLO(T_UYOXASH5I2*~.
INZP7SUWJ!OK5 M>J;Z?I18!>@.I2N1.R6;8PS"82701VWLH2^8)!SZ)\$8 ^^(319WFO#F M3*14K&1@>"F UN6E3-
_C0@QJN\$0&_K4I5LZ"5"2A2GZPU?XJ7I8^9B;R M>XW7IYA!FTP-I8SBI7I6H^I8U^M(XP!M.B^213AMXV0UCAE=8_@KJ1=I M'LII MJ#T0@S-
RWK&7I&N>=CB3M6DEI1>)NFR^TMJ!%G^N\$1PYCJ8\$Y636 M18I2KJ1VH UHO\$E^9\$#>4">R.V-PCB;O#X#>I;TC2I&TNS^4G)N>Y83
M(C*B^7E4*E4P.&MHJ20 "M%1:4+J!%XQG>B@<LR\$T%&_!R&C875VG@^L0# MYO/HC:JD@TB:EJ^PI>I2:C"S^I^A0M.S32@S+X7W/8"+IP5Q2.
ZSF6G MB&8.GFPY: @9GJV_79I2"5\$EZ+[-SO.D4E#+3->YA)W+EIOI*Q1%I%G(TM M<M4?>-3I^5 M-4R\$S)ZQG/I2@+^SX1B57!_1K..PL^QIC-
ZL!)?H>+!>EAE>->GQ&EJMP MLKA+Z^!D:NQ-0P.&^25HOF#)333P;1DS@V2I!ZS.)XZDDJ+TP59HD7!N.MQ.1<3+J5T5O0WJDY*
<&=O.3I%#"^I9^"GICE?5_9 MXUK!@27^VP%[BSP^=^BIOQ=3HWB6D+JD.JI6J5T./RIO\$&+N9:I^L2IWT M;_!IJ69% ML.P@LI6>QU
MN#X2IFQ^QJ5A/H(6)V4I&YS^2I2 M\$[5O9I2L1A#_*ELHR3@6\$R(KU+2I)R_9GOI#&AXNP:F@M:Q9&Q4J>^C3I>-
MKO.A:XJ<+TG31O#0P7H%=>O.AOIRE;*RFTV=LICU!8L940&I9P91+2I)S^D)C1I#=#ZUA@)JX.4^R>(T:Y1ON."=1_5I#I^I X&:
\$P0^M>C+CB@W<-M M@Q/XOIGP^RS3I(M C88L4I=8TVC\$BNJ)U?Q9(L'IG!8I1W"7A=J!>M^O MT0-86<&-L-X:2:PTDS@I9E IQ"^-I-

X2:2PTDS@I9E !L*79@ (OSQ0Z2:"0 MAX%IQA,6<?>97*W &# 251\NCS\71D1P\$ 3/X \$C'3 6C*%SYC'S%KE&S MCXCXUQ4(5@#T6F-5\ZF7,709\U
F2*:"\GX&623B\U51&4:@4BDCP'O\ "9I.MI4&-S016D5E5%0/S:0M:0Q_6IE+5 \$R^L&UZ%AC2\IV9Z
X)10GBV\ZM^Q)3SZ(FITNZ:4"+X\$N\JOHP"HJM\$S69.15K3 MLP@WBL_N-2,9ER*7@&@&\$FWFIS RVJ;2L5E5J0=L@.YL5Z_OY\9A:A'>CV\W
MUM:"KT1(+>+7)25X^K E6XAM)M\$4WKX0DS'?@I\<Q_L M\IV@J_#9(=>S.02\YVK6N2SBU\Q0_A/PX*B"C-U=4\$J?LUA6B\NN6U\6"OTC
M(E2L>>=>CA>)0\$XW^D^T^E>:WR&V\9RO4&\$F6CJ".05="=763.@\$+>^J3\ M3JAH/#-9%)YHA0Y\&J@<
" \&Y0\$616F\NW^Q=N3^_TK6L.GNM74HZZ^G-; U MOT%P\NJ.WOC4S\N^Q+N+9:CJ6G3U3&M\$U\J ("DNL&AL6 H/: TH8%H0!"
MI(71\IG.KOC@% 7\$;10&U=;2BC:(&#HV@TP.+L T.J#(Z7"C0A:IRA2YJ.
M>%\$(7K%11<7V^MH9:H.Q+VX;9N/V'1=|V|HP>^C(2_Q320N<4P61V4)AA989?^V
M45=8=M5%"UB\95093\$S2;K0M^|RZ5J.C\MIK\;|B\N828H0>IV3X<ZD:U MO &35^9JCF*^~|F5HMF8B^~+!H><="2\DAH MX=
_MX3KL; >^%2DQ\$WV<2BE9;G5E?25WW\I04#8_MZ2D5X"-525\>-5\I;5 MEY0*M\5M/2M^*0W MSQ^#VYI2(+6HF;) _35?2<(<0?/:U^K)>R4#;
(&#>R\$ M.NC#^Q\$J^D;_36MD9C=;|S%)I1<P@_K#%M4I4@#T?I?+*?Z=*&|I|&+ M2_2R\%6(*7_.ZBE
05N<_I\W.CD'9\^+>9LL;7@_FJ\BMJ MC=0\$25A36E;|=0J8265I+2\I=K8263ZQ\NWE9J_J\ICYSQ&G<6F5AQ@O : MARL?
NBO(BF3_%VXYR6D4A@%7%.45-PGRC=BT?3110'=E!>_R0M1H\5-MQO\F^*)NRG#G M!EU+>H^F72*C99 E=).#|/#E0
MY8+9X;6=V#JG;L.M\1C\9H_70+O:E4IF\YA&VND8L&F;HHU\LL+KP_~45Q8FM M^ZYX\I)22.-7\H994F\UN\I3C39G_0+>P3K=W@>@CMV^.;7)"I
|VY9F8H.M\67K&\$JL\$;IBJAD\?CS<3^TM;_9\0^00#0+FW8WK\Y_.3QWBX1R7<1^N MU1MAL1\I.2J8_2J30\N^1\I.2J8BP^3\|>=Y%
0XY(\$S\IG7&!\\$S\^J5R=M> M?&R:~6D#&+E6G;JK@=KQ\=XDNZ\PSB M;E%QO>_CK@^H^*3.C22>NJV+2M1.P_KE'!WY=.E#-
PE(SUM6Y:4IM4&+U4 M2^D-04^<#Q9\I)LD;+O&MZQCVP3CQ\$TKO>>9J.60LTNE(P2" U2AA@C\?^G<
M66\$Z^6A<="&GJ\NH8\I9_2\$ 2KW\$(FB;Y5&EDJ^)\312_A%#(/@.)_-S^"1\ MZV;N1-9PCT\I@_-JE(C%\$S9Z;_@3QGF6YM\|EK*29DE&U(TWP3B+
KV3:~)A MNX^=HM74.XB1*\$V;_6JL&PO^BTD\A/ M 1="O-ZAC<^Y\|+4RIA=;J@+;K.HEJK/FP<@QFR'\$5^P11MA4\B7N)Q
M^I9Q4@3=\$R Y>8RK@A033VK5EQ\I\W(47^*4Y7V\|XQOQ^N\Q\G:H)66DGY\I MU(G85A:L5(&(\$NHJ;_20(N+3E\I\(-#32\;4_/F^)/3D-
9<|I(=*IT^?)Y>D. M#W@-V8(U3072 >&@C^)&(XC+@)\I;S*K\I2>@J9_OV_#6;#A024^|/R+X\I;P
M8W\$W\JQ6_UJK>K5LA.M8#60HVEW3="WE5P;3SGI B9X;NR^@|&G;#6#112\J\T:4 M04:A8&|
|672A\$;KTK;H.0+JA+G2XVD:0I8+|@&|RX7;J\I(1^Y\I3X3S^?96_P_MZT4UX2>Y;_3(&3^IK*(3F7_-R>)|B>LMGNGNR0NX80\07CGL\1^8)=H>;|%Z42 M1?
JC#QQ_%C^*U _D@=C4;^YZ\G60>M@-M-9^D^L>|B5L\I_P:6^03>+*|I2@_C21 M_#_""|J3R%I\$5-33=S9WE=O&(X@C>K8+&S TA?
RQ7T&Y+&S_#9Q\$;_&:3VY\ M9Q(K6^99"?@>9X0<3N0QX5\IIN^_..7\1^4\YLP<@_@J0_@TDL5@Y@EYV@M M+@_DIG.54-EC 'UX8)01\I\+>^>
(Z\IY&OKA6Q%;;|I8ID@N?'=|I7N3D6;T M\$@3\N-M+&\$F9HU@|4LELLC_(&_2KA54I4+TVA^Q0S\TF@|XO\;6Z02\UD_ MET@-
|/S+&|I3MD07;7Z\$J^N^X>|39^>_(&T^0G\$0H.1@B89^Q^_E\B:7M3QN M^G5_0^7Q%OI= 9ZDXS\$YPL4AB\IMX^E3(67_#SIIE^M) ^1P^|(&)XSISY
M18Y>|;SKG#1+V^#M H\J8;STCB\H\^&E\I4KPA=#E\I;U(BR3XN8GSR\77 MKIS^&^>(&E=@0VM^_S^|675(16"SM4Q208+&
(KX^Q^HW8UE_&Y@| MSX4PEJE7\VPY(Y%_>A\^2<(#B.IG^ ^3J&;T0O\XT-1?2%X35/ M=)ODCNM-|J\$PE7XR@(_35FIDQ\FJSEW;<^Q:Q-
R(MP&G^Q^N&EBDL\|A_A M5&|;2Q^5559P(#0\$J\$S;Z;J\11HMR@E:ECRLH4B=M_)FOI0\I284%0PI#"
M&5Y&GE^Q^5A\$^+P^PCL_P\JA^#^SILD+RRCB\QO\R64Z;_&|6;_2L2%PTX\ M_L\ DJKY7HAQ^_IOV@|XB^VSE#-\$\JK4YH&*@
M"BKFW.8&&HNW;W U@YG(3_@8DD^E<#5D+^JATC 6&B072.V0>P7006R\IOX3\51T3.KS^XJPT_\$ MD_Q_4U8B2=2VO:@59LM^\$G0CD<;
|GSZAX\|P\^0H1;=BFY\MO_ ZEZ&YSUY^S^("IK\K\^7T\$Q&+|WQ6@ELR\J^Q=+|F^FS<%'>WL_(<>Y\F\9 M;QU;DA\LA.MAY2\^RVRT^*79(;%
I\;6QATENS^YUSRO5F66UDUG\R9A5\1 MN-47LY7P5I4J\+MH\;Y\$FO6\FLX@UF8)<8&I;Z;XHR9M^SMB(=M(78\|D- M\$74\IYIV
XD6_&+>272\J0\$=73LAD\|M\+;1#; "YU5%VL-6 F \I|>^<^NL ML\N\YNOBWN@EY>_%9HMXFE-1;^6I
MD@GM\I^OFLH=|>|>#S_5Z9\NHJ^_L^MW^_Q^D8UL^N^+22RM&^FEP<4\SC4
M\#7WA@WFR=YVSU=ODI>0\$^J@=R;IBQ5N^Q^X^UW>=%|>F+2\$|JVH3R28S\| M/V&R7(D\|_ /EV4MV\5YIEU;BVD\?D.J>WS
@FC9\I%17;:6^9^A45 MH\$J\|GGNN^>BKJ^-ALOSL C+|LRIALG78V+W04>ZN<8V\;E06|=DTF8T)"IQ(A'A'(YLDG>DC?4
MQ_2:AS%IE_ZN>MX88-"N6Z72^<|<\$.L X2%K\LV.B)GTBW7;V&E1.XA-B#-\$P MF+^9_-L\+^3Y<_NM6ITW\&7_."A>|M%\$00&O>@4)843(-8WHJ?
#D.T H+5N M;2\$>(>?>?>Q)C B^3<9XZ\$^6BZ9>_Y=B&S(C%E47(TI2\I.MW)&4W@## MXOU\Y\U4L_)^:PM^7=.%.S<90;6W3?
^Q@Y+UB8DA-(G0%/83&\$;O) ^8N/ MB-"X>LW=E@_C\7\7^MKM2RUBL84S\MIHJ
M6KTKSZY"-7\K59\E@MJR9FU1UG^*VY^6AK^5;QWFZB.O*%Z;2K\IATF= MP\I\CUA3%OCK2C^#_.9JH5FZR2\SH22'S?2V^
=&^0K1.5\IS\I0>5Z@PC+ MO6;6B8XDR9#-4\I2JE5Q:"NZX?Z^>FSL^*KF^4>|0*>KWP5&5OL'36"1D MY(9_ EY)3@90H7P)A?;:5MJX-
TW7\@F3%<GXV\|T;A\AEX9UA&|J\I^Z7 MJ"C^J= WEFMSCG7@>_1(H+&L(6#;;ZLQO^*= " ;)C;HS1&(5\Z+^#6^ M;
|R^Q^PH;J4\$K7IGU6L;C6^YV#+1E2^*G07U?L;HG\JP^SY<<<<>O)2^7=Q M\$+NIUW\)-TO_QNE5CBNT13?^%UU
@|JF;J=N\A08V^""G7B\$^18EU;RD>Q@_+0U\A2\N\OK\|_?H MQ^*+20\IKPQ;A4E#=#MJ8237^_I.C\I2ANXA(SL6B53AVN6RJY;"#|77\$K001
M;Z>34P_7PX^A^_U+OUM^*UE\I_ZQ;U6^T+PD?E M_ZD\I;3H41RV=GN1-^H^>=>R<^|U\I0;X;BLN1GO_@|ITJ^_4C1CQ= M#')?#9)^DQZ\I-P-
\$)-W\4WW^NA;JHS-/3SF/T9Q\H=@=A:(GC+%3_BP-J_?C M=#J.RH \|\$_UCV7ME.MJ M^S6+'PMD- L?JT8\;LJW1380&FD+A?
Z\=8Y;J^5B\I@&Y\I(6&S&PE\F\UL MLD^C6S;6ABNKA^CV-51864+ M@O6TM2KBV3\BB\IH+Q^:WSFKQ&A1@-D+&Z MC5?K<35<61\$=U5?^_3I?
O3KY\T_7OW\W\ _I\I;^G^GWYPOW\I\O\I^_..MHB\?OVR\O/>|? ^NW7Z=|>^H^:W;UWL\I^>W\J\3Z MR_6?
NWTXS_%.|N3S\N+IUWBP_CW_#O\|=?? GN<8;C\GWY>-JR\I2O=^&^ M^7Z =8VOWOUZ&OV\N\ISUYN?>UA^&WYZ_?7+QP=Z_?ONU^<<V>??
XW_..|B\N9.Z;3\I?N\^S3F\|ZQSV^N^Q+N+^V;CX_C_-3E3^X;N_A-K MQW\< >7MFH_XRZ^_M_SNY\| " W9%_+A^T6\>KU\|_-O>ST_7I=JR5U_>
MK\|O?J^ OKG^< M7O(X722\X4OHU5@|C^JO+>^<^>V;44.AV=MH.4\I>"-6.BZK=G/R MLK=8LK\$=DGYJ#@ (9YVR6RY?
|SXQ\$X\|HJ59G&L\|(^U: #DZZ5BKLY%<|<@ MB^AOC\%;(L\I_7%-6@^A+HH05A71.Q9(-6\)% S@2;_MM^<_<LDQ28 MI\I= M9KY+7<(&E2
X6%.5\$29<I MDD1M>4XV5KC2%\$@<_+>U/KMG^*IU47^TTS^F10ULUVUGUY>E7^N\$150\$[S04? M=K#&+|<^&_7I0C70\J\|4DI><|I\$KDQY<7U\$P9-
|UANRD\XCL\I\76\O>L MV?=/S-GWT>LJN\@>0EU Y=8PK>3#FT^7VXN&^&M5^8F^>^"V0<6I6\KE M:O\AL+
<P6;RQ764>K^;FH\|5L@M^?IE1_+>M\I\N+>N<1\I7JF24P\I^P^S6_7C\$C_ _U#_DVL2;3N1G MMWB-BZ89)EZ\>ZX\$RY-(
S9C4@9QXJFARP4^R<="R/N^*")R&|;8E>|I\ MO\H^?_0>-JA^|?FUX\I.J4R\I?T=<50S)GTMH0\X\|>@>|DEKP.KIA:9
M@MP=WSF^*S0\I>?%SAJ\^B\I9.MGWY>#@&|237\MK\I>9;_==45\ MWT?+VCD M\NS&|_9(P&(OH9AM85.2^YR \5#^A%J6^\$&SX1W\T-\$0N-):I?<
|7\I49E2 M_#6&#UBF-5\@E8^&^"TVR^HET9>CS8\5HES<^EY^>="AMWQ.F>|@I 877%)C
MW_P(Z9SU^X(6#MDJ5J^F5+7.0AT7\3B0:1^%21+^VB-8R:QO^>5MRA5= M+3@|6J\8H\I\149 /W1>OQ^=0P+5#0N^8^T^J^A\?
%\$|P3F\^E^X\T^M_ M=IDF@A)=T5\Y\X.+>N\77@TB\F\I+TR^R\JF;96KGR;"=|>OJD^H:~R M;6G;9S##4J\ WW:ENPP2^K78\I\I)?
R_J3IEF6\1^HB+J6Q_UO_F\UR3^&HX M0;W9B8KJL<_&WF09ZFL^Y^X=Y6PKM@RH8Q^P+JX.39;\$3 MMN\ZGB\G\2^1_G\I JRRYJ6F^B?)\$S?<
T= LWV\>KT7&(\VWE+6QE08W\$K\ MIH^%+KLEQ03YPA4.ZB\$VX&7^T64\GOE9KL+)^XBZ=&3" J;3L=E(L5=PL= V" M_D52ZYFLI6A-
7Q5\170C+^TU^")>=M:X7XG-E.EUD#;LX+& M3<2^J&^ARI^MEB\^TYO^N)5WX_-2\$D.C>C\PAH/H-LA/MCFFT\H7 M.%\;VVV3>T-
561T\$R9YV7S^P@&|H@&|(UKB&1:7S7;^3JK5\$|DB\IOW<^ M<^XV,AG9VFR04NME+|H6BW>|TA?|NA2\$K\Q(E-*4MX).IOI=A3TSJ_&# M*?
<_:=19G\;J0^3B\FU=^?767\$Y7&=M+&MC@|4^ALXN;R\$&T^J8^GYC+ MWR90=89@^JL2 H
JDDPEN+FX(HCTR_83&QOR>R+C1Z\I:|OXTV&R_NG8R_M_016%Y\|>|>S\ GC@I#719QUU&?^P1S62\I=W0SB)/%29FZ^M
MB:~)B)V:V4<W>C0YB \N1.NEE^H7<^WFP<4Z6N_F&|Y2D\$+N8;R^J MAU(,95\J2 M_&QHFV5^1*=H22^
(XKA^CS%\$@<QTCZ;8+>1BQ\5;HZ\$A^<|I^ MP&8L+<7WF:C7> SG7^J^W@*|I&J^&@VAM-FP6LW2B.Z6RM^|+RC\$NU^O^Q>D M^SOJ=G?
YK\I\D+VO_7R0SRL^5 OK;CC\|X^3\I J1B-Q\|ZH_|XDI4740^> M63@F.7E#O;J4ACOBZ^@OR^3\U@^2Y^&YZ\$E\|C8NA^NR;S_D_%;Z^* M
|RX4.OG^7330ROLG\|C\^%=>V_3&6BDH\|@T^?>P7\ P\I\W+Z\B.LFZ3^58><<_5\$Y4BY7\\$_*6;_7#J\I_ *MT.L\8&S9?HQ9U8\RI+<
^@S3A>Z^EIUNRP&#^|V\K&<_(>V\3.G6A_+L^LWS-\$A-D8F&6NDX\I^>J\7L&T^M M3^75-X2@^%\$?J2EY=BNQJ\I>@92\U^Y50^U70L^R2-
JMR(HK572YI?I-VH MKLVA.VO_B+Y(H%)?(99_*XTI\WJ_ ^(\K67E^_%47S>0E7E.U7B\$XV1?W2 M&S_N\$8C=F\B P73^M^W(#LR= -
J%#=#C;L\B7ISS>5R407\^?);_Q3B2;2_MX>E_Y3L^OP_UCD(=7^M>X2?>JIZ^G\2+>5\I92E.EDL6EY\=T\I&A;G;32< MA4&
(.N#=#Q.68F\J5O.R\I@W\$F8\B5G;G7(S+^J<=#8IW^@R&C^&H739\ MR-RL^J\B;~&2\1TAY\|UWFL\%OIL\$E\$;H1#<9^"FP_U6YC\$|C\;_Z\J=M)^0J
MG==+V&%4.Z^NHJF=277M529BD3OILL3;\$|H^K.\$+|ZJLXB;M&6\^*!N?O MI--Q^LC4L^G9\|H>BB4Y.4B^1+/(0\|&I\;M9^R(VI7X;#
<L\OYID&^M M#_DJRY7>|<B^<^A^M\WZ\$QKG0KIM\J\ R KQO\LHYX3.UHQ_5^K%>@X^9.2\ M\$S>|3E<^&R\I^R^WAF;7RR@)2^C2^527+|J>
<|IUXNGLT4H M3>K>3^F+G^#M(SVSED+;^8W\@S&-DO.&Q^*771UV_U3;@+30+>^0A:K\IDV^R M.OC2E1N\I!
|DW5EQ4\|>=HA^MM\J0\$>+ Y^ (FZ<5\|LB#)#R\I!& (M_@IYMWR_82\H2;M.ME1)D5;K&\$|IGA&4= M+;RHYX^8.23 4T;IR_@|>?
|2|PV<<^>^>Z8XE0J9>^MO2;+|L\|T^PVWS:UOPL!^2PMVS_2UQJ4E/ SM9\B<5 M_-^9R)5\WBO#D/Z =63P4ZXH+PL5+F+;WL610L
)DDB\HA;B>BM;#1R^K\I^0?7\ W#<|ME M5^0Y\K9SW;N\CK=0@>Q>+SR<|>|WYWG@7PTI^*=N|>JLL^Y5ZQ2YD+=446 M^BZX=>^WZ4\%
I\6FPB^M\I)F65M\$^SM&6\|E2D.KIEVS8Q_Q\$-I\NZ\$_.E62Z\I^F%QIE^%GMEI7&5;|IEH MGM-2^I;4KU26\JYZ^R0%0%
|<KW4H)W_FKCD= WUO&8K_@ULH_IDM_*\I ML2MU V9^R^KQHXL2X^YDUYE\DIUS+ C>R^I\YQIR_-JIPDIY.G
M8>|G\$J\&41R\;FV(M\$9=DH^#& /W>_H%|S\T;J\I;25;T^W66P\^| M(N>=>EV(F-\$) 04)T3SP2;L5^KDXK_T@G&8/8=NXI-|_F\IGIO=|W_YR/P@
M2>6G\$J^N^1H2\?>D^I^C<4^I4JIG&IPY@>+GUFL\I^?W MG3\I^Q^NY5+>^!ELM\I@I^?2V_@Q5(6G.WH4K@OTJB^4\| Y<=V\^2KI5\I
M6ZALBJKIN<|9^YQ1\#^OZ\Q_Q:8N(C^TSW0IK M787U^<2<#)HLZ\#M\I^R>+^H^*|G(Y@\$WR^*1E/(OUE\KB&9Z3P\<^;J\I^R= MH
|>J4<=YVY?24#^WQ(4U5&HM3FM\$S4U\^714<0\|Y%3^80 Q_W2U+|^>M R7QOM&Y_Z>54T M
Z\)=N\NHYRN^%9B (DR_-B;1H\$;H-L+>6^|I^ ES\5D+&Z\$N^#6^TN MNR1#HS7B^W&H<@&FW&
(G\$E5\+BC#"/.2.7NIT2H@8U5DNCPC3\$56FG\|/"G" M?F!&_#A-WXHIA9_J0?7&X8PO+^*8J9DR@T_-O^*NTZEKGO<#IR_QTE2\=D
M0FQ^>T=8(LIS6PL;9\<^U?>^F#A^&|J9&+6;S0\I\W1H90Q5T\I(6A\9B MT0\$8MG=^< SSPFK1.Z
8BJKAY\I^D: P\U\$MFI&P&\$DOGF+TZC@\$W\^C\ M06^7M^PTSN^SC?;JZK>M^*J^+|^I^D\MT\Q.)XON^CO#^*0;G:1^J\3Z\;HZ M%X22=MN
Z#X@+D^L.V%)_5K^*Y\PD\$L+>+8)T;2;Y0>TAKFV&4;ON;QT^ M+R<+|C^Q^F=T2W^|0=S=DBQ\XC0R\J\^=F^;UN3M%.B\KB)^?IK#_*ZJGI3
MQ9\15;4&S6@&8=|^&Q(9P=XDQ>+5M7;U;O_C\IHB6^D1Q>5AQ<78W;_5 M#6@E+(2\$1TU-N\B=C.E.OE#^_8IL@-C_?B6@D C^VQ\4MW?
MLDQ_:9;D>T MMRZ6JN^1\I.M7-A4Y7DQOIQ\$55BC HR7^L5^FL(K5?&I^#ZV57_U485><5(NW.M1MBC7YZ@Y3^M3P \I5G\ME5R0K.^
H\J9F^W274ZTUART\|+>+>+B\O\$4\$3Y\ES^LA-Y6;B63<<=V&E<2^BGBY@IV_MMC0>E@.0^*I^NEAX;P2^C7
RT\JDK4^M=>YNE+1MN@KRI:P+X\IN^ M1^LU^X^N^5+&K>HH^(\1A\>_HE^+2T\I\FOH25\I^2-SS44^8
M?Y=8UC\O2^N1SA\7NTE5HOIV^3Z)N535BY^KX0B^?7-7+CQ>+>EMN;G/=+ MTOLEZ^V2\I+TGLP;U?
^OF_KSNQ+C^&GKM0Z>WB\$8^+MYKEV3\|VZ2\^"B M^* OXBQ+5=ASXWMFZ@_- MU&D0N=89BS^N^+L5;HFB9)EC6&ECH\|MJ&7H M&

HJZR<IFTB3D.1#2:F1M&UX- 5NG"?N1/1H3.15*RE"TG#>64+JXR8HT*QI+(E(FN495T+&^J9^Y0I/QJB8@V#;:8Z05=PD:IZX=P39I:Y0E717&; M#? N8<.2G.[1C^F1&T!SOFI*EI^4&D&B5F!P+4/44R=+3#M!^S@2.^0 MRH.X-9.)9B^DH%K^Z:+U4?F.ZF4^:3XZ=PD31?WM:.(I&@41)JX1%P%5 M>F>J>12;T:@)Z^IDI=^EK5UIQ2QK<_SP@*YI_DNZ\$Z/!A*0!C!(V6@|DFJ:C^HE!51!-"M4/UJ": MKI@+1^Q=J|J| <2@*H@FA>J#-:C-: 13YR^G6W^**WSM1%!C.KNP&.*Q&V5 M^T!X|KK8.::18;Y2NR0VIXQ0C)I0I2I3Z/4I+HHSIVL:SF/LCAI^8<%N MF^|J| 3I#EB)ILTQ/H=@I^I2<*^? M6IY^10:UX^5X92YI?U37AA2Z4+2/L MDXHZ1>C^167Y.FY=LIX=W0YQ8SIXV^RP.^Q\$Z.JM5I M6V)HP2TO43GY7FDT39>^21W+W7ZYE^/E16WSYMK(WI0R26M MP1IWM23@4LJDITSZC>XIXDP4G)U2-\$4>N&K_LNR&4C1OJ^OP>||U:<"13"+\$ MIAAM2@|8_YL%:V|KJ82@K225ZID+UX\$DK7A^K.KHT7V^"K>37:PW27%>4+ MEKK60-;)^73>^N(= E)E 8AHBY?F("QKZ- DM|A>\$^A:T4\$EN:6?SQJY+HFI MZWEFNU*(H-SLDI@)EOD(4Z^<1C79NFOI0J:E,Y^S3W6B!\$Z\$ZJZ^|_ C4 M4^K)+C91&R#&C0+L.F_GI 8&QF.9.TJ8R1.EJ M^@0X0.2V3EALJMS"E^Y@CI^ IX^T2W@I7;_JML1G<>:91U ^V@6DGL/ M5I4RJ6H&U5S.D)K) ((.E+9X=4Z|I/|>1%=4I03Y^"JX"DCU^S:Y(W6HL^>^E MCN8@#5-2G#Q(VV>15#I/ Z\$XEZAHEA6?#@JCGJNGOP&B?YM^!_P27A)@Y!% M<:E(\$38W6L.L.G5TOK2RBH01VX&GF:XCUZK<*2W^"*)GE+Y?P#154 M>ONZ\$@F*PTS82H;X^YMEBA=K@|\$2MD690A^%- 8\$J|HZ|+B0 MN4M^|P6QC^Y1(,1==>A^)=RAW:DJY0I04;:G07 QS=BEJF-1A^")&@T^M^MW4S6E)H12Y8U:= I^I9^M^|S+0;J|S@.W3NI:~7KWUY^DTG.1T2TY_SD-R MM.%12)S@DCH*=-18JC.+U6K.;)2-IS>5IWG#.\$%HI24C3CK22/<0VBF (W,M.):7RJ\$J I0IUVW^1/1&C1S2>240^12^P\$S_QI7RB06M=GF7%ZC9&4.#K M.^|J|O1398+8/0)W5ZQ\$FKY+L|R)NVO8%5)W2ZLV_6JY@Y!>=C5YV(SO MB/X:QUE1|SJ.06K:9PVF):R|Z+2BBG/SZ!<^XM>319ES&FRJ)^66;JAC M.3.^J^3I<1^?EEJ^7/06;J2 OC1BG^W4DP9FZ10(3%-2? ^80^X1GS:*MXZ02+H MGGBO\$AO)V^V)GY^?P@8L82>+6D6M0HORR.68.2 51KH01XRZ(INK.NL3TB M9CF@:0?ML>@@@THU|:(%1H^JXA: IRO\$8YMZLB(N^I+GYNWPHL4QY^U6^AW MD7(R:N8.::1I@X.5^C:#BO+U2A^A^(\$1,"7^KILQ%"ICOFN^PKZTG7|_7 M=ZWP9.(9\$B)ZO:R^X^?8NQ3.RM(I^T+E1#5IX#74>4#2MD156>3VIFQJ9 MN00|\$4)M=0&;+Z<Z&K^K>=U=@/C/C<|A#-M". M=!*:YB+SXX[""]JSS/5=>9B>...>1#)1\$-070.QI9.[+0DJ]^>O/WR+R/Y MOGLOIXC018T6H..16:AG;_TR<+V- MKE.X:M+2^E<2,2U(P19)A|G&#D^<+C M10?T&@<+P15:AWKK@|YL|Y+Q18^?)CVI^/V.6N("^(PZU-B)IQ\$^N4N|:N MN.R:9!^DHGGUN^ IX^2^P^DE3TQ|X<4^?I4^?GKVG1^?OF>="1:0E.66VDM+L MC:2YGV+L1:EJTZ8-G=,1J4E>-WWELM|JL^HG3+L|U>#7<4J(AK@^I.VSD-R M32YDFC.AW U8:9%6Y\$7DQPM0U@="2;^N8U^"Q+NP!> (=Z@Z\$Z\$VGU MB&UC#K.WP(1K^9CN4Q&LD:2>E|B67W:E.^RAI&4JZ1K.8N^5%1%Q-G?7^C MIB|F?="G&S\$+P; BBLM0.JRIBFK227WD MOQ@&ES2Y^/P150MRU|ANM^KI5P|>_QV|YI.V4=\$D28SJR H1K FYM3M3G MZXWG;S...V^7WKC)Z^<)2G (%:6I+^+VHD;P=AS/L^LJBMZM#2.MEY0H6VH#?R MQ\$NOAZ3^R M.S^1+1^?9^A5-2+^".PO&_91-GHYJIN1C/)E2A6?F|D01A^M(KIA? B+AJG:Z\$SZ|IEFX1SNYS29\$+JL6PLP_6F|L|>F""@Q2-%>7^LW1\$4^N^PHRA+YOTRCKA|RF(NAI%>5.6|IG6>NBIW^Z^".K M7BRPFR^/98^8%LZK;#ZT<+0!8;J_8\$UK.A.N^"LD^"X+604F(O5/1Y3Q,+M MG^">.<.;OD.0NC1T;U Q=2% MM2HRNK4QNZ/V9.3D ?BEB=? (:@A90>75@G06-NID|>L5C^%#?B^#V;L^S^M^N^W^"D^"@|8(F^HMM>E|D R:YK^"|<4+8HSU A7:VX4\$>(76 ^7^Z1\$10#0/IQU MZ3^|=C%)R+B^\$Y^_QO||#X=L3.\$\$TD.' "JCR"7A)5WXW^:S^LDOP9/ ^/MK M4^B.DK|7|4\$|^!|0 (&V:%EP2IAXE^4 &RE"@ : 96\$P.C\$Y M.#0T+3\$P<5D;V|U:F:R2:YH=&WLO6MWXDB2/R=7Y^"=N|6I0\$7\$0>^?IY^M MN^QNSU:97MLU_ -Z2-\$8C0E)H2=C&_HW(3%T "21T06Z9G;9H\$MDV^"R M(O7 =CIL.7.MF:2^SUOZ2+OG1|JCF6#>.. I?P|+FYO ^G^#RBJ|J=?) M;J2|EN+0.1DMR:4YFS^J&GFR%..>F.;O^ F|TF=3!UG_O^#A|?7UPL5KK%5 MS:*VN;4:N.T%X7C|NT*#|L(IFV-)K0I^|CTB|CXW.OV:?'NZ?)#;O^+ MIPX "8 :|D? QS+I6Q7Q^WE\$5UXZ|I|V.D:52Y^W2|>#92/L 7^ #1WH7E;E= MB9 KYG=M;ZGBG53|GLZD^ V?N<^R5&I3Q>OY W5Q\$5^*=XAUQO>-E-R M|Z|_UR<^&%;TV61+4#7^VW@&T/X@K0/M^1Y%TKP:6&KAGT^I^?/S0=O M|JR_X|AT51S@# 2046_(=4D./O."UAYD+N@:<^1V05&5N+| JETZBUR/% MINJEMN7^E^L\$;L2/EQ^X.^N/RO^?/_"<7Z04@P_1J|LW^Y0C>>|(VOI^+2= M# S+X^7;-BH:MJ.8JK>V^J6B_Q|3#A7|E.M=I7:8=?I(MZ<_OGY5^=TIM0@&+UY^=PX/R6T4YILIX4^"XWR^_YNATO|Y^P^15^Z9 M442@#5#.#.# RAOXS_|7P MRUAI(G:SU.E?JQ.X|B.1&G.^/DS:I- @DH>S^E|U@/-2)(+6U297XN3|_O>OHRF>ETMJ|JHK^Y"20=>33X=GOS=69/#X-GZX>? DP^B%HP1_I M7EU^> |AYNKEZ|;S^3JY>_#V| NR^7=U^ WCP^WMS=E|H+^_U/L\$@:"C@E|W_7QO>0%N=WT^QZTD0#5I=W#5^+JN.C81JWBQD|4.4:|(? S0"= K:K@|^C^*M#_IE^/C9U.%:PR^Z2ZB>3>@_7BI=WH2^"(K4|_O+QI6GC0XHOEA>=5L:X3 MTZ#0#TSN|63F/@Z2E/E^T>FJ8473>=D?DCC O"=Z^8|@|^4^GIN6L(2\$ M|.I|W6YU/ZSO|_O?^_I^ZN^+AG#U^W=PO.Y_ ;P&UX^T2>|@AHE2=0^41J M5NX>B-1^ WY|J|T^?7^IP&4\$O^S^KZ5^1W7FLV03(LZ4DCI=NI Y^<= M0SP|AI/G@O.D CB&N|<_@BE203Y6E04E5:PZ<+XX)Z|Y MZ=RALQ&U2+12ZYIKC5;5?1_PLNOX1-|Y>G-Z@#|V|DVEL_IW6V<_TSKC(&OE M0I(&H;\$=(JO):1?U/I/3T:Q|OF(X|J|I2NN^+2K PB|ZRV|UVKG MHIYWAG:AN(CO&.. LJ|U?6Y.F:YQ^HL^_VYXKJ IT8SD^L|6|J|GKRM& M^G|K3H@OS@6_AB|KU@+CT<|V+YH^P%T& J^3A;..D|R M|GS49Y:VMT-R^MRU_&I9S@J^3@#&WMOR^YV5C^%CJ_ S|BXH^K.GMO^V J|JW#? MD^*KCBUG_AM#-2TP|2SO^XA77YH+PI&6E^8X^M=6M9H+KRJEAT% >8\$ ^ M>:N%#(K|YROH)1^7\$SAEM|)%2&UG5:T>UFC.RV7& T6QVFW.A^F62J.QA M\$7!<3!/<+/*OA:798TUESHLY^65D?1A4M^? LENM9I70_LW^7E\$DN^7/8(< MUWAS17Q>#&N9G=7%*+>VJ5^7%6B7G9 "SE\$:#=CB|JY^>+9E#) M%_9^ISKHREW2_L5>S.?%|@ B7#%VHLZ+J_)L@=1+U:#KRZ5OW(GNO.1;O MO=9-#)2S>>TE^IG/9FOQHHC#"M&=/ 3M+YGI2:F0NZL>|!D&MO^"KP.M.GM M/S="T/W>C -98A =*\$+1HP87TW8+@+1/OQ@V E^X<8S!4Y6DBR^18#<3ME M^3/<^_V&#-IS.(I>X551P&Q.GZ4Y&C)IRZ|H8B9+RQ|@3D.QX3^ M1Z\$DM^UW-E?2^&2=:@Z/S>W3T&@<^85;DDB^B^ABV|UH8T^PI_-4< M6L=0 "0"&6HI^?G2)G21J^".B0H28J^K@>|2!JG(PES%46/3 M4IB!)? %S.1J|^SGY_ON7^MDGD61ECTA|5^T!<7M.6)/P6U|^S?&I9\$9R7/3^%:"I^F^RG6E:M|O=U|+AZZ^EO<\$%CUA^AQ%:S- S|K+VE1^M.M6TC^"J^V6/ES|:Z5;.. M TX:~DM1YR 11.%>F>Z&V.B5^*OGJE(*PSK|B|^5^6588_2U_6ZGR3GI/ MIHH-3JT.G|JBZ|)W10?NSX6& IAMX;2J+H!G>AY<\$!/^O^I^#^J|^E&2IV M^#56/9 Q?N6^R^=6U2ES(O).F^07:E^3P/|(8^1^I)JM3\$O2UWU|V9^LX; ML1568420>0WB\$6K&S_9W.US^H;H+O1 ^%>#U^Y^X^":\$0S1%B#&+LR\$9Q_ M<_3E^PTR5E|V1=)U^7^H^LN^I0^*#E8|C.*LU1S)HE7|2>X- YL:T.N36)5_A1 M\$;4FE>1AD^F>9@UPW5@8R6::|VT>S@>J9:DAM49HK^DE^?4?A10=KK_P_M |EC.M6.6I|^"=^DU6@CXSI0YX7.I04>ZT D^6^H^XENLRA=P_O|@+83.|>= MV^TL3M^R.^? =XUQ|OT_EP\$4(88\$FZ|P93.4+RLX|TQOH6:@^/XALVMU|E MX^7@/87H1%Q^%16B2M\$JAC2S4^N%?@.L|L%\$/_<*> 9/#6RQ7FQ^L1%*.90V5 M.#P_-14G;:M2W%!(+|L MM;+T_&_#U>N2^=KS^?R93^*%VW^_ MOVV%+46J|^MPHY\$SSMWV_L9>>LG?& <1JN5\$ZUHC2EK6X0S@WZ:CFH568AZ9-UKUJ^"18^ZRC^9R|^P^*L7LL:7\$(*O13P?I2WSYJP:O MAM<2 U9DHPD2T6RFP\$4#5%1Q.^?7Y^P<4@;>|>:8)U@AJXZA-D>8JY7VH MULL_1#><:;W|^1A+?/(2,K<7%Z=NIV^A^*)XAL7IQC)/&AGFF@Z|C\$7.L- 6ML0D6-22&1YU M^BOO;+NTN02# E8GH/+4L|U2SYM+T3H+JAVS<9N&%"%:(5&\$+5P#?:ZW> MW%ZO4M^%8S.ICTZF+2T+2^R=+-OJRI^ |6SA.C&\$>P=L^BT>9W|T^P|QID^IA MA^CMZ@>H^U^W4I&@;L+L|^X:?:>WTO6^6V0#2?ML &|V0^"S_3/(07.F M^RIG\$|SXYX(N^J|Z- M&5E4^5X? 41|N@^S.5A^KQ."8^" |N#W^*)C|:-4AX^PD|I(C\$@6U7E8^ ME\$U^X^_BGXOZ^TV^+OKOYNICZ3J|O/^CZO|JNN05P_8/UWA_@3(%Q|^4 M|OQ:Q^VH<@ ZREC6T SJ5L7PC^L(G^%R.IE4_WP.LU++8G9BV1E9FOTU^-:(<6R2WR=6?^U9GHZ_-| M4@H|U1Z0801|1BDWPKI|N/U^&I9NA0.G6&UQ11^WYH.W.R88N|QE+O+3|V MSCQ:; Is+BH^DF\$+UQK7? U4.Y9DQLKO/SLQ6/5I9 =A|IX^"CZTM:830=E M (6\$U|@-0.47NCK+O^W21&2HEPKQ.)I-1/6WG90:KYR>2E|R(= _1W=V?& M6^YK SN W#2+DIM^G+G+SOUBU|8\$1T^|X5@&^RHB|^8L.FFO<#BCN^(7#BB M^XT|:9WXM(IN71@5N>LW@MATU9!^IE./IRITMW^W.W|:IMTR5CI\$K\$YR MVYI8&_1L|J|WXS|=X.9W>LB+&V=^1.XR|J:MU9^&V=? Z+^B.R^9/F^I MC8?V15KGC?K|N.8 WOFMZW^&A:#15I|^Z<^<I|N>W M.4Y9H(9F6@/^?/JR?)^G^O^J FMU|U53.HT+43^BHVD)@Y^C)|F@|!QI- M^&A^84@&^YV2N^%N|3 G2GM55W|F&HCS3FTNCS.%GPY&3^Z\$E ^*| C M\$;4G|8S0^|L/|^1=RA|TZ;B=S- V=;K1WRI.U@|\$.Y.C@#\$;9D>^O&; M^X|YV^H0&RX>|A\$|30@C^6^4HN|A|N9\$<71%TIV28>K M|G8 MG^U06^N|VP+\$\$^*^?73WXPX? M&BKD3\$!WBYV^4)&D.JOZ&8R0I-JVKE|AS9RO.C^>ANG=3UB(|\$S-A:T88QLG M65-4S3A@L^X=&%0+A2)G=|7>|I-K;:9Q%Y^FZS;@:3^G MZ)5J\$U_||X^3VJR.TQIWA.%RISDWVIB+|8^/8^80R722Q|3U^+9CG ^W ME.W:X_AEQ.=_%=I0T(2W01=)R|3:9C:KS8|ULN;_%>V:4\$CC@K(KPDU=-:(% MXN^CXQ6;:(@|3:PTMV|T>(VL301=%Q5|PTO6+HG|=I6775.;JQ|7 M^GW37Q/7^"Jm9#10% CPl>+R<^T805FK.MB|O^K^CSC|CFH3^&Z|N|0^= M216R<+;@W_!\$#6.#6#;P8VQACU<C^G|@V^MU6AN#1^>+Q^X87L(55)D0WB^P MPKM@8V|J9H8(CR^3L25N|X6|_DYO79@GW;+1@E1_- N8I4CQ1?CISE|4^QC MT+^"0M/M2CMIN&OQAT|^<C&%(B|A^=2 U: ^U6-R7F^F^&-D^Z3>_FK3DV^~6J MZE1A1S>+/. |3|T^3N^P%\$S5D+D<^ZC8;0-U63>J|L:G8^V2=^"M=7K%"40^M^G^K^WZ\$S1QH3^F&|^B|>9|9/B8_BG)69YL_KOBZP|VQ|/3DQ9:0+DOSV^#|K M|K M@K@UY<|<#M\$1^R(O&:Q7&@W BP1#6B.*OR^*YAZ^5R>JB|G^8^018RA\$C M&Y^D^MY&UB.^1Y_127F+4.E- L74S^L|P^CM|I)PG.M<A|I9T|Y\$SBHNY MTZ);&EV1#=:7:3-5V=|O-O>B6I3F-LJ9|AXOJ.9A|38@":7|!VL\$JMU.V / M5B^:%8.>C6D9? 2.19#CMT7L@:_P^31J6\$N>+F^Y2.A<=(NZ5Y7^ 2LPY6I^*K_L<2DAJ|=NPWY?F3U^CK@REMM4J|6Z+?0=N MOL(OUSI80-)? IUC34^):DAID:"%31EC^R2985#B&.P?^%S^>00I0%, MGJ@UX^M-KF2^1+=B:KQPN6_-053AJHE+4\$K9VH>JX^8R-A?@)=(4.L8JU4GIV&*2 MEK&8K@=,UZRUFN=RA#I^G66.3M\$P2^M;|V|AUK9C|S|N KE MS6R6^IB#JW^"(QF^&O|Y^N7FZN7HDP|OY^|I)O_L^HZN^1F|G_O|JNGOY9 M00R\$^IALLR1N+6N^2->+Z^*|0T1C|J|B^7=|V4-C2&0+^J+SZO@<K;+TKIW?7%F2+@JEQE.K.9XQ# MEN|N^O^4) G5DIL15817GK+24)7S YWTY:"/S\$!\$< MNSJ(46-6 E/ LM^<:|OTRTB/E^E7_JN.5|F(1ZF#&I@^FD|&I-TZ|! MU:9J:MI^Z9TF^|LR^C=NC^*GX|ARK>IX^|3.R.V+1>UV==^I M=6)4>69\$|7.11PGIO-R^/IX=4^T^A2^19:M^%90U^Y007Z4^9B^Y^|/KMM4 MK6L ZE-M^P^9P.2^W@/O^M|N^K^PY|B7-ME DPD%YP4A|W+6R\$|7C49# ETLVLAJ M)+ZUNKF|3CHS@|^SODL|WUX\$+Z^8%X|B<U+&1W|O.(% M\$N^&MA>Q5I=M%\$V_9.)|.#+^"MW^|=V% .%&BZ.(/ M7|7&^7YE#.2^P^M05=79IL3^)++@S.\$L=F|Y|DZ> <_R.Y1+Z7#|3_&I MWDJ|SR ^N_D7>\$Y^*XA7KH^7W83LZTDU^|PK|^D- 9@+@X|(WHD&)-@_2Z M43H513T|3YVM3^H MU^4= D+G&:XNN2|QX>Q&Z^D+FI5AED^? E>O&9;Z/4)OH5.>^|S:Y2MV2P1K|XBJA@O=W+V%+/_SG0A^*W4Y:FO4DW%CPGP53")?NG#HP^ON-&I2:(%LEI-7)@/S+C<-M(+V>V|3M8 MQ+1/|1S|@V|JC+=9\$U^=E)@|J(A^J^+V4)G|V^Z4133V^48GXRT=13H M^&^|Q#\$")^<#>9XZ|(&=@GAI>L85%<#1W^JUIZ_&W^|G)T|_-)^*<? VPI:1 M1JW4|NSVQ|OK=HCCPG|>V>1Y|SR6WY5P.XX|I(8UB-70^>Z1;Z<#24Z M4JFFK^Y^*9 I0=PU JL.V V5R2U^J@SE3|K MH\$;P)FGRBCP>>|KS>WPX<:@D.^VY>R0WMY<71:HL_+2TTB7_8U\$ M^CTJA-E.T=3.9@.6^MV|GXA\$&=J+FOQ^U^?Z@4!113LO^@K|<_ YMSQ75_705YV&3I2MS&X3>_>T3>=7& MSA2A:2S.17XV028MT4ZG;_W|W%QIQE^H2-NH\$L4=C98Q.WCTR^K^_FL MMOEF59E:8YBOU^("6UBYM0QS).H>Z LU^IL3.%P#&7WGEA&X.9|TJ4:ROOQ MO|BY|76012;5PL7^3K1PYDBCM3M3N@OWI? -1.X>^*^HY^X.^C^%VNLXT M3\$|1E\$T|^0^DE1K|W8>S|J3.3D9I<+HV.6G<^1/QO|TIC.P)IZ-E.TRM.Y MU9NR?<|TQVG|9H=08FCQW|V.=_8\$ X^V=GPOVGF&9CQ(RR|J-FBE/L J M35 A^H-G5ZTLY8K+8BS+V^L.NB#1_6.I^RN^&Y^WOHL1HM1=U0RO^5ON3+ MFX3SY1NU9N130@I^7^IG- 00.X.3Y3JW?^VNP+^W^D|9|E0=J452IQT@C^| MU|WY+>T^?6X|6=M=>I^"R6;I>.-@-@|YUYIH^"J|=H.O_ ^WHIB0:7 M|X.25K_&R^G|K^F|Z86\$ZX@?)72&K?="Y1%|I^84G.N|Z6>=(S^A/VHU.K M;F|PIE-&B;

MEI6VIR9F8D10#-6<4<1>DE;QOM3%R;J2\3/4^EJ3036\HON7J,7(VJ3UYM>^*3*1%O2ZY^=="K=9L9>D&G3JYL#.N>J)(C&8;/M7XKP
BQ5R&FY2G8\$Y M^F^WQ%GIX(K3/C(3%DO^EZ,GTQF8rVZ&WV,9,14=P;@YHR&W4.#&<(%% M8#*66S1G6W78^2UFI#N346VJP5D;?
SP5SF0VO^4H<9;&R4J%.TS?RD57662# MLU2>:2JDM7 FV.YA3T>PWUT= *9H!GFG@V?^G@&"&9XKUG?(F19NJ^"X!-.*@1
M@SK^JH^>BMZL!;SB19@Y^J^JB1031Q1>IHJQA.=S4U+L98W1FE6B:RU-A9/ MM^&R^*T3NJN:GW@QBW^X:@!+^Q\$AB"@M#; IJM
M%6L;1W6CRZ=;!0LYH1 MT:HX+2A%2!^C^+143>.*U3K?2!;2UA37&1=;9UD;1. M95_VI7^"ERIW=VYTC.QLR-V.FJB?
VHW>3ES)WEWQO/I4/E6#.C1IX=!"Q"?%T'N8H@.GWISYF8G_UN/7S^K=&F8+4ACD+ M^YPN;I(3&5SWG.=
I:K%C@P6>@H<^AYI>N^!C+.%^JY6DUC=H(RT)^X+9K@X: M%Z\$%62MY^GNDC(Z372IEB;1.DCKYPS%ES%;F\$=Z9K3X\$>.A&:V7I/KT<(R&
MQ^Q>M.;+66T>D!..S<25>(>C^7:F&S&I;(258E;..OF\$_.7UA^_4P>Z5^H M^EE;#P&R!&T Y 8/(&^/" VN:F O^=B12 ODY1IEG8(XT:119>X1.?C?
LE9.A=V:(B8\$!D.WJH%UKMN# T..T/& M9IA&^!ER5U8!YC3.607->DDJVO MT^%19X;SY12&3ER5_HIT^Z\$3160?>34
M118LRFBI^N^XU^FOLG@IIF\$.H.WG;(Z5\$455SE.E.UA.^G<(V<4P@A3A^&QE# M^N;H^XOKTPTOS%43\$=I;/_X^L^SRJW\$57@H>D;/_E+O4ZN-
J1/YI8/1/M^+^1102422(O6ZN)HI^WY#8 @^V=;>@ H(S;^*YO6;2#G^T^%W9JL0;^* MJ1YKS9N+1
(!@8\$^H&J@>^XNW^WR) ^TG,^"AY8RT1/Y194 D>+K8FXD(W M^72P^08EA(Q^KXB<+7R^*+J J(@AZ^Y^X9NH/_=D^*1:P&_10@HJDA;|""^N
MPZ2H09F_5^8:E3^.;.9H+I4 9Y0_3YINQ-I?#AAOQ^I^7SS>UQC^3FIO^B M4\$;#2XJ57094\$7DT5- F/CBG;YV13/(QU3.E3<> &EJ#
W^IM;4G6>ZK M09KX?2^*3P5^UJ77A!#^"W^O^>VYXKJ_KWJ MZZJFKBMS&Y2^J^ILGX^Y=VFCIS L8XTU>C940W\$SV124.MRTI.E7I&K^0LLH M@.
(B^"HJ^IXOXT;S!E8B74?>6PIL?R6^7I1H>J2G.T@B-D-O.G57:(1SRM# MT \$8#BGZ+R/KPP^L6ULJ9GUEIC+55:S1;Z\$G2+J3S;M.I.)
<1:PH+6MAOSP7S!#O.T=6BIMW%\$IOIZ\$3#B^L>U-X(H;S%&8\$!\$G-M5S MURV(19GS1\$++\$IICA2_008?G?%JYM_CO.^9?
W..&12YAB;XC."S@CA^X5 M1+I4 4PGFIJ=\$9P;@MT.^I^X^I;Z.7^4^"MMGNX6W^L;0.QO:V@>D M61M4I=RH->4I5.6QTVTV3K%&
I8.L13:8>=:6>#A0IKM^\$Z&F/E^X+?4. MOIDN.2W06.6\$!\$I3U2S^% M9X<I5&+&P/L\$M?AZ\$8^3;DF-
79^7V5GB/9Q.42;.&01_#FMC!#MO4^*YYE M)Y7VK.NCTU"=TC%D7.BI18.KIG=4E2(PM)^M/^PSJDD;6HJ;+UV_YH;Z M>7-
JW&112J26(PUE)UYB/I^UDQIE=-G1QWFER)ZNE!>ABDL(OCTF%)15M-G4NK(OIXR 8M8BI)CQD8#-3DWN)3_H MYV3(GI1:XI4L95^NH)2
+G>;16HG\$=800<(4H9CN\$)9OS5=O+C+M91MXZAR6X?2^MYGM M>*AC00SV<4TEOGWT^*3R)EL0-
\$.N(L..I!"Y4560F2)UC@S?^IKKC1@L<I^H+^C/T;:W8A^*#Z2XX?#?)NLM4I^OOL^&FNNH M.+FN8+EJD 1Y SOL))NMPU86\$Q).?I!(4*3KO=M3Z^I-
:2EW8^Q^M0<=KG M^*3T^IK>64S<.)LIDIR3VL_3QO_U.2ZK5 MBMTI37/@T3VHEE:POVT_//ANKW:LW&JLK MT>W160K?HNZAQ5^4JW:S5I
MG@>)E+I972Y=F_IN^N(QN;.&=I;7F6^<= 7@>^!C3.XS-PM)^E^&AW2^I-B-DVJ2CJLM(%(I1W6?>289SYQ 21&6P& MSU-V5G.XO). \$!^4T?
9CLO=JR^3^K8J5IKMXC-V)3^HVSXQ0_.P(=5PC M-S8\$^\$K3YV2 3-N<H>I+J@^ OIGW/+DYS)JMS<XQ(IJUC^&E)BGA. MENP^
I7HV=IGG&Z2Y&GY1P6/K24D:9^<(K<@IAPMMR:BHA^FZ8-1%2XM7# M3Q2^1A95OM=%0.^?T.T\$MA."+(UB\$^ D5>8)_SE07AQ^3Y%3XJK1X-
K MTR+;E);S:#D\$S^Q!L.K\$EOR#^#D^OC?D4I^I&OQBBG1.HA+OV08>7<_C MRFV(98L^M^OQ<I)(Q-
%\$KRG;#47:K/#W4;1NI=I^XSO64V(EY@BGHT^08RU M2634T6\$N.L!^E^U=I&2;"16AGC?WS6\$N..PUBMF(N.V.Y2=[^:?
X!#OF7IS#@/"1ZN=\$706\$>IWI."RI>_\$.J/ MS@C."LAH^ROV^9FO:2C-!3%613Y;>R^BI5NL@A2_!RBI;SH^JE-!#NE M^6%"B.Y!CFGJI
6MIJOUQI\$=SYT^5J^X<=<5GU.2EIPG^I7R.^XHLA^GC16T M.T.H.FBVDRGLI5[9;.>^X)E:U4_?@9^RR#)BA M7I(U-4G;3WV0 @I-B75BAZ+57;
(HXL19+G60DJ4QI^>N0G<@ MGOS(I-CZXCR9LPS27GF)DL.AVDRGR6CM M.U<.\$4<0%-VN=;0I9PNV0E?I?
S1!)3JY4:IXOH!V%I?;FEF+23@P(P'+LCR M0?8+8Y_>1ZADI^IHS.R9+JX^*(6 M?;/&>92EFK^U=B9W\$V:PU&[MW=T^6V ?
4JPA^ER&JRM#W4W0\$JAVN55K-Y-=>SW32^>57PK^U<N^28 M>8.3 (IRW-6V!>X0I0S^XF0SDFHIA.5.RK814:FMP^<^S^9DT\$S&A?OL(I1^A
M/GJDA7E(5.;>+&-H!^JYS@:_O8DFHR(+7K+&S^YRYHN^C#^J^V1_?>L^ M^9SN>I^T/>WU1LR&=T%GQGZM<.;1T=)I<4 MW#I
O!)N0^J^IY2H.O^A&@PVPS=7%J2^O7KC7ZNI?OCY)X M0I1_SQTYP^MUNVBXYB V3X)^%MW&:0E.(QCO(!S)ZP(I01JHOM.D7=Y# M*=H^"0B-
"DI;:N1SXI8VDV\$&U XX2D:7J0 (7HI<ICXU)JB(A=LV6.X MNLU-196I7F6R(FWZ;2+UZ; 35HZZ4IKS6V6B.S&1_K76EWF4 9.;>^XQAI^ M4I?Z9#
I_0&IA_(NGI;^I(L.L?72?>OF%22K?;!&YG8TPE6FC812 M2I07T^6&6%).T&I/(BDI6\$E55@9RG;D(A M#\$WR4=I0)=>(P+>Z3!P^9&IA?
6.H4GI^T(MY;?6NVM904I90N.WIT&?Q M-TI7Q(CO750^K^3-I2CI^W0N\$%.(NQ4W\$00V2&YV:WV/EY4&=S5-). W8# MADX3^ W5/Q>:A6&?
I7RESM01^69^A.;>1LK!>=N+4EE:KUNH?M18M732_M@PW2;\$.L:%%!_ WO%8QJ4ZU!>61I^DS8E+^H=IJ8RDGB?YI^DN122U(QOEQ_M=MQ9*
J)L(L^7Y3I0I^C:W1F=#WOK^SCP3EV>B M<I1GE(6CK!N=^UK^M+N+65R>B4YUOS64I0AOTDR8W^<=I^I1GCW.LFGN+I9 M8>NITJ(I2-
7.C5IE2I9F.8^I^N8Z0T^R^2^D&4^>_8.T723C-VI?PYGFM.O MZ&I^HZA.^N<+>+<^O<2_-70W6 " E/PPCIA^%0%+?2
X)7F>#+\$IU=;Z393I16K_?IL/YVZE/@YZ_YE^*;X(^I M8^KG-YU^I-WQI(V&5.NUDL_I/M-?Y6>9B=Z/R..Q^V>^ H0I&I/E/[9%2 MHJC83^*82I
7.4P^N8F0_E=-8=&^&PK^O<.;Y-\$.5\$Q\$W1 3#X M^O@&@I(OLX^49I.6I_KF@ADH_D@ZIU1753(CY M^#8^0@C^I^IAS \$9&?A.2N#S8P<I^VSV)
>7YB;I7^6MIFB3T@&#B-@^* M^W>7_(DI+>>P!&^EC#34U^D">9HN341ZW@B@31_?I+P-^HUKT^ MHJ
VX+ESANX@L)T08!&O00P%"&K^*.\$O#^*+Z_!FC^WLA!^4V;*XU&I/E/ M&>0JW+^_I_ OOMI<#AJNR.IW7SI?
W/IV2&YX+T^*1R&IGLOEYX^N0PH\$&H MJ0VLG;U4I^FYULU7NV^HW0U\$-L^X4W^A0W^AOR_RJ>^>N5KV?5&OC.+H\$KPM 8_>^*YI?2
^@ALSFJYIJB5?K6E3FURI-!S=QIOJ\$R^H M@7VSE^TX ML\$S-TYW-+8C5A1K^I^X^YQX PIZ@PB83RYPIM_AOG%)H4^NBHJ62IG_<(^>^SB0XQ
M9IPCR!>B(FK17&G0>Z BA5;I>I^X^\$U=7KSRT.^X7PO:X0XC!^@6!8RI&C@M MAI 9_!1_5US\$+>#?!.>0%1.1IP- 14EJZ2=F?#X?
WN\$OQRIAC^%.WN1-L0I^H^9^O2>@ES6(=B9P1XZ2Y.^ZL^\$AJVIRB(I^NMQX9(G%F7UP\$G<I
MX#EWDG7PG;I8%MOX^P^*QH1N0IRQGW^IFRC^@%UI<@&#&@N%KM4H\$+O& M\$=@3@5)UT.H5)P+9^<#C<_S?/8?P I#I^5:I^T.HI&O^I
&G-HJ>VQF^J M^PI_ALX^MVSHAGO>1X_#93K.^4IVF I5I8N1.IZ:F67;LJ!>:1V@I LI_M@W5CHN?JAZHO."EYTRI02ZIHG.YI:E6.N:V1Q4^G.
I8E&ZQ3OZIU%PIQV.MD\$HRL^QSI1.FPU#EEMIOZ^BK?I27:Y(10\$_.P^GLI^M^I4#6 M)24=)T1F^Q6QW^T^OLS^R+DDISTI^IAC@-F3#5I^5^ZLXN!2Z
M.OZ!0>36RP?> "6E4P.L2_ UNB102L4S1^."X7&(IGF6FRUW9H6^?B9^N M^2--!>_6Y.U1QO^P:%%P<.;\$LPZIV^);M^1!#<&^J.Q?^?2
_WOA!+ 4PG MU+>+H6.PE#(TOI_K87D.RBXISEZ5;=.M=KJL.B^Q^E6_!#0SFDO;R.L@L^Y)S(NDI^TDE9EZR0V/S+>?
9GEL#Y.A\$90LVU8MP^9F@> 6ZSLTEI8 M+>+."I:8PSQ/4K9#WLX^%I^T^OS:CUU+^8#IPA S&:CVKJ^*2C3_&9WR M0VRSIA.Q.ID)
^Q&J2X&#U7^&I;Z(N+ N^I^E.;4&5SB)5IAPE^I^WPU MI7T^2.UB^E@&2+Z&U^!"S<=T4<LID7_F9L#>@I6_>_>K(D?6^I1I^IV M:5+;
<0/I154^W7<= B5U;5=VKE=;WL=<=98AL^I^G6G1OZISG M.JI^J^>J).EK(U^?Q&IRWS1I03I;_+;X#^@>
MYZ^7B8XIH&.WUNIEJ/A3)#K+6_1)^F#RU3^9XDCUO)OL35T?)(%6K=LI MI=9OCB^2^T+EZD!NU=HOAN< MZXKA !?BK-
YYW#;97A/LFU3\$;LVP5;I.AX?K^L<2@/I^ H5CA3>Y.G M^XGY^I^QOQ-N^0Q?I^GLF^I^Q+>L3#5#M;@&@-CT;H(I@>I>A?F^T2ZPIH!6I
M5;@P%>@W>^MP>5^KL1HG3^VGJLNBK&+^VN9^A^R?2^JESWVI_9B_!P:%%>^FQ4+Z M^2#37;Z
5/1XW_H&.0=6I+M(A1^&P3.O=9^>2MB3T6Z4US&^&^3TJ@ORLE3\$ MD90%JZZZCO:&A+DA1I0!F\$^%L.OCDQ7?
U9PP@_UDNG7A13@=BHN/IUKW^XRX5YP14=-RX2PRL(N45AXS)M5;_Y5; M\$JKBJSEVT^IG-4-6G.XV/UIU^4 906#6^&LKN7.U1@W^F%PL&AT
M82WAI;Z>C5;5P?^8L02I1CAAE!>0QKDWK@WX(I^9K&@^?^P7I_>^9XC1@M.C96DI.IH8OC.65#^*Y Y2_O65L^M^W_LH?
@I^X\$KIZFF&>UCAI0Q#^PN8S/B@.09I.JIJKWJ?>Q2+2IM4SE\$+ M^HX6NS4I3EGMU;IIC5G-8=LR.EL>);0UJ+/FF&@^X.E+PQ=1V^3MS)CIU"
M&\$O.81%(.?>F;=>FINS^1^G_IGI10(F7_W=V&I^M^O^X^CJNW6_M^C-O\$QN9BI-8I^F>D8&DCLAS_7S0MI^D2.D3IG<15@I)09: R(
M8P^>?^T63QH&F!1I5IY-T0\$P@!(E(B^&@KM8+&V^YR_U.KG6 MJ#I^2.Z59Q^I1I^NU%>I1I(EI;JXFDW0R&0G^OKOF^"4D0G%)RYC=O^S
M7;Y6=6.QIDJE^FO-FXOT@I@>@>@>^J#N^BI<?2(GIK2>.V?H#>+;"0\$61K\$4I^#(M^P\$QI^O@>+&GZ^*X6KV0V^%3_FCT>@BIRJ^?%E^-
/AI_7F=0AP0WZ_+^Y MYO:W1WIS>PD2@/I1AIR N^7UT:6GA2X6^6HA<>UKHT="18+X(IINK)IG_IH MCN^FIG80@I04CX09I;Y1S256M"-
TZ^M9I40T+I^F0!P#?6I2&=2FB:IA M8K_9SYJMZJ;IL@3O.I7W52_!J98I^N^OQOGC^4^WUR9+CQ= !9+>@IAI_1D6 M&E>
>>NO^ULS&U7^H^LL9C<1W4T=SB8WAGI^WCE3I/U;GRZYX^I^TOZI+V604^56QJ2#&^& M.V.3W\$5I.) (U)=F>-O^HV^+(05!>=0:G?
Z1+XZ\$^!>A^X\$6FA029@7I?D\$<- MK9:F3M4\$FY^>.2BIRN^CU W^*K) O^&N+DCU KIF^7OX0+^I MO2-
WJHL2!1%.PCU@C-.089KIH^R^GER^7%X W@C_0^2#28;I MQA07I^P19G^*Q^*6A0V5JR^6_[>+Y\$;LKR^648I0^YA9N A@ EMIZ3?B>U M7C18"
I\$7(IU;XJUKI^&2WS+P-E\$L.CFISZW.#(A!#C@SGIX^XDV866/<#8 M^*+SNQL^*00EX%Y5Q-370U!7I4E+I)9Q1S@_AISP<>K^#PN9H\$^&6! 1&U
MD826N7B>AJQI^%55>=ZYWH=I&CT397+I_O;=>I^J_9IGC!>Y25OBA%Q#900QF MU8#3GH\$!+I%0U00R0S)2CW#TWA8+! RTI.M1I^F:~C(
(P+M)H@164#>Z6P\$G^+K0>@QZM)JR44H2D21I^JWQ:@3.XRL.GX&5^M.R6:~8L^>OBA^L1:QCCL^KIZ&S\$S^Z09K0MI^A)7Y54IV8\$031^&
(M+IG/M3I)U2^T^G19E4G.8GE&F=WM3(9^8I@QO^EQ.YI^7%7ES?Q^M^O M7&OHLWC3V2I^@L\$YB;G=Q.V@LIE?2KMI^?)
RJS.80^%JSOYSNJ@Z@^! J= M50-KI=6%0T9P6PVU&F/G>:!.#70BI(+>C0?@H+@_).3.6NOTC79BOR=T?> M>H;(EVI10I^9ZHX;" 4LB+QVP6^DI?
^>^!^X=(IJBJ>R^8CBAN(L4&)KN^ M978(62@MOWG.1.V831^5^U^*;\$Y\$=>=K1I^B<I(Q/S6(N1%.?>D9FQI3RUT M4\$S\$+I^5ZS@%(FZ^AI
^>I>^\$AS4H_&X\$&S.EA)PLBGH(R-6IKN^ M9_O^4S^_W-&S0=">3<=>KINMD1>@>_OIZ\$^T-U+>+^TL+&E-INJ^N2+31XE.V^!%=C\$ /9 ME?
I\$R^A%.*M;0GR\$^+X&IAI2^"O!T^W3^*)+I^ZLT5BD:O^&I5^5Z\$S)BO MKDNZODDUJA#P(IC^C^C0P^V!^P;0)G=7^Q&:(L\$.)OIXYB@I^BM-.%?F
MI&^ZDDZQI^UHF^I^Z^F+I^VNIPMTY^J^7PD+2:6K3%\$?)?&@4(T\$8M2(I_J# M^SQ^QI^&E5^U^T0R!DDI0?&I\$ID44IJN.^I(IJ0I B)XA^*
H0^;HHD.WB^W^U M7VQ@T4FEXD^?+;I^NWA&^U47/I^DLKL^I(DH@+&I VVS3N8>I?2DB?%O MM O^Q/OZ9R5:7QS)VFWB/38I^1+1 M<2-9^<-
F036^IYD&EKH)=UBD;H+I^X%MN;+;1+TH5839NZRD0I_>2Z^L(I>5&I)SKV\$D_>=20I&XV(M2^A9XXI>L^I^>I^VH<0 I7TEE@0A18C7;G
ML.870).YL#^E@=R(TP87QMA>_D.M_V^B@R:6Q6DN88Y M+LQY;I^YX=-G%IG8O&=).#1\$IB#ML.344E^3IQ73X^P(NNIT I^@W5L^ M0(>X-
^9EEVKP.5<9(L.5^>N81(B^3N=X+S^Y.Y@I%Z4SX^+BJ+O0KNJPGE(OKP8PW30;.%5_Z.60F\$[^XJ M9^ZACJN.L^L+<-
^GNHRZ^OWN^QI^LE3X15N7C3XEV4;I^ZJ;T689IKBL M6THE^56C.XLC?2I=(#I^ZRI/Q? DR2Q0=>8I^XCDZ6FE^I^%VYMR)-TI^ZF MI^P+
I9G>H^8CN:O1Y9&N=EL.Y4>B(I6=HWJ7IWOA7/G6S2J@I0S3331)LI^K M<^Y55K87SG?Z^S^NTO^70^W6F6_#O:L40MS:E.INK^D(E/W^N^:KNA-
9+<+>MID?I^+&@MNB< 4M_AZ3TIX@R<=BOV?@5HISIOH=?F^A>D/^>CI=<6\$!<0%CHTG.^LJO?I^U^NE8S.^6^I-LWAL^ED+9BDNB^*..NQO
UFL+M M37IAI_9I188EC@KN3BGM&(3A^2 D#P(98F^HOX^W VJ=-W\$C^"60&IBK&^/O^T/I^J+>Y^KOHSO; MV%Z5MX 20^"BOFOTIF0
(S\$Y^X4A.OKORB>=3+NR0/O!PI<~L/I1I3@C M^6X#%D(MS5/1MNLUKIMH.X FO4237^*)>Z8ZYF^IX&1 IV8UX\$6V?49P4USLKM^&P_M@>2 6
M^HTI^DGYOMI^ (W M^7#&#SP.)>4>TF>C5O-IU)D18\$SR4C+2HIC^Q?I4?I^8_9."S1^7AU+ZKRJ;#E=96-
UI\$DDR=OF+I^TW.VV#1XC01XS6/IR^XIMJB.X MF^EV)93_YD&E+^C.EX.YR0N5:H\$J8Y=I04!Q%1DAC/H48&NXX!)&LVU(##_ M<&>8CB=^F-
+%.G^593T020<I\$>.*MLI^C8A6Y%0L?CQ7&G^\$A_&BNP+ M2QAB<+I^PX2RL=^?C2TD@>NO+>^?FZE.(F #H15W1E7^X9H\$JD:KJ2%TRI
MXZJ^8H.41#D&4I7\$20:U<~JZJ.X>+8EG5=DZT0^HU D00I^H\$QAB^Q^N M0.VINO@Q.40_UH8^MJ?# HW>8^7JIE."B/17&MZO^74I61LUD/MU
MS!)= YI FM; 9X.QL^1BG6@7@?TQYI^?8-#N23I^N1ROBI^1H<~ P-WK(%& M^HBSU9P^U;DI+ V^+NIAVJ^Y^RM
#_XH6IT=6E^+OPF@>SVX>E^L2?+ MKR.BH4:R0_@1^I&5YW?)^JXP9.6^3ZQI^P^WO M0I70TG;4(E5F6YI0#_ZDGHY1D=ISQIJ
MU5_A7FQDA=VLB^?K?^..5A^&^U^R-YNHWHY2G^KAB7>=I0AEFC;MA^>^>N^K M6V^KJFFUJH:5^W^-/U05NFK
BH;50^D\$4I^P3+HIJ4E#%\$-->W&FEG0 M0>MCKQ^P3A+I(Q^SYE O^I(CA.B.P^O^M^I&F&J;2^>=TB&6ZB@T^:IYS> M>

IPP5LS:T9@A6R4CP394[|B)V&K&6"D8I(245 |2+TD3 ".W K02\$6(ZAMH M;R8#Q2*7'D.5P=QP MC;O!C^KBKG%81LN
MOA93'DIA_FIF^;?B*9L=|/;&H: J9.6%|Q\$T.6=|3WLMJ|Z M81^ |@6ND7Y QDO++|!\$HTI-U9@54AII^|^9. @|A|=4>"F3
MOO|R+X&"U9|OW6C>.^879JW547|YARFGMW&?^*^:74)8S|AK.O\$47X(0ERO M2T'AU8#&N=|2JNH&|)PU>+&H!6)Y.V:(^&-&))
(U:92L<:FFPO? M\$O>=>@8@M(Q.M:|L.P.:+&V?F MRX. "R9|4V#5CZ\$O-20\$B:8|!>^L|@+&/3;1UIY|6IL\$ DHS1F^3-1(B38&:MEP1)&"10|.00"L3\$-
ME>UE2PIK^V2_ BJ_1N|?_V(^>+ME|3+SA+V?OBM^C7Y\$4)&T8X0<=(1ZM_S\$740RV.^3NK&GSJ 2\$2=\$D)5>209-1|Y|_56ZF14.->%
MO^OAFXA8P3%QXNID'M:~%M:6<\$|Y|J|DW/ <<LWP>NX5#&(3;3E)UL-"O&I7 3.S\$|A9Z5Q@|'Z:=%0B SP4O&L1.%F_QN=(&L|@.\$"+A*SNA(6"
(EMLL7(LA7W)E6Q*F012D2\$Y8UIP2N\$@ZMTDY4|BTZ0 M.W:RM.&@?U|U"1|X:B77Q\$C(^|*!\$N^NRR;K7RA|Q\$059X MQH5|!/?
=Q+&4EP|&5M1"N)8>B9A0|4LXFE5=CR3RT6"-F1\$L~%:Y 4_MXC<(&|)MB1>
<"51=RUOZ?TV18F12GUBP2A|>:6|A#^7966 E=59>5576-JA M|S2RCC|<SL>MM2%6X6VN'3|S\$5X.FNG\$(=^G8DWOLF:6C:FCL(F-P6KR\$P^
M^D.P9| S7N|SV|23HW\$|YR:0F?24|537Q2\$1?ZVBF82 |.FB MNG|GQL^K-G:F>+GC9|V-5|NRMP& |CIK;KC&|JPG39/H|&FEOS'UM/%FY
M:L Q(9|(N|8&Y\$>#"3%AS:O ^L2?9|F.L-F5MSK\$~.J^>+J+X:V45| M6IMX@=? 6A|JH.ZDV_L0W|:O\$G|A-
|I|(04P1.YF14K\$?W"AL:"&+8^YE-^%0+5+=8R2P(L-GZV@S2:1HKU+@+ M TB-9W<3%EMCL^SB%>P|KJ\$4|H9EFA0L=K%M,F(=7PR\$|>GD7-
"\$M:~Z= MN:F>G:FJR*_|@?K 3&^%CU5@E4VBA0.@.\$"!*(.NR##090YKTF:CA65OY+Y|
MEX2|Y@V\$X\$K9=0JA=|L:|Q6LZFE4EM9/C|B|9F.S|@4X|819JX^M^ZK|3UW|2XU7D7P MTXY.|LPH(^|LZ\$|J|!7:(?+&L:FSL)=
G4<3^"EY^+Q&@PH+&P2H)GHT\$ M^|<+U^N|N|O&+YC |U^"O|WRKL+U3|&1D-2|/3BN08%8G(X/FG#4PH
M75\$|O|2,S7)WFW.V'5|P043")/*Y0>>:3Z@%EC8|KX<^Y.RBHZ|FEM-51R-0 M7.M6^W@1D:|&UV4)W%|(R+G_N_5X5CV\$O9KQ-R'4)
I=4Z|J|16\$|CU2P:~|I^"M^R1Z|6N|J|E.HXQ=W(HQ^|I#65>2FR>|/8ZB+Q2.7S|58J6PZ>?2|>C F\$FXX| M|:Y|7?PIK.U:6%&4?T|JA@?<8^Q:#HKC:
|IG?7-:J|>:W\$OCV|V.S M^94|>:(YV# N|8EO^713|@102%W6R7^KL0^_06|/|8W|(P|V.B0IWWY.M+Z.Q:7&5|W2+12+5\$|RW6|)BNEA8+
|XB1M^"QH|JHD?%|!ZOO05%|/ ?2^+=.2=X M|M#PT3MYB#1ER3_PP7LD|^E3|Q=B&PK^D-Q@|(C@5C^V| M|:Z:|AMP|L|)9TSD|?XN:3X\$T:(
YMW @/13:5C2GPL3K^#1NP8|J|5>AK MS86SSYN|Q|35*(@PN>^|S*B^17S<:=|9K3&F6^XJW|S>F8A+L^&F^T^8|CB
M^A8M^X3\$K&M&Q48FE6(12-8|J| F^%&S/4%VS|I5<@O|B@>=70>!!9V|L.RP&Y\$>K&|F=^J|B14F|C|^RB5M|&Y.?V?UQNI6@7G M^*F|C6|?
1MC:S23ZW9.Y|U^H=KO@P8\$|=WUO#11UNE|)DXR.O|\$F |.-@7Y^T6K# 4V|BZQ|L^
MPGFE:KL2^Z82W^UD@RL#6CDE:8@%DW@<#3L:T>L058-89%DFT^V>=\$K<8?<(-J M2=Z)@P^M|WZ8&WQO)?:-GLK04(\$K|J8/4U3R/ &-/_8-
% 4T|X\$9UQU=4 M^#0V=M A H/42S8O|J|4%|?>LPY|N|ZHU|=4L6/7!|=1BG0IG|Z\$=|.0LWD6 |P M(XX|J|
<|I#>.Q |>|UMYH^Q79U|^15%K |D:P^|ML|USW^*|(Q\$1+S8Y^> |ACIT M(AR _|VA |^/3<8Q=5E96E.C**KNI&#U9B:\$KB0#W
ML#75JY^<N|J|:IS+|J?+|JGOGLN|ZKXW^8N6|/^2>=M|Y.DD>\$=-;=(LUZ M0V^1B-|\$4O-
<>|U|=|F6|+162|H^N|OBC8KD3URCY:WV^VBXG3D3I|5Z3|K^MQC8K|A2ENS@|I4+>UMTC|N&>*4>9=YXDIVN|!##^8 M\$.>M#JY-
P@J@<80V\$4X=9^P.IE|J|U4U^SH\$Z\$%XV^>|HNN.|\$K\$G|C| MOC%EGHFFAU|EHBCOW?Y>DE=4 ")EC4&L.%47=:#|/ \$FGX(^8"-CE-7|@5Q9
M<*5J|SEB96OF=V?G6.(#^N)MN=DWOF+ 6- M T^U??&X80J@4X|Q|R:U|A|J R 7^+&3."PID1WP|>"C|G'2W |J0E5\$2\$M<+ MX\$|KK|SFF-
4UEJ&P^|>+7X/3?|Y8F:C|USRK(W M^9N-DZZL^"#\$S |.C.C-D2AY9C78>-|J)G:|U&Q.A_6MV\$^J@|YQH!|L%&R M;I-W/ &^8W-A
P3V^X|7<^%CG3\$M\$|QNC2OAC4MDLZ|<+&AG5 F M\$BOI^=24L|105X|Z=Z7B/OYXQ&+|X|^"CZ|2&%@%#GBPD2S1#PP+&W?ZTL
M%+YRUK :9/WUE82^+2>?U3:~?U&K/M,U|I \$|@)^'!C-&6F|9%8SZ-W3/<2HSI=#7_13QS|/U6Q(B^>8A@|Y MZZT_.6LF&G+F+M>|/3WY#=#P+
<|2|56^+2|X|J|@U=R<M2BYROP@8YQ-3|^"||&L^U^YD.VD1^C96|I4Q|9N502^6EH<P=32X6>C>7MZL# MJ2^W^IGP=7P^LFD>:
A_Z2VY7C\$^V|@BERD24RV@R^&+T^T^9|&F|HUP\$C M\$|L|:|==\$%>6\$QMP4>G|L1B\$O^"JEMU09|.^+01@QC?:@Q|J|&G-CQ51J M.\$->|%
<^O7XW)2_FZ|^OOSLR |JFO:~%9MLM.Z8N0\$^|V\$4:.\$O^-!-VQD+30:~\$%Z>Q@=C6Y^C|) M|2PV8LV|F%V0REX|F+V+NG|ZQ29|J T8">K65LN:
<##\$|5F6*26N)PIL9 MC9K^*3 MNPERPXUA |PYR3F|MU|6|ZWOJ80D>..J VKU|C:~\$*73|@NII4G:\$|OI| M|Z6N)MN:~
XD_R3T^|)RM^PQU:9^GU5;\$O|)64O:6N|@=^?44>#%J@+&|S|S6 M6#|I-
1M.6PIPV|C>U3O&X3EY=|2"|!|=71P737|9K0W|D%#XE@M60|MX#>:TH\$^R4 MWA 'T|POAPL9|
|I|V59=KFE|9:F06 |UH.6^V^1M|6S|E&MAN|^76@ |L^MM>Z3=6Z|J|^U<9C^T?P^L3@+>C> XZKBX1T22#?OK^132U|4G^W3H7:
(O+PKY:CJF? W8?E2L1 G(7^/R|V\$ 'CL' 6Y^Y+SP)H4 MBK4DIA6.&6?M7#6?NNRPKN 6.IW M:OSW@15K|L@T8-
P\$2:OL2|GP|=OU<23\$MW|PEXOGC15FR^2079>^6Z.WPVY7^M^"S(=|2^9GFI^1Z#|1N|L|>:<)&C^2VA:~<\$S|U|O|97F@+&3SKGHBMCQEI
M^<^WN9))<GMHRR^+)-VPI|MX:8I80(U=+R|I^0?YX|^ W%@ M|:K7/HJ4R:~
_7L.^Z\$M@UV|5J|T78PY^V2M#V|6K>8P>>GAI>.&9:X|2YB#|JGAX6JN|>IQB.9GY U\$G>XQ(^P@K3R=WEM^V;X|
MUL^802.'TXMQ=;.@|D|K4|K^1+I4+8GNNW>E8T8N|C|Y&K^A+C7^ M.8|S4:2>HDZ|TD&^75CV:IF0L|F5+Z_7DRG2 MLM\$P02P0EJ=
|=@G^V @BQ=(HD7|I1\$FV|U&Z2#?+@|D)?#E3.HGY2-MC4Z(MLTQ2^*^1.X.ZZ3|9IE ED7|I^72B6E:AI5)CTF<+&-CYP.
<J|S1|N95HEIM5>@Q|O) M#2:96CE3^QOKV:T.C^Z9@YVC^H^12-17\$AR6S^B^2002>|JW|N3.E#P5+|=
MQPMP|4 +^#8^'PUOT+VYG^#0>K7.O+N|L\$00P^CH3<0L 4+EJ7X|D|K=H^ MQ|>:=9V&U@ZT2|.L|H^W6.CX? &8_5P38^S3^G| *|ON).N37
>#AL4PK4CE19|J^+CK M >O:6_LWY>|6|_JRP=|F>GJ-2)?|XKD&5BFH2|I_Z<|C%)U7R8Z9_U15\$ M#C7JWOZS|0@.WL|@\$/NPO8|0@Z
9(Z<58LZCZ|L+&#|JL|1 Y|T=LF> <1 MNZ2BTWQ+HL>=>|JRR|8\$|@.@PD\$GQ_+V72EA.38C)\$S_> Q3R07Z?PB3B?2 M)?
|+ 4ZN=:H|OY|I5G|<Z>+&J|A|GH4Z^|RYBOY<+K|52@: A:AGM MNOC\$M^4= &Q78F3S.(#_1<|U|J|RW3|UPN^U0B|BK%>
<.7NFC^I^4<5C2J^&5C7F^B^WX^IQO-R:B(M^|*8|ET.2X\$>AW#|36RJ^*|J+@G|SYPS?06 | M<(< B7H.8^IYE=E^7OZ\$%|?A4S1G3@M
MO^Z|>Y3Z.U&|=:@|J^RN|X^Z^1| M|<6#?|TGN8|^48&RMJN^B^J.BJRX|X^1-EIK93ZWS! @>@.1L.2GK2|:BMA M.Y\$?<
Z|LN04TA^J^2^U^"B^PGP|O^"PP=^L7&RF ODH>ATA|IC86D\$U4TF M|^4S &5YIAO_&R>7HR4ID^KBT46R0^6Y7MV&J4 508TW^QF=
|P|A&3&1 MM>K^P>+..N|G|XEB B3X23ITEO|^|U|S^&^J|M:3M3P^O|G6@V|A|V@QT=:@.(G&F^BP.2-|JF^I&8YF|M:4SD&4-
7%^T8#A:7|I|ME+Z^FPDXN5# |2 M|:QWU|J6BZW3|>8&B>.|J|U2.3/8^&P^VML57_0|O5_2-3BULY(KP|)TN8(A MDC8^9P^6-F|JYJ<_9D?HE
&K0|A|F|82|P|L_4YEFC|E|J|O6O&E&Q4| M|/ @7N|C^P|J82\$Z\$SL.M2NDF @I=|P|P^KO|75^FVD(4-I (+O.9|4^&K^N+DEJH|?WPV
M9Y|A6|HX8X%UE^<^71+6GCLKKR/7R.5FF^L.FV50L^TCM82BE5\$D|YV5?@ MH#G+X#^2J|C:~>Z DGC |GG <(>
W01M7(FA:~1R:)H^NEZ:&7A^TOP_MZX^|MMNG4XR |7>Q=^AI^X^J-3+J MLDWH^R\$T|J8Y^?Q=(N^|I@-R|C^7VY(D8L|49G^MIE3EG<=|M|?
WE^_0C MZSOBC>:Q5S>)>9@V|V8^U|IBRW<64CX|VW|N^Q^6>IKRQY.E9VKHO^3 MX.W|I^*^|O^4B:~93MU^)|J|TZB|:|>=|P?W?
W|Q|8+H)M^U:EAZN:SLD94 MW:1%|D\$%GL|C^YOE|B|J|Q|D3RA|J\$#^"JY@SBOK\$5#^+|<@ U:~:22^TW2>L0 M^N|:6|+&#<3|JMYK^S-F23C_?L?7?
B=?XMB@AN<<.P88>P|DI&X)2 :SQ M9 -+&.B\$ZF\$7U66+9OS/^"P^O?>SY>D2^FH.O%P:2@*6X^24|/F@Y&YFZ MJW& ?1U>"CU|088|4|S173-
57E|U|H6G05NE|J25W|^D^UWXEFO|C|3C+MZ-|J(V4AT#^4@>?>|@>@DH>X^5%|B.XC|I^"RFV|6U7 \$H=R^T|9RF@?59
M4TOIPZWX^&EB63\$D+J\$5|XPA3\$WUY4|F<I-R4+C@>=437T M3&K@FIC.G|88C^=C6T|V?4.OLX50<|4%9|GL:4UUS-CK|MC#^J|.V:~%V
M)MLG |PSTQ\$0)8OE:GFX T|WNYT0:C?I^DD/D|@57:12@Y_08T|O#3(M5STN:~4Q *1--
\$>:1. (^W@4@V^UZR5Y^";P|W0E^@OA)OT35PUL:|KB^6 M5&H9-A+|O:(6D|T\$*N(NJ^|JX^:KF2:=^U|V|J+|S.Y^PER| (6YK2JQ|S
M^MAQLB|JRHQ.(R|S|C:~W>T\$V3B^|<^SNE|5ERES^K0XV75&^6^7^" +T1 MZ|L)|SIAPP&ASHE\$6\$VQ^T7\$^FXMK6|U|2|
M|J0R2E=U#Q\$G|LOAW:\$|5^>OZNVZN|/"RAAD^D<~4HEPR<CB6=|JMW# M(370V8VE7EER>W\$S<6|JLB^R|D|J|^>TO^|I^+00
ZSC^A3|K^U7|3\$S\$G9. MA%O|K|H0|H\$|6:~SLW2&B|S|^20/36LCIUD?7X^V^%T6^7E2%>U^"F)|P MH|^J|DS|>:~B^<
|45150GKE:PA)IQ|!"LRY.431.V56@."|WZ|^J MDES^LAC70(2&L|V1)\$|.8|N(N7O)-^|RJ?6|^I-Q9DK-DK|HCWH^T^C|M^FEU-A5)
|RX2VEPS^+|FDW@OEE^|E^"3JH|V^R^P^YK\$J4SK:(97YH(4 MB)=1N^C|KZB|:(L 9">8B^0^ 848^H(W82 CV.6C8| MV D4
MME|L|O:20\$E9XF^#G=F@7IK^JF|E0^*K Z:CWP^?7TS:OC.2E:~4@O5ZV9: MR^4^"M0K3HTK(4G-
<6#;ZK8U+^RFM|>~:2Y|T=YI2^7|2E%PC@7)O^8|>6J M^?Y17Z|EOKGTO>XG|8E|!O&K&4MLOY%:~O^5BUM^IOK4WKH^V^Z8-)(K M.V):@:
(D.2VXD|_IEV?|O^T%Z|M_?WKA|I^?>|GN^<^|?7 |\$7\$M^M^ MB|J|N)=C2|LVJM|O1K <=TPQ85.R7BA.B^+7N^2^R.Q+H-O|N^30A|>EQ
M4JG.9:(HVV:~J^?274>|QCTU<:&3.T^W3R+ZHK#TPR8&559^M6>=>L^C6> MG6EELF |.6&^8HU8BE:CGSN0NGHB:" ^-ANRU0-AX>|A:
<==+>~.R7= M<#4U|V\$Q^FZHV^N8:~|6Y\$^Y%9D>XIGF@Z-H3K2^9EAYR6531C3=8RHK1 MTE25Q64L^%ZROS.|>K\$|^4VR2\$60D6^?
(A^M4^+&^2@1^1^K>+Q%F WM2CQ7 M^*6>^J|M=9L9|CE@J|=>=>M|G84C|KUO9^WD8=V3|DZV^NX|E|+&|F|7C|
MPG:ZR|?EZP.&^Y_OFTV:~2=Y&1!6+>=6.5UD\$(.X7%:~FDZGH^W^N4&RC+M4:E8^ 4.4 MB|ROKX1LE 90Q09^>=?E+FW5|:@):87^6M|I5M/
|5+FSYJ\$UDW0E9+VM= M=<3<|>XN11E|W+ZC8(R|^# @1^9P^W^OQCM=Z^4|MJ|>?M^W^XVOC^E^FMK M\$697N|C:~QJML
LS:5H3.IASDW0A4KH6Y|J^P6W^2V|RHDIH>+8D|I(C WED.N9-I93^#6R)?E-W^A#> M|J9AM-7|A.%N:NG^RG<~#Q& \$615PX1:~|/I6|M^?KOOA|8
8G6Y|J+0#FP7 MU)5|>#F^%7BDAF9#"202|@D_I&E:8^9>>9K1NIRO\$P|AJ4TR86<&T& MBC|B?2 %G%(4TT3>*S|U--LV|26%39Q:Y-> 8#
(+57SD4449H|L7|FAD24 M&9B&)&48_10M:60S@|15=50Z|T+PY|^"H:DK50;<=T8B8R-7L^C^H&M ML|J|V_&Q0\$->QOK.9XH>)"_A|
EL7> S^S^#9("8 @ MQ=V(L\$456967D? 57Z0Y^YC^SCQ|2;A\$^D0SY|VO|Z|/237|I|2|9GUCO
M|6|HAYT|IB6ME9N".6TKC8^%C@:K3KD^YVG^* A P2|5^O&V39@Q1&^U|5CB MM^D8B32VDM:*IE^JF0!MQD^SR0^UV-~>H?>P\$^:ZY|R)^D^M:~
FKHD@_O.D MBY(VY6:4N6622%|M5\$&^_VVI^>8>TL98#E|G@?M1|K2|JWKAY&X|^5T| QTB M4NW4Z>RJ|X|^59#>="P+9&I|C-@|/?
EYJL^4&ND.F.NX|H|BG\$<3I&9 MMZ3\$00|I0L.56% MOL=48&R0AN^2SVCEK| (9?K^X#^HH\$>5E|O5F\$>R>|BU
M:KE^F^U+|CQ^"KK5V^E|:~\$J|^7^EC=6Q|^1O&:G9\$4|/I3R @^J|^+C^L^M4|2|D^FC/4NE:42Q\$4^XXX2IO.S=|&^_W|X|J|V.=C|H|^I^?FQO8&H
M4C|B^26S80^RMX|JZ|IDG_&_J:~D^9>T2)WN7Q.E8XF63GDCA9 M=)DT\$|JTOF6.0=8P|9 N6|41>*8:JL|+J|BLIN#5|T%_JM:~HRYKO^=5
M&2|^|.S+>?TQOQV|JF8>)>@&9)OMAOLJQ^?AP^VTI?>CK|TS1N9C^4^CCZ M^)& OCO>ZIE2@.6^"B5D^IO>?>HW- MBZ^WG^NA^R= >
>4JOMDC|>OR&O/KPA^X2\$W\$@|(N|J|U2^Q0<|D6<^RRM? MD^8^I^9/BD.&G OIG0^8<5M^X^RQ|B|BMZRU2@J.KW9|G.COPE9><:QCHF M|E
|@LH|N> >D:FI|G6<D|T2)=X#0>_P_Y%5 |S:GYX|A|3&W^87P^|SFF M|307@X:~5:~L \$.SU%>O<|TV0#|I|3)S:~)7_!\$H|J|=W\$SL@I-B_?&X>
(TW^MKB|B=4|JIR|6%FF:J^GC">~>L-M|J MHO-3^D6:~F^OHA&+VQ3|3C FR<+A|DT^X3=Y5.6)P^V>~>L|J8M^~Z) 8W^_ M|L_P_Z0ZOM7@24^>@HQ-
G%#|9|<12:8YS_U_2L|AFB&8|DHVFKFX\$^VIG5Q= M|Y|L:01A&H|^*AC|B|<^JZFCJ4:U|EFM^1YKF9W3ZU)=X|^J#G= |P^D#|^L^M-
FG85|F9H(L&#|J PGWS %>JD8 5=222\$D^W%Z9 (TM=|?)E+BJ(9U5I&XV M&G.*R2|FV/7#^JD%|JMV|BM>PG^DD^L^C=CK:~)6_60ZWI2KD|J=>?
21: MOY|T^LFT19|EAFICS:8^+2E-ILUM1 -J8^<Z3^?>~>L^C|E&P2L(7S>~>= M=ZB_U6QX&H:N^YX^*:@O-XF|^>V\$O^<|J^D+R9L|I)O9%&X?
EDL.G|UW>|L MW^8E6^J0Q?2\$ M_#OC8XJ|S:~+&6X^7|>HVCIE S1@Q^RMBPN\$= M_YB^C^M1ZX.W=9.7ID05>+5 J2\$>2\$^V|
|GG|:GFVX359+T7@K:~I^WQ\$5_ M\$E\$XEXU4NI&R=+>L^O|DF^2_S|+FT2D|!>+WYXYF^2.34R^3^05=>=>YK)YCK^SGT MD>ZAVLB-H5(&2|^5?
&~>+>O^K|I-A|Z^C MG|1LNY\$O|XBG24SZ8QRZ&F=+>Z3/965^Z^H-Q4-R4B+IY+T\$J|G1I|T2+BR? MNGO|I|JDAU_R|2_YU)=VZD|^J3XYQ:O?
LL=+>PG5YY=002N08EA72L6@>^Y MTZ|Z80&F>F>=>ST|9C&H_|J4.S.Q|A|D^I|B|JG1A.U|H.KZ|^YU|? MAB M8U\$BDCD|I6W%|5|E(
M25^>X8EERT|J^U7#&O:Q2W^/ULP^2-ZACXA3N=^T|I8|QXCL^B^|BLV:WR&6|MF|B5P0Z|T|J0WTZJ@Q15M\$S66@US2>#HY|^?OOU3^|OVS5B|

```

<1Y>+<2V M4"1(F@QYN#79BK<:5)E"EA-4XHN&ZGM1LXZVZOZ3*1+ M#EC* IC+5,ZNH=
M_%.|/ZIC4Z4H^02_ N^4JZ1+9BEKYI( OL'GRYV<_K0_*Q@9E.PX|UB:>^6% M9JKS)19+V1>J=^K1^J1/W^CW <4J5FCWPK24?
REISKPTGZJ/AOY$H#>^WP MO<QO!XJIEBB8NF\13.VC>+79|17M.FB9>9D!-FI70|ZVFV?9*0!)UNF&IFY M14/ JCPA8C(J-QY<19KIN|CIVS
$R3FVOK7-32M2:>1%MYO-&=IL=VS6U 7 ME=Z^>4$M+O$8(XLISVFEVBXIQ(0?==HNWG:JITTK&:OQ14%MI6X10=>8.YQ*=/
MVEPVIR9P5223(T."CG:;%3G*W16:/L)1W1*0QJK|DPYQ_3.R76.1(=^RWH=# M1J)EYOG:+D1 1DXS@P7@/.*.DEDV=>^4XIVZKS>N1J.
MK*O.K.A^9D3MRZ^O227?1Z^HXJL1|CE@<$.25.1J."0)MBP*3D3.LPGF+1J+1+FF36BD1D92V4YIPEN?24F H#QZ>3%JIE.2H0>0%NTC|HM|5FW:-G-
HJK T M45.FEDX:UGFY<."4FF YVFB=SG27YDO.<6%1LS-JE)B?|IPLW3?D">+1.A@ MG_ JC:>9C+YOCK 1 D06)BRC/-Y29@:XYU86?&SXE.D:>XZ//
IS##L>H M5!>GL-^ID^RE:3E-8&XKH"D">^<P+99^!Q|SK+^D5=(1+CH^<U|OYSX4 M%| 7D1-.%1OV+KB|W^<.*P*8KZG>%.GA-UT8$?V..
MY$SA?2AG@O1K:3+>D- T-JT*^ T-9|IR8(=X^N1D)0BR#^13G% CY&#>=0R<M"1J^<T^ZIVLS_.3J+>S TVR1<^<|TLP|U63D?>S0Q1U01:L^<T^Z^2 A2&R0
M:1B21Z4@0<5614>X.M^"1YWPV!D P2O:P B"10BBR|J|CJ|E13=,9 MEIX$US+0!<Q244H.HZNLBBI+>G^L1S:SPD52@ EG|NH:<^1J8 13A@1S5
MFH-9*F.V)1I(AC(=>:X<@>9>LL5=>*O$5EX+JW4@C0+>GWE!>9:13 RVPX MAS9^7Z8CA=3Z?|GJ@D2O_%.POA7)E991|
N5V@8V+A1W(CX8R9P@A17H0+4>M=>V1642^9|Y5M3GHU+A.P-S14 C1^4N-68HU61|OVL12%8"?/>1D|AY5?
MS3D10|NSQ$R<^<@AT|UM> YLH%?T1|&?>."1!&T+>5%:AN51+L+ET* MT+P1PX3$1G|<^IH4?>^!%RV7(R)H6N@K&|Q31HT^IDOGC|UE16FHL
MXU.A.Y(691$W)314RF ^PJU2.#SA ?OMN|BQ5 5M1-&8KJ160QF>:EL6W1V1 M22:8)AEZS7$+1)CW:MXPFYOYZ?>U>3K^DSGT1?JQNO":
|LA$S1_<K^N(I)3N MDR^P+--|P1Y=6K1?IV%5:Z15+GL R**GF 9-WWXGU&|O:Y> KI B8&= CV M0T8% U*^<3^~|MU1 N24 MW15F=E**W^
MLD>=>1/>1>0JSDN^>2MR58...%1/KM:SNW"POY=4||>HYW!47#:/5V<9M1& M-D1F>(F'O5 XN@F2J*G1:~XU567P"/IO M2-
U=OJLXT+K24)=>K^F7<1K2L.NC|>Z1VM |^V1RE=E<66GZ9R|M=T^%G>W? MC_3.MLVI11LE&B.U1O&Z1.25LT.T^>10T$6R6B0?7QW
+LX^K=F4). M+U(TZ46*)|YCRUP#31E5|9|@T4*Y M_>=1ONZ9GZ?7Z7Q?W^<KB3N*EQV3#SR1^<F12M7-:8Q4:OK1.BZ6=3ADXQ1)3.
M4BD:"ZIGA8_.. |O:~#A1N(D+E9>Q$)|51VM1ZD^2NA+1V3VS0Q*BL#@# M_7#SE R3?:(~1^4YQ?ZLOI=Z9*M@J-<81-
F81|Q?>*9B-H.H|S6AF MTJX|S1R#(C8*B/W~W*1J|MD=CUOB2^F1.T.G&8 P C_<R^P:XP+U%510D1Q M<~<Q$)71.*V( $Y3MA^8:33IY+>7F=71U|?
98+=U4*OUSQIKV GKI S^>E8@ MZK3+|E$Y1FEVDBAWT^4?<"HG(5G='1&4| M7P9071-HKYS)BTBJSY"~R6#SD+13YR2:661OPG)W@>A_
=$1261$SWXP(+>@<@75MK&R#46NRRB1I2U:(3KZROE1==8% Q6M:RL<+>V-X4@.BL M@K16K11|>88|VH^B8UT42^C)5^L|J1N1-
C%82TG10?UJTL R^BN4 M:-U>X>4JB=Z7^Y6SB@V-QS154_*7Z=DJSOIKO.RIAKDZY*0OLG^L|U>+>M00%V9297B+YGM-
$MO>MFDP8^IUNH@XVKL:~OIAS?_2ISX3L+IY M-6S_1)IOME1_+>1^6MO46#3B+6 631D@SDG3 3IV+9|XSNS^9K<%$8Y=CR^MMV1$?0_1JW0:1?
P^NSGP6V15T0_29-14M2T@Q@<G-X1O|WQMFG$54Z4>S5 MB^1.LKDWD9G!|:"D/YL:WC#<#D%O>+>X1 2>0.3V4U1H(P=>1-3YX1^1^8Q
MWO|Z>10$|>1W:1^Q F $A6312V$E&D:R26.TVB T_-N5 MD:<(*3 NPQ=V:Y1Z M1.S29?>#57>225XE^D2CX2KOY.9D SO?N1^059FOQ
"1|@<O'9YV>1@+>($ MBI7IOV 5W.R+@<1 L|S.C)6!DEZG%-_2220$1&-LC:2>0 <>1%4J19 MC1J)UJ114N1YJ8/+O-380-3>95YJP2-2X6_?9=T.2**
H$2<_H$S21680MSK015ZN090 M^1J C1X(I@GZ9P19H63N1&^<|3V1(1S57RW<=<O>+>SQ42YD1.3H28.M$2 M=E|LYM8PNTXZ1+9BEKYL* MI
^1-1&1OMT:2.5 @<NL<Q^J1^MF#M-C1JN|WAW(I16=1^NLN-52O1J^ MWG?TNZF>@6%5A-F4.>|AW$R2?|^"1^4M021JXZ9%~B*O<.-E>#
MM> M9|BO?EV$S)>+>|E6@1I63<9_./G=P 6K7R>0^1)1TDKD7C0ZIS?3X=D+O4 M/D^GBN1A3N5?E^Y7$TE=^*=VB^8G7EF#&Z)7(S
>9>O&O N>1#$<E_2P26U7*W1W^ MNO:G1%>+PW97/KC(4$S-O5^9M1=VCVB/RG?T=S^*V/H6_@5K%1|@QP:3L MEGQG6G0POS.8O_1)(+F5XIV:J.C-4.$
2$.<8*F1J+>5JAN2*G_ B1E1B<(<MN|I192A1+>3:(Q4|>LZD3M+A+YG^ZK&X95.0)ZUDB$Q>7L1O1V@<A-
L|2<@>1>T^617%AD|JR1YRZ11V2H;CM18?<N?JNM$?>=F.122OS&T/C*?)>:<8:6)R4DORUHU?|JK<$ _Z/L5:11$E !MVX
M)2=>G$<BP$5E//^#1E34OC9Y91%<X2_7:1C(NO436"> MH%V.N@X31O#<F^<P.U:61#P:|B1P8KPW:7UX|J80K_NL/728|66VE )=|Q
M6VCR<_L2BJ3^<(KLHEO^5 K0X6_@:Z5VR|RX9+>+FE&K(9U^54S9C-N$ GN M^Z_<Q^6^7"19W6B1L|>+<59C?PBN1OT4880?
J>A3Q1|6Q42:B^<@<S.Q.1+^1GRX JR19?>+>P&4Z^ MIQ6^01E5L0G0C3M( 0L|BH.Z4.G6&D77 |E^RA28-1@5VL@??
JR980=1K086@8/E01W&_448T9(C_S_>MSIGS=<|JKD0?>"H OY-F-A*Q_R^D:EI+Q5=1^KCI:B18=+>R^+1)BE>X(VM% M(Q1E@DR?
=U1N)^VSZ$UU31L 4B>P01^EP6U&#F+>TFBK(Z>3.XN56@< MNNCC> KR4#?FIN=(Q=* B7J1=X3TD.CH2)$>XAXG?UF&$&B0B1EOW':3CE1
MBDA1HD0?2Q'DG(B9X21+2+>D RM@A21^+BN^<C%<X4$<B1 BR(T4S14VUCB1
MNNY&KUALE9KJ1^0(DC3&2:H.BW1.@1>4^1KZT&G.4X1$6>_0.0<1UE$ MB1001"?L:E%*@<J%<5(BE +N1|G:>^K_4:13+81-&648'SF^@ &P_1K?
97Q= M1-MCWK.G$VY^&6Z^0Q4N1:8C:2:HAD.E&Q<#R^1I4<C1 7>Z>3SJRCD); M5J>4^ 0G466T.3.A.#?F1-8
IY&5W5_1J_#40Y851Y^YBR@C1T(S3C7+>M(K25V.9^L.UDW^KEQ7S.ZNM8>S<1Q4W+5MOE^<ALB<=<X+=
M1MK1W<7GVY%Q:2M3W.5^81D? OFY66 4^1XAI HE_*2/LP1Z4S)B_&M1S-2F MXOB07ZF=(WFSUP:3^1L7E5 $A?
C01^VC1Q1U21VJSE<01|S0^N$ Y.N-Z6^E M3&_401Y7GB^ 2P41MV21$E@AS$P51?IPANS.SVX^+>DZ1T:~A1A
```

E=LQ1:4SVI\$=@C?'.TCXBF4_4S>9I5<[5\X0CZ.9F9:J& MDZ4[1JSSIJME|QBKS^@9\$SXE^@3EF=Z6|1C^@Y\$8@|ML6A|ETC|X=H|>E(9|F M\$(W:-@N4VDO|O|IO|H0:403T|J|-4 K|L|6B|J\$S%|H^-42MR.3Y+&6Z|OC|L14 M^M L?|I|:U#N=|N |* IC|XO:^^S@|:MV8ZG;<,6%=YECKCXU-5TLFK2=5|A M.:+2=O\$,%E+ CL 0?|[-/6&|.!)IM|L3<52A:Q&5Y|!|^*^:JR:TMQD@?T M-/RA D>8>84.BU<4D? 3Y?|T83>EHD|@Z2%QZKAYXU|+455N\$H\$|N@ M89% 7IVL1F2 &5.+:@:6VO.PZ-.K|J|70B4%W+4|CS0 S4X+...?B8%0 MU(6? C(TO|(\$9T\$JN90"SE@.P90)F=0&%|A_>+@/|RX2#|JB3T|IBTV@910: M^<+&V\$246*0H8IE\$S.Y^55BGF|0KT.D&5EL2.W=5;.DC ?Y#1) CDRK2M\$M MNEI\$4V@%<^FI=K.B.".:+^W&IF\$(472**QC:J5PAK14./LYG@?7S/EQ|2 MR0^JVN+U|A^0WG>+?|7|G|IXOP? K_I0I4QXCYID6_NOVJFR85\$RM|!\$G|)B2#4 M8:;>Z9J.^GGCX\$2.&V(13>0 MD6_/@N|9|HU&SWY4IJ&(*KAMHA9>CJV39|IJZ.A=SI? *.0|J|H|6AH&+CW MYNIQ2:Z9@5+<0W|)14L0G6A|BEX7G7G<\$<|K|1^A@E% DP43:=05R&Z9DL MO 4^O|N%?1>:*P4HOC>?;A >? @|K4*+.9<..%<7|+? %BZA1=L|L.YCZ M044PBL40.^0?V|0:\$\$X #6#WV|J| +^B607|F.Y.V|:L5T9@44:|S|6C.D M|Q|O9#(4_942 *)R14K|>ZUK@| N1|G=1^>A+|B4P#E3>G25<%"MR8_ZMPM@'0 M|LS2ID|!\$0A@+8.;^&#&^!_79MK.P7(*2M1|J&M%F:7".*P|18|S|Q|L)DCG M6#*=NX/%6|O|N68+|J- \$0\$2?^6Z8M/W**JHG**AP\$WP3T V:&H|:5^H@N2D&+ MP)XBC|!|.PA8@|JWU|4Z&AP |QX?F|SR7N"PT|.YIE*|>.-5N:|>+V6U?LC-C MV9GC2W9F 5IULH|J|O6Y0.N12^62+9G|JZNQA'M |J2 N?GL17^8W_9|241# M%_U|5W|4|JGTL+S\$XLU8-:.#H|J*ET|U-2U>+|B+|U+<3.B^40 L+&S|R| M|K|4D-2YE|>1\$F#D/4^EA\$-A|B^GFLY#.(9):4(U<@W^A.Y86WZ_1:+ M2#&5J0 B.K&6PN5VO>RTBV|IF6B4N|3^I0+7 M^_6< C.D:|R+A+K+&# D|J7_UX@EKW:~RV|ZAIM:4TTPC+!+&P*L|M87|6 M4=^8#N:P|7|X&IKM=CL M%?)*|M5^YN+4|N|G|NZD|!| INV|_2Z|+5V5|JVR M3G0?U78L?2(Q8:>|GYU ==>X.CC=C<|1R|IT8ZDWD1|^J8MLN^@ N>J_1 M&1<1/..R|L|TD9XJ W_#J>M3HG&K_QX.\$2A^@&^&(A\$>O>V@CY**RP:U/Y6M M?&\$VH|HF|DOXSG1SC5Z^T^|3E7EZ|3\$S_|S|ZV5&6:C^|QRPVQ<+R|JUDE2 M^|1V|E\$CN^"K_Q08%ECBP|L|RQ81_PSBW|IBBHV|QBF9*7N GEW\$T&|/6=D^1:8RL^0X1Z:1^%V|E|0|8AFMRAR|JVKZ|C5&0 M>&3M-7ED\$5LZ|X:5.ODGQYF|9QKPVN8W7B_N6W|TOD |JOE|IYD|H|RC:PA:XV3 M126DD^WOG6S4>X_F4LBZ=1R<.:<| /~RY|J|X.N|QO.BH*X^0BYX: WDX:Y M7N(=+(MG:0@('1|J|:JZPO^0BUL@# =%P+ &"D|P?~Y|P|NF%1:;@9W=\$%2UN>V|NMWV.GOB MU|C0 K2XX.(1|8)?(1|DHL|A^B_XWT&KX|MCVN=>#@6UT_-B.%5V|72K&M@&KK5SA7-DK|KNLN:U_5=*|G(1#MBY|L|I|=|W=.:?|0KM|QA_H=B M64|JXR:~?|N|CY|ZP2?^C+|=GON3Q|@A&M#A&N44:~C|U|D?7=#0)=&->| MJV|J|T0|S&?3.*QH1S|):~V- A2.A7L7Q|TS(60G&^&\$ (W@:|@W&|8|W>.>GXW|JDPGT5|Y^&|J|C7=RHSP5@LV=D^GL|H_&3GR|JE491|88.MX|O|8ZA/&=C#|8EGNE2"HH-X|XHPB3Y06.48>3WOODM&^>@:'ERNY|Z^ZE MT-HIN=Z\$S6PNU1:7RJM+Y76K|/2.N8X;D|6(0T:9<(K54ZB^KO3K:C\$ M=80:~T*M^K#"M<90|54%56R^_IB="G\$...U7|=./4|R/4HN=E0%56|I^A|G MM=K49:~TBB|JW>H-.*V9=T^2;\$ZFI\$V09_9.M2SY\$7|4 OG\$O6:C|J\$5 MR<~<"WR&2|0CP42B@VZM7|F26M(MMK.922MT:7#(PM|K|U|P:~0|13<).8^<5 M|_-QCM=6Y7V0|G-H+2K.ZQH:=EQUM02ZF5(>|J0S2M@U%PO=4EY|I>X\$NHO M2.7QH6|_4|S-|8|P4@ (:ZLIG\$Y|>G_?#D"E:T.5UY|:=8X4+>_5P>48Q>F M|W|IBP|:YT|@U2L^>BE6#W/_S6U|L7EN0L.P(O&ESQ/TV1P^560* AQ+VZ MY>#KV_EK.QV|MK+V0|RIQO4SC|I|9_/O7A|I7_1C^GT M:K@|O? |H8|8|X8H0|J|=X#..TL>5\$ Y^!UH2|+6|?5|."|J^B:MP^RV|S9W MGD|Y|_+CY6|@) ^|%00*\$JL|EAQWLX6C_7Z?7|W2>X.6S|?6H:U_7@R+6K: M>ZPI0\$DM"+XNF7QKKM:*4|(#|BVL7_15BWS.5G &SQ.COAOGKS_B#:\$2 M83|)CO)#%H847C|3^O9H=+Z%2^M9QM^ZZD8 |I|DZ=LIK@V_HP|K3AP|QWX MA6(^%>LRF_9#*H|."50C)C|K-CROYE|@KABCO.PFH+8Q|@|91X06C^|X&M>|!43\$4 >? @:|O|B|69KBWCT4T+L|C|TUV|J+;_O_%Z#+:Z|X+>_2S_10 MMS/2Q?9WK5BX(C_QE6!|/6_JMS54W|7C|DYZ4V6|J>X|J|H|_75\$H" MI^":U&^|F8-KV@Y" \$\$_P06^LZ\$!(3^E~UYP7V3\$E B|<=F8Q57-L^7JF M@-|D:Y@|DC|3+L^D?>L6^|A2K^OBN:3A%&?%:AW|X|H.T#;HJL5NG=2% MN2&4|T:TP&| M2|60#-|2^?7IKV2*~?FF(HB+O5^3>.:!%|L|QU|!+HI=|8DG M2C(XV>|F|_3&3&ABZ)D.F(2?OPG:5CME|3->GQR|N_R\$|? UG#R&PNN_~P7 M2#3.(60Z7SR:~@SXT*|^IGY8*8")>_T^6|3H^UOS2D+&@Q7A|P|I=|NP6 M_|L&40BES5|)7SR|5CQ(@-+R|J|GZ^X74#^5_VNTQ|IIR71PQ3Z_O@0V|QB= M KFS8.C-144(G^D^N:1-W=9T@X+)|UHA|^1Q0^|6P(XU_L.CKE@Y-)|UIPE.6X?4/(3 M^DP^H37@QS|J|@|DF@6GN^Y_|06=&<29|K-GN\$YBSM^1VG2P\$|RP^5|M M^O:8KX5|&^>3C57F\$=EM_+&O2OSB^2^2UO4^|9TS7|C|W>#_Q3 MLV#5T|CH +BWT=ECL3U>SX#N^SK-F_Q H6@FTM|GC^HU5N>KT^E9Q\$6H\$M#=#D|7QAT^"(4.^YX|U|Z-|2L_ZHYJY:M#Q6R7)?D#=: RU4L\$S\$Z@D|> M9|AXXM_.\$|OJ_~4Q|)2A/N6B H5(ZZY\$LBX0|J|2|JBC<~*2|Y_O_0.6^2733CS|@20|N4|P<W_|W|"-69-M# =X|T>N|J?XF6DPG&VP&W#C|)OPIVFAV>|V3A\$.)|J|T-C RTR#F2->M0J_&I2+0 C-FPU^P M^40QM&3:72S =(C_IJZYID &^DD@0UW^4R4|BK|_!|00 L6FCJ=RU^XMDV| MXHJR.EOB7G%MH2O+? +DEF.03P\$E.E5&QV4|Y_.\$N|BG^E|B MGQ|2\$|^>2^?^C|J^Q&8-|84D|P|368U|I229N|S(B|J^Q&8%3WR|G%GIROX^LXA_C^V+ M_X|K|X|D>=>|L#O ^UGBK7A|!\$A2|JB@U<3U^H:H^&8---4A|@A9?M|+| MU^6\$B|FZX.S\$|A4G|I4\$V@2^1:Y.2=C)?@|JLX296P|KH&A2D.VC2_|L_| M**=F|C?9AL;<0 |L^GNYT|_~?X^K|Y|&M&2?P\$|JAI<~^6BCZGV_JG^YR# MKAV7|A| PYO.>>7T3-EM9PF1>6LEZYV#|8#%E@|ISK^~|S|L|CG5|4D\$UKL M.RA8M*X^7Q|T|2IP-NXG|_*ONZ|H.GQ2|W<@U|@B(RMD|P^|U|J+&DEF M^|F|H#_1JZ.5Y|P24^XR4F|>+&V|S4F7=WC7_1|W<Y|!^A|+? 3%Z5HV.=4Z M><60U_*|!SZKK^G.S\$HTTTH7Y|UOQ8T6 GXCB(O^:~@|G2@|P)^H*092\$"@3BJZL\$|!\$53|C_+V M22^5C^P|OR@YY G^|<+56;6G/(GO?>W@A|I.Z\$CV6%-SW:7|QSO@4(Y#HS MJHS947L|L|8.9NT9|I:N-U7^>N5F:H<0^X.S00:8=S0F+K MH^M=-|9|1AS"|2RY=>23 X+|X^GH-W^Y &2^Q9|2WQ&C=YUV4|("JMR^XW|K7^4F|G^?Z^X-D M2A|+Q^TW.2HX93\$|E5|LO|9/67KVSXNOKR\$ |R49.A^X6^405|/2DF^4UH+ M_5GXE4AJK|+O82|^)\$|I|@Z|P^&B@7B1|N|N|JX>_H_|!^:MAOPC#5@|_N8E MM|W|K0|J|>R^1|KF44T|J|5K|1069:5K|Q9Z=AFB:6N8WN_P|_6&@29ZFOR| MXW|43D+GFO62E@_K47:P_|L_|"B%|NR^0E 9|@B(X|Y:Z3A0^Q|H|H0P6 M=|B0|."2)"YW&|C_0^6|Z|&S(8:3FO0+&P:J7^3879MP-|I6EW#|B2_ MVV6U_D7^LZ|D&S_JD1R%- +<%0|6PMX^48>Q|HC^|A5|04_X|_|/ ^TETP/(H6^ MQ#30>Q.)1>#<X\$=I|XP=XA7Y)|\$|!(O.O^@1?N.Q|W|+2WP9:|Z%J V MJOB^YH+9 +8D^%=A2&^FKR?2?@O\$GL%Y?PP|HFBUN\$^#|D|_|>L-%N3+^E^#&6K+7T|@S.AA^FCA^1F3) MRMPA|HM?XOX7&SN^2JB+ <57?^RFNO^IG#&E:E0HG.#6^41^+JGSZ5X|!9 M-I+LS6QFN@:|18-P|1464(-UO4-5&SOX|F(K9\$&4^L_!B\$H|:B14%ZH\$4 M|86#5H |YT2.1|O:EYY-R-O|J|8I8Q|U6W2VJ?<="T^G3FV_W8_+^6Y%&9: M3H3Q

IG^L\$+2%5|E+(\$4).L+>8<1S-5|CBA MPY_P&D(|!R^~^:PX|R|/(E@=\$)^9Y|Z|^=R%(42GU^R9NX+&# "T):\$J M&O.ZD.|6N%8H@Q^DP\$PA^|!C>88E_S=@2LFO^W<L.P+?T2A8:E*#)R9O|E MMG0OF2W1S)9N^Y+9%"A"?^!L1D&2Z|Z\$#%|12 M|!|MTS Q8B\$2/RK>7|44|<281TSBTKE&J:@PQ6%-5&E25MXD3^59H9B|J: M|@|J|A^? @TE2|HP(Z|>652:&*RW(N_X-TR3<_RL5^E9JG;%^R|J|M@(* MR2N@~":CD4@P.6Q|9R7E0F#Y^P?^TF^UEY6FZUX^X^X|ZH0|_0^KV|S- M_|J+VFLRO+^C@%>F54S^DP1_14 CRN-)\$|P\$.2H%EB\$|X|X|T|"QOXS#3- M^4H9^~|G|^|6BOC0Q>+&|R?T^REK|O6|2C.HXP73^264|O-D&9AV&MUHS|L MM3K>|U% G3|_*IXN7^TVZ|H3X_|M0.GT7:K_|K@^Y5B+7|(|JHS 85=SHD M_|L4|L|R_M+POY^0.Q:W:HWBK"(J4NP0BF:~L7R7V^_SB\$CFM%U7Z0)F8|DGM= M_|A+Q|J\$!MT5C|ML9|8)C_|JRSX+|7^~B H|G|KNE3?T^20SQU4252WA^ZA=M^JJRNFDLFNC_E=31-OQ^R>UY^<@ (5)R=?WEW=&)*= PW^Q^"LWZ37|X\$S: MC<Q_N WUCUB|L.WLY|Y|=|MV0<:|(OXJ|N|MN992+BC|UW@2|2V^*=4@FK& MA:9?24QJ_UF0@:\$6%+J=?S^C^P/ M? Q&7T:C|K=S|@B9#;S#HCRSY+J=D+@C#2\$&\$9LN^2G:5CQ=K YUA:E(&#.(\$ M:STFU MK^O^VEF|KG3D^OBT6P74V.W+0|P@N|CMHO|J|076|PU:CX5|>?U| R2XD+> MU5^Q40<*=A#YU!\$1?4SO#YF/WKUZ+LR8#^H-:~N+IM- 4A0TT<@AXUT M@(|N&G&B|J|EC0^4+8M|^W#^+ M/MW=LFTMT040C|9S0<@U<|0S5P^C228- TQ0|TJ4V\$1KN|J|XPF>PUV4^4A5OPP(X)5)S5TC-6)4XA+U^D5ZX5^W\$K|? M@O<(F%M+&63\$|V^L\$|I TY%\$MX6+ M^R^+KK.E87M). ^~<^3X6CRRQ^5(K|V|VMH-5|L)8PG^@K@0Z|D06_0% ML:D? 826FV|NVR=>7G%O)8_U^60^FU=R.Y^=MG|30<5X^F>=:W.SG%JB M6S02ZIS7^RXA=^MZC48.T.">#ZZ=<47-\$=S:C3@3897W-:/JOU_1- (MT+?7EQ^>|YH<=<DRU|UGBK\$PQG61_R|6IU#<9+Y\$23=H(QF7 ?B)O@:|B-E+ |JVV M3_@v?::|RS.P3%WV?38NHT-L?WS+?1%B7^5|JX M483CAT&Z@KX:"|S)I|S_56&S^H(8?^OLS=^83)=.S\$X3AZ5M^7^3_@QW#3BW M)_9|G|J9R&S|QVO\$>#>RQW.D^WP^U|J^66|JL <3DY@V^*HC1_&TX3072@Q0 M:(EWP<09\$MBV|COLJ? &AVN|J>_H.K|V^K^PV:E.+P_+ #1J|^+L.1729^# M3^BCTU?# <@1A^NH#_-2D1|L5>+1PK-W|U|>WYN|P|P+H^NHRLO@OCM|?20 MF)8&>Z\$N/M0+| WS.@>:1/4C2^06&|L-@>_1XX&R(VN_V^FITE? XK^M7^ER|&<(F^8J-8KBZ^YX+|VBADEL^ZID=|@<4.%Y-7XOS|PX?@% M@XK#^S:C0B|YF@-J|J|LV\$^DPV># <18^A88@1Z3^PX0^D:|9^D7D&G0C^Q> M:@N\$|L=<02;+13B|V\$MN@6- @P0R#PEV|5PZ|LBH13C^U+949WGC^MY8Q(23Q|S^?7N^7..@A2D.D@<:~U|UXW20B\$N3>|HF1Y0FOX\$ MH4+%GUH(-M&W.^W@N? \$+GB|L.F&F^2QF3?=>=|Q_1>|XD<+|IBZ63^0\$K.3| M+O&#-KQ1.ES:U|LB|3^8^2DCN>|J2|Y3G:B?GT.%\$YX@.MC.%=N|9R&9|ML M\$WZB0^/%#>+&NQ|X6A|L:CP|HB =_VD|H|P6M#&#|J:~#>9RT~U^T|7# MAVZ|2_3=XU|BEO|PU.YVZ^K8WKR=Z^XQ? OV@|JH8^T|_VBL78H|E|H|_O8| M#K-G@O|!#A2=GQ^9C^U_OZHA5|O3|9X3:N>?Y|R|<=W-YET|L^M^R#H#>U?5|4EYU@ |FKD|J>|S^FXM%G1:/@|>C1XRYOX9_N<.:CL9:~Z MX<9K:GFE_|J59(ZY|OU+ _ENL7RW|B7?+2NE:6|3?|3S^=%#|J|=G_|J|I2 MVVOA^#? #H6&^T|/T|/|G|J9|M26:"DQ^Y8R_|L_|MZSZ<@WZ|6N MS43CAL;@T^IHM.N:4YQOP6:\$_G=N<7|>DS|B+&2VN)7J|I(P4^1%|<<71^ MT// |XUE+YH1U|N>~VHTES7^|P6|OQ_|I0D1R95AKYND69|T&_H_|I^U:WBS MLC|V^AZ>_F|=X6AR+&P7)N)ON>+&FDZG|D|ENL5SO^30XW&@VITZ<_X62S MA|CV^CP^M"(5BB^C^~)OP@~29PE) BYZ@TV&7X(9,A<"0N1Z| 8XK|E PV03B#=#5H|F-D3_7 MA&D TA (T^DU6^6U8KUP^H|HP>1^ET=IF7+T#(I.PD^9@>QD=X M^#HGAT5Q&#| |J7|L_|@.S|JR|.J44L.S9C^3@+>8M/R9S^C MB>8:8@%|85 MR|+9^2AA.8|YUZ:\$SIM=XUL&KN3%*#&^&#&L^&#J>+>A4LZ-RX970_H M? HSU^<#&O(DLG+9YV#<|<.:=\$?HBJ|ML+L:&R5_HJG5Z2K.S>./>TM=>2^K^ M2E^Z|I3>DG|C9ZT8DP/W^@S^37E|C4|@D<21^1Q42G;@>^'@|O^ 32L.GX: M>_QW7|HFZX|DX0N^!S|G|O6=|V|2@&3|J|E|D9|J2@10D|M- 2N.B^#XW_Y_MCA48^9COY(T^D^N>C|>+G8LZRO? B^_G^_%Y|G_Q59(WR.K;+J_3B=N<=<5OWD0?H|00| MJG|OH=3|X^Y^OTUA@:~B|O^?B|.#|F|ENK|J|U_1CHXB023K|T6SS^5 M2W@.E3J3+B^&_1 POYV_|2|M=F^T^SFHGQ@L|BD7WRO@8Z(9AX).8S(ER3 M= BA5N& <8J^ZHO(G-46N1E@5Q|W|DL^ZX^T>38P.OI#^39|UU(|@J5^~^|S6| M(\$SQM92:~WF8HSAMP9#|12G_|6T/4H+2Y^N^1/L2HYO4M^E.X1\$7^"AE|33 MP#_D1.O|T@N^+M|3?V?^XF:|?K|O:~6J)AD|T^A^FU^5?&_OXO/^B_M|T0B3V=,~WE\$4@^~SYW|P+~D9EX\$C.67B^70^|J.VZ2^1NZ^D2_1L M_+&3Y.J<#R7|9Q^ZGE|K|)HFRD&RRI_P|\$>OBC30X^7|SAXF|GDA^~J|JM_S\$|6|L31Z8M>^A8(PNAQ5BKCA.CO5+TO+RV2^X-@:3S|U: L^* YX:4 M.RHRE|P8KX|QRM3X\$S^HC|)JD(>WKP^C^S|J|^ZL:26Z^KXN=N@JEVYWO M8_=<0K-YV &9JD@P|J|E_DJA3P9DN8|L.M|L=L^D_7^P24R8G^Q7^J\$CC|>U MP+>[10F>7+&CXPU|D_3C(K^G(ASB:T.Y&B^&J9F^H2VG^RI")Z>>3YU:8 M_V|P\$C.W\$1LHH9CPW=25%YJ2^AP@F^|AS6G-FEX&@X|I|W>?&+I|J3+^#D|J2:1762_9|2W@U|F|P M^FOU-9E0|J|P|>V#S- RKSO1FHVN+&QOM4W=11|H5FCOC|^&=3^G_^(48>N|C|^*KQUB M3DN^XW/?&R&G&Z5^Q7^PPDGK(B= ~CRP|FD~CBD^B&8Z^M9 =>|U@.Q|D|F MRA016|J|(UR&9_|@&L^#2+T@ LEOP:FRFN^>KTL^1C^4@&T_78|FT^ M80(*|^84A|0|W5 J_|G|A=>|_10T4W0A-B|JW48F^C^AX2X.RV<|JNGY M74IG2M6=-PO^Y|PR8>(Y4T+OD0|I)U+.#=3\$1(12_1Q6D7Q_+S^E|RH^ MNPI^<57D- ^0\$2K>D+&L2_|C(%G^O^*3.%9TUKV2/E&F^E_?S:JZGZE:M@ M\$)DZR#~;G+L<CXU.OO|S^NOPN#%+_8V.82)3C^P8^TN^KQ718T%43IH^1)

M)LLP?C?0L.R-79#/?X/X32=1723->6=423)%KSA4[BC75'+J?*.#].2I]5G1Y M)2:60BQ\$/(Q:L+S<+49EWW+XB*!^?/@5Z5A>-
#IH!O5UR:3P42B/64>N\$ N.MC:8.#6@6@# 15@.WPBW0\$D\$E.OL!OLY!P%3IA/G:G4IYVR?W\$E QUM,5ZM M1&L!@L6%3)W+;; 2+<),
^1E&@4&QY&ZXJH"/N#5X%- C2U%Q/ P# M0E(79"\$SW8\$7X6:X3=6I)@ \$CRNZ(X)/ Q*=%D/L.2PT\$^<^Q5!_(BTG):#E MY:MJUO
L3K0EZA#F)./6X(+@:WD87.8Y45C [KJ.]EL+98>F/IJ:1Q3=-@ MG:7JLR:5^H8O UH:9BZN3A2TPQ0IDFQ@ 1X9#@,<1X1(6<+/-8#FO. =6.
MG_<NB!P72NUDXKL+QW8XPQ5\$NMO1T88Y6.128L#N@5@UVQ&:-5@M-ACXMPW1
MUK*Q+P0I2V2)6UJ)@27ZV(KI8NAS:)&Z/3NIEP&9*9J2(0ITR*B D+26%.6 M.(+%)^9(P^TE<=9USJ:%=I\^@0#.&I#HH(+*Z(<Z,O/
FYXKG\$9I&=[G9^P8XQ7D0I!^8^61NI^ L7EEP5Z+PA+Y%#)12=1UB#V^I@ ?!:# MWF@OW./NRP 4OSTX18?
O5E;&IB?7ACCO#"\$>3HT3A?+>G(ILAK4<*1RT MX0!%D8631U/YW^Y^Y00F!?!7U("M!6"BR"X0S(*+ZR 2-1-ILX"KLU3"G! M!@%BDP
WK15%6PM"YLUJ-9B4XJ!90TV^H/D D/JL:2!SMFE:PH+&A DJ MSLN:TRI^XB=>2/E194Q5A3OR0KJQM22S="LOO)V^IP%:.8B.72N>*E3"Y
M2LNMKCSQJWA!)^B&4^%517QV5RAJ <I9B(^.4.#>Q32H<I9MJZ2. 2^Q07T M@P=:1W(3I3#^HD^1-0G+
9I4N.6\$&HLN.;B:D.IKRB64)5D.6DF XUD3 MQ^:CW>6:7QV*0^-S!MXI N: 125:'S%3W.?UQI/YOW<^T^4YMST'^8%7G)
M.N.*S=1WP%P1:3G@XZ-Y.UU5H9CGJG^XKLOJ/VXWMS-&BW2UCJ1C4QMRZQ M5J)M3?2(ZM=Y W!<^I^6)EPTNL+!8KZUJB9<6&A<8E
M&33#EOSAQU*:.DIEUDGYK6SJXJH_TB^V.1=P3JHU9B1=*)JIT<^2XJII7IGK.ZB?% MFBH&LYL/W3VXA6A=MOMK@JB)=9^?0>A!&10+<+
J4C>B>(M.:T>):UYVG.D MT9GKA>1^<I<E(QWSV?#SUI?T^86?2A0!>.UL.T 7B!4@WNNM/X.Q/6# M^L.V?6 HZ* ZII^?^ IT^1)P-3.Q0_S#
M#X<95+V/WFE+=E^0&J: /J^FOO1Z> /QI&J^J^@S+IKY43. ^M627PSI0&GS? M2I@I2B^QQ"\$S5B!XCTC@/VJ^!<S?6^2F3#?
I:3I^~7ZD'WTS4B4_&F@7I9P=L;R_C MTZL>G[I5\$U4R)=U1GA'6&&JRO7WE>/^J.AW+4.SETI=I-OD8\H7QI/_0("IAs MW)%2&V?R
M7RYH^KPHWE== 46F&EY59 _R^&+1U=KJF10<^<4+15!SO-JF>@:1 I>T>\$&Q MBZ^%Z85!^>+: ?RWQO^OK _M_-5VY?+A./6S
MXO98I _W+=K&&Q&6JN%.WYR)HC6VA6+>UL>I#N:~5IEWM5VZ)=82F=T:8I M^C)C6UPPK@6EZ.(8-Q^S)!# _#U!72I^EM:NK-
\$.6R3I!I9VAZ4^2%GSY.RRI M8JU>O">.:%+>JAMIG<I9:Z&I?Q*-B/5C4@E*E 3PRZVFI6+>IP:GO^?6: T-:=I?JSTY3-I:O Y2^YIJ^*=8?)=8=5K#M*
MKCNJZ[L\$UQW^UITU5R03R+7H^BOB4L&RXQ3.E\$^7YC-L-!QE#^2XYQZ72^J^K;OH9RAP1+I^D/N&I\$B\$PQV^!0! L MD^IEM/(I-
N)2WJ08^N!16HH0 1*1=I/MZ\$QJSMWME::3298^65;ZN:1J8) M3ECIMN(1^SHTJ=B&FTE^I.AGYMP.V^AHVG^!1!T&N4DN&C1BTY2!^H\$"RUX
MT31B!^9X9M&+IG^J.B4LILB^N5!AN^AUWTWEDT2NGS^WG0T6O^O#='K' MYW2I-/F^Q)RNEZ(@=Q.)3RRER)
I>Y7PRX:2:7SR*73J.K=#98I.IIT#X^ MIQNDZ\$^XW.Z08JVL\$IPNNJWE<^ ^PE>6/EVTFBK7S:W3*.631*Z2(A7XZ&ROXY6*1H<
MGI_-4X/XB<+I^A^FX-T^!K2:~40JB=>Q^*YT6VFTY7+U5PMM^I!I%Q>#XZ MJ# /<+ ^H*W!>5PG\$P^H^Q^XWD1!??
5AKC^C^K4X:RA^QJVTESA.RDQ1:B:8 M=R4I2:~3A^X^V^A6+I!J3<4\$JZK@T!.SWEQ59MPE^"-!!J<+9 MJE3DJ8^3MIFRHT6IM%YM^B-
8XS*IG^<FR=I1Z?I/%* @D)H49I7<1)M^B% MC\$=1995I+>TWIA2-WZ^*=<2M^I0V>K>^'180&^VE:B^NHI^Q^WC^WWOC
M\$0<8:RK!)OJP5\$!^H0TG2V!127J@FXJLD^C^C^QJ^N&>+L2(MO%G+I^I.S4.MU4 S^D7:4 _F:IO/EN)JI^>K/^<^U\$)STK@->:I^HZD8@.D/?)8%RI^;
MW#@<Q).W10G=F:87MG.MV1^G^H^FQ L^3F.G^V^O/^>^>^MO+I^V 3PY7G>=O& MX@<KI^F?^&T;G\$A=;^C_ UH^HNSQ^Y22#^VD 2!^90=92-
?":2EZ^0VSA(4I M^2ZV<4^:#19!>#: 63C9FA>BR?X: FGJI:HK>.\$IEC2J5.73S\$\$.DZ=\$DD= M)J3^LDZ=LO@DP?#*.6^TC9).+BR3IVV>"<:;,"O11.-
DEPLD.G:I%X=RL MEV+^3^KB90T4^CY)<+W:/I.#S.+NK5PAY=?#7H^?
MI^=6XIA2.P:CJ EDI5^7I!S7*3I28QI^BP+W:6H/ WV\$CPB#TWXSJYJ^ML> M*(DV^7N^+A7C88VOL&I6^YPAI[#0Y\$!UM+49I
I/NZ#O:&Q:XB;ZLRXU3)S.= M4A.DDF?I+?<9_XIM8>QI@X>I0^<1Y:YIW?+T4R6S^J^HZU1.YQV#I?*=6DP(52>EG.S M\$WSXP:R99C.?
CWPU^47>9BMJRGU^W+G?B(22>UAA&RG^/EIS5DP>R>E M^JW&Q^Z@G2MX8 3.(9#H7SL(Y!O _N)@E90=IPD0^IO=UEK2NEDRRR M.
I#J25I<^<KDB1R9M(K:Q)6^7E:B=OGKCM@I^J=>M^C/2J29.^%G^J^ M9%65<6:NG(2I9^E2ZJF03I)I5ET^+9T:9^9X5^!<6^MEK.U2N@J^RR^SX8
M.\$<5ZAS>L(L\$^_85WOL5>R2BW[^AV)EU!)W445I6XH\$RZ9-Z0Y2)-E=B5O M(A42^2Y9UNU_4 2257=EK9Z^@.KX8AKDDS5TU?^&I.UT^N8-
Z:M.L#2>4:~ MEXUDU1PG@:.*#W\$P.V.&FVL%N)32N.R@*Z Y3=I^P+P+A3^MW@PUZ\$;BQ2:S^ M0>2JFB:XQD?KYGI<\$>:~29.T?
I)+X.#.C012.K=^NEFZ^K^N=Q%K95 _{& M8O^EN^*%T^Y 12D:5Z5I? U4N>^LR^PP^I.9:A08-V&J^_%WIA)9HGJW<^; M TNP-TDY\$^I^,>^#TL(>8-
CRV!^5=>:~^I!&M\$SRIL Z&I^4PT0:~I.R+8G MO7:K^R&20G9>UK I6P.^2F E@BITUOS-ET+ I9_K3#^OISG/6IGW!>2GYN
M_9A:>LNT%CIW^W>SYI8N<7:~%L5V+82YWM_2I^QH0YV)^~Q.Z2I0I@#G\$3^G+3IP4IRP4DG^F>7^@R.MU0V.U0V.U>7^NI(=XP4TW0.X-
^~1.B RLZ @&X AFX AFZ @UZ @UZ @UZP MV5XON:U.9^NP^X2I0I9VX<<N^M\$!U: I(LOB^4:WYH^C I4.5OXXK^M+IGO#
M^Q1LMUEK87L^?^~I!&+&2I9Y58@C.V5FCL^&5V/IP62SRXUICW6VR.TUL MROC 3A:O^YU^%#2UHTNRU@Y7Y:~^~^"LC!XF
I^HK!#M7_KEJ\$#+<1P.BPX M<_2_7^Q3I^RZIP>+^%T4^80>J<&BYVD(Q<B?PQ8I.R#+5!O^3\$!94*& FQ MUK69YGSB >-5;
<4^X7A!Q>Q^R^JRN@K^I^DN3FAV9?72N/ ^#B8_3I:~92 MD6IOL5^86?TG/X(^ N L>B>Bj<(-P).#8GX3L\$P=HX^Q^+Y<I8P2BY
M:6#~2QI0RL>~Q^HPY(\$J2^E 8:O2RGZTJ.OSV?&S:~U25:LX3^5^1U^OC^55EEKJ+OP.)H+> ^E 9:90^~^9:~7I!<^C%:GDW10+\$S.L!^0LPY/OT>L
M^IJC5T^4QU+V.FUN=L.O /-TA^KC^C)^T^V L57+6E- ISANDE>DD=8:~ _I MP7-.1:~>V^I-OJ^ZN/?BI=U7X-SJ!^NO=(P^I^I0L26P2I^Y6MP^I7(O5<:
M^H_C^WHLI6E%>+PXM^IYB:WR2)+=BV>IJDMD@80+I9^M^U9L24=FI^I(K.@JGV M+DZ?<^I^LO>-X: ^H^K=C?>@^"E%I+I^NE92IU^! J4TILG:(?
PWNEF.KEO6F@-?@ M^TE/I+VZ!^~I!I^IKA_WXJNAJWON%+RU^O QZ5%55V^IB/+92I^GKEO 9W31V4O2?P
M^!K<+;52I!I^Y6MPG=1^V2L/CZ_!^5C:9:~I+>X&IT@MHI=UZI(Y> T.E#I\$ M+VN^~^@:CFV.E5O^G@-
CIKZ^I^KA [7D+&A^AEI!<6A58GMURU/IQ> M5A5EY5D80#BT^G5HE8G^BT/KOQI@Q%U%ISU.ZMFDI@^IJJQWB7X-
SYIBJ9:ITX#7X="KCVLJ=^E^@#Z#:8A6>OY-KAIZ?EUKMEIL=K P&I^E:2E79:0 TMH1@I4TT^D^W2\$!L M:3?; 7R4^ M1H91_DH8TZ#"-(*I?
R3I+J<M^)*I&U/FD(43:SVQ#>77V M^1?Q2?F+>V^P^X\$JX^I^2ECGY45^"XO:G2#.72IN!_C9FFZ^I^#K^@CTY
M^K^RA<:LCQIOSQ^KHYT16\$!>#A>^~IK^X7ASN;I/I+^E2DLHY.DE7 M4PF\$=I^W!+=1.DTVI^W<I^!^4:\$D<9J!)
(XI99;&HL^W3INABV.R%TL5)N9J^H(N.6N:2.R5<40Q:G8^N8DB_*^B>(D^58E\$70AFN(BOY) M2TU@QVQ.2X8?
^58>Z.3=4X5C.FOI/MWY9I^E^8&+2=1D)5A2^TXR^?<I MJ:~N>:NCDW7Q04X=MKU67H3F2^PVV!UEMY7Z10Y4:%4<+>^PQ.GBFA@)(S>
M0A6&U^OIK.VEKYNB.#Y93^07Q05@C%..2GS1#6IFKHZ32QAR^1=I:1% MAL:%>7<IRH@2I\$HS-2I.OI<_ KHI^Y.3=>*=&V7LJS^TRJ^DW4?
7BKT7%5R M^<OW#SGK^TLBB@U^A.I^O^K\$?%4H6%I_ ED<@BI\$3&I%ND\$CFY^#S MXS?+A-%MI>Z8ML^PCN^I^O^Z=-
GBCI+G@IM207:72&EY MJBE^IAJOTSZ!ZUE +>3/X: IJIG: 2%8S!1 SWZQOCGB I^> ?Y MKR-K.OIIL^U=V9-B2MI^I4 ?
5EH(\$^E4C54^XBB+^."H5?>A2I)2(003 M25CII#=\$S2I1B7)4U>+>170#?F2+>_>_O2O%ZY9GJH/>?"RWDI>O^0+HSG M@MKTQ?
UNMAKY^S204N/I5Z1+I2D.Q 2@^43HERJ2@S/6K=6G>= MBG 4^NOT.F>_LY5KW(V.M?H5^I17>?ZL5-.I2WZJ8LS-IP6&Z^E_K/L6
M:8HW%:I^Q:~I3?D4E>ZD=12=WSC:JHLFU5EV.^JU _B=^=V M(AT2IIG23:~V^?%DXFU>I/OU=K^GYK^I5X(M^AUHYHCJ7%WZSG=
MF:&4ARZE>N^N)I4N06K(MUK^BROSP>-0:0=4MI7@O17R6LL%+4UDDS2^OGOMVJO^ WI<IDSIT 4V0I<1I/K1?%IR^7*MW-9)P
M48ITI^K:J5.-YIUU.2U:BWB>I2I(>^FKPXL9I)AK5%6DKJ5K.^#FWU)^*N25 M3#5IOB:P3:BBSQ="Z\$^WYQI=>UBI3N1^VB+2^Z^IY-
4=805W @F)I\$V M8.7G:7QSDQ15B177^8F>~*1 3/4.7X6>^E:OK?P>QSS^3%:K3 MR6/U^D^I^1@-8_5#OBE^A-^#H>WQ.E^&4K40V
PNAO?S^5EY6+U M.:X12J0#>C Z^-10)4W9XO2V M.)-OGC\$P:=OQ\$AVR!JXZ6M(^6_6\$!L+^*71^JS+\$.OY4+>RH^# MG92:I?^WBZJ\$AW\$ ^ZO-
\$R(+HGY:C)@2I0Y1^HUX\$G(4^X3I^8TH^OEC M5X^8GC>RA^Q.E 4Q^FF)Z \$Y\$B+^ _EOA#3DI^T3IQT4^G.C^8#3%I6EDI M_?
HKZ(8P55I^Z92:8X!>KKHW)[XGKN0N(3Y308J5)""IR^A:WK040L<M^HH6)\$^N:F4+1@^7(C550M.P(<DBIT7^HUI?JV^YC&EI@UJII^)\$-
MZKZL.B6>#S%:80#&HZZH9.M^CPE# 6^5L+ERS\$=R2Y(R).P00HX>:I.OM- M^PU0R2.G+QJ3ETLQ&-
_R9:KQG3SLV(9DPI:IJO:~%)2=I^LYA^N&0:8^J M/EOFO- Y:OH:U>K.LJ.%225Y8:~E!3PFS^KD=RGHZ84&^">KVYI EI:195
MAI\$A98QI<11QIE.V8T)H:4LAVI^X&KN.EJNDX^Q 2;.D?>7.I!P^FCI3^ M^WP8@LZM^2HM71L\$15I5/>2O#^#^H0=)B&
R_BH)M^EBCAG^H3TUE0&LUL M#B:)HTF=CA&R 2HJV^U@O.@8:OKX:GP8U^IKN/CA/E.GGERS^>68.3C
M6H)11CM9#8OD0927@S!>IZT7I^F39I2W4&B^)&F+^S1^U.Y.V)-VM^V#M M@R:CI8GPU2Y1INTX:R
9+PV\$K\$XOR09+IV#KS:XYOL4+8)U:@K%G)NL9(MJSI^Z214N: \$J=T.IC&2TJ
MVJF5/CGDA^IUXI.ITPPX&4%QOR5NLX)15(E>+>6:FHH^4TYI;J6/I1!+I MJ(I^J&^>XONVIMDL'+6T1QF&W4B.%M5@D1P+Y."H
MK((6^IPO>3@#P7#=#R5Z?#SP3(X6_N 0^%X>1TN.<@.+XNC)4XI(>7PI\$B MJ/<=%I&FANNP19W2:%K4D^1B^NVT^"R20!OC8IYCZ@9#VR*
I0KA>:G.S(INW%)MYHT5^7^P^FI\$!2: M8QDV848I^&FKI&C\$E+526D^I+DEY7NDE^I^%VGH%DD&QEXTAHM0GI= MZ^V-DC.^7HN.^AK!#JVP"
(* EA5A^W M\$9+BT""IIL\$IFUC1V\$WW#XIN#GK MKE<76I2XJ^IT^XO&C=YOJU32IALYIWX:O:A>O-V^X3E\$4RC_ZO=J+UKJM M?
XIW>^A0M055-CUIQC2PL!TUPA::OD49I9SUHJR/PK9G MK^3X(O.:M1>9I/ M5I_HI^OI=M=
IC2I:0M(W\$Q9I)9P\$W:QCIN\$EKIZ^YSWDC/FATX/L^E.I^BG M3HFV7X67^ILN/USX&C+8Z# ^F>9I!^IUI+ P04 ^!M@&A94^GPU8^ M^#O+0^@
&5A.#Q@T-# Q97@S.S.2TQ7I0.6EN87I+>EAT>:U:84.C M2I+I/M+AQ2K4 R^I^FMOM9I)-XEDALR 9SFOG8L M^I8ITVTG7^IIO>IV M(P
W=#)C<*TAL5U=5V^ UJVJG>1^=7GV_EWS(O#;>^3TUPP[X65PUJRY M3URM59>YU?MS^PZ^P9_+>3J+PX88WZN^&AS(1A73E?
97QW.G/8^MM\$QOV M^I!#>_QA:@KIGDJA.D)TW(X^DY9Q050XK^"~I8/PON1G@("W:4&I^T^=(MI/?Q4M#+W\$K:~?V4+
<>.1%X(2/^D@.^_0I!5I/^I@I+3L^I/595 TI(^NOI)?3OII^ONR\$+KUC_YC)@C2- OW&I^Z^5 M&AIVWON.IOIMH/^~W?
A1<"ND6>_ \$W:~^~3>O+V MKYGQONJ^609LM3P^I5M\$15#^D&AR^2O_<I^P^7^U>?+H^I!I5N1I6ZX=K2^6.
MKC<I^I 2%#^9I9QU:~GQ4C.E.W:~9S0X\$IHNL6+\$BY.W#OIHDJ^ _#B^U@LO+ MZYI^ZG3_&GOF.^>WZL/3I^=293&1E&^OYV5JCQ M3K6D-TC+?;
IKB^KYI.ATVXA/I^MA(C.14Q.^\$~I^OD&A-9ZPOODH73.LHI@9 MONS_S53^VBj3(=>27:@TEOG0L\$X>^9PNSP\$^N^YU.PS/_L.\$-NBZ.&GPU!
MTSDW^0IDLW8::ZFJ8B^PG.^@T^Y*!8+^7I4LPE N<I:QJ5YH40I3.\$+D6%M U^I(=22JF4Z+72""&^ M\$809)2&D>#5RAMJIM&>P(NLTP6A1!?
4>*IOEU^UV.)^*8379_PV=(6%)M:~9I!1^2HGHT.I0YI^="W:~JMLKMIMV+^G2I^Q030)YM#^'.WQ15(ZE7% M=
I^I.17IEDHXUIC8(LZV8/8UV^P3_F4\$JG8BW%:I^CWA.08:<2IGSY^M:MPP M^I(QI?^6Y.M)@WJ:~@%Q.V\$ZFD0&5KRNV4K/9Q-FP?0I?
I6^BL:QI@+&P2@0B MV)+>P^6.15TG)^*+2B:IR^N?#ZF6RKL1+9.-4S02N3D?^*19_P\$?PVIO4F@>O MC>R^I/QOY:I 6
A7Sj6.CI2^4I^OLIKOFV.)@H(I^9>I3X5^R_Y9=I^W\$ MPKIX@MD # \$WCOW6X^" "OHJL^5F2V1O^_XOI?WQJXS7ET4%N<3.E>
MW:+&P0=>R6ZVO^ESK)G:PI^WK>:>V! \$IUS(2N:9M49D2^RX\$U0)VVU:LRG45 M/ITI=WNN>QDR162R>VLOA&KT@VWW^VIZH?=_%I+ P04 "

#8+0 '@&5A.#Q.3@T-M# Q97@S.2TR7V10:6EN87)I+@T:>U: M84 CN1:JOM+^IPOIK4 *M 5F1IYTD4(EDILVRU/VOGHDD[K]8D[<=+2I^Q? MN7::IB@S91=XW5Y0)OD^OHXJ3G/DRS9IUQ8P-5J3OYYPV^W(M9+2^AFC:7I3+Q4-^R&Y2LJ8D2C)PE(!M):W+IJ7@!#6 YESDX:1K 6ZU- MVB6 I^DJ3_E IUV/OYR^H^ITCM^IJO "D>8B_ZL:WL07^5:KM I=5G0 MBO4^G6ZKTW=OV^6GZ^X(KOO6N\$.S-2OSI/J8K 62KU:OK^!WNKXN(I<-Z:SI MN^MG=OUF=IC@JL:CS5_W:Z_KYI4M MIVF? V_LKMLFES/ZUOVZIUUMV@XW>I M6^:IT:IVNIJZO_3>I_Q_3FU@/@:W>I0<=J_Q>I@BE2\$ G+GY_5C.F3PNH+ MM^Q=^O:~N/\$^X IY:K? U^@_O>5.HI[I]/PN=RVB^=I%OF)F8Y7V36?4^~ M9^2)Y6.>GIUWITLZ:N7(#++N[FYI:LM4/7O?]>.>ZII?B>5~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~NMIVZ^ZS+C18N MU &I2CZ4LNZY:FB^DHO&K17>AE769E.>%<1-BJX M+^7D^%S3:Y9\$RW)V W>TA^N7249 : AGTW8M-E1%_C^"3?R;+Z.%+32C:~JA ML.%B^6NF%&O/I^"<4_*A+960N^V2:AMV?F:1^ F/9)= D!@%3.IB;M=Z:% M\$M>I137F>EG9DCL9\$800V+^Y'Z6ESEDIT5<IG ^G^2?I^JBW:"?? HL=WL.6 MC^F:%^ZD\$S:@:R?J>53Y @7E^"/EO<+:%Q+I/RE>EEU6A. (&62R#P^XBM.M%02H2^EZ^C^)/F^Z&I^FHP5GJ3.7.P4XDLA = "D4:F(W0@IVR09W99M MJ@Q^B1H34YIM#->?WR1^%I?Z6? \$MMS=F@MJ3^6<Z.J:~C.TLPIQILL0G ^&5 M.Q^VJW2-G_0#:58VL7F+8BL7:F@Q6IY=>Z4F/E8)IAG6= 8V<^"(P.V%+Q3BVDI+I5.530>54RD? ER^ZL~^"1 M3&(U^6I@Z&R0K6/R1J^>ZDUCIJ.V1OIH.CIV7X_10^"D1T^M&^HIY1_-Y+YI M4PA#E>5D+U/ZIUQV@#AGK(MF S0%/ML/Z>E765B.BUV+K+^U1/ M^V/ 6N)7/7B7 MV?>GVO2+I0!4\$#!0 (&V %G/WX5E50_*P/> 96\$P.C\$Y M.#0T.#%E>#R+3%? 9&IM:6YA^2IAA^11(ADP)^F2 M!\$>=H2I8H>Z?QI=>P5W0762I-W^~ 6:10M+VJB-1IW1.LR=>:;9V6=F M:&OHQ0KWCH^LH6L^ ^OZ8_DC? ^SVK&:QBZO-M9_9ZL6:\$%4W#>:K2L9A^J\$Y_-W0>I^H:G9A/W9 N:*RU^COABRSMOG(I MW: G^NCZL^ID?3^U.9I[K:=5L7EOOH/I? A#\$SOJWK? CYV:J\$>^JE:9KM5ZJ1 MOSI3+~J^GGMHHPC(IOS&B@F-PSM0^UHO/Y321FW+I="G^9^"A)1."AG\$AV M? #04<#&I!@98^UGSP+0I+5V1JL&(T0)X\$5^TIA&D4L0I:X M98U3JLE (AF=,P/2M5GLLD:CTC)U#@=L)Q16%UEB)IAY MQQF]>DEFENP@SS56F&KLI<3=LM.):O)OXPL4IIF1).VLO= NCUT8N..Q M- L^HIG^S6SEE />IKG^R3T+U4JF:K 5MYL^?^Y:O>4>BBIH2:WL MWY:O5\$8E00LBW71!!ZYG\$!>1?^OYVB>_1JD"&KTK^1UV4Y1FM8RRG ^4:8V4I5(ND=VLE8(I-LR>=H#<^JE^-Z M W/F+U1O&J F33EE H^GB=06 MVSUJC?^AKNP\$#DLAZ("9IAL=5_?NAOI!="9%16^Q=O<3D ^I# \$SR9 M2/I!2?7/ NOHOB5QH(E5J^YW=3VQN^#%FX=#K:S+HRE\$ '@ &5A.#(Q.3@T-M-# Q97@S.2TR7V10:6EN87)I+@T:>U:8:6_2I#^BG 88IT42(9."2I4G^I M^# B%0.*>GR<:71%=[UFO&I^?I-^ (21-KU<=O:W3I0%BI^PSSIP^,^/8 M&GF.3B7GJ(L02X) IC>6-0XO2L9O&+IJURV:I=#>I>J>XGSH="^CJ0.M M%0@LIBE.Z2.L1\$RX4=PPP^62A378M^YB@ JIK/60T: ^NPIING7%9ZYWO99ITW)@ MAM5W%MYX..I:WG@VA?G=PKVSIQYXLR/\$B.Y:-W^7S.:>SA^W%6T^I^UW.IN^.-W+ M1>WJM1QZI(?)LXIVU/KI1- I^RWEIGN6 M^A9NWUO.ARIC#KJ@G/I^*OZ3^3^U1K2&RHC\$S\$1.6-!\$2 4BA(I&F>2>G9Z M110PODIAS/TH&G.L-9U^PD(EN7)I0X=LSF5I= & (A8R1:OT3AS+FX I|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~S.MI+AGVPUO/I^#7:G7^M^U9%SA MLWT5R171^~.<.<_1&UL4\$L A0#%>@:8IH6:HM@(.P MR+&# \$I4 (I?R\$^&I0:6&M C-R# Y.SI29&5F+GAM:~I+ M O4 Q0 ^I^%&E5K7>6IX0_&N!@ 5 ^I< ID M:VUH+3(P.C0P.3.P7VQA8BYX:6Q02P\$%^4 " I^M@&A9CTIIT=H "S MIP.%0 @ ^&UL4\$L I MA0#% @ :8IH67I^*F^BYO_*4^ I^H (I^ZIXI^&5A M.#(Q.3@T-"TQ_%"29&IM:6YA M "4H.@I^E83 R.3DX- ^0P.65X.S\$M.EID:VUI:F%R:2YH=&U02P\$" M%_4 ^I^M@&A9SI^%9#R+3%?9&IM:6YA XML 82 ea0219844-10q_dominari.htm.xml IDEA: XBRL DOCUMENT 0000012239 2024-01-012024-09-30 0000012239 2024-11-07 0000012239 2024-09-30 0000012239 2023-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2024-09-30 0000012239 us-gaap:SeriesDPreferredStockMember 2023-12-31 0000012239 domh:SeriesDPreferredStockMember 2024-09-30 0000012239 domh:SeriesDPreferredStockMember 2023-12-31 0000012239 2024-07-012024-09-30 0000012239 2023-07-012023-09-30 0000012239 2023-01-012023-09-30 0000012239 us-gaap:PreferredStockMember 2024-06-30 0000012239 us-gaap:CommonStockMember 2024-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-06-30 0000012239 us-gaap:RetainedEarningsMember 2024-06-30 0000012239 2024-06-30 0000012239 us-gaap:PreferredStockMember 2024-07-012024-09-30 0000012239 us-gaap:CommonStockMember 2024-07-012024-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000012239 us

domh:InvestmentInAutomationAnywhereMember 2024-09-30 0000012239 domh:InvestmentInXAIMember 2023-12-31 0000012239
domh:InvestmentInXAIMember 2024-09-30 0000012239 domh:InvestmentInCerebrasMember 2023-12-31 0000012239
domh:InvestmentInCerebrasMember 2024-09-30 0000012239 domh:InvestmentInGroqMember 2023-12-31 0000012239
domh:InvestmentInGroqMember 2024-09-30 0000012239 domh:InvestmentInAdvEnMember 2023-12-31 0000012239
domh:InvestmentInAdvEnMember 2024-09-30 0000012239 domh:InvestmentInAndurilMember 2023-12-31 0000012239
domh:InvestmentInAndurilMember 2024-09-30 0000012239 domh:ConvergentTherapeuticsIncMember 2024-07-012024-09-30 0000012239
domh:ConvergentTherapeuticsIncMember 2024-01-012024-09-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2024-07-012024-09-30 0000012239
domh:RaefanIndustriesLLCInvestmentMember 2024-01-012024-09-30 0000012239
domh:AmericanInnovativeRoboticsLLCMember 2024-07-012024-09-30 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2024-01-012024-09-30 0000012239
domh:ConvergentConvertibleNoteMember 2024-01-012024-09-30 0000012239
domh:ConvergentConvertibleNoteMember 2024-09-30 0000012239 domh:RaefanIndustriesLLCMember 2024-01-012024-09-30 0000012239
domh:RaefanIndustriesLLCMember 2024-09-30 0000012239 domh:AmericanInnovativeRoboticsMember 2024-01-012024-09-30 0000012239
domh:AmericanInnovativeRoboticsMember 2024-09-30 0000012239 domh:ConvergentConvertibleNoteMember 2023-01-012023-12-31
0000012239 domh:ConvergentConvertibleNoteMember 2023-12-31 0000012239 domh:RaefanIndustriesLLCMember 2023-01-012023-12-31
0000012239 domh:RaefanIndustriesLLCMember 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsMember 2023-01-012023-12-31
0000012239 domh:AmericanInnovativeRoboticsMember 2023-12-31 0000012239 us-gaap:FairValueInputsLevel1Member 2024-09-30
0000012239 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000012239 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000012239
us-gaap:FairValueInputsLevel1Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000012239 us-
gaap:FairValueInputsLevel3Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2024-01-012024-09-30 0000012239 us-
gaap:FairValueInputsLevel3Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-01-012023-09-30 0000012239 us-
gaap:FairValueInputsLevel3Member 2023-09-30 0000012239 domh:ConvergentTherapeuticsMemberus-gaap:FairValueInputsLevel3Member 2023-09-30 0000012239
2022-07-11 0000012239 2023-01-112023-01-11 0000012239 2022-09-23 0000012239 2022-09-232022-09-23 0000012239 us-
gaap:ConvertiblePreferredStockMember 2024-01-012024-09-30 0000012239 us-gaap:ConvertiblePreferredStockMember 2023-01-012023-09-30
0000012239 us-gaap:WarrantMember 2024-01-012024-09-30 0000012239 us-gaap:WarrantMember 2023-01-012023-09-30 0000012239 us-
gaap:RestrictedStockMember 2024-01-012024-09-30 0000012239 us-gaap:RestrictedStockMember 2023-01-012023-09-30 0000012239 us-
gaap:EmployeeStockMember 2024-01-012024-09-30 0000012239 us-gaap:EmployeeStockMember 2023-01-012023-09-30 0000012239 us-
gaap:CommonStockMember 2023-10-012023-10-31 0000012239 us-gaap:CommonStockMember 2024-06-112024-06-11 0000012239 2024-06-
112024-06-11 0000012239 domh:RestrictedStockAwardsMember 2024-07-012024-09-30 0000012239 domh:RestrictedStockAwardsMember
2023-07-012023-09-30 0000012239 domh:RestrictedStockAwardsMember 2024-01-012024-09-30 0000012239
domh:RestrictedStockAwardsMember 2023-01-012023-09-30 0000012239 us-gaap:WarrantMember 2023-12-31 0000012239 us-
gaap:WarrantMember 2023-12-312023-12-31 0000012239 us-gaap:WarrantMember 2024-01-012024-09-30 0000012239 us-
gaap:WarrantMember 2024-09-30 0000012239 us-gaap:RestrictedStockMember 2023-12-31 0000012239 us-gaap:RestrictedStockMember
2024-01-012024-09-30 0000012239 us-gaap:RestrictedStockMember 2024-09-30 0000012239 2023-12-312023-12-31 0000012239
domh:UnderwritingMember 2024-07-012024-09-30 0000012239 domh:UnderwritingMember 2023-07-012023-09-30 0000012239
domh:UnderwritingMember 2024-01-012024-09-30 0000012239 domh:UnderwritingMember 2023-01-012023-09-30 0000012239
domh:CommissionsMember 2024-07-012024-09-30 0000012239 domh:CommissionsMember 2023-07-012023-09-30 0000012239
domh:CommissionsMember 2024-01-012024-09-30 0000012239 domh:CommissionsMember 2023-01-012023-09-30 0000012239
domh:AdvisoryFeesMember 2024-07-012024-09-30 0000012239 domh:AdvisoryFeesMember 2023-07-012023-09-30 0000012239
domh:AdvisoryFeesMember 2024-01-012024-09-30 0000012239 domh:AdvisoryFeesMember 2023-01-012023-09-30 0000012239
domh:OtherMember 2024-07-012024-09-30 0000012239 domh:OtherMember 2023-07-012023-09-30 0000012239 domh:OtherMember 2024-01-012024-09-30 0000012239
domh:OtherMember 2023-01-012023-09-30 0000012239 srt:MinimumMember 2024-09-30 0000012239 2023-06-302023-06-30 0000012239
domh:DominariFinancialMember 2024-01-012024-09-30 0000012239 domh:LegacyAikidoPharmaMember 2024-01-012024-09-30 0000012239
domh:ConsolidatedMember 2024-01-012024-09-30 0000012239 domh:DominariFinancialMember 2024-07-012024-09-30 0000012239
domh:LegacyAikidoPharmaMember 2024-07-012024-09-30 0000012239 domh:ConsolidatedMember 2024-07-012024-09-30
sharesISO4217:USDISO4217:USD shares pure10:Qtrue2024-09-302024false001-41845DOMINARI HOLDINGS INC.DE52-0849320725 5th
Avenue22nd FloorNew YorkNY10022(212)393-4540Common Stock (\$0.0001 par value per share)DOMHNASDAQYesYesNon-accelerated
Filertruefalsefalse627613834030002833000377100013547000141810007687000312100089800028500031770002476100028142000265000344
224535000-
208763000382670005292300043431000575580004043000963000115840001034000723900040670002032100016980000300072390004067000
3196000-3104000-8737000-1594900028000020800072900050500089000-150000767000185000-429000-2086000-
2120009550004950006445000495000-1015000-437000-7035000-17000-4211000-3541000-1572000-15966000-0.67-0.67-0.66-0.66-2.57-2.57-
3.39-3.09632826163282615345312534531261295046129504515950151595014659630418326318400060148-501000-
2203240004235900032103119000119000-4211000-42110004659633628626330300060148-501000-
224535000382670004659534531226058500060148-501000-19830600061778000110000110000-3541000-
35410004659534531226069500060148-501000-20184700058347000465959506526218700060148-501000-
20876300052923000341221116000116000-15772000-157720004659633628626330300060148-501000-
2245350003826700046595485096262970000468017-3322000-1858810007376700052971514850001485000-
250002366309390009390006444993760000644499-3760000-15966000-159660004659534531226069500060148-501000-
20184700058347000-15772000-1596600028700026800079000570001200064500048200011600014850003762000-1249000-
3361000897000-2086000-212000-165000229000-30100064940003622000257000-345000-38000-628000295000152000-
2990001100031400066000-5800096000-11902000-
1748800040070003406800014767000245720004190001120007500008500002390000107000150000750003500000200012472000-
10359000939000-939000570000-2878600028330003317400034030004388000<p style="font: 10pt Times New Roman, Times, Serif; margin:
Opt 0; text-align: justify">Note 1. Organization and Description of Business and Recent Developments</p><p style="font: 10pt Times
New Roman, Times, Serif; margin: Opt 0; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-
align: justify"><i>Organization and Description of Business</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-
align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify">Dominari Holdings Inc. (the
“Company”), formerly Aikido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a
biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology.
The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. In an effort to enhance
shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari
Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services
industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer,
registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange
Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance
carriers as an insurance agency through independent and affiliated brokers. </p><p style="font: 10pt Times New Roman, Times, Serif;
margin: Opt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify">On September
9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS
Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned
subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the
Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the SEC. Pursuant to the terms of the FPS
Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”).
FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The
FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which
occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller \$2.0 million in consideration for a transfer
by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership
application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017
(the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March
27, 2023. Dominari Financial paid to the Seller an additional \$1.4 million in consideration for a transfer by the Seller to Dominari Financial of
the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify">On October 13, 2023, the Company
entered into two separate Limited Liability Agreements with Dominari Manager LLC (“Manager”) and Dominari IM LLC (“Investment
Manager”) which are both wholly owned subsidiaries and whose operations are included within the consolidated condensed financial
statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability
company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Dominari IM LLC (“Investment
Manager”) was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the
Master SPV. Beginning in March 2024, the Manager established various

series of funds (the "Series") of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

On May 21, 2024, Dominari Financial and Heritage Strategies LLC ("HS") entered into a Limited Liability Company Operating Agreement (the "JV Agreement") of Dominari Financial Heritage Strategies LLC ("DFHS"). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominari Financial and HS are the co-managing members (the "Co-Managing Members"), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement.

Note 2. Liquidity and Capital Resources

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company's past equity offerings.

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

Note 3. Summary of Significant Accounting Policies

There have been no material changes in the Company's significant accounting policies from those previously disclosed in the 2023 Annual Report.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP"), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of September 30, 2024, condensed consolidated statements of operations for the three months and nine months ended September 30, 2024 and 2023, condensed consolidated statements of stockholders' equity for the three months and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2023.

The Company's policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Joint Ventures

On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC ("DFHS"). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of September 30, 2024, there has been no material activity in DFHS.

Use of Estimates

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company's significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company's deferred tax assets. Certain of the Company's estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company's estimates and could cause actual results to differ from those estimates and assumptions.

Deposits with clearing broker

Deposits with Dominari Securities' clearing broker consisted of approximately \$14.2 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of September 30, 2024.

Leases

The Company accounts for its leases under ASC 842, "Leases" ("ASC 842"). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - "Leases").

Revenue

Revenue from Contracts with Customers ("ASC 606")

Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

The following provides detailed information on the recognition of the Company's revenue from contracts with customers:

Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company's clients are recognized as other income.

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet.	Other revenue includes revenues such as miscellaneous fees and reimbursed expenses.
--	---

Long-term equity investments

Recently adopted accounting standards

In October 2021, the FASB issued ASU 2021-08, *Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers* ("ASU 2021-08"). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company's unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

In June 2022, the FASB issued ASU 2022-03, *Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions*, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted ASU 2022-03 on January 1, 2024. There was no material impact to the Company's unaudited condensed consolidated financial statements from the implementation of ASU 2022-03.

In March 2023, the FASB issued ASU 2023-01, *Leases*, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2023-01 on January 1, 2024. There was no material impact to the Company's unaudited condensed consolidated financial statements from the implementation of ASU 2023-01.

Effect of new accounting pronouncements to be adopted in future periods

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP"), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of September 30, 2024, condensed consolidated statements of operations for the three months and nine months ended September 30, 2024 and 2023, condensed consolidated statements of stockholders' equity for the three months and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2023.

The Company's policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Joint Ventures

On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC ("DFHS"). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of September 30, 2024, there has been no material activity in DFHS.

Use of Estimates

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company's significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company's deferred tax assets. Certain of the Company's estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company's estimates and could cause actual results to differ from those estimates and assumptions.

Deposits with clearing broker

Deposits with Dominari Securities' clearing broker consisted of approximately \$14.2 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of September 30, 2024.

Leases

The Company accounts for its leases under ASC 842, *Leases* ("ASC 842"). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - *Leases*).

Revenue

The Company recognizes revenue under ASC 606 - *Revenue from Contracts with Customers* ("ASC 606").

(“ASC 606”)*<i>*****

Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.
Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.
Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet.
Other revenue includes revenues such as miscellaneous fees and reimbursed expenses.

Long-term equity investments

The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments—Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

Recently adopted accounting standards

In October 2021, the FASB issued ASU 2021-08, “Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions

In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted ASU 2022-03 on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2022-03.

Leases

To require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2023-01 on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2023-01.

Effect of new accounting pronouncements to be adopted in future periods

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

Note 4. Marketable Securities

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months and nine months ended September 30, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows (\$ in thousands):

	Three Months Ended September 30,	Nine Months Ended September 30,
Realized gain (loss)	\$432	\$762
Unrealized gain (loss)	\$97	\$382
Dividend income	\$78	\$230
Total	\$537	\$762

Realized gain (loss)

Unrealized gain (loss)

Dividend income

Total

767
 The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months and nine months ended September 30, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows (\$ in thousands):

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
Realized gain (loss)	432	762
Unrealized gain (loss)	1,249	3,762
Dividend income	230	382
Total	150	89

 Note 5. Long-Term Equity Investments

The Company holds interests in several privately held and publicly traded companies as long-term investments. The following table presents the Company's long-term investments as of September 30, 2024, and December 31, 2023 (\$ in thousands):

	September 30, 2024	December 31, 2023
Investment in Kerna Health Inc	2,140	4,940
Investment in Teva Motors*	2,794	1,972
Investment in Xpress*	1,033	1,000
Investment in Masterclass*	170	170
Investment in Kraken**	597	597

--	--

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment in Groq</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2024, the Company entered into an agreement (the "Groq Agreement") with Dominari Master SPV LLC whereby the Company agreed to purchase 25,000 Series XII Groq Units for \$25,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment in Unusual Machines</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unusual Machines, Inc. an emerging leader in first-person view (FPV) drone technology, closed its initial public offering of common stock on February 14, 2024 at a public offering price of \$4 per share and the shares began trading on the NYSE American under the ticker symbol "UMAC". As of September 30, 2024, the value of the Company's holdings in UMAC are presented within the Marketable Securities line item of the financial statements, as the investment has a readily determinable fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment in Tevva Motors</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 22, 2021, the Company entered into a securities purchase agreement (the "Tevva Motors Subscription Agreement") with Big Sky Opportunities Fund, LLC, who handled the offering for Tevva Motors. As of December 31, 2023 the investment was valued at \$2.8 million. During the second quarter of 2024, the Company identified indicators of impairment for the Tevva investment as a result of liquidity concerns. As a result, the Company recorded an impairment charge of approximately \$2.8 million and the investment in Tevva was valued at \$0 as of September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment in Tesspay</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 23, 2022, the Company entered into a securities purchase agreement (the "Tesspay Securities Purchase Agreement") with Tesspay. Under the Tesspay Securities Purchase Agreement, the Company agreed to purchase 1,000,000 shares of common stock of Tesspay for approximately \$0.2 million. The Company also invested an additional \$1.0 million for pre-IPO shares with Revere Master SPV LLC-Series VI, who handled the offering for Tesspay. As of December 31, 2023 the investment was valued at \$2.7 million. Management noted that Tesspay filed an amendment to its SEC Form S-1 Registration Statement on April 30, 2024 wherein Tesspay disclosed its intent to IPO at between \$5.0 and \$6.0 price per share. However, given the uncertainty around the probability of the timing of an IPO, the Company has written its investment down to its cost basis. Through the first nine months of 2024 the Company has recorded a decrease in the carrying value of the investment of \$1.4 million, with a carrying value of \$1.2 million as of September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment in Anduril</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2022, the Company entered into a securities purchase agreement (the "Anduril Securities Purchase Agreement") with Forge Investments LLC, Fund FG-MHM, who handled the offering of Anduril Industries, Inc. shares, a privately-held defense products company. As of December 31, 2023 the investment was valued at \$0.5 million. During the second quarter 2024 review of the investment Dominari noted news activity related to a recent arm's length funding round, raising \$1.5 billion. As a result of this the implied holding value of the investment had decreased slightly per the Company's independent third-party valuation. As a result, the Company recorded an impairment charge of approximately \$0.1 million and the investment in Anduril was valued at \$0.4 million as of the third quarter of 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment in Thrasio</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2022, the Company entered into a securities purchase agreement (the "Thrasio Securities Purchase Agreement") with privately-held company Thrasio, LLC, an aggregator of private brands of top Amazon businesses and direct-to-consumer brands. As of December 31, 2023 the investment was valued at \$0.3 million. During our first quarter 2024 review of the Thrasio investment Dominari noted news activity related to Thrasio had filed for Chapter 11 bankruptcy protection. As a result, the Company recorded an impairment charge of approximately \$0.3 million and the investment in Thrasio was valued at \$0 as of September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment in Epic Games</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 22, 2022, the Company entered into a securities purchase agreement (the "Epic Games Securities Purchase Agreement") with Aeon Partners Fund, Series EG, who handled the offering of Epic Games shares. Under the Epic Games Securities Purchase Agreement, the Company agreed to purchase an aggregate of 901 shares of common stock of Epic Games for a total \$1.5 million. In April 2022, the Company invested an additional \$2 million for the purchase of additional shares of common stock of Epic Games through the Aeon Partners Fund, Series EG. As of December 31, 2023 the investment was valued at \$3.5 million. During the Company's first quarter of 2024 review of the investment Dominari noted a \$1.5 billion funding round at a lower price per share than the Company's initial investment in Epic Games resulting in a \$0.9 million decrease in the carrying value of this investment during the nine months ended September 30, 2024. The investment was valued at \$2.7 million as of September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment in AdvEn</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2021, the Company entered into a securities purchase agreement (the "AdvEn Securities Purchase Agreement") with AdvEn Inc. ("AdvEn"), formerly known as Nano Innovations Inc. Under the AdvEn Securities Purchase Agreement, the Company purchased a 10% senior secured convertible promissory note (the "AdvEn Convertible Note") in the principal amount of \$750,000 and warrants ("AdvEn Warrants", and together with the AdvEn Convertible Note, the "AdvEn Convertible Securities") permitting the Company to purchase an amount of AdvEn's common voting shares equal to 50% of the number of common shares issuable upon the conversion of the AdvEn Convertible Note. The Company paid a purchase price of \$750,000 for the AdvEn Convertible Note and the AdvEn Warrants. In the fourth quarter of 2022, the Company identified indicators of impairment and recorded an impairment loss on the total investment held.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 11, 2024, the Company entered into a securities exchange agreement with AdvEn in which the Company agreed to cancel and retire the AdvEn Convertible Securities in exchange for a number of shares of Series D preferred stock of AdvEn equal to 110% of the outstanding amount of the AdvEn Convertible Note that was cancelled multiplied by AdvEn's initial public offering price, which is convertible into shares and warrants (the "Exchange") and carries a liquidation preference of \$1,000 per share. The investment was valued at \$0.9 million as of September 30, 2024.</p><p>The following table presents the Company's long-term investments as of September 30, 2024, and December 31, 2023 (\$ in thousands):</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="vertical-align: bottom; text-align: center"></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><tr style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cost Basis</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Carrying Value</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September 30, 2024</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><tr style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Investment in Kerna Health Inc</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"></td><tr style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight:

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif; font-size: 10pt

	1,129
--	-------

The following table sets forth a summary of the changes in the fair value of the Company's Level 3 financial assets that are measured at fair value on a recurring basis (\$ in thousands):

	September 30, 2024
Notes receivable at fair value, current portion at December 31, 2023	1,129
Collection of principal outstanding	(750)
Realized and unrealized gain (loss) on note receivable, net	2,086
Change in interest receivable	1,128
Short-term investment at September 30, 2023	1,128
Change in fair value of investment	74
Note receivable, Convergent Therapeutics, non-current portion	250
Accrued interest receivable	74
Notes receivable at fair value, current portion at September 30, 2023	1,372
Notes receivable at fair value, non-current portion at December 31, 2022	1,100
Note receivable, Convergent Therapeutics, non-current portion	250
Accrued interest receivable	74
Notes receivable at fair value, current portion at September 30, 2023	1,372

As of September 30, 2024, the fair value of the notes receivable was measured taking into consideration cost basis, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. For the nine month period ended September 30, 2024 the Company had realized and unrealized losses on notes receivable of \$2.1 million and for the three month period ended the Company had realized and unrealized losses on notes receivable of \$0.4 million.

The following table presents the Company's assets and liabilities that are measured at fair value as of September 30, 2024, and December 31, 2023 (\$ in thousands):

	September 30, 2024	December 31, 2023
Fair value measured as of September 30, 2024	1,372	1,100
Total at September 30,	1,372	1,100
Quoted prices in active markets	1,372	1,100
Significant other observable inputs	-	-
Significant unobservable inputs	-	-
Marketable securities	1,372	1,100
Level 2	1,372	1,100
Level 3	-	-

[illegible]

Change in interest receivable

Notes receivable at fair value, current portion at September 30, 2024	Black 1.5pt solid	1,129
Notes receivable at fair value, non-current portion at December 31, 2023	Black 1.5pt solid	7,474
Unrealized gain (loss) on notes receivable	Black 1.5pt solid	212
Accrued interest receivable	Black 1.5pt solid	6,336
Notes receivable at fair value, current portion at September 30, 2023	Black 4pt double	1,100
Notes receivable at fair value, non-current portion at September 30, 2023	Black 4pt double	1,372

3177000750000-2086000-56000285000112900010001128000130001200010007474000750000250000-21200074000633600011000002500002200013720002100000400000400000

Note 8. Leases

On December 1, 2021, the Company entered into a Lease Agreement (the "Company's Lease") with Trump Tower Commercial LLC, a New York limited liability company. Under the Company's Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the "22nd Floor Premises"). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company's Lease is seven (7) years commencing on July 11, 2022 ("Commencement Date). Under the Company's Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to \$12,874. Effective for the sixth and seventh years of the Company's Lease, the rent shall increase to \$13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

On September 23, 2022, Dominari Financial entered into a Lease Agreement ("Dominari Financial's Lease") with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial's Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the "Premises"). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial's Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial's Lease, Dominari Financial is required to pay monthly rent equal to \$49,368. Effective for the sixth and seventh years of Dominari Financial's Lease, the rent shall increase to \$51,868 per month. The Company took possession of the Premises in February 2023.

The tables below represent the Company's lease assets and liabilities as of September 30, 2024.

Assets	Liabilities
Operating lease right-of-use-assets	Operating lease liabilities
3,048	402
Long-term	Long-term
2,748	2,748

The following tables summarize quantitative information about the Company's operating leases, under the adoption of ASC 842:

Assets	Liabilities
Operating lease right-of-use-assets	Operating lease liabilities
3,048	402
Long-term	Long-term
2,748	2,748

[illegible]

Black 4pt double; text-align: right">3,048</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"></td></tr><tr style="vertical-align: bottom; "><td></td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold">Liabilities:</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; "><td>Current</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; "><td>Long-term</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 1.5pt; padding-left: 9pt">Operating</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,748</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; "><td style="padding-bottom: 4pt"></td><td style="padding-bottom: 4pt"></td><td style="padding-bottom: 4pt"></td><td style="padding-bottom: 4pt"></td><td style="padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; text-align: left"></td><td style="border-bottom: Black 4pt double; text-align: right">3,150</td><td style="padding-bottom: 4pt; text-align: left"></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>304800040200027480003150000The following tables summarize quantitative information about the Company's operating leases, under the adoption of ASC 842.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: justify"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: justify">Weighted-average remaining lease term - operating leases (in years)</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">5.7</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom; "><td style="text-align: justify">Weighted-average discount rate - operating leases</td><td></td><td style="text-align: left"></td><td style="text-align: right">10.0</td><td style="text-align: left">%</td></tr></table>P5Y8M12D0.10During the three and nine months ended September 30, 2024 and 2023, the Company recorded approximately \$0.2 million, respectively, of lease expense to current period operations.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: center"></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center"></td><tr style="vertical-align: bottom"><td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="font-weight: bold; padding-bottom: 1.5pt"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net rent expense</td><td style="padding-bottom: 4pt"></td><td colspan="2" style="border-bottom: Black 4pt double; text-align: left"></td><td colspan="2" style="border-bottom: Black 4pt double; text-align: right">23</td><td colspan="2" style="padding-bottom: 1.5pt; text-align: left"></td><td colspan="2" style="padding-bottom: 1.5pt; text-align: right">96</td><td colspan="2" style="padding-bottom: 1.5pt; text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net rent expense</td><td style="padding-bottom: 4pt"></td><td colspan="2" style="border-bottom: Black 4pt double; text-align: left"></td><td colspan="2" style="border-bottom: Black 4pt double; text-align: right">630</td><td colspan="2" style="padding-bottom: 4pt; text-align: left"></td><td colspan="2" style="padding-bottom: 4pt; text-align: right">178</td><td colspan="2" style="padding-bottom: 4pt; text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net rent expense</td><td style="padding-bottom: 4pt"></td><td colspan="2" style="border-bottom: Black 4pt double; text-align: left"></td><td colspan="2" style="border-bottom: Black 4pt double; text-align: right">586</td><td colspan="2" style="padding-bottom: 4pt; text-align: left"></td><td colspan="2" style="padding-bottom: 4pt; text-align: right">490</td><td colspan="2" style="padding-bottom: 4pt; text-align: left"></td></tr></table>2000002000017800053400023000960002010006300001790004900003300096000212000586000Supplemental cash flow information related to leases were as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: center"></td><td colspan="2" style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: justify">Operating cash flows - operating leases</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">548</td><td style="width: 1%; text-align: left"></td></tr></table>548000As of September 30, 2024, future minimum payments during the next five years and thereafter are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: justify"></td><td style="text-align: justify"></td><td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: justify">Remaining Period Ended December 31, 2024</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">186</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: justify">Year Ended December 31, 2025</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">698</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: justify">Year Ended December 31, 2026</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">685</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: justify">Year Ended December 31, 2027</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">685</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: justify">Year Ended December 31, 2028</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">685</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: justify">Year Ended December 31, 2029</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">685</td><td

[illegible]

[illegible]

[illegible]

[illegible]

cannot state with certainty what the eventual outcome of potential litigation or other claims will be. Notwithstanding this uncertainty, the Company does not believe that the results of these potential claims are likely to have a material effect on its financial position or results of operations.

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives' former employer. This notice was filed against the Company's subsidiary, Dominari Securities. The Company does not agree with the plaintiff's claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company's technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

Note 13. Regulatory

Dominari Securities, the Company's broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company's broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of September 30, 2024, Dominari Securities had net capital of approximately \$12.46 million, which was approximately \$12.31 million in excess of net capital requirement of \$0.15 million.

Note 14. Related Party Transaction

In 2021, the Company engaged the services of Revere Securities, LLC ("Revere") to assist in the management and building of the Company's investment processes. Kyle Wool, one of the Company's board members, was previously a member of the board of directors of Revere until June 2023, and currently holds approximately 30% of Revere's outstanding equity. From time to time, Company participates in offerings of securities as an underwriter in transactions in which Revere is also participating as an underwriter. On such transactions, the Company earned \$313,960 and \$39,000 in the nine months ending September 30, 2024 and 2023, respectively. The Company incurred referral fees of approximately \$45,000 and \$80,000 during the three months ending September 30, 2024 and 2023, respectively. These fees were included in general and administrative expenses in the unaudited condensed consolidated statements of operations.

0.30313960390004500080000

Note 15. Segment Reporting

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy Alkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy Alkido reportable business segment includes Alkido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy Alkido.

The chief operating decision-maker ("CODM") has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the "Summary of Significant Accounting Policies." While assets are primarily held within the Legacy Alkido reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations.

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Revenue	10,553	1,031
Operating Costs	(1,031)	(1,584)
General and administrative	7,138	20,321
Research and development	13,183	20,321
Loss from operations	(1,660)	(20,321)
Interest income	545	184
Other (expenses) income	729	767
Gain on marketable securities	545	767
Unrealized loss on note receivable	(184)	(767)

[illegible]

	(4,211	
The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations.		
Nine Months Ended September 30, 2024		
Dominari Financial		
Legacy Alkido Pharma		
Consolidated		
Revenue		
Operating Costs		
General and administrative		
Research and development		
Interest income		
Unrealized loss on note receivable		
Change in fair value of investments		
Total other (expenses) income		
Net loss		
Three Months Ended September 30, 2024		
Dominari Financial		
Legacy Alkido Pharma		
Consolidated		
Revenue		
Operating Costs		
General and administrative		
Research and development		
Interest income		
Unrealized loss on note receivable		
Change in fair value of investments		
Total other (expenses) income		
Net loss		

|NLOl:L%1JY""O6L|M<)B/IX6